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Abstract 
 
Amyloidoses are a group of protein misfolding disorders which are characterised by the 
abnormal accumulation of highly ordered filamentous assemblies, known as amyloid fibrils.  
More than 50 human disease states are attributed to this phenomenon, many of which are 
neurodegenerative and pose an ever-increasing threat to our aging society.  There is a clear 
need to dissect the processes behind such disorders, as well as to provide novel and much 
needed treatments and diagnostic reagents.  This thesis was motivated by the recognition 
powers of RNA molecules, which can be discovered through the in vitro selection of RNA 
aptamers.  RNA aptamers are a well-established class of research tools, imaging probes, 
diagnostic reagents and therapeutics, which are showing increasing promise in many fields, 
but are currently not exploited in the detection or treatment of amyloid disorders.   
In this thesis, the recognition power of RNA aptamers was explored in targeting species 
associated with the most prevalent and deadly amyloid disorder, Alzheimer’s disease.  In 
vitro selection of RNA aptamers was performed against immobilised monomeric Aβ40, as 
well as two structurally distinct Aβ40 amyloid fibrils, formed in vitro.  The anti-monomer 
aptamers were unable to recognise native, monomeric Aβ40 in solution but instead 
displayed enhanced affinity for the fibrillar forms.  Using fluorescence polarisation, the anti-
fibril aptamers have been shown able to cross-react with other fibril polymorphs, formed 
from both Aβ40 and the unrelated protein sequence, α-synuclein, indicating generic 
amyloid selectivity.  Aptamers were, however, unable to recognise amyloid fibrils 
assembled from short amyloidogenic peptides.  Amyloid recognition by aptamers was 
shown to be largely independent of the RNA sequence or structure.  Further structural 
characterisation, including competition experiments with generic amyloid-binding 
molecules glycosaminoglycans, indicated that binding was most likely mediated through 
the phosphate backbone contacts with ordered repeats of positively charged regions of the 
amyloid assemblies.   
Overall, the results demonstrate an inherent affinity for amyloid by RNA molecules, making 
it highly challenging to select aptamers able to distinguish between different cross-β 
assemblies.  However, the seemingly universal amyloid-binding propensity demonstrated 
by RNA could allow development of generic amyloid detection tools, more effective than 
current methods.  Furthermore, the work indicates the need to explore possible roles of 
RNA associations as a general amyloid toxicity mechanism. 
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1 Introduction 
 
1.1 Amyloid disease: A modern epidemic 
 
Protein aggregation, and specifically amyloid formation, has become a subject of intense 
research efforts in recent years, owing to the association of amyloid deposition with some 
of the most debilitating disorders to threaten human health in the modern world.  Amyloid 
formation is defined by the conversion of normally soluble peptides and proteins into 
insoluble, highly-ordered, fibrillar aggregates, characterised by a distinctive cross-β type 
structure1-4.  Despite a recent explosion of interest in the field, the phenomenon of amyloid 
formation, in fact, was discovered more than 150 years ago.  Rudolph Virchow coined the 
term amyloid in 18545-7, based on the observation of abnormal, macroscopic structures in 
brain tissue.  These structures stained blue upon application of iodine, indicative of the 
presence of starch.  The term amyloid, therefore, was derived from the Latin “amylum” and 
Virchow evidently considered amyloid to be carbohydrate based.  However, by 1859, 
Friedrich and Kekule first recognised that amyloid was proteinaceous8 and attention shifted 
to the study of amyloid as a protein, and later, a class of proteins unrelated by amino acid 
sequence.   
Through the years, advances in technology have revealed much about the amyloid structure.  
In 1922, Bennhold et al. 9 observed that the common, industrial dye, Congo red, was able to 
bind to amyloid deposits and later, polarisation light microscopy studies10 revealed the 
enhancement of Congo red birefringence in the presence of amyloid, indicating the 
possibility of an ordered microscopic structure.  This finding encouraged electron 
microscopy studies11-14 where it was confirmed that all amyloid fibrils studied shared a 
similar, fibrillar ultrastructure.  X-ray diffraction data15, 16 demonstrated that the ordered 
structure of the fibrils was made up of a consistent, cross-β sheet architecture and this 
characteristic is now considered one of the defining criteria of amyloid. 
Amyloid was long believed to be derived from a single substance, but it was not until the 
1970s that the pioneering work of Benditt and Glenner first demonstrated the biochemical 
heterogeneity of amyloid17-21.  Over the following decade, around 20 normally soluble 
proteins were found in amyloid deposits specifically associated with a range of disorders, 
now termed amyloidoses (or amyloid diseases).  In some cases the deposition is localised 
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to a single organ (such as the brain in Alzheimer’s disease or the pancreas in diabetes) or 
found in multiple organs or tissues, termed systemic amyloidoses.   
Today, amyloidoses are known to be a biochemically and clinically heterogeneous group of 
disorders of protein folding.  There are approximately 50 disorders22 (discussed in Section 
1.2.6), with diverse clinical pathologies, where the misfolding of normally soluble, 
functional protein leads to the conversion to an aggregated state and subsequent 
accumulation as amyloid deposits.  The fact that many of these disorders are associated with 
aging (e.g. Alzheimer’s disease), or with our increasingly sedentary lifestyles (e.g. Type II 
diabetes), means that amyloidoses account for some of the most common and debilitating 
medical conditions in the modern world1, 3, 22.  Alzheimer’s disease, probably the most well-
known amyloid disorder, now represents the fifth most common cause of death in the UK 
overall and the leading cause for women23.  It has recently been termed a “21st century 
plague”24 as the current number of people living with the disorder is projected to triple in 
the next 40 years, with an estimated 80 million new cases worldwide24, 25.  Research into 
amyloidosis, therefore, is required in tackling this wide range of increasingly prevalent 
disorders, which represent some of the greatest socio-economic challenges of our time26-28.  
 
1.2 Protein misfolding and aggregation 
 
1.2.1 Principles of protein folding and misfolding 
 
A native protein fold (the protein’s specific, three-dimensional conformation) is often 
paramount to its function.  Since the early 1960s, and Anfinsen’s classic work on the 
renaturation of ribonuclease A29, it has been known that all the information required for a 
protein to reach its native conformation is encoded within its primary sequence, and that 
the mechanism depends on a search for the structure with the lowest free energy and 
therefore highest thermodynamic stability.  However, for a protein to sample all the possible 
conformations available, at random, in order for it to find its single functional fold, would 
be impossible on a biological timescale30, 31.  This paradox was first considered by 
Levinthal30, 32, who proposed that specific, kinetically controlled, protein folding pathways 
exist to reduce the number of conformations that need to be sampled to achieve the native 
fold.  By rapid formation of local native-like structures with enhanced stability, fewer 
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species would be populated en route to the final energy minimum and folding would be 
achievable on a biologically appropriate timescale.   
The process of reaching the native fold is often explained as the transition from the high-
energy, unfolded state to the low-energy native conformation by traversing a “downhill” 
energy landscape33.  The energy landscape describes the series of structural assemblies 
sampled en route to the native fold and is plotted as the free energy of the polypeptide chain, 
as a function of conformational space.  An idealised energy landscape or “folding funnel” is 
shown in Figure 1.1, where the internal free energy decreases with the conformational 
entropy, until the minimum energy, native fold is achieved.   
 
 
Figure 1.1 An idealised protein folding energy landscape.  The funnel landscape represents 
the protein folding event as a stochastic search for the lowest energy native state, beginning 
as a disordered polypeptide chain, at the rim of the funnel, and progressing with increasing 
negative-free energy, to the native fold.  The vertical axis represents internal free energy, 
whereas the horizontal axis indicates the conformational entropy.  Figure redrawn and 
adapted from 34. 
 
In reality, energy landscapes for the folding of most proteins are described as “rough” 35-37 
(Figure 1.2), as the protein folds by populating several specific intermediate states, en 
route to the native conformation.  These high-energy barriers and low-energy troughs are 
sampled before the correct folded and functional state is achieved.  The species on the 
INTRODUCTION 
 
4 
 
energy landscape are in a state of flux37 and many proteins will fluctuate around the minimal 
energy fold, forming some non-native contacts between residues.  These species can 
represent functional or “on-pathway” conformations, however they are not the only 
structures available to the folding polypeptide.  The event where a protein becomes trapped 
in an alternative, low-energy conformation is the basis of protein misfolding, where the 
formation of persistent, non-native interactions effect the protein’s overall architecture and 
often its biological properties.  Changes to the thermodynamic stability or the folding 
kinetics can increase the likelihood for a protein to adopt an unfavourable conformation.  
Various destabilising factors in the protein sequence, such as mutations, could contribute to 
this3.  Changes in the cellular environment within which the newly synthesised polypeptide 
chain must fold, can also influence misfolding events, including pH, temperature, or changes 
in protein concentration, owing to overexpression or ineffective proteolysis1, 3, 38, 39.  In these 
misfolded, partially folded or unfolded states, the hydrophobic core of the protein, usually 
buried in the native conformation, becomes exposed and prone to forming undesirable 
contacts with other molecules, and crucially, other misfolded proteins, leading to 
aggregation.   
 
 
 
Figure 1.2 An energy landscape depicting protein folding and aggregation.  The rough 
landscape illustrates the multitude of conformational states available to the polypeptide 
chain upon folding, and during misfolding and aggregation.  Figure redrawn and adapted 
from 37. 
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Aggregated forms of proteins can be amorphous and consist of disordered assemblies of the 
same, or different, protein sequences.  However, in several notable cases, aggregation can 
proceed to form ordered, self-associated species, known as amyloid fibrils3, 4.  Interestingly, 
there is no clear similarity in the sequences, native structures or functions of the group of 
proteins known to form these highly ordered aggregates, yet they all adopt the same cross-
β architecture3.  Although the amyloid form is generally identified to be associated with 
disease, in recent years, a wide range of proteins that are not associated with any misfolding 
disorders have been shown to form characteristic fibrillar structures, indistinguishable 
from those formed in the disease states.  This, along with the apparent lack of sequence 
homology, has led to the suggestion that, in principle, any polypeptide chain can adopt this 
amyloid structure40-43. 
 
1.2.2 Cellular response to aggregation  
 
As protein misfolding can have such a profound effect on function, polypeptide sequences 
with an increased propensity to aggregate have been disfavoured throughout evolution 
(although some amyloid is functional44, 45).  Conservation of proline and glycine residues 
(unlikely to form β-sheet rich structure, owing to conformational restraints and flexibility, 
respectively) as well as avoidance of extended stretches of hydrophobic residues, or 
sequences with alternating polar/non-polar residues, are all examples of strategies nature 
has adopted to reduce aggregation and maintain functional folding46.  Proteins that must be 
natively-disordered for their function have also evolved to be generally less hydrophobic, 
with a higher net charge, reducing their inherent aggregation propensity47.  However, 
polypeptides are clearly not entirely optimised and misfolding and aggregation can occur, 
often leading to devastating consequences. 
Cells have developed a range of elaborate quality control mechanisms to deal with aberrant 
protein aggregation48-51 (Figure 1.3).  Molecular chaperones are conserved and ancient 
molecular machines that are required for correct folding and assembly of complexes, 
prevention of misfolding and aggregation, and in targeting a protein for degradation52, 53.  
The prevention of the accumulation of misfolded proteins is controlled firstly by the cell’s 
heat shock response (HSR) or unfolded protein response (UPR)54.  In response to a number 
of cellular stress signals, including but not limited to, temperature55, expression of a range 
of chaperones is upregulated.  These chaperone proteins then bind to exposed hydrophobic 
regions56-58 in the misfolded monomers, and consequently, prevent further protein-protein 
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interactions55.  A predominant family of chaperones are heat-shock proteins, which not only 
interrupt aberrant aggregation but are also often required for correct folding, under non-
stress conditions.  In cases where chaperones are unable to restore correct folding or 
function, large molecular machines known as chaperonins can be recruited, which isolate 
the misfolded entity within a central cavity, away from other cellular components, and 
promote refolding56, 59, 60.  The UPR is another quality control system that controls the 
folding of eukaryotic proteins as they are co-translationally translocated in the endoplasmic 
reticulum (ER).  The UPR prevents the export of misfolded or incorrectly post-
translationally modified proteins, acting as a cellular “checkpoint”.  This too involves a 
number of ER chaperones, which may become saturated by an influx of misfolded species.  
This then leads to the activation of a network of intracellular signalling pathways (the UPR), 
upregulating proteins involved in folding, trafficking and degradation61. 
Many cell types have also developed strategies to sequester aggregates in specific cellular 
locations, reducing their effect on the rest of the cellular environment and possibly 
facilitating their removal62-67.  In mammalian cells, inclusion bodies form in the ER (termed 
Russell bodies68) and the cytosol (aggresomes68, 69).  Aggresomes can form and move to the 
nuclear envelope, via microtubule assisted transport, where chaperone expression is 
believed to be upregulated to combat the accumulation of misfolded species68. 
Degradation of aggregates is clearly the ultimate protective mechanism in the cell.  In 
eukaryotes, aggregates are degraded by macroautophagy or the ubiquitin proteasome 
system70.  In macroautophagy, whole aggregates are engulfed by a double-membrane, 
vesicular organelle, known as the autophagosome, which consequently travels through the 
cytosol to the lysosome.  Upon fusing with the lysosome, the contents of the autophagosome 
can be degraded via acidic, lysosomal enzymes71.  Alternatively, the ubiquitin proteasome 
system involves the recruitment of a multi-subunit proteolytic machine, the 26S 
proteasome.  This complex specifically degrades proteins that are tagged for degradation by 
the covalent attachment of ubiquitin chains72.  
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Figure 1.3 Controlling protein misfolding in the cell.  Protein misfolding and aggregation 
activates a number of cellular quality control responses.  Chaperones bind to the unfolding 
protein to prevent aggregation and promote correct folding (i).  If unsuccessful, the 
misfolded protein is transferred to the chaperonin where folding is promoted in a protected 
environment (ii).  If refolding is unsuccessful, or aggregation ensues, the protein is 
transferred to the proteasome for degradation (iii).  For secretory proteins, which are 
synthesised in the ER, misfolding is prevented by ER chaperones (iv).  If folding is 
unsuccessful, the protein is retro-translocated to the cytosol where it too is degraded by the 
proteasome.  If the level of misfolding saturates the capabilities of the ER chaperones, the 
unfolded protein response (UPR) is activated (v).  Degradation of aggregates can also be 
dealt with via macroautophagy (vi), where whole aggregates are engulfed by the 
autophagosome and targeted for degradation via the endocytic pathway.  Specialised 
inclusions of aggregates can also form in the cytosol (aggresomes) and ER (Russell bodies) 
(vii), sequestering the aggregates to reduce their effects on cellular processes and 
facilitating their removal. 
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1.2.3 Mechanism of amyloid formation 
 
Amyloid formation is characterised by the aggregation of soluble proteins or peptides, into 
insoluble, fibre-like structures, via a number of oligomeric intermediate assemblies.  The 
mechanism of fibril formation is known as nucleated-growth, where misfolded monomeric 
proteins first come together to form an ordered nucleus of a critical size that is necessary as 
a template for further deposition of monomers (Figure 1.4).  The formation of the initial 
nucleus is thermodynamically unfavourable and occurs through rare, stochastic 
interactions73.  This is the rate-limiting step of the aggregation mechanism, which leads to 
the initial lag phase in fibril formation kinetics.  Addition of pre-formed fibril fragments, 
abolishes this initial lag phase and therefore supports the nucleated-growth model74.  Once 
the initial, critical, elongation-competent nucleus is formed, addition of further monomers 
is thermodynamically favourable and proceeds rapidly to form the mature amyloid fibrils75.   
 
 
Figure 1.4 A schematic representation of the nucleated growth model of amyloid formation 
and the species populated en route to fibril formation.  The formation of fibrils proceeds via 
two distinct phases; (a) the nucleation phase or “lag-phase” and (b) the elongation phase 
(solid line).  The lag phase corresponds to a thermodynamically-disfavoured nucleation 
event, which is the rate limiting step that proceeds the rapid, thermodynamically-
favourable elongation phase.  The addition of “seeds”, i.e. an elongation competent nucleus, 
to the beginning of the reaction, abolishes the rate limiting nucleation step and dramatically 
decreases the lag-time, templating fibril growth (dashed line).  Redrawn and adapted 
from76. 
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Although the primary nucleation step is required for the initiation of amyloid fibril growth 
it is not the only process that contributes to the creation of new filaments.  Secondary 
processes exist where the creation of new fibrils is dependent on the existing aggregate 
population75, 77 (Figure 1.5).  Fibril fragmentation is one such example, where each 
fragmentation event increases the number of aggregation-competent ends and initiates new 
growth, leading to an exponential proliferation of fibrillar species78-80.  Secondary 
nucleation is also possible, where the surface of existing filaments catalyses the formation 
of new aggregates, accelerating the rate of fibril formation via a positive feedback 
mechanism.  These processes can contribute to both the observed lag phase and the 
subsequent fibril growth77, 79.  Some recent in vitro studies of the aggregation of the 40 and 
42 residue variants of the amyloid-β (Aβ) peptide revealed that, in both cases, rapid 
proliferation of aggregates is dominated by secondary nucleation78, 81, where the formation 
of aggregates becomes exponential, due to the positive feedback mechanism upon the 
formation of fibrils.  These additional aggregation mechanisms could be important in the 
progression of the disease, and the proliferation of toxic species between cells, and 
therefore indicates that therapeutic approaches may need to be considered to target fibril-
catalysed secondary processes rather than (or in addition to) primary nucleation.     
 
 
 
Figure 1.5 A schematic representation of the main primary and secondary processes that 
contribute to fibril formation.  (a) Primary nucleation results in the formation of new 
aggregates from stochastic interactions of monomers.  Secondary pathways depend on the 
pre-existence of aggregate and can enhance the fibrillation kinetics via a number of ways; 
fragmentation events (b), which produces new, elongation competent ends for further 
fibrillation and (c) surface-catalysed events, where new aggregate formation is dependent 
on the concentration of preformed fibril.  Figure redrawn and adapted from 77. 
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1.2.4 Structure of amyloid fibrils 
 
Amyloid fibrils formed from different protein sequences share remarkably similar 
structural features on the nanometer scale3, 82.  Using imaging techniques such as 
transmission electron microscopy (TEM) or atomic force microscopy (AFM), amyloid fibrils 
appear as long, unbranched polymeric assemblies, often several microns in length1, 3. 
The core of the fibril is made up of an array of either parallel or anti-parallel β-strands, 
stacked perpendicular to the length of the fibril and held together in a highly ordered 
arrangement by backbone hydrogen bonds.  This arrangement is known as cross-β and 
produces the characteristic X-ray fibre diffraction pattern observed for a large number of 
fibrils15, 82, 83 (Figure 1.6 a).  The pattern shows intense reflections at ~4.7 Å and 10 Å 
indicating the regular spacing of both the intra-sheet β-strand packing and the inter-sheet 
distances between two associating β-sheets, in the formation of the mature fibril (Figure 
1.6 b).  Fibrils usually consist of several protofilaments, which can associate in a number of 
ways (Figure 1.6 c), often by twisting together to form rope-like fibrils or through lateral 
associations to form ribbon-like structures that can be up to 30 nm in width3, 82, 84-87. 
Amyloid fibrils are also known to display universal dye binding properties.  As well as 
exhibiting enhanced birefringence under polarised light upon Congo red binding88, amyloid 
fibrils exhibit a conserved ability to bind aromatic dyes such a Thioflavin T (ThT), leading 
to enhanced fluorescent properties of such compounds88-90.  This property, therefore, is 
often used to monitor fibril formation in vitro and further serves as an indication of the 
generic features shared by amyloid fibril structures.   
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Figure 1.6 Structural characteristics of amyloid fibrils.  (a) Amyloid fibrils display generic 
cross-β architecture.  A typical X-ray diffraction pattern from fibrils formed from islet 
amyloid polypeptide (IAPP) is shown, with the characteristic reflections at 4.7Å and 10Å 
indicated83.  (b) A cartoon representation of the cross-β structure inferred from the X-ray 
diffraction data.  Spacing between β-strands is determined by the backbone hydrogen bonds 
and is consistently 4.7Å, whereas the spacing between β-sheets is more variable owing to 
side chain interactions.  Taken from 1.  The direction of the fibril axis is indicated by a single 
headed arrow.  (c) Cryo-EM reconstructions illustrating the variation in protofilament 
assembly leading to extensive structural polymorphism in amyloid fibrils87. (d) Example of 
a high-resolution fibril structure.  The twisted morphology of the fibrils formed from the 11-
residue fragment of transthyretin (TTR) as visualised by TEM (left).  This technique, 
coupled with cryo-EM, allowed for reconstruction of the fibril (centre).  Additional ssNMR 
data then allowed determination of the fibril structure at the atomic level (right) illustrating 
the hierarchical organisation of the amyloid fibril91.  Images adapted from references where 
indicated.   
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Knowledge of the detailed molecular structures of amyloid fibrils is becoming increasingly 
available owing to recent developments in cryo electron microscopy (cryo-EM)91, 92 and 
solid state NMR spectroscopy (ssNMR)91, 93-95.  Recently, an atomic level structure of a fibril 
formed from the 11-residue variant of transthyretin (TTR) was demonstrated (Figure 
1.6 d) revealing the intricate details of the packing interactions which facilitate in the 
formation of the hierarchical assembly of β-strands, into protofilaments, filaments and the 
mature fibril91.  These techniques, therefore, have allowed confirmation of the general 
characteristics of the overall structure of the fibrils, which is indeed attributed to the 
hydrogen bonding pattern of the polypeptide core1.  It also confirms the basis of structural 
variation seen between fibrils, which results from the manner by which side-chains are 
incorporated into the fibrillar architecture3, 96, leading to polymorphism.   
Structural polymorphism is not limited to fibrils formed from different protein precursors 
and seems instead to be an inherent feature of amyloid formation.  Fibrils composed of the 
same precursor can exhibit entirely different packing arrangements within the fibril core.  
For example, fibrils formed from the 40-residue variant of Aβ (discussed in more detail in 
Section 1.3.4.3) have demonstrated the ability of a common precursor protein to form 
structures with entirely different organisations of the β-strands.  For the most part Aβ40 
fibrils form a parallel, in-register arrangement of β-strands, however, out of register and 
completely anti-parallel structures have been suggested in some cases97-99.  Structural 
analysis of more than 30 amyloid forming peptides – fragments from full-length 
amyloidogenic proteins such as Aβ, tau, prion protein (PrP), insulin, α-synuclein among 
others100, demonstrated that, although all fragments share the same cross-β spine, 
structural variations exist that expand the range of architectures available to a single 
protein species and could form the basis for different biological properties seen by different 
polymorphs.  This same structural polymorphism is also seen for a number of larger 
amyloid forming sequences97, 101-105 many of which are associated with disease states and 
therefore suggests a role for different morphologies in specific disease progressions.  
Distinct morphologies of fibrils, found present in the brains of Alzheimer’s patients with 
entirely different clinical histories, indicates a role for polymorphism in vivo, that might 
correlate with variations in the disease106.   
In vitro studies also indicate that polymorphism can significantly alter the biological 
properties of amyloid assemblies101-103, 107-114.  Two fibrillar polymorphs of α-synuclein (the 
amyloidogenic protein associated with Parkinson’s disease) show entirely different abilities 
to propagate the formation of further aggregates, in the process commonly referred to as 
“seeding”113.  This difference in ability to template further aggregation could have a 
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dramatic influence on the progression of the disease state.  A current leading hypothesis in 
the field is that amyloid seeds can have prion-like infectivity115, 116, where aggregates may 
initially form in only a small number of cells, before fragmentation and spreading to distinct 
regions of the brain.  If the distinct structural morphology of a fibril determines the seeding 
ability, polymorphism would play a key role in the “aggressiveness” of a disease and 
possibly the variations in symptoms seen between patients106.  Targeting distinct structural 
morphologies, therefore, may be critically important in treating amyloid disorders, as well 
as in identifying the key assemblies responsible for propagation and toxicity. 
 
1.2.5 Other structures of the amyloidogenic pathway 
 
Within the lag phase of amyloid fibril formation (Figure 1.4), a vast array of oligomeric, 
intermediate states can exist.  These thermodynamically-stable intermediates may be 
formed both on- and off-pathway to mature fibrils, but detailed characterisation of the 
distinct oligomeric species formed has been a major challenge in the field, owing to their 
heterogeneous and transient nature.  Insights into these structures, their formation and 
characteristics has been the focus of much research, as it is the general consensus that these 
oligomeric intermediates act as the main toxic entity in amyloid disorders, rather than the 
mature fibrils54, 117-121. 
Formation of soluble oligomers is common to all amyloid forming systems and it was 
proposed previously that conserved features of these intermediates may contribute to a 
generic pathogenic mechanism between amyloidoses122, 123.  This hypothesis was supported 
by the finding that oligomers, characterised from a range of different amyloidogenic 
precursors, were found to display common features; being generally spherical, between 10-
70 nm in diameter and crucially, recognisable by a conformational-specific antibody, A11123.  
These “A11-positive” oligomers are significantly more toxic to cells than fibrils of the same 
precursor123.  Importantly, oligomeric aggregates formed from proteins not previously 
associated with any misfolding disorder, were also shown to be cytotoxic122, furthering the 
idea that toxicity imparted by soluble, pre-fibrillar aggregates is an inherent property of 
protein aggregation. 
Although the current consensus still implicates oligomers as more toxic entities than fibrils, 
it has become clear that the mechanisms underlying oligomer toxicity are more complicated 
than a single conserved feature.  A vast number of structures have been discovered with 
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various degrees of toxicity, which can be broadly characterised based on their overall 
morphology124.  The A11-positive oligomers represent one class of structures often termed 
pre-fibrillar, whereas the second major class, termed fibrillar, are expected to contain a 
higher degree of β-strand content and possess more structural similarity with the mature 
fibril.  These oligomers are recognised by a second conformational-specific antibody, OC, 
which also recognises mature fibrils125.  Owing to the lack of high resolution oligomer 
structures, these two antibodies serve as a convenient method of classifying intermediates, 
based on their underlying structural organisation, rather than size.  Fibrillar oligomers (OC-
positive) have been found ranging from dimers, up to >500 kDa in size125, whereas A11-
positive, pre-fibrillar oligomers range from approximately tetrameric to ~75 kDa125.  This 
suggests that the two oligomer types are formed as part of two distinct pathways to 
aggregation (Figure 1.7), rather than the pre-fibrillar oligomers preceding the formation of 
the fibrillar oligomers.  One pathway involves the direct formation of fibrillar oligomers 
(OC-positive) from monomers, which may represent seeds or nuclei that can directly 
elongate to form fibrils.  The alternative pathway involves the formation of pre-fibrillar 
(A11-positive) oligomers which may need to undergo a conformational change to become a 
competent nuclei for monomer addition and fibril formation.  With oligomeric assemblies 
able to readily interconvert126, these simplified models may represent only two of an infinite 
number of possible pathways.  Clearly more detailed insights into the various structures are 
required to allow further understanding of the mechanisms of amyloid formation and to 
elucidate any general toxic species. 
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Figure 1.7 Schematic representation of two possible amyloid forming pathways.  The 
existence of two distinct oligomer populations with differential reactivity to conformation-
specific antibodies A11 and OC indicate two possible pathways to mature amyloid fibril 
formation; (a) where fibrillar oligomers (OC positive) elongate by simple monomer 
addition and (b) where pre-fibrillar, A11 oligomers undergo a conformational change 
before elongation. Figure redrawn and adapted from 124. 
 
1.2.6 Amyloid formation and disease 
 
A number of diseases result from the incorrect folding of proteins, one class of which 
involves ordered association that leads to the formation of amyloid deposits.  Several of 
these amyloid diseases are neurodegenerative, where aggregates specifically accumulate in 
the brain and exert their toxic effects.  These include the two most prominent forms of 
dementia, Alzheimer’s disease and Parkinson’s disease127.  There are also several examples 
of non-neuropathic amyloidoses, which can specifically target a single organ (localised) or 
effect several areas of the body (systemic).  Some of the main examples of amyloidoses are 
given in Table 1.1. 
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Table 1.1 Examples of the major human disorders associated with amyloid deposition. 
 
 
Disease 
Precursor 
protein 
Organ-
specific/ 
Systemic 
(organ 
affected) 
Extracellular 
amyloid 
deposits/ 
intracellular 
inclusions 
Clinical 
features 
Ref 
Neurodegenerative 
Alzheimer’s 
Disease 
Amyloid-β 
(Aβ) peptide 
Organ-
specific 
(brain) 
Extracellular 
Progressive 
dementia 
128 
Alzheimer’s 
Disease 
Tau 
Organ-
specific 
(brain) 
Intracellular 
Progressive 
dementia 
128 
Parkinson’s 
Disease 
α-synuclein 
Organ-
specific 
(brain) 
Intracellular 
Movement 
disorder 
129 
Dementia with 
Lewy bodies 
α-synuclein 
Organ-
specific 
(brain) 
Intracellular 
Dementia and 
motor problems 
130 
Transmissible 
spongiform 
encephalopathies 
Prion protein 
Organ-
specific 
(brain) 
Extracellular 
Dementia, ataxia 
and psychiatric 
problems 
131 
Huntington’s 
disease 
Poly-Q 
expanded 
huntingtin 
Organ-
specific 
(brain) 
Intracellular 
Dementia and 
motor problems 
132 
Amyotrophic 
lateral sclerosis 
Superoxide 
dismutase 1 
Organ-
specific 
(brain) 
Intracellular 
Movement 
disorder 
133 
Non-neuropathic 
Amyloid light-
chain (AL) 
amyloidosis 
Immunoglobu
lin light chain 
Systemic Extracellular Renal failure 134 
Dialysis related 
amyloidosis 
Β2-
microglobulin 
Systemic 
(joints) 
Extracellular 
Renal failure 
and paraplegia 
135 
Lysozyme 
amyloidosis 
Lysozyme Systemic Extracellular Renal failure 136 
Transthyretin 
amyloidosis 
Transthyretin Systemic Extracellular 
Peripheral 
neuropathy 
137 
Fibrinogen 
amyloidosis 
Fibrinogen α-
chain 
Systemic Extracellular Renal failure 138 
Type II Diabetes 
Islet amyloid 
polypeptide 
(IAPP) 
Organ-
specific 
(pancreas - 
Islets of 
Langerhans) 
Extracellular 
Insulin 
deficiency and 
resistance, 
hyperglycaemia 
139 
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Exactly how aggregates exert their toxicity in different disease systems is not well 
understood but is thought most likely to occur through a gain of toxic function3.  This is 
likely as a generic mechanism owing to the fact that non-disease related proteins can form 
amyloid structures that are inherently toxic122.  There is currently no single consensus 
between amyloid disorders, in fact it is most likely that toxicity is mediated through a 
complex network of dysfunctions. 
Several disorders are associated with extracellular aggregation (Table 1.1).  These 
aggregates have been shown to activate signal transduction pathways (Figure 1.8 i), 
leading to apoptosis, and thus present a possible generic gain of function mechanism for 
disease-related amyloid deposits.  For example, RAGE (receptor for advanced glycation end 
products) is a surface receptor which has been shown to interact with amyloid fibrils 
composed of several precursor proteins, including Aβ, IAPP and PrP140, 141, leading to 
activation of cellular stress responses and immune responses.   
Another possible strategy of amyloid-mediated toxicity is membrane disruption (Figure 1.8 
ii).  Amyloid-membrane interactions are well documented142-148 and have been shown to 
lead to a perturbation of normal cellular activity, membrane damage and even complete 
rupture147, 149-154.  This, too, is independent of precursor sequence and again could be a 
generic mechanism shared by several amyloidoses.  Oligomers, formed from many amyloid 
precursors54, 155-160 have been found to form pores in cellular membranes (Figure 1.8 iii), 
leading to problems with signal transduction, ion homeostasis and resulting in apoptosis or 
necrotic cell death.  Unstructured monomers of IAPP and α-synuclein have also been shown 
to embed within the lipid bilayer151, 161, 162 where amyloid formation proceeds and causes 
membrane disruption.  
As discussed in Section 1.2.2, the cell has developed many strategies to deal with the 
accumulation of aggregates.  Therefore, a possible universal toxicity mechanism could 
involve the sequestration of essential cellular components (Figure 1.8 iv), such as 
chaperones, leading to a competition for these components and a depletion of cellular 
resources.  In one example, conducted in a yeast model of Huntington’s disease, cytosolic 
huntingtin inclusions were found to sequester the molecular chaperone Sis1p, inhibiting the 
clearance of further, non-amyloid inclusions of unrelated proteins, which formed as a result 
of the disturbance of the protein quality control system.  This chaperone competition 
mechanism could indeed apply to all amyloid disorders, especially in the case of age-related 
diseases where mechanisms of proteostasis are already in decline163-165.  
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Because the native fold is usually essential for a protein to function (except in the case of 
intrinsically disordered proteins), most proteins will lose their ability to function upon 
misfolding and aggregation.  Loss of function mechanisms could account, therefore, for the 
toxicity in some amyloidoses (Figure 1.8 v).  This could be through aberrant interactions 
with any number of unrelated proteins, leading to a loss of function of the co-aggregate166 
(Figure 1.8 vi).  Toxicity could also be attributed to the loss of biological function, 
specifically of the amyloidogenic protein in question.  In Huntington’s disease, the 
huntingtin protein is thought to play a protective role against apoptosis167 and disturbance 
of this biological function may therefore lead to premature loss of neurons.  In amyotrophic 
lateral sclerosis (ALS), the misfolded superoxide dismutase 1 (SOD1) is no longer able to 
turn over superoxide anions and therefore leads to a build-up of superoxide radicals168.  For 
both of these diseases the mechanisms are still unclear168, 169 and there are arguments 
contradicting the loss of function hypotheses in each case167, 169.  In general, the toxic gain of 
function mechanism, possibly universal between the many amyloid disorders, is considered 
more likely. 
 
 
Figure 1.8 Mechanisms of amyloid toxicity.  Many disorders are associated with 
extracellular aggregation which can exert toxicity via aberrant activation of cell signalling 
pathways (i) or membrane perturbation or rupture (ii).  Oligomeric aggregates formed on 
pathway to amyloid fibrils can exert cytotoxicity via pore formation (iii).  Possible toxic 
mechanisms of intracellular aggregates include sequestration of cellular components such 
as chaperones and other proteostasis machinery (iv).  Alternatively, aggregation could lead 
to a loss of native function of the amyloid precursor itself (v) or of other essential proteins, 
through non-native co-aggregation (vi).   
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1.2.7 Therapeutic approaches to amyloid diseases 
 
Owing to the many potential mechanisms underlying amyloid toxicity, the development of 
therapeutic strategies to intervene in these disorders is extremely challenging.  A deeper 
understanding of the mechanisms involved is therefore the first major requirement to 
enable the development of suitable intervention strategies.  Equally, the identity of the toxic 
species remains elusive, further hindering the search for effective therapies.  Due to the 
complexity of the aggregation pathway, a number of plausible therapeutics are under 
review, as discussed below.    
 
1.2.7.1 Inhibiting the production of the amyloid precursor 
 
Perhaps the most obvious route to prevent aggregation is in reducing the level of the 
amyloid-competent protein in the cell.  This strategy may not be feasible in cases where the 
amyloid precursor is required for function, but when the precursor is a by-product of 
abnormal processing of a larger, functional protein (as is the case for almost half of the 
known amyloid diseases170) it may prove effective.  In the case of Alzheimer’s disease 
(covered in detail in Section 1.3) the abnormal processing of the amyloid precursor protein 
(APP) leads to the formation of the aggregating peptide Aβ.  Targeting the enzymes involved 
in this processing event, therefore, has been an attractive intervention strategy for many 
years.  However, the challenge in this endeavour is modulating the abnormal process 
without disruption of the formation of functional fragments171 or effecting the enzymes’ 
ability to cleave alternative substrates128, 172.  A phase III clinical trial of a γ-secretase 
inhibitor, Semagacestat, was aborted in 2010 due to worsening of cognitive impairment173 
expected to be a result of the inhibition of alternative cleavage events.   
In diseases where the precursor is formed from the full-length protein, inhibition of 
expression with RNA interference (RNAi) may be plausible.  Short, double stranded RNA 
molecules are introduced into cells to silence specific genes by targeting complementary 
mRNA for degradation174-177.  RNA can be introduced with the use of viral vectors, where the 
vector can integrate into the neuronal genome and be expressed long-term.  RNAi has 
shown promise in a number of amyloid disorders177-180 but the delivery of such therapies 
across the blood brain barrier (BBB) is a challenge181 and may only be feasible in disorders 
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that effect a small region of cells (such as Parkinson’s) where vectors could be injected 
directly. 
 
1.2.7.2 Stabilising the native protein 
 
In the case of disorders where the precursor is a functional peptide or protein, stabilisation 
of the functional state may be a promising strategy.  To date, only one commercially 
available treatment for an amyloid disorder exists, which works by stabilising the functional 
tetramers of transthyretin (TTR) in the neurodegenerative disorder, Familial amyloid 
neuropathy (FAP).  In the disease state, the native tetramer dissociates, whereupon the 
partially unfolded monomers subsequently form amyloid aggregates182, 183.  The Kelly group 
therefore developed a “pharmacological chaperone” Tafamidis; a small molecule which 
binds and kinetically stabilises the folded tetramer, preventing monomer dissociation, 
which is the rate-limiting step in TTR misfolding and aggregation (Figure 1.9)184.  In the 
case of Tafamidis, its discovery was through the use of a structure-based design approach; 
a method which, unfortunately, is not applicable to the many natively disordered amyloid 
precursors, as they have no unique structure to target.  However, further chemical 
chaperones have been found able to stabilise prion protein (PrP)185 and Aβ186 via alternative 
means. 
   
1.2.7.3 Inhibition of the formation of toxic aggregates 
 
Linked to the stabilisation of the native fold, inhibition of aggregation and, therefore, the 
prevention of the formation of toxic species, is an attractive therapeutic strategy for all 
amyloidoses.  Development of ligands able to associate specifically with monomers and 
prevent aggregation, therefore, is an intense area of research.   
Inhibition of fibril formation by the introduction of “β-sheet breakers” has been performed 
by various research groups.  This strategy involves a peptide inhibitor which is able to 
associate through hydrogen bonding with the aggregate due to a complementary region, but 
is unable to promote further fibrillation.  This could be through the presence of a bulky 
modification, such as the addition of a steroid at the N-terminus, which has been shown to 
effectively inhibit further addition of monomers in Aβ aggregation187.  Alternatively, 
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substitution of key residues with prolines can reduce β-sheet formation188, 189.  Similarly, the 
use of N-methyl modified peptides can be used to block fibril formation190.  β-sheet breaking 
methods such as these have been found effective in inhibiting PrP, α-syn, IAPP and poly-Q 
aggregation in vitro191-195.   
 
 
 
Figure 1.9  Tafamidis stabilises a functional tetramer of transthyretin (TTR) in treating 
Familial amyloid neuropathy (FAP).  (a)  The structure of Tafamidis.  (b)  The mechanism 
of action of Tafamidis.  Tafamidis binds and stabilises the TTR tetramer (top left), 
dramatically reducing the dissociation to dimers and inhibiting the cascade to amyloid 
formation via the misfolded monomer (bottom right).  Figure adapted from196. 
 
Therapeutic antibodies may have value in targeting amyloidoses, despite years of 
disappointing trials for some disorders (detailed for AD therapeutics in Section 1.3.5).  
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Antibodies are indeed able to inhibit aggregation197, 198.  In fact, the A11 antibody, able to 
recognise an array of oligomeric structures from a variety of peptide precursors, is able to 
inhibit the toxic effects of the aggregates123.  A major drawback of these molecules is that 
they are unable to cross the BBB and have been found to exert toxic side effects due to their 
immunogenic properties.  Recently a small peptide “affibody” (an antibody mimetic which 
may have better BBB penetration owing to its smaller size199) was developed, which was 
able to bind Aβ with nanomolar affinity and subsequently prevent oligomerisation200.   
Small molecule inhibitors are another promising class of therapeutics in amyloid disorders, 
with advantages in their small size and therefore broad tissue penetration, lack of immune 
response and enhanced stability201.  As all amyloid fibrils have long been known to bind to 
the dye molecules ThT and Congo red88, it is unsurprising that an array of further aromatic 
compounds are able to bind amyloid.  In many cases, the molecules are able to interfere with 
the aggregation process202-209.  The aromatic rings found in many of these compounds are 
proposed to interfere with the π-stacking of aromatic residues, thought to be important in 
fibril formation197, 210, 211.  Epigallocatechin 3-gallate (EGCG), one of the most well studied 
amyloid inhibitors, is able to prevent oligomerisation and to disaggregate preformed fibrils 
formed from Aβ, IAPP, TTR and Sup35, among others 202-208.  A number of small molecule 
amyloid inhibitors have proceeded to clinical trials209, 212, 213 and could prove to be a viable 
approach in targeting these disorders.   
Because the identity of the toxic species in unknown in the vast majority of amyloid 
disorders, targeting the earliest stages of aggregation might be the most promising strategy, 
as via this approach, all of the potential toxic entities will be prevented from forming.  Only 
when more details of the toxic mechanisms associated with amyloid disease become clear, 
will the design of therapies targetting single structures from within the amyloid pathway 
become feasible.  Recently, secondary nucleation processes (Section 1.2.3) have been found 
to be important in the propagation of aggregates78, 81 and implicated in the formation of toxic 
species.  Polymorphism of fibril structures (Section 1.2.4) has also been associated with 
different biological effects and may indicate additional routes to the prevention of the 
proliferation of toxic aggregates106, 113.  The process of secondary nucleation adds to the 
complexity of the aggregation pathway and may mean that therapies targeted towards 
primary nucleation processes (the initial formation of oligomers from sporadic 
accumulation of monomers) alone, may be ineffective.  Therapies targeting fibrillar 
assemblies, which stimulate these secondary processes may be required, therefore, for 
efficient inhibition of toxic aggregate formation.   
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1.2.7.4 Accelerating fibril formation 
 
Mature amyloid fibrils are often considered the inert end-point of aggregation, as they have 
been found to be less cytotoxic than their oligomeric precursors172.  This observation has 
led to the investigation of an alternative therapeutic approach, involving acceleration of 
aggregation towards the less toxic fibrils, therefore reducing the population of oligomers.  
Indeed, a peptide able to recognise Aβ and accelerate its aggregation was shown to reduce 
toxicity in vivo214.  Although an interesting concept, there remains substantial evidence that 
fibrils exert toxic mechanisms of their own149, 150, 215 and this should be considered when 
applying this approach in practice.   
 
1.2.7.5 Stimulating aggregate degradation 
 
As discussed in Section 1.2.2, a number of cellular mechanisms are in place to deal with 
misfolding and aggregation.  Enhancing the regulatory processes of degradation systems 
may provide a further, universally applicable therapeutic strategy.  Small molecules are 
currently being developed to enhance cellular chaperone levels and aid clearance of 
aggregates216.  Drugs such as Geldanamycin can enhance chaperone levels216, 217.  
Augmentation of clearance mechanisms, through both autophagy and proteasome 
stimulation, could also be effective strategies, although increasing the turn-over of 
functional proteins could be a major side effect.  Small molecules are under development 
which facilitate specific degradation of toxic misfolded proteins through the endocytic 
pathway218. 
A further possible strategy to encourage amyloid clearance is to inhibit stabilising 
interactions formed between aggregates and accessory molecules.  Glycosaminoglycans 
(GAGs), apolipoproteins and serum amyloid P are a few of several accessory molecules that 
bind and stabilise fibrils37, 170.  Disassembly and clearance of fibrils has been promoted 
through interference of the GAG-amyloid interaction219, although disaggregation to more 
toxic oligomeric species could be an issue if these are not effectively cleared.   
Owing to a lack of understanding of the toxic mechanisms of amyloid diseases, it has been 
difficult to design effective strategies for intervention, despite intense research and the 
numerous promising avenues mentioned above (and summarised in Figure 1.10).  
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Consequently, there is currently a lack of disease-modifying drugs and the available 
therapeutics act only to ameliorate symptoms220.  The search for disease-modifying 
strategies must also be complemented with the development of effective, early-stage 
diagnostics, as evidence suggests the initial stages of aggregation occur decades before 
symptoms arise221.  This suggests that administration of therapeutics when symptoms are 
already apparent may be futile, as extensive and irreversible damage may already be done. 
 
 
 
Figure 1.10 Major therapeutic strategies against protein aggregation.  Prevention of the 
initial production of the amyloidogenic precursor peptide can be achieved by RNA 
interference (i) or through modulation of the processing events that give rise to such 
species (ii).  Stabilisation of the native functional state can be effective in preventing 
unfolding or misfolding (iii).  This can be achieved by upregulation of cellular chaperones 
or via treatment with stabilising small molecules/peptides.  An attractive strategy is the 
inhibition of aggregation from misfolded monomers to potentially toxic oligomeric 
assemblies or fibrils, via β-sheet blockers, antibodies or small molecules (iv).  Conversely, 
promotion of aggregation to inert species (v), with small molecules that accelerate 
elongation, can reduce toxicity.  Protein aggregation can also be prevented by promoting 
degradation with the enhancement of proteostasis regulators (vi). 
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1.3 Alzheimer’s disease and Aβ 
 
1.3.1 Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a debilitating, progressive and incurable neurodegenerative 
disorder, which is characterised by memory loss, severe cognitive impairment and 
eventually death222.  The cognitive decline is accompanied by many behavioural and 
psychological symptoms, including hallucinations, delusions, apathy, anxiety and 
depression223.  The symptoms of AD can differ in severity, yet invariably take a severe 
emotional toll on the patients and their caregivers.  Current estimates indicate that, 
worldwide, more than 45 million people are suffering with AD25, a figure that is increasing 
each year, owing to increased global life expectancy.  The socio-economic burden associated 
with AD, therefore, is vast and the current worldwide cost in estimated to be in excess of 
$604 billion per annum28.  These statistics emphasise an urgent need for advances in the 
effective prevention, treatment and diagnosis of this grave disorder. 
As already mentioned (Section 1.2.6), Alzheimer’s disease is an example of an organ-
specific, neurodegenerative amyloid disorder and involves the aggregation of two major 
precursor proteins224: the amyloid β (Aβ) peptide (Section 1.3.2) which is found in 
extracellular deposits known as amyloid plaques21 and tau, a microtubule-associated 
protein which forms intracellular, neurofibrillary tangles225.  Together, these two amyloid 
assemblies are considered the pathological hallmarks of Alzheimer’s disease226 (Figure 
1.11). 
Tau is a neuronal, microtubule-associated protein, predominantly concentrated in axons227.  
It has several roles in stabilising microtubule structure228, modulating microtubule-
dependent transport of organelles and biomolecules229 and is expected to play a role in 
apoptosis, through stabilisation of apoptotic factors upon phosphorylation230.  However, 
hyperphosphorylation of tau has been implicated in the onset of AD, due to the enhanced 
aggregation propensity of the phosphorylated precursors, and its loss of function228.  As 
work in this thesis targets the assemblies derived from the Aβ component of AD pathology, 
the remainder of this introductory section will focus on this peptide, although it should be 
noted that in the context of developing new therapies for this disorder, both tau and Aβ 
should be recognised as major molecular players228. 
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Figure 1.11 Extracellular amyloid plaques and intracellular neurofibrillary tangles are 
pathological hallmarks of AD.  Post-mortem neuropathological analysis of AD brain.  
Extracellular amyloid deposits, composed primarily of Aβ, are indicated with white arrows.  
Cytoplasmic neurofibrillary tangles, composed of tau aggregates, are indicated by yellow 
arrows.  Figure taken with permission from 168. 
 
1.3.2 The Aβ peptide 
 
Aβ is a 4.5 kDa peptide derived from the sequential enzymatic processing of the amyloid 
precursor protein (APP), via the action of β and γ secretases231.  APP is a large membrane 
spanning protein, which has been found to be expressed across a range of cell types, yet its 
biological function remains largely unknown232.  Within the central nervous system it is 
thought to be associated with cell adhesion, neuronal migration and synaptic 
transmission233-235.  APP processing can proceed via two pathways, one of which is 
amyloidogenic, where Aβ is produced, and the other is non-amyloidogenic (Figure 1.12).  
The non-amyloidogenic route is the predominant pathway, where APP is initially cleaved 
by the α-secretase and subsequently the γ-secretase, resulting in the formation of fragments 
sAPPα, CTFα, AICD and p3.  The cellular functions of these cleavage products are currently 
unclear236.  The alternative, amyloidogenic route proceeds via an initial cleavage by the β-
secretase (BACE1) enzyme, producing a shorter variant of the extracellular domain 
(sAPPβ).  The longer transmembrane domain produced by this cleavage event is then 
further processed by the γ-secretase at various sites, producing Aβ peptides ranging in 
length between 39-43 residues.  The two major forms (Figure 1.13) are produced by 
cleavage at positions 40 and 42.  The resulting Aβ peptides are amphipathic, with a central 
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hydrophobic region known to be critical for amyloid formation237-240.  The peptides also 
consist of a charged N-terminus and a hydrophobic C-terminal domain.  The biological 
functions of the Aβ peptides remain unknown, although it has been proposed that Aβ40 
could be involved in the modulation of synaptic transmission241.   
 
 
 
Figure 1.12 Pathways of APP processing.  The majority of APP is processed via the non-
amyloidogenic pathway (a), with the action of α and γ secretases, producing non-
amyloidogenic peptide fragments sAPPα, p3 and AICD.  Alternatively, APP can be processed 
by cleavage with β and γ-secretases via the amyloidogenic pathway (b) producing the toxic 
Aβ peptide.  Figure redrawn and adapted from 242. 
 
Although Aβ40 is the predominant form of Aβ in the brain, cerebrospinal fluid and serum243, 
Aβ42 is the subject of the most interest in AD pathology as it has higher aggregation 
propensity244, owing to the additional hydrophobic residues Ile41 and Ala42.  Aβ42 has 
been shown to be more toxic to neuronal cells245-247.  The longer variant Aβ43, (with an 
additional Thr at position 43) is often overlooked, but has been reported to occur in equal 
abundance to its more well-known relatives, specifically within the dense plaque cores248.  
It has also been shown to be more amyloidogenic and neurotoxic than the 42 residue 
variant249. 
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Figure 1.13 The amino acid sequences of Aβ40 and Aβ42.  The additional hydrophobic 
residues Ile41 and Ala 42 are highlighted blue.  The central hydrophobic region (residues 
17-21) is highlighted green. 
 
1.3.3 The amyloid cascade hypothesis 
 
The amyloid cascade hypothesis has been central to AD research for more than 20 years and 
posits that the deposition of the Aβ peptide in the brain parenchyma is the critical event 
which ultimately leads to the onset of the disorder250, 251.  Since the discovery of Aβ as the 
major component of AD plaques in the mid 1980s21, substantial evidence has been 
presented to further support the role of Aβ in AD.  The discovery that AD could be inherited 
in an autosomal dominant manner was a seminal event in AD research, as the mutation 
described252 occurred within the gene encoding the Aβ precursor, APP.  Further mutations 
have been found, subsequently, within genes that regulate the processing of APP, namely 
presenillin genes 1 and 2253-255, which code for proteins involved in the regulation of the γ-
secretase cleavage event, leading directly to Aβ production256.  Duplication of chromosome 
21 in individuals with Down’s syndrome, which carries several genes involved in Aβ 
production, including APP itself, is thought to result in the early onset of AD in these 
patients, typically around age 40257.  Further, mutations in genes that encode proteins 
thought to be responsible for efficient Aβ clearance258-261 can reduce the age of disease 
onset.  These mutations all ultimately increase Aβ production, or disrupt the balance 
between production and clearance, and therefore add further credence to the central 
amyloid hypothesis. 
 
1.3.4 Neurotoxic assemblies of Aβ 
 
As with all amyloid forming reactions, a vast number of intermediate structures can be 
populated en route to the final fibrillar aggregates that are deposited in senile plaques in 
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AD.  The nature of the toxic assembly, that which causes the neuronal loss and synaptic 
dysfunction associated with AD, is the subject of much debate in the field1, 24, 126.  
The Aβ peptide itself exists as a natively unstructured monomeric entity, although some 
molecular dynamics (MD) simulations suggest that Aβ42 possesses a more constrained C-
terminus than Aβ40, forming a β hairpin, which may be responsible for this variant’s higher 
propensity to form amyloid262.  Both major Aβ peptides (Aβ40 and Aβ42) are able to form 
an array of higher-order structures, enhanced through various stimuli, including most 
importantly, an increased concentration of the precursor peptide263.  The amyloid forming 
pathways are apparently distinct between Aβ40 and Aβ42 since the dominant oligomeric 
species formed by Aβ42 are larger than those formed from the 40 residue peptide264, 265.   
 
1.3.4.1 Aβ oligomers 
 
A wealth of evidence has been presented to support the hypothesis that it is the soluble, 
non-fibrillar oligomers that lead to synaptic toxicity in AD (reviewed in266) and provides a 
possible explanation for the apparent lack of correlation between amyloid plaque load and 
disease severity267.  Within the lag phase of Aβ amyloid assembly, a large range of species 
from dimers268, trimers269 up to 56 kDa assemblies270-272 have been reported and 
characterised.  Pentamers (5mers), hexamers (6mers), low number oligomers (LNOs), 
globulomers (12mers), annular protofibrils, amylospheroids (APSDs) and Aβ40:42 mixed 
oligomers are further examples of the many species classified123, 142, 273-278.  All of these 
species have displayed inhibition of long-term potentiation (LTP) in hippocampal brain 
slices; the primary experimental model for investigating learning and memory in 
vertebrates, thought to reflect the early cognition defects in patients with AD279.  Of these 
examples, the majority have been shown to bind the A11 antibody and possess a 
predominantly spherical nature.   However, the degree of β-sheet content and whether the 
assemblies exist on- or off-pathway to mature fibrils differs substantially126, 280.  Further 
heterogeneity of Aβ oligomers is derived from the co-aggregation of the full-length peptides 
with multiple Aβ derived fragments273, 281.  It is also especially complicated as Aβ oligomeric 
structures are readily able to interconvert and co-exist126. 
Based on a plethora of in vitro and in vivo experimental data, it is clear that oligomeric 
assemblies of Aβ impart neuronal toxicity and, most likely, play a role in the onset of disease.  
Several oligomeric assemblies have indeed been isolated directly from Alzheimer’s brain 
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tissue238, 277, 282, 283.  However, a lack of a consistent experimental description of the toxic 
entity, as well as the fact that the dynamic and transient nature of these intermediates has 
so far precluded their atomic level characterisation, has hindered the search for the generic 
features responsible for cell death and limits the suitability of the “toxic oligomer” as a drug 
target. 
 
1.3.4.2 Aβ fibrils 
 
Despite the reported lack of correlation between fibrillar plaque density and the severity of 
cognitive impairment267, 284, at least one study supports the opposite conclusion285.  The 
progression from a state of mild cognitive impairment (MCI) to AD has been found to 
correlate with the quantity of brain amyloid286.  Similarly, although asymptomatic elderly 
have been shown to develop plaques, the quantity of the deposits are generally less than 
seen in AD patients287.   
Fibrils of Aβ40 have also been shown to be cytotoxic in vitro97, 103, 215, 288.  A number of 
fibrillar oligomers, expected to share the cross-β architecture of mature fibrils, have also 
been identified and shown to induce cellular defects215, 288, 289.  Aβ fibrils are able to cause 
oxidative damage290 and initiate inflammation291, 292.  Thus, fibrils remain as likely 
contributing agents in AD.  Fibrillar assemblies of Aβ40 and Aβ42 have also been suggested 
as instrumental in the generation of potentially toxic oligomers through secondary 
nucleation mechanisms77, 78, 293, 294 and depolymerisation210 (Section 1.2.3).   
With the recent advances in cryo-EM and ssNMR, several groups have endeavoured to solve 
the structure of the Aβ fibril93, 103-106, 238, 295-299.  As with amyloid fibrils derived from other 
peptide precursors, a large degree of polymorphism is observed for fibrils formed of Aβ40 
and Aβ42, however, the extent to which this is a consequence of differential in vitro 
conditions, rather than a true reflection of polymorphism in disease, remains unclear.  
Crucially, a recent study by Tycko et al. demonstrated the first experimentally derived 
structure of Aβ40 fibrils seeded directly from AD brain tissue106.  They describe ssNMR data 
for fibrils derived from two AD patients presenting different clinical histories and 
remarkably found evidence that each patient possessed a single, predominant fibril 
structure that was morphologically distinct between the two brains.  In addition, the unique 
morphology presented for each patient was consistent throughout several regions of that 
person’s brain.  This work, therefore, is the first indication that unique fibril morphologies 
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could be associated with distinct pathologies.  It also provides compelling evidence for the 
prion-like infectivity mechanism of fibrils116, where the proliferation throughout the brain 
is a direct consequence of fragmentation and spreading from a common, initial fibril 
structure.  Based on these observations and those presented by others107, 113 there is clearly 
merit in studying fibril polymorphism as a general phenomenon. 
 
1.3.4.3 Structural models of the Aβ fibrils 
 
Two in vitro-derived Aβ40 fibrils have been described by Tycko and colleagues that have 
been well defined structurally93, 103-105.  These fibrils serve as a good model of fibril 
polymorphism, by indicating the substantial differences in amyloid structures that can 
result from the assembly of the same precursor peptide, under different aggregation 
conditions.  One morphology is the ‘striated ribbon’ (2A –Figure 1.14 a), which was 
originally formed under agitating conditions103 and exhibits a two-fold molecular symmetry 
as determined by ssNMR.  Electron microscopy discerns no resolvable twist for the 2A 
morphology (constant width = 5.5 ± 0.5 nm) whereas the fibrils formed under quiescent 
conditions (3Q –Figure 1.14 b) display a periodic modulation in width (50-200 nm period, 
12 ± 1 nm maximum width) consistent with a periodic twist.  ssNMR indicates that the latter 
morphology consists of a three-fold molecular symmetry with a central cavity along the axis 
of the fibril.  On the single peptide level, both 2A and 3Q fibrils exhibit an in-register, parallel 
cross-β conformation, with almost identical regions of β-strand, non-β-strand and 
disordered segments, yet with some key differences in quaternary contacts104, 105, 
conformations within the non-β-strand segments (loops) and, of course, the overall 
symmetry.  2A fibrils contain a salt bridge between residues Asp23 and Lys28, which is 
absent in 3Q.  3Q instead displays a partial salt-bridge between Lys16 and Glu22.  In both 
fibril types, the N-terminal residues 1-8 are structurally disordered, a feature consistent 
with other in vitro Aβ fibrils95, 300.  Other key differences in quaternary contacts are 
highlighted in Figure 1.14 c and d.  Interestingly, the two fibril morphologies exhibit 
significantly different toxicities in neuronal cell cultures, with the 3Q fibril being the more 
potent neurotoxin103.  This raises the possibility that some fibril structures may be more 
pathogenic than others, which might lead to the discrepancies found in the correlation of 
disease symptoms and total amyloid deposition, mentioned previously.   
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Of the two brain-derived fibril morphologies (mentioned in Section 1.3.4.2) also identified 
by the Tycko group106, only one was taken forward for full molecular structure 
determination.  This fibril type was seeded from the brain of the patient presenting classic 
AD with possible, additional Lewy body dementia pathology.  It displays the same in-
register, parallel β-strand arrangement as most Aβ fibril models described to date95, 104, 105, 
301, 302, but does not have the same 2A or 3Q structure as formed in vitro (although it 
possesses three-fold symmetry - Figure 1.14 e).  Also, unlike the in vitro models, strong 
NMR signals for the N-terminal residues indicate structural order in these regions.  The 
general strand-bend-strand topology is retained, but involves larger non-β regions and an 
Asp23-Lys28 salt bridge.   
Until recently, the related Aβ42 fibril structure has been poorly defined, despite extensive 
efforts95, 303-307.  The first atomic model of a structurally homogenous Aβ42 fibril299 indicates 
a distinct triple-parallel β-sheet arrangement (Figure 1.14 f), unlike the U-shaped, strand-
bend-strand conformation conserved between almost every Aβ40 fibril modelled to date.  
This S-shaped motif is stabilised by a salt bridge between Lys28 and Ala42, indicating why 
such a structure may not be stable for Aβ40.  Indeed, this Aβ42 fibril morphology was unable 
to template further fibril formation with Aβ40 monomers, suggesting that there may be 
unique pathways of misfolding and amyloid formation by Aβ40 and Aβ42.  Such differences 
in the folding pathway of Aβ40 and Aβ42 are consistent with kinetic studies308, 309 and some 
recent observations of distinct Aβ isoforms in the brains of AD mouse models310.   
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Figure 1.14 Structural models of Aβ fibrils.  In vitro derived fibrils formed from Aβ40 under 
agitating (2A, a) or quiescent (3Q, b) conditions, have been structurally characterised using 
ssNMR by Tycko and colleagues103-105 and display 2-fold and 3-fold molecular symmetries, 
respectively.  Cartoon representations of the models are shown with the unstructured 
residues 1-8 omitted for clarity.  Both fibrils are composed of a strand-turn-strand 
architecture and are shown with the N-terminal β-strand in green and the C-terminal β-
strand in pink.  Loop regions are represented in blue.  The two fibrils present different 
overall morphologies as visualised by TEM.  2A fibrils present a striated ribbon structure, 
whereas 3Q fibrils demonstrate a periodic twist.  TEM images are inset for each.  Key 
quaternary contacts, that differ between the two fibrils are indicated for 2A (c) and 3Q 
(d)106.  (e) The structural model of the in vivo derived Aβ40 fibril differs from the two in 
vitro models formed from the same precursor peptide106.  (f) A cartoon representation of 
the recently elucidated Aβ42 fibril299 with a unique triple, parallel β-sheet arrangement.  
The β-strand containing residues 12-18 are in cyan, 24-33 in yellow and 36-40 in green.  
Short coil or turn regions are in silver and disordered residues 1-10 are omitted.  A unique 
salt bridge between Lys 28 (blue) and Ala42 (red) is indicated.  All fibril models are viewed 
at the fibril cross section, with the axis of the fibril running into the page.  Figures taken and 
adapted from references where indicated. 
INTRODUCTION 
 
34 
 
1.3.5 Current state of therapeutics and diagnostics in AD 
 
Drugs currently approved for the treatment of AD do not prevent, halt or reverse the disease 
and only serve to ameliorate the symptoms172.  These include inhibitors of acetylcholine 
esterase which increases the levels of the neurotransmitter acetylcholine, which is depleted 
in AD brains, leading to an impairment of normal cognition311.  Antagonists of NMDA-type 
glutamate receptors are also used to prevent abnormal neuronal stimulation312.  The impact 
of these drugs, however, is modest and transient.  Development of new, disease-modifying 
therapeutics, thus, is essential in slowing the growing epidemic that is AD. 
 
1.3.5.1 Reducing the production of Aβ 
 
Several therapeutics have been trialled over the last two decades with the aim of decreasing 
the production or enhancing the clearance of Aβ.  Drugs designed to inhibit β or γ- 
secretases have been ineffective so far, owing to difficulties in delivering such molecules 
across the BBB and a lack of specificity of the secretase substrates, resulting in cleavage of 
alternative substrates such as Notch and voltage-gated sodium channel subunits, both 
essential for normal cellular function128.  The γ-secretase inhibitor Semagacestat (Figure 
1.15 a.i.) failed phase III clinical trials due to worsening of disease symptoms173.  A γ-
secretase modulator, Tarenflurbil (Figure 1.15 a.ii.), which was designed to selectively 
lower Aβ42 production, in favour of the shorter and less toxic forms (Aβ37 and Aβ38)313, 
was also ineffective in a phase III trial.  This was ascribed to low potency and brain 
penetration314.  Further studies into Notch-sparing γ-secretase inhibitors and more potent 
γ-secretase modulators are currently ongoing314.   
Inhibition of β-secretase (BACE1) is also under investigation.  However, many compounds 
able to inhibit BACE1 have remained in the pre-clinical phase mainly owing to the same 
major problems encountered for inhibitors of γ-secretase.  The active site of BACE1 is large 
and requires bulky inhibitors that are generally unable to penetrate the BBB.  BACE1 also 
has other important physiological roles that need to be spared during inhibition.  A phase I 
trial of β-secretase inhibitor CTS-21166 indeed demonstrated a reduction in plasma Aβ315, 
but further clinical data into this candidate molecule is yet to become available. 
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Finally, in the same vein, the enhancement of α-secretase activity, the enzyme responsible 
for the non-amyloidogenic processing of APP (Figure 1.12) is another potential strategy in 
reducing Aβ reduction.  Etazolate (Figure 1.15 b), a small molecule agonist for this enzyme, 
inhibits Aβ-induced neuronal death and demonstrated good tolerance and safety in a phase 
II study316 but its clinical efficacy is yet to be confirmed. 
 
 
 
Figure 1.15 Small molecule modulators of the enzymatic processing of Aβ.  Drugs designed 
to inhibit γ-secretase mediated production of Aβ (a) or enhance the alternative non-
amyloidogenic processing of APP with agonists of the α-secretase (b) have shown various 
levels of success in clinical trials. 
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1.3.5.2 Maintaining the balance between production and 
clearance of Aβ 
 
The increase in Aβ production associated with familial AD accounts for only ~5% of all 
instances, with AD occurring sporadically for the majority of patients317.  This majority, 
therefore, do not have increased Aβ production resulting from mutations in the APP 
processing genes, but instead the balance of production and clearance of the aggregation 
precursor is somehow impaired.  Strategies that target Aβ clearance mechanisms, therefore, 
may prove more effective in treating the majority of cases. 
Many pharmaceutical companies have turned to immunotherapy to encourage amyloid 
clearance.  Clearance of aggregates by both active (vaccination) and passive (monoclonal 
antibody) immunisation methods has been shown in animal models and is thought to occur 
by a variety of mechanisms, including direct disassembly of plaques, neutralisation of toxic 
oligomers, activation of phagocytosis and activation of specific-protein efflux processes318.  
Famously, the first active vaccination Phase II clinical trial with human Aβ42 (AN-1792) was 
initiated, after promising results in animal studies demonstrated a clear reduction in 
amyloid burden in mice319-321 and no adverse effects during Phase I testing.  Unfortunately, 
the trial was aborted in 2002 after an apparent activation of immune responses led to 
meningoencephalitis in a number of patients322.  This study highlights the dangers of 
aberrant immune-response activation in antibody based therapies.   
There are a number of Aβ-directed immunotherapies in clinical development that involve 
passive immunisation with antibodies directed against various forms of Aβ (reviewed in323, 
324).  These are all based on non-selective antibodies that are able to bind multiple Aβ 
species, ranging from monomer to mature fibrillar aggregates323.  The fact that antibodies 
used are generally not specific for a single amyloid species could constitute a major 
drawback in the development of potent immunotherapies.  If indeed the route to successful 
clearance was through specific targeting of oligomeric assemblies, for example, use of a non-
selective Aβ antibody (that also binds monomers and fibrils) would most likely show low 
efficacy.  This would be due to the extent of competition for antibody epitopes by the 
monomers and fibrils, which may not be the desired target but exist in higher 
concentrations in the AD brain250, 325, 326).  This problem would also be further exacerbated 
by the low levels of antibodies that are able to penetrate the brain327.  Nevertheless, passive 
immunisation trials have been conducted with moderate effects observed for a subset of 
patients.  Bapineuzumab is a humanised, monoclonal antibody directed towards the N-
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terminal domain (residues 1-5) of Aβ and recognises both soluble and aggregated Aβ in 
mice.  It displayed no significant positive effects in a phase II trial and induced serious side 
effects in some participants.  However, the antibody was able to produce significant benefits 
in a subset of patients who did not carry the apolipoprotein E ε4 allele (a genetic risk factor 
for late-onset sporadic AD) and therefore was approved for Phase III trials for the specific 
treatment of this patient group318.  Solanezumab, a monoclonal antibody directed against 
the mid domain (residues 16-24) of Aβ, failed clinical trials in 2012, due to an apparent lack 
of potency.  However, secondary analysis of the data indicated that the antibody may have 
been effective in slowing the cognitive decline in patients within the early stages of AD and 
therefore entered Phase III trials, the results of which are expected by late 2016324.  If 
successful, solanezumab may represent the first disease-modifying drug for AD.   
 
1.3.5.3 Preventing Aβ aggregation 
 
One of the most attractive therapeutic strategies for all amyloid disorders, including AD, is 
the stabilisation of the native monomeric structure and prevention of aggregation (Sections 
1.2.7.2 and 1.2.7.3).  Despite extensive efforts in the development of small molecule and 
peptide-based aggregation inhibitors, and the promising results seen both in vitro and in 
animal models, only one Aβ aggregation inhibitor has reached Phase III clinical trials.  
Tramiprosate is an ionic small molecule which binds to soluble Aβ and maintains its random 
coil conformation, inhibiting aggregation and reducing plaque burden in mice models328.  
The compounds inhibitory effects are thought to be, in part, due to an interference of the 
ability of Aβ to bind glycosaminoglycans (GAGs), which promote fibrillation329.  Results of 
the trial, however, were disappointing and were eventually discontinued, although recent 
data suggest that tramiprosate may promote the formation of tau inclusions330 and highlight 
the importance of testing potential drugs on both AD pathologies. 
Two further Aβ aggregation inhibitors under clinical review are Colostrinin331, a mixture of 
proline-rich polypeptides (25% proline residues) isolated from ovine colostrum, that 
inhibit aggregation, and scyllo-inositol which stabilises non-toxic oligomers of Aβ40332.  
Both molecules produced beneficial effects in cellular and mouse models of AD, but 
demonstrated limited efficacy in Phase II trials314, 331.  In addition, as metal ions such as Zn2+ 
and Cu2+ are known to be involved in Aβ amyloidosis333, 334, metal ion chelators have shown 
inhibitory effects both in vitro and in vivo335.  A number of metal protein attenuating 
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compounds, therefore, have been taken to clinical trials but are yet to show significant 
effects to confirm the validity of this approach336, 337.   
 
 
 
Figure 1.16 Examples of small molecules shown to inhibit Aβ aggregation in clinical trials.  
(a) Tramiprosate has been shown to bind and maintain Aβ in a random coil conformation.  
(b) Scyllo-Inositol stabilises a non-toxic oligomer of Aβ40.  Both molecules inhibit 
aggregation and show beneficial effects in AD mouse models but demonstrated limited 
efficacy in human clinical trials. 
 
1.3.5.4 Alternative strategies 
 
A number of therapeutic approaches that are not directly linked to Aβ aggregation are also 
being investigated.  These include modulators of tau phosphorylation, aggregation and 
degradation227, anti-inflammatory drugs338, anti-oxidants339 and hormone therapies340.  In 
addition, some strategies to target synaptic dysfunction341-343 and autophagy344 directly are 
also in development.  However, so far no effective treatment has emerged from these efforts.  
Owing to the clear complexity of mechanisms contributing to AD pathology, it is likely that 
a combination of therapies will be required to effectively combat the disorder and, 
therefore, continued efforts into the development of new and innovative approaches is of 
paramount importance. 
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1.3.5.5 Diagnostics  
 
Clinical diagnosis of AD is currently made using a combination of physical and neurological 
examinations, assessment of a patient’s medical history, neuropsycological examination, 
neuroimaging and laboratory tests, with an accuracy of ~90%345.  However, to date, 
definitive diagnosis can only be made post-mortem.  The pathogenic process of AD is 
believed to begin decades before clinical onset of the disorder171, with gradual neuronal loss 
in this prodromal phase.  As proposed therapeutic strategies are likely to be most effective 
if administered before pathological changes spread throughout the brain, early diagnosis 
with reliable biomarkers is essential.  In addition, more sensitive and specific imaging 
reagents might allow for earlier identification of people at risk of developing the disease 
and potentially distinguish between classic AD, mild cognitive impairment or other 
dementia types346 and help tailor appropriate treatment options. 
Currently, there are two principle AD amyloid biomarkers: amyloid positron emission 
tomography (PET) which measures the amount of Aβ aggregates in the brain parenchyma, 
and biochemical analysis of Aβ42 levels in the cerebrospinal fluid (CSF) (along with the 
detection of tau and phosphorylated tau347).  The former requires the use of a 11C-labelled 
modified derivative of Thioflavin T, known as Pittsburgh Compound B (PiB), which 
preferentially binds aggregated Aβ in dense plaques.  It is, however, less sensitive to diffuse 
plaques and amorphous aggregates containing less β-sheet structure, as assessed in post-
mortem studies348-350.  This may suggest that the compound is insensitive to some 
prefibrillar deposits that may indicate an early disease pathology.  Some additional 18F-
labelled amyloid ligands have also been developed351-354 with similar amyloid retention as 
PiB.  In AD, CSF levels of Aβ42 decrease to ~50% of the levels in aged-matched control 
individuals355 due to aggregation of the peptide in the brain356.  Together the inverse 
relationship between CSF Aβ42 and PiB binding leads to a relatively high diagnostic 
performance for AD357.  One suggestion to further improve diagnostic accuracy is the 
measurement of the decrease in Aβ42:Aβ40 ratio as it is proposed to have a more marked 
reduction than Aβ42 alone358.  Although the diagnostic value of these two methods is clear 
in established AD, current recommendations for diagnostic research criteria359 put far 
greater emphasis on defining the pre-clinical states of AD and the development of sensitive 
biomarkers and imaging reagents that might allow the advancement of preventative 
therapies. 
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1.4 RNA aptamers 
 
The discovery that RNA is not merely a carrier of genetic information, but a molecule 
capable of a vast number of biological applications, not only reinforces the idea of an RNA-
based primordial world, but also indicates the great potential of RNA sequences as research 
tools, diagnostic reagents or therapeutics360-364.  RNA has been shown to possess catalytic 
properties, in ribosomes and other ribozymes365-368, and is also capable of forming complex 
three-dimensional structures, which mediate binding and molecular recognition.  Aptamers 
are small nucleic acid ligands which adopt a functional secondary structure.  The term was 
originally derived from the Latin ‘aptus’, meaning ‘fitting’, as these short, chemically 
synthesised oligonucleotides are able to fold into an array of structures that demonstrate 
specific target recognition, with dissociation constants often in the pico- to nanomolar 
range361.  Owing to the breadth of possible structures available to oligonucleotides, it has 
been postulated that there is probably an RNA molecule with the ability to bind any 
biological target369.  Their remarkable molecular recognition properties also mean that RNA 
aptamers are often directly compared with the ability of antibodies to recognise specific 
ligands.  However, RNA aptamers demonstrate a number of advantages over antibodies, 
including simple chemical synthesis, reduced size, and limited immunogenicity362.  
Aptamers have already demonstrated their potential in a wide range of biological 
applications, from biotechnology to therapy360, 361, 363, yet the commercial exploitation of 
such molecules has lagged behind other research areas (partly due to the issue of patents 
on aptamer technologies370, 371).  Finally, more than two decades after their initial 
conception369, 372, 373, aptamers are emerging as promising research tools.   
 
1.4.1 Early development and SELEX 
 
In the early 1990s, Szostak and Ellington pioneered the in vitro selection method that was 
first used to isolate specific binding aptamers for small organic dyes369.  Two further 
groups372, 373 also worked towards methods of synthesising large numbers of random 
sequence RNA, selecting out and amplifying those sequences with high affinity to a target of 
interest.  The Joyce group used in vitro mutation, selection and amplification methods to 
isolate RNA oligonucleotides able to cleave DNA372.  The Gold group used rounds of selection 
and amplification to identify sequences required for binding T4 DNA polymerase, and 
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subsequently coined the term SELEX; Systemic Evolution of Ligands by Exponential 
Enrichment373. The process essentially works as a paradigm of Darwinian evolution (Figure 
1.17).  In vitro selection experiments can be carried out with double stranded DNA (dsDNA), 
single stranded DNA (ssDNA) or RNA, as well as synthetic nucleic-acid-like polymers 
(termed xeno-nucleic acids, XNA)374.  In the remainder of this thesis, the term aptamer will 
refer to selected RNA molecules, unless otherwise stated. 
The SELEX procedure has remained largely unaltered since its conception, but various 
improvements and optimisation over the years means that the process is now highly 
efficient and extensively automated375, 376.  The procedure begins with the generation of a 
random nucleic acid pool, which can be readily amplified (and transcribed in the case of 
RNA) and be able to form an array of diverse structures.  Therefore, the first requirement is 
the design of a degenerate DNA library, containing a random region to generate structural 
diversity, and two fixed flanking regions to allow primer-based amplification (Figure 1.17 
a).  The 5ʹ region must also encompass a T7 RNA polymerase promoter sequence to allow 
in vitro transcription in the case of RNA aptamer selection.  A key consideration is the length 
of the random region.  The sequence space available within a nucleic acid library is 4N 
(where N is the length of the random region).  In a typical in vitro selection experiment, the 
maximum number of molecules that can be handled is ~ 1015 (ref 377).  Therefore a library 
with a random region of only 24 nucleotides is required to achieve this.  However, in order 
to promote the RNA molecule’s folding into functional conformations, the random region 
may need to be longer than this and libraries are typically 30-60 nucleotides in length377.  
This presents a problem in that only a fraction of the potential sequence space is available 
in these experiments, however this is circumvented to some extent by the lack of proof 
reading functionality in the enzymes used for PCR amplification, transcription and reverse-
transcription (RT-PCR), that means sequences not initially represented in the naïve pool 
may arise via mutation in the later rounds377. 
Once the initial pool is designed and synthesised, it is incubated with the target entity and 
sequences which bind are isolated and amplified.  Partitioning of the bound species can be 
conducted in a variety of ways, with use of nitrocellulose filters, separation on various 
support matrices (such as magnetic beads or agarose/silica resins) or via column 
chromatography360.  High affinity aptamers have also been isolated using Surface plasmon 
resonance (SPR) to isolate sequences with the slowest off-rates378, 379, and capillary 
electrophoresis has also been used380.  Bound species are then eluted and amplified to give 
an enriched pool of molecules for further iterations of the protocol.  Typical numbers of 
SELEX rounds are between 10 and 20(ref 360) although high-affinity sequences have been 
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shown to be isolated from a single round of in vitro selection381, 382.  The resultant enriched 
pool is then sequenced to allow identification of conserved motifs that exhibit high affinity 
interactions with the target.   
 
1.4.2 Modifications and technical innovations 
 
Major technical improvements in selection technologies have emerged since the earliest 
aptamers were developed, including significant reduction in the time taken for high affinity 
species to be isolated.  The Ellington group were first to automate the SELEX process376, 383 
such that it is now possible to isolate high affinity aptamers in a matter of days, when 
previously it could take several months383.   
Polynucleotides are susceptible to degradation via nucleases, and to a lesser extent, 
chemical or physical factors384.  Therefore, a key area of improvement in aptamer 
technologies has involved enhancement of aptamer biostability, with a series of chemical 
modifications designed to stabilise the molecules and extend their lifetime in vivo (Figure 
1.18).  Although highly dependent on sequence and structure, it is generally the case that 
RNA is degraded in seconds, and DNA within minutes, via blood-borne nucleases384.  
Substitutions made at the 2′-position of pyrimidines are effective at reducing degradation 
rates385, 386 and therefore introduction of 2ʹ-fluoro (2ʹF), 2ʹ-amino and 2ʹ-O-methyl 
pyrimidines is a method commonly used to increase the stability of aptamers384, 387-395.  The 
use of 4ʹ thio pyrimidines has also been reported396, as well as a number of modifications to 
the C5 position of pyrimidines397-402.  Another stabilising modification frequently used in 
selections is the substitution of the internucleotide phosphodiester linkage with a 
phosphorothioate403-405.  Since these chemical substitutions might alter the structure 
compared with wild-type aptamers, selections are performed with libraries synthesised 
from modified nucleotides, a method that was made possible through the advent of mutant 
polymerases that allow the incorporation of these bulkier substrates during enzymatic 
steps406, 407.  A further, elegant approach to generate nuclease-resistant aptamers is through 
the use of L-ribose based nucleotides, to generate biostable “spiegelmers”408.  As nucleases 
are faithfully stereospecific409, they confer effective resistance.  However, because RNA 
polymerases will not function with enantiomers of the natural D-ribose, the protocol 
requires selection against an enantiomeric target molecule.  Synthetic preparation of a 
speiglemer to match the selected aptamer is then able to bind the original, wild-type target 
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of interest and display identical properties408.  The major limitation with this approach is 
that it is only applicable to smaller targets.   
 
 
 
Figure 1.17 Schematic overview of the SELEX protocol.  (a) A degenerate nucleic acid 
library is designed with a central random stretch of nucleotides, flanked by two constant 
primer regions for PCR amplification.  The 5ʹ primer region contains a T7 RNA polymerase 
promoter sequence to allow in vitro transcription of the degenerate pool in the case of RNA 
aptamer selection.  (b) Basic outline of a single SELEX round.  The naïve nucleic acid pool is 
incubated with the target molecule (i) which are then partitioned (ii) to remove lower 
affinity species (iii).  Bound species are then eluted (iv) and amplified (v) for further 
iterations of the protocol.  Typically 10-20 rounds are performed before sequencing of the 
enriched library and aptamer characterisation.  Figure redrawn and adapted from360. 
INTRODUCTION 
 
44 
 
 
 
 
Figure 1.18 Aptamer modificiations.  Structure of an RNA oligonucleotide with the sites of 
common modifications used to increase nuclease resistence, indicated.   
 
Bioavailability is another key problem that has required optimisation, in order to establish 
aptamer technologies as suitable as in vivo diagnostic or therapeutic tools.  The 
susceptibility of small polynucleotides towards rapid renal clearance can be avoided with 
chemical modifications to increase their size, including the attachment of polyethylene-
glycol (PEG)393, 410-413, cholesterol414, biotin-streptavidin415 or lipoproteins416, all of which 
have been demonstrated.  Unconjugated aptamers have been shown to clear from the mouse 
circulatory system within 5-10 minutes, whereas PEG-aptamer conjugates have shown 
circulatory retention up to 24 h387.   
Innovations in the SELEX protocol have also enabled improvements in aptamer specificities 
and isolation of aptamers with specific properties, thereby expanding the repertoire of 
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aptamer functions.  Toggle-SELEX introduces related targets through alternating cycles, to 
broaden the range of specificities between species417, 418.  Photo-SELEX has been shown to 
improve binding affinities by UV-induced crosslinking of light sensitive nucleotides419 and 
tailored-SELEX can be implemented to create shorter aptamer sequences using ligation and 
cleavage of primers, before and after amplification.  The latter methodology is 
advantageous, as shorter aptamers are more amenable to chemical synthesis and therefore 
more applicable in various downstream applications, owing to the reduced cost of 
production420.  Using traditional SELEX methodology, aptamers are typically >80 
nucleotides long377 and require further processing to be suitable for large-scale production.  
This is usually achieved by identification of the minimal sequence required for recognition, 
post-selection, and validation that the aptamer “fragment” retains its function.  Recently, 
selections have been carried out using living cells, termed cell-SELEX421.  This method 
involves selection of aptamers against cell surface biomarkers, avoiding the need for 
purification of targets or even prior knowledge into the identity of the biomarker.  Counter 
selection with control cells that do not express the target biomarker allows specific ligands 
to become enriched.   
 
1.4.3 Applications of aptamer technologies 
 
1.4.3.1 Therapeutics 
 
Aptamers possess many features that make them suitable candidates for use in the clinic.  
They are able to form tight and specific interactions with theoretically any target, therefore 
they are likely to work via antagonistic mechanisms, through interactions with cellular 
proteins and subsequent disruption of native protein-protein interactions or other 
functions.  Indeed, many aptamers selected to bind specific proteins have been shown to 
inhibit their function422-427. For an aptamer to be an effective antagonist, high specificity and 
affinity are required to maintain a prolonged interaction, as well as a long half-life in the 
relevant biological compartment.  The variety of potential modifications mentioned in 
Section 1.4.2, are in place to fulfil these criteria and produce aptamers with great 
therapeutic potential.  Aptamers have also been found to display agonist-like activity.  For 
example, aptamers selected against the human epidermal growth factor receptor 3 (HER3), 
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a type I receptor tyrosine kinase, were shown to promote oligomerisation of the receptors, 
leading to inhibition of phosphorylation428.   
 
1.4.3.1.1 Aptamer delivery 
 
Therapeutic targets can be divided into two classes; intracellular and extracellular.  
Aptamers directed against extracellular targets could be simply administered intravenously 
or subcutaneously, with pharmacokinetic data suggesting that RNA delivered via these 
routes is readily distributed to target cells429.  Although aptamer degradation and clearance 
is inevitable, repeat administration could be feasible until treatment is complete.  Targeting 
of oligonucleotides to specific cell types has been shown via a number of methods including 
modification with cholesterol to mediate association with low-density lipoproteins and 
delivery to the liver414.  Tagging aptamers directly with lipoproteins, specific to other cell 
types, is another attractive strategy430.   
If the aptamer target is intracellular, delivery across the membrane is a further 
consideration and potential challenge.  The negative charge of oligonucleotides means that 
they do not readily cross the anionic cell membranes431.  However, a number of options are 
available, including liposome vesicle transport and the use of viral vectors427, 432, 433.  Indeed, 
aptamers themselves have been used to facilitate delivery of siRNA for RNA interference, 
through conjugation of aptamer sequences specific for certain cell-surface receptors431, 434, 
435.  Viral vector systems can also be utilised in delivering sequences to be endogenously 
produced within the cell of interest, termed “intramers”432.  The technique works by 
transfection of cells with a retroviral vector that encodes the aptamer sequence, leading to 
long-term expression of the aptamer in situ.   
 
1.4.3.1.2 Aptamers vs. antibodies 
 
Aptamers can be thought of much in the same way as monoclonal antibodies; owing to the 
similarities in affinity and specificities achievable by aptamers and antibodies, the two 
recognition molecules are often directly compared361.  Antibodies are undoubtedly one of 
the most useful reagents in both therapeutics and research, with four of the top ten 
biopharmaceuticals being monoclonal antibodies, worth more than $24 billion in US sales 
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alone436.  They do, however, have several limitations, where aptamers could provide a safer 
and more convenient alternative361.  Firstly, unlike the traditional methods of antibody 
production, no organisms are required for the simple, in vitro selection of oligonucleotide 
aptamers.  Once a single, functional aptamer sequence has been isolated and optimised for 
clinical use, aptamers can be produced chemically in a readily scalable process.  On the other 
hand, antibodies are produced biologically in a process that is more difficult to scale-up 
without adverse effects to the products’ characteristics and where viral or bacterial 
contamination can effect product quality361.  
One of the major advantages of nucleic acid technologies, over antibodies as therapeutics, 
is that RNA elicits no immunogenic response, which has been shown to limit the suitability 
of immunotherapy in some instances, through the emergence of unwanted side effects, such 
as inflammation437.  There has been no evidence of antibodies being generated in response 
to synthetic nucleotides362, nor problems arising from an innate immune response, that has 
previously been associated with recognition of viral RNAs438, 439.  Any possibility of these 
issues occurring is eliminated in aptamer therapy via modifications to 2ʹ nucleotides, which 
have been shown to abolish any Toll-like Receptor responses440.   
Aptamers are generally much smaller than antibodies (Figure 1.19), which is advantageous 
due to their increased availability to biological compartments and efficiency of entry384.  It 
also means that aptamers are often able to target molecules that might be otherwise 
inaccessible to antibodies, owing to steric hindrance364.  An example of this was seen when 
researchers attempted to target the interaction between HIV-1 viral coat protein gp120 and 
the host cell receptor CD4 and its associated co-receptor CCR5, which are hijacked during 
viral entry441, 442.  The CCR5 binding site on gp120 was shown to be inaccessible to 
antibodies, due to occlusion by an adjacent hypervariable region441.  However, an RNA 
aptamer specific for the co-receptor binding region was able to access the obscured epitope 
and neutralise infectivity442, 443.  This further indicates that aptamers could demonstrate a 
wider range of functionalities than antibodies.  In addition, some methods of antibody 
development are limited in the ability to use negative selection pressure, which is simple to 
incorporate during in vitro selection of aptamers.  This could mean that aptamers have the 
potential to be more selective than antibodies.  They can also be used in instances where a 
target is unavailable to antibodies, owing to problems with expression in a functional, 
recombinant form, such as cell-surface receptors.  Development of aptamer technologies, to 
extend or improve the work of antibodies, therefore, is an exciting prospect that may 
advance areas of research where antibodies have previously failed. 
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Figure 1.19 A comparison of aptamer and antibody size.  Space filling models depicting the 
estimated sizes of an antibody (human IgG) compared to a 17 residue anti-thrombin DNA 
aptamer397.  Figure taken with permission from 364. 
 
1.4.3.1.3 Aptamers in the clinic 
 
In 2004 the first RNA aptamer-based drug was approved for use by the Food and Drug 
administration (FDA), to treat age-related macular degeneration (AMD), the major cause of 
blindness and visual impairment in the elderly444.  Pegaptanib, known commercially as 
Macugen™, is an RNA oligonucleotide which works to inhibit binding of VEGF165 to its 
receptor and therefore antagonises its pro-angiogenic effects.  This RNA aptamer was 
initially selected from a 2ʹF pyrimidine library with a 30 nucleotide random region (N30)410 
(78 nucleotide total length) and truncated to 27 nucleotides to decrease synthesis costs 
(Figure 1.20).  The 2ʹ-ribo purines were replaced with 2ʹ-O-methyl modified purine to 
increase nuclease resistance, a 3ʹ terminal cap (3'-3'-linked deoxythymidine) to reduce 3ʹ-
exonuclease-mediated degradation and a 5ʹ linked 40 kDa PEG moiety, which increases the 
inhibition of VEGF function in mouse models, probably through prolonged tissue residence 
and plasma half-life410.  Pegaptinib is administered once every 6 weeks and works to 
ameliorate the loss of vision that results from aberrant angiogenesis in AMD445.   
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Figure 1.20 Sequence and predicted secondary structure of Pegaptinib.  2ʹ-O-methyl 
modified purines are highlighted red and 2ʹF modified pyrimidines are highlighted blue.  
Unmodified ribonucleotides are shown in black.  The position of the 5ʹ 40 kDa PEG moiety 
and the 3ʹ terminal cap are indicated.  Figure taken from 393. 
 
Currently, several other aptamer based therapeutics are in the process of clinical evaluation, 
targeting proteins involved in disorders including several cancers, type II diabetes and 
pathologies associated with blood clotting dysfunction and stroke (reviewed in 361, 446, 447 
Table 1.2).  Aptamer technologies are also becoming a popular methodology in anti-viral 
intervention and, although an anti-viral aptamer has yet to be approved for clinical trials, it 
is an active area of research (reviewed in 448).  The host-viral interface is an increasingly 
popular aptamer target as nucleic acid-protein interactions are critical to viral replication.  
Therefore, the plethora of protein targets which already possess nucleic acid binding 
properties (for example, the presence of basic residues), are likely to be suitable targets for 
nucleic acid ligands.  Consequently, aptamers have been selected to target a number of viral 
proteins involved in several stages of the viral replication cycle, including viral entry443, 449  
and replication450, 451.  Overall, although aptamer therapies are in their infancy in 
comparison to immunotherapeutic approaches, their versatile and adaptable technologies 
suggest aptamers have great potential to become attractive tools in the clinic. 
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Aptamer name 
(Company) 
Condition targeted Current status 
Pegaptanib/ Macugen™ 
(Pfizer/Eyetech) 
Age-related macular 
degeneration (AMD) 
Approved in the US and EU 
E10030 (Ophthotech) 
Age-related macular 
degeneration (AMD) 
Awaiting Phase III 
ARC1905 (Ophthotech) 
Age-related macular 
degeneration (AMD) 
Phase I 
RB006 (Regardo 
Biosciences) 
Coronary artery disease Awaiting Phase III 
ARC1779 (Archimex) Von Willebrand’s disease Awaiting Phase III 
NU172 (Nuvelo/ARCA 
Biopharma) 
Coronary artery disease Phase II 
ARC19499 (Archimex) Haemophilia 
Phase I/II (status 
uncertain) 
AS1411 (Antisoma) 
Renal cell carcinoma/non-
small cell lung cancer 
Awaiting Phase III 
NOX-A12 (Noxxon Pharma) Tumour Phase II 
NOX-E36 (Noxxon Pharma) Type II diabetes Phase IIa 
Table 1.2 Current status of aptamers undergoing clinical trials.  Table reproduced and 
adapted from 447.   
 
1.4.3.2 Diagnostics and biosensors 
 
The versatility of nucleic acid aptamer technologies has meant that aptamers are beginning 
to play increasingly important roles in a range of diagnostic applications, from disease 
diagnosis via imaging, detection of diseased cells in tissues and serum and in the discovery 
of novel biomarkers452-454.  Aptamers have also been shown to function as sensors in 
environmental and food analyses, and even in the detection of biological terrorism threat 
agents455. 
The high affinity and specificity achievable with aptamers make them ideal diagnostic 
reagents.  The simple chemistries involved in conjugating dyes or functional groups to allow 
detection is also an advantageous feature of aptamers.  For example, fluorescently-labelled 
nucleotides could be incorporated for confocal microscopy or 2-photon imaging, Cy5-
tagged nucleotides for near infrared imaging, as well as 18F or 19F labelling for PET and MRI 
approaches, respectively.  Importantly, aptamers are also rapidly cleared from the 
bloodstream, leading to sensitive detection with high target to background ratios452.  As 
mentioned for therapeutic applications, modifications be can optimised for better 
biodistribution and clearance.   
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Development of aptamers as imaging reagents has been especially successful in cancer 
research456-460 but other disease processes have also been studied461-463.  Imaging tumours 
via selective delivery of radionucleotides has been demonstrated464, which is particularly 
useful, as residual radioactive aptamers are rapidly cleared and excreted, avoiding toxicity 
to normal tissues that has been shown to result from the slow clearance of radioactive 
antibodies464.  Aptamers conjugated to contrast reagents for magnetic resonance imaging 
(MRI) have also been developed for specific tumour detection459 as well as activatable 
fluorescent aptamers465 and quantum dot conjugates460.  Fluorescence-based imaging 
reagents are especially versatile, as ligand-induced conformational changes can be 
exploited to induce fluorescence resonance energy transfer (FRET), differential fluorescent 
dye binding or quenching360.  A recent report of an activatable aptamer imaging probe that 
targets a membrane protein on the surface of human leukemic cells465 is especially 
innovative in that the optical signal is quenched in the unbound state, but upon ligand 
binding, a conformational rearrangement in the aptamer dissociates the quencher from the 
fluorophore.  With the development of automated high-throughput isolation of aptamers 
and the relative simplicity in chemical modifications that allow sensitive detection, large 
scale diagnostic arrays should be feasible with these reagents466. 
In addition to a role as imaging reagents, aptamers could also be used to aid clinical 
diagnosis, through both detection of known biomarkers and discovery of new ones452.  
Aptamers have already become a useful tool in detecting diseased cells in tissue sections 
and even in trace amounts in the bloodstream.  For example, an RNA aptamer that targets 
the cell-surface epidermal growth factor receptor (EGFR), which is upregulated in a number 
of cancers467, has been used to quantitate the number of diseased cells in the serum by 
capture on a surface468.  Coupling fluorescently labelled aptamers with flow cytometry has 
also been used to detect a variety of cancer cells from mixed cells in media469, 470 and with 
some optimisation could be extended to detection in ex vivo samples.  The success so far 
achieved in imaging and biomarker detection by aptamers for cancer targets is encouraging, 
but is yet to be extended to many other disease processes.  However, the clear advantages 
of aptamer technologies over antibodies and other traditional diagnostic reagents, should 
mean that aptamers could become valuable tools for clinicians in a wide range of 
applications.   
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1.4.3.3 Research tools 
 
In addition to therapeutic and diagnostic applications, aptamers can be used as analytical 
tools and laboratory reagents in a number of biochemical or cell-based assays, much like 
antibodies.  Their key advantages over antibodies could again lead to greater, more specific 
detection abilities, with broader applications360.  By utilising aptamers that disrupt protein 
interactions, it would be possible to dissect and characterise cellular pathways.  The 
exquisite recognition capabilities of aptamers could also be used to probe specific protein 
structures, involved in various disease processes. 
Another obvious use for these highly specific and high affinity molecules as a laboratory 
reagent is as an affinity purification medium.  Several examples of the use of aptamers in a 
laboratory setting already exist471-474, one notable example being the use of an anti-selectin 
aptamer to purify a selectin-receptor protein directly from Chinese hamster ovary cells471.  
This methodology is said to achieve 15,000 fold purification in a single step.  Aptamers, 
therefore, could provide major advantages in these applications, owing to the high level of 
discrimination demonstrated between closely related species.  Indeed, an aptamer 
purification method was employed to isolate D-arginine-vasopressin from its L-enantiomer, 
which was shown not to associate to the aptamer-derivatised medium472.  Also, tag-cleavage 
steps are not required for these single step methods leading to potentially greater product 
recovery360. 
In summary, aptamer technologies have already demonstrated enormous potential in a 
variety of applications.  Although these tools are gaining momentum in some research fields, 
namely cancer research and virology, they have been slow to emerge in other areas.  With 
recent technological innovations, including rapid and stringent selection strategies, the 
future for aptamer research is bright, and these promising reagents should finally begin to 
take their place in the clinical and research arenas.   
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1.4.4 Examples of RNA aptamers in amyloid disorders 
 
1.4.4.1 Anti-prion aptamers 
 
Prion protein (PrP) is the causative agent in a range of protein aggregation disorders, such 
as Creutzfeldt-Jakob Disease (CJD) in humans, Bovine Spongiform Encephalopathy (BSE) in 
cattle and Scrapie in sheep475.  The conversion of the normal cellular prion protein (PrPC), a 
predominantly α-helical isoform, to an abnormal β-sheet rich amyloidogenic variant (PrPSc), 
is thought to lead to the pathogenesis of these disorders.  Selections against various 
assemblies of PrP represent some of the most successful cases of anti-amyloid aptamers.  In 
one example, Rhie et al.476 demonstrated selection of 2ʹF-pyrimidine-modified RNA 
aptamers (116 nucleotides total length, with an N60 randomised region) against purified, 
scrapie associated fibrils (SAF) isolated from hamster brain; a preparation therefore 
containing a range of PrP conformations associated with infectivity.  The lead aptamer, SAF-
93 (Figure 1.21 a.i.), was shown to bind to SAF with high affinity (dissociation constant (kd) 
= 23.4 ± 1.2 nM) and cross-reacted with a related, β-sheet rich oligomeric assembly, 
indicating recognition of a consistent epitope conserved between the amyloid forms.  In 
contrast, the relative affinity of the RNA for the α-helical form (PrPC) was much reduced (10-
fold higher Kd).  This finding was explained through the identification of two distinct RNA 
binding sites between the PrP isoforms.  These included a non-specific RNA binding site in 
the unstructured N-terminus, which also encompassed a “hinge-region” (residues 90-110) 
which is occluded in the α-form.  The aptamer was also shown to inhibit the accumulation 
of the proteinase K resistant β-sheet rich assemblies (PrPres).  Later work by the group477 
built on these original findings by determining the minimum structural elements required 
to maintain aptamer recognition and specificity to the β-rich variants (Figure 1.21 a.ii.); 
identifying regions that were amenable to modification, without loss of function, and 
thereby facilitating the design of modified aptamers, more amenable to a range of 
downstream applications.  Together, the work highlights the many potential uses for 
aptamers in amyloid systems, from their ability to avidly and specifically bind a range of 
amyloid assemblies, their inhibitory potential and their utility in probing conformational 
differences between amyloid structures.   
Other examples of anti-prion aptamers mainly target the helical isoform391, 478, 479.  In one 
such example391 2ʹF-amino-pyrimidine-modified aptamers were raised, from an N40 
library, against a short fragment of full-length PrP (residues 90-141) which is thought to be 
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involved in the conversion from PrPC to PrPSc 191, 480, 481.  Binding studies of the isolated 
sequence, aptamer DP7 (Figure 1.21 b), indicated an ability to bind to full-length 
recombinant PrP and inhibit PrPSc formation in a prion-infected cell line.  
 
 
 
Figure 1.21 Examples of anti-prion (PrP) aptamers.  (a) Predicted secondary structures of 
aptamer SAF-93 determined with the Mfold structure prediction algorithm, constrained 
with information from structure-sensitive nuclease digestion.  (a. ii) Predicted secondary 
structure of the 60-residue truncation product from SAF-93, named SAF-93(1-60).  Figures 
adapted from Sayer et al.477.  (b) The proposed secondary structure of aptamer DP7.  Figure 
adapted from391. 
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1.4.4.2 β2-microglobulin aptamers 
 
β2-microglobulin (β2m) is the amyloidogenic protein associated with Dialysis-related 
amyloidosis (DRA), a disorder in which aberrant aggregation of this folded monomer leads 
to the accumulation of fibrillar deposits in the joints of patients undergoing long-term 
haemodialysis482.  Bunka et al.483 demonstrated RNA aptamers able to recognise a range of 
β2m fibrils of distinct structural morphologies (long-straight (LS), worm-like (WL) and rod-
like (RL) Figure 1.22 a), as well as the monomeric precursor, indicating the conservation 
of a structural epitope between the assemblies.  The aptamers, which were raised from an 
N60 randomised RNA library with no modifications (predicted secondary structure of WL-
2, an anti-WL fibril aptamer shown in Figure 1.22 b), were also shown to cross-react with 
fibrils from other amyloidogenic precursors, including ex vivo assemblies of β2m and 
lysozyme, isolated from patients with the respective amyloidoses.  The work supports the 
idea that amyloid species formed from a number of unrelated peptide precursors share 
common structural features, which can be targeted by aptamer ligands, and that raising 
aptamers to synthetic amyloid formed in vitro, can be directly relevant to the isolation of 
aptamers against in vivo, disease-associated fibrils. 
More recently, an RNA aptamer raised against monomeric β2m was shown to be able to 
discriminate this target protein from its N-terminally truncated variant ΔN6484.  As well as 
displaying remarkable discriminatory power in this system, the aptamer B6min (2ʹF 
modified 44-nucleotides (Figure 1.22 c), truncated from the 110 full length variant, which 
was selected from within an N30 library) was able to disrupt the kinetics of co-
polymerisation of the two proteins.  Co-polymerisation is a feature common to many other 
amyloid forming peptides309, 485-488, which adds significantly to the complexity of amyloid 
systems, producing further fibril polymorphs, with diverse architectures, stabilities and 
biological properties309, 485, 489.  Aptamers like the one described here, may therefore help in 
discriminating distinct amyloid species from a pool of closely-related molecules, decipher 
the underlying mechanisms of aggregation and inform the design of novel therapies and 
diagnostics.   
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Figure 1.22 Examples of anti-β2m aptamers.  (a)  Distinct morphologies of β2m fibrils 
imaged by negative-stain EM in the case of (i) Long-straight (LS) fibrils and (ii) Worm-like 
fibrils (WL).  Rod-like fibrils (iii) were imaged by AFM.  Each scale bar represents 200 nm.  
(b)  The predicted secondary structure of aptamer WL-2.  Nucleotides corresponding to the 
random region are highlighted green.  Coloured arrows indicate sequence-specific 
enzymatic cleavage sites used to validate the predicted structure.  Cleavage by RNase T1 (G-
specific, red), RNase A (U and C specific, blue), S1 (single-strand specific, green) are 
indicated.  (c)  Secondary structure predicted for B6min.  2ʹF pyrimidines are circled in 
green.  Figures adapted from 483 and 490. 
 
1.4.4.3 Aβ aptamers 
 
Several examples of aptamers raised against different Aβ assemblies exist in the literature 
and provide indication that targeting this natively-unstructured peptide, as well as its 
various higher-order assemblies, is a distinct possibility.  The earliest example of an anti-Aβ 
RNA aptamer was isolated by Ylera et al.491.  Here, aptamers were selected from an N70, 
unmodified RNA library, against monomeric Aβ40, immobilised on a Sepharose support 
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resin.  Nanomolar affinity of the selected RNA aptamers was reported for the immobilised 
monomer, however the authors were unable to demonstrate binding of the aptamer to the 
monomeric peptide in solution.  Instead, the aptamers were shown to bind fibrils, allowing 
the group to speculate that problems with the aggregation propensity of Aβ meant that 
aptamers had preferentially targeted aggregates formed during the immobilisation process.  
The work highlights the difficulty in aptamer selection against these highly aggregation-
prone monomeric species.  However, more than a decade after this initial publication, the 
lead aptamer sequence from the selection, β55 (Figure 1.23 a.i.), was taken forward in the 
development of an optical imaging reagent to detect amyloid plaques492.   By use of both 
biotin-modified and fluorescently-tagged RNA sequences Farrar et al. were able to visualise 
amyloid plaques in ex vivo human AD brain sections (Figure 1.23 a.ii.), and in vivo, in 
transgenic AD mice models.  The in vivo 2-photon imaging methodology also allowed 
visualisation of a diffuse “halo” of positive staining on the periphery of the plaques (Figure 
1.23 a.iii.), indicative of reactivity towards oligomeric species that often surround the 
dense core of the aggregate.  Dot blot analysis confirmed that the aptamer sequence did 
indeed bind both fibrillar and oligomeric Aβ.   
A further example of aptamers selected against Aβ assemblies reported the potential for 
RNA to interfere with amyloidosis493.  Takahashi and colleagues expanded on previous work 
in the field by selecting unmodified RNA aptamers from an N40 naïve library, against an 
“oligomeric model” of Aβ40, assembled on the surface of gold nanoparticles.  Despite the 
author’s report of relatively moderate binding affinities for the target assemblies (Kd ~ 10 
μM) two aptamers (N2 and E2 Figure 1.23 b) were able to redirect the assembly 
mechanism, by inhibiting the formation of typical fibrils.  Instead aptamer co-incubation 
resulted in the formation of oligomers, protofibrils and amorphous aggregate, as assessed 
by TEM.   
Finally, another study where oligomeric assemblies of Aβ40 were specifically targeted was 
performed by Rahimi et al.494, where they selected RNA aptamers against a covalently-
stabilised Aβ40 trimer.  Aptamers in this study were again unmodified, and from an N49 
RNA library, and were reported to contain a high G-content, however no sequences were 
given.  The authors found that upon characterisation of individual selected aptamer 
sequences, the RNA displayed no affinity for the trimeric or other low-molecular weight 
(LMW) species and instead associated most tightly with the fibrils.  The lead sequences 
(KM33 and KM41) were also shown to associate with a panel of further fibrils from 
numerous precursors, including Aβ42, lysozyme, PrP(106-126), IAPP, calcitonin and 
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insulin.  This work again indicates a conserved structural motif common between many 
amyloid assemblies.      
 
 
Figure 1.23 Examples of anti-Aβ40 aptamers.  (a. i.) The predicted secondary structure of 
β55.  The nucleotides corresponding to the primer regions are boxed.  Regions conserved 
between this aptamer sequence and other related sequences from motif analysis of the 
selected pool are circled.  (ii)  Confocal imaging of a human AD brain section stained with 
biotinylated-β55 red and showing co-localisation with amyloid-specific dye Thio-S (green).  
Scale bar: 50 µm.  (iii)  In vivo 2-photon microscopy plaque images from an AD mouse brain, 
1 h after topical application of fluorescein-labelled β55.  Scale bar: 20 µm.  (b)  Predicted 
secondary structures of N2 and E2 aptamers with randomised regions in bold.  Images are 
adapted from 491-493. 
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1.4.4.4 Other anti-amyloid aptamers 
 
In addition to the RNA aptamers selected against the above amyloid assemblies, there are 
some examples of DNA aptamers raised as analytical tools against α-syn495, 496 (associated 
with Parkinson’s disease) and the Sup35 yeast prion497.  In the case of α-syn, aptamers were 
raised which selectively bound oligomeric α-syn assemblies over the natively-unstructured 
monomer495 despite selection against a supposedly monomeric solution.  A later study by 
the same group496 isolated further DNA aptamers this time against soluble oligomers of α-
syn, which also displayed cross-reactivity with prefibrillar assemblies of Aβ40.  Similarly, 
DNA aptamers raised against Sup35 fibrils497 were able to bind to various other aggregated 
states, including the SDS-insoluble Sup35 aggregates isolated directly from yeast cells and 
two further amyloid aggregates formed from murine PrP(90-231) and a 103Q poly-Q 
expanded variant of huntingtin.    
Overall, although there are relatively few examples of anti-amyloid aptamers represented 
in the literature, the studies published indicate that aptamers could indeed play an 
important role in dissecting these mysterious disease systems, sensitively detecting and 
characterising the distinct structures involved, and potentially interfering with 
pathogenesis.   
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1.5 Aims of this thesis 
 
Alzheimer’s disease (AD) represents one of the greatest health challenges of our generation.  
There is an urgent need for novel therapies, diagnostics and further insights into the 
processes underlying this disorder, and other amyloid diseases alike.  The aim of this study, 
therefore, was to harness the power of RNA aptamer technologies in these endeavours.  The 
focus of the work was to isolate RNA sequences, through the SELEX approach, specific for a 
number of assemblies of the Aβ40 peptide.  A small cohort of individual aptamer sequences, 
isolated from each of the selection pools would be assessed for their target binding affinity, 
and specificity, before lead sequences would be chosen for further characterisation.  Only 
after confirmation of the aptamers’ avidity and specificity for their own target assemblies, 
could the project proceed to address the secondary aim; development of the aptamers as 
either novel therapies, diagnostic reagents or use them to probe disease processes and 
expand our knowledge of the mechanisms underlying amyloidosis. 
The work presented in Chapter 3 outlines the in vitro selection of RNA aptamers against 
both monomeric Aβ40 and the two well-characterised and structurally distinct fibrillar 
assemblies from Tycko et al.103-105 2A and 3Q (Section 1.3.4.3).  The resultant enriched pools 
were sequenced with next generation methodology, isolating ~106 possible binding 
sequences for each of the structures.  A thorough bioinformatic analysis of the sequencing 
data was then undertaken in order to isolate lead aptamer sequences from the vast quantity 
of possible binders.  Chapter 4 documents the characterisation of anti-monomer aptamers, 
with emphasis on the challenges in optimising suitable techniques to study binding to this 
small, aggregation prone peptide, in its monomeric form.  Chapter 5 covers the 
characterisation of the anti-fibril aptamers and the extent of their specificity for their 
cognate fibril morphologies.  Upon the discovery that RNA aptamers display generic cross-
β selectivity, the focus shifts to probing the structural elements responsible for the lack of 
binding specificity, in the context of both amyloid structure, RNA sequence and comparison 
to another generic amyloid-binding polyanion, heparin.  Finally, despite a lack of 
discrimination between amyloid assemblies, some practical uses for aptamers as imaging 
reagents or inhibitors are described. 
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2 Materials and methods 
2.1 Materials 
 
2.1.1 Technical equipment 
 
Equipment      Manufacturer 
Centrifuges 
Avanti J-26 XP Centrifuge    Beckman Coulter, Brea, CA, USA 
GenFuge 24D Centrifuge    Progen Scientific, London, UK 
MiniSpin plus F-45-12-11    Eppendorf, Hauppauge, NY, USA 
 
Incubators, mixers & shakers 
Gallenkamp Economy Incubator Size 1  Sanyo, Watford, UK 
ORBISAFE Orbital Incubator    Sanyo, Watford, UK 
Stuart Magnetic Stirrer SB161    CamLab, Cambridge, UK 
Stuart Orbital Incubator S150    Bibby Scientific, Stone, UK 
Stuart Vortex Mixer SA8    Bibby Scientific, Stone, UK 
 
Gel electrophoresis equipment 
Vari-Gel midi system     CamLab, Madingley, UK 
Slab Gel Electrophoresis Chamber AE-6200  ATTO, Tokyo, Japan 
Standard Power Pack P25    Biometra, Goettingen, Germany 
OmniPAGE Maxi system    Geneflow, Staffordshire, UK 
 
Protein purification equipment 
ÄKTAprime plus     GE healthcare, Little Chalfont, UK 
Superdex™ 75 GL 10/300 gel filtration column GE healthcare, Little Chalfont, UK 
Superdex™ Peptide 10/300 GL gel filtration column GE healthcare, Little Chalfont, UK 
HiLoad Superdex™ 75 26/60 gel filtration column GE healthcare, Little Chalfont, UK 
Fluorometer 
Photon Technology International fluorometer  Ford, West Sussex, UK 
 
Spectrophotometer 
UltroSpec 2100 pro UV/Visible Spectrophotometer GE healthcare, Little Chalfont, UK 
UV-1800 UV/Vis Spectrophotometer   Shimadzu, Kyoto, Japan 
Nanodrop 2000 UV/Vis Spectrophotometer  Thermo Scientific, Surrey, UK 
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Microplate readers 
FLUOstar OMEGA plate reader    BMG Labtech, Aylesbury, Bucks, UK 
NEPHELOstar Galaxy laser-based nephelometer  BMG Labtech, Aylesbury, Bucks, UK 
CLARIOstar plate reader    BMG Labtech, Aylesbury, Bucks, UK 
EnVision 2013 Multilabel plate reader   Perkin Elmer, Waltham, MA, USA 
 
Microscopes 
JEOL JEM-1400 Transmission Electron Microscope  JEOL Ltd., Tokyo, Japan 
Zeiss LSM 700 Confocal microscope   Zeiss, Oberkochen, Germany 
 
Mass spectrometer 
Synapt high definition mass spectrometry (HDMS) quadrupole-time-of-flight mass 
spectrometer (Micromass UK Ltd., Waters Corpn., Manchester, UK), equipped with a 
Triversa automated nano-electrospray ionisation (ESI) interface (Advion Biosciences, 
Ithaca, USA) 
 
Other equipment 
Biacore 3000 Surface Plasmon Resonance  GE healthcare, Little Chalfont, UK 
Monolith NT.115 Microscale Thermophoresis  NanoTemper, Munich, Germany 
Soniprep 150 Ultrasonic Disintegrator  MSE, London, UK 
Corning Costar 3881 96-well plate    Corning Life Sci, The Netherlands 
Corning 3575 384-well plate    Corning Life Sci, The Netherlands 
Grant JB1 Unstirred Waterbath   Grant Instruments, Shepreth, UK 
InGenius Gel Documentation System   Syngene, Cambridge, UK 
Jenway 3020 Bench pH Meter    Bibby Scientific, Stone, UK 
Series 2100 Media Autoclave    Prestige Medical, Minworth, UK 
SnakeSkin Pleated Dialysis Tubing; 3,500 MWCO Thermo Scientific, Surrey, UK 
Techne Dri-Block Heater DB-2A   Bibby Scientific, Stone, UK 
Heto PowerDry PL3000 Freeze drier   Thermo Scientific, Surrey, UK 
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2.1.2 Chemicals 
 
A  
Acrylamide, 30% (w/v): 0.8% (w/v) bisacrylamide  Severn Biotech, Kidderminster, UK 
Acetonitrile      Fisher Scientific, Loughborough, UK 
Agar       Melford Laboratories, Suffolk, UK 
Ampicillin      Formedium, Norfolk, UK 
Ammonium acetate     Sigma Life Sciences, St. Louis, USA 
Ammonium bicarbonate    Sigma Life Sciences, St. Louis, USA 
Ammonium persulphate, APS    Sigma Life Sciences, St. Louis, USA 
Ammonium sulphate     Thermo Scientific, Surrey, UK 
 
B  
Benzamidine      Sigma Life Sciences, St. Louis, USA 
Bromophenol blue     Sigma Life Sciences, St. Louis, USA 
 
C  
Calcium chloride     Melford Laboratories, Suffolk, UK 
Carbenicillin      Formedium, Norfolk, UK 
Chloramphenicol      Sigma Life Sciences, St. Louis, USA 
Chloroform:isoamyl alcohol    Sigma Life Sciences, St. Louis, USA 
Congo red      Sigma Life Sciences, St. Louis, USA 
  
D  
DEPC-treated H2O     Severn Biotech, Kidderminster, UK 
Dimethyl sulphoxide, DMSO    Sigma Life Sciences, St. Louis, USA 
1,2-Dithiothreitol, DTT    Formedium, Norfolk, UK 
DNase I (bovine)     Sigma Life Sciences, St. Louis, USA 
 
E  
Ethanol      Fisher Scientific, Loughborough, UK 
Ethidium bromide (EtBr)    Sigma Life Sciences, St. Louis, USA 
Ethylenediaminetetraacetic acid, EDTA  Sigma Life Sciences, St. Louis, USA 
 
G  
Glutamax      Invitrogen, Paisley, UK 
Glycerol      Fisher Scientific, Loughborough, UK 
Glycogen      Thermo Scientific, Surrey, UK 
Guanidinium HCl     Fisher Scientific, Loughborough, UK 
 
H  
Hellmanex      Sigma Life Sciences, St. Louis, USA 
Heparin (LMW)     Iduron, Manchester, UK 
1,1,1,3,3,3 Hexafluoro-2-propanol (HFIP)  Sigma Life Sciences, St. Louis, USA 
Hyaluronic acid dp8     Iduron, Manchester, UK 
Hydrochloric acid, HCl     Fisher Scientific, Loughborough, UK 
 
I  
Isopropyl β-D-1-thiogalactopyranoside, IPTG  Melford Laboratories, Suffolk, UK 
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L  
LB broth, granulated     Melford Laboratories, Suffolk, UK 
Lysozyme      Sigma Life Sciences, St. Louis, USA 
 
M  
Magnesium acetate     BDH Laboratory Supplies, Poole, UK 
Magnesium chloride, MgCl2    Sigma Life Sciences, St. Louis, USA 
Manganese chloride tetrahydrate   Sigma Life Sciences, St. Louis, USA 
3-(N-morpholino)propanesulphonic acid (MOPS) Sigma Life Sciences, St. Louis, USA 
 
N 
Niad-4       ChemShuttle, China  
     
 
P 
Phenol:CHCl3 (5:1, pH 4.5)    Ambion, UK 
Phenylmethanesulfonyl fluoride (PMSF)  Fisher Scientific, Loughborough, UK 
Phosphate buffered saline (PBS)   Thermo Scientific, Surrey, UK  
 
R 
RNAse inhibitor (murine)    New England Biolabs, Herts, UK 
 
S  
Sodium azide, NaN3     Sigma Life Sciences, St. Louis, USA 
Sodium borate, Na2B4O7    Sigma Life Sciences, St. Louis, USA 
Sodium chloride, NaCl     Fisher Scientific, Loughborough, UK 
Sodium dodecyl sulphate, SDS    Sigma Life Sciences, St. Louis, USA 
Sodium hydroxide, NaOH    Fisher Scientific, Loughborough, UK 
Sodium phosphate dibasic, Na2HPO4   Sigma Life Sciences, St. Louis, USA 
Sodium phosphate monobasic, NaH2PO4  Sigma Life Sciences, St. Louis, USA 
Sodium sulphate, Na2SO4    Sigma Life Sciences, St. Louis, USA 
Spermidine      Sigma Life Sciences, St. Louis, USA 
 
T  
Tetramethylethylenediamine (TEMED)  Sigma Life Sciences, St. Louis, USA 
Thioflavin T      Sigma Life Sciences, St. Louis, USA 
Trifluoroacetic acid     Fisher Scientific, Loughborough, UK 
Tris-(hydroxymethyl)-aminomethane (Tris)  Melford Laboratories, Suffolk, UK 
Trypsin EDTA      Sigma Life Sciences, St. Louis, USA 
Tween-20      National Diagnostics, Atlanta, USA 
 
U 
Uranyl acetate      Sigma Life Sciences, St. Louis, USA 
Urea       MP Biomedicals, UK 
 
Y 
Yeast inorganic pyrophosphatase   Sigma Life Sciences, St. Louis, USA 
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2.1.3 Antibiotics, markers and dyes 
 
Antibiotic Solvent 
Stock 
solution 
(mg/mL) 
Working 
concentration 
(μg/mL) 
Sterilisation 
Ampicillin 
Purite 18 MΩ 
H2O 
100 100 
Filter sterilised 
through 0.2 μm 
filter 
Carbenicillin 
Purite 18 MΩ 
H2O 
100 100 
Chloramphenicol 
100% (v/v) 
ethanol 
25 25 
Table 2.1 Antibiotics used in this study. 
 
Marker Manufacturer 
Mark 12™ Protein Standard Invitrogen, Paisley, UK 
Precision Plus Protein™ Dual Xtra 
Standards 
Bio-Rad, Hemel Hempstead, UK 
10 bp DNA ladder Invitrogen, Paisley, UK 
Table 2.2 DNA and protein markers used in this study. 
 
Dye Manufacturer 
GelPilot DNA Loading dye, 5 x QIAGEN, Crawley, UK 
Gel loading buffer II (Denaturing PAGE) Ambion, Paisley, UK 
Instant Blue Stain Expedeon Protein Solutions, UK 
Ethidium Bromide (0.1 µg/mL) in Tris 
borate EDTA (TBE) 
Severn Biotech Ltd, UK 
Table 2.3 Dyes used in this study. 
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2.1.4 Kits 
Kit Manufacturer 
QIAquick PCR purification kit QIAGEN, Crawley, UK 
Wizard ® Plus SV Minipreps DNA 
purification system 
Promega, Southampton, UK 
RNA Clean and Concentrator™-5 Zymo Research, Irvine, CA, USA 
Illustra Microspin G-25 columns GE healthcare, Little Chalfont, UK 
PD10 desalting columns GE healthcare, Little Chalfont, UK 
Illustra NAP5 columns GE healthcare, Little Chalfont, UK 
KAPA2G Robust PCR kit Kapa Biosystems, London, UK 
HiScribe™ T7 High Yield RNA synthesis kit New England Biolabs, Herts, UK 
Transcriptor Reverse Transcription kit Roche, West Sussex, UK 
Table 2.4 Kits used in this study. 
 
2.1.5 Media and buffers 
Media Components 
Luria-Bertani (LB) Media 
10 g Bacto-tryptone 
5 g Yeast extract 
10 g NaCl 
 
Made up to 1 L in Purite 10 MΩ H2O 
autoclaved 20 min at 121 °C, 15 psi 
Table 2.5 Media used in this study. 
 
Solid medium was prepared by addition of 1.5% (w/v) agar (Melford Laboratories, UK) 
prior to autoclaving.  Antibiotics were added to media once cooled to < 50 °C. 
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Buffer Components 
2 x SDS reducing loading buffer 
50 mM Tris- HCl, pH 6.8 
100 mM DTT 
2% (w/v) SDS 
0.1 % (w/v) bromophenol blue 
10% (v/v) glycerol 
SDS PAGE cathode buffer 
200 mM Tris-HCl, pH 8.25 
200 mM Tricine 
0.2% (w/v) SDS 
SDS PAGE anode buffer 400 mM Tris-HCl, pH 8.8 
Tris-borate-EDTA (TBE) buffer 
890 mM Tris, pH 8.3 
20 mM EDTA 
890 mM Boric acid 
Made from 10 x TBE powder (Applichem, 
Germany) 
Transcription buffer (10 x) 
400 mM Tris acetate, pH 8.0 
150 mM Magnesium acetate 
0.5 mM Manganese chloride tetrahydrate 
138 mM Spermidine 
MOPS selection buffer 
80 mM MOPS 
96 mM NaCl, pH 7.5 
Fibril formation buffer (Aβ40/Aβ16-22) 
25 mM sodium phosphate, 
 0.01% (w/v) NaN3, pH 7.5 
Fibril formation buffer (α-synuclein) 
20 mM Tris-HCl 
100 mM NaCl 
0.01% (w/v) NaN3, pH 7.5 
Table 2.6 Buffers used in this study. 
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2.2 Molecular biology methods 
2.2.1 Bacterial strains 
 
E. coli XL1–Blue (Stratagene, Cambridge, UK) 
endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[::Tn10 proAB+ lacIq Δ(lacZ)M15] 
hsdR17(rK- mK+) 
 
E. coli DH5α (Invitrogen, Paisley, UK) 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 Δ(lacZYA-argF)U169, 
hsdR17(rK- mK+), λ– 
 
E. coli BL21 (DE3) pLysS (Stratagene, Cambridge, UK) 
F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) pLysS(cmR) 
 
E. coli BL21 (DE3) (Stratagene, Cambridge, UK) 
F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
 
2.2.2 Preparation of competent E. coli cells 
 
A 10 mL culture of the desired E. coli strain was grown overnight in LB media, at 37 °C.  This 
culture was used to inoculate (1:20) a 100 mL LB culture, which was grown at 37 °C, 200 
rpm, until the OD600 reached 0.4 - 0.45.  Cells were centrifuged in a pre-chilled rotor at 1,400 
x g, 4 °C for 10 min and the pellet resuspended in 10 mL of sterile, pre-chilled 100 mM CaCl2.  
This was incubated on ice for 10 min and centrifuged for a further 10 min at 1,400 x g at 
4 °C.  The pellet was then resuspended in 2 mL of 100 mM CaCl2, 30% (v/v) glycerol and 
divided into 100 μL fractions and frozen on dry ice.  Competent cells were stored at -80 °C. 
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2.2.3 Transformation and cultivation of E. coli cells 
 
Plasmid DNA (50 – 200 ng) was added to 50 µL thawed, competent cells and incubated on 
ice for 30 min, with occasional, gentle agitation.  The cells were then heat shocked for 45 s 
at 42 °C and incubated on ice for a further 10 min before the addition of 500 µL sterile LB 
(without antibiotic).  The mixture was incubated at 37 °C with 200 rpm agitation for 2 h, to 
allow the cells to express appropriate resistance genes, before 20 - 200 µL was spread on 
LB agar plates, containing antibiotic resistance.  Plates were incubated overnight at 37 °C.   
 
2.2.4 Preparation of plasmids 
 
10 mL LB cultures containing the appropriate antibiotic resistance, were inoculated from 
single bacterial colonies picked from transformation plates, and grown overnight (37 °C, 
200 rpm agitation).  Cells were pelleted at 4000 x g and plasmid DNA was extracted using 
Wizard® Plus SV miniprep DNA purification kit, according to the manufacturer’s 
instructions.  DNA was eluted in sterile, nuclease-free H2O, and stored at -20 °C for 
subsequent transformation reactions.  The concentration of plasmid DNA was determined 
by absorbance measurement at 260 nm (A260), where A260 = 1 was assumed to be 
equivalent to 50 µg/mL dsDNA498.  DNA was sequenced by Beckman Coulter Genomics 
sequencing service using universal T7 promoter primers.  
 
2.2.5 Plasmids 
 
Plasmids encoding WT Aβ40 (pETSac, Appendix 7.1.1) were kindly provided by Dr. Sara 
Linse (Lund University, Sweden) and Prof. Dominic Walsh (Harvard Institute of Medicine, 
USA).   
pET23a plasmid encoding α-synuclein were provided by Prof. Jean Baum (Department of 
Chemistry and Chemical Biology, Rutgers University, NJ, USA). 
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The plasmid encoding K16A Aβ40 was created from the above Aβ40 plasmid by site-
directed mutagenesis, which was carried out by Dr. Katie Stewart (School of Molecular and 
Cellular Biology, University of Leeds). 
 
2.3 Protein expression and purification methods 
 
2.3.1 Expression and purification of Aβ40 
 
2.3.1.1 Expression of recombinant Aβ40 
 
Buffer Composition 
10 x Buffer A 
100 mM Tris-HCl 
10 mM EDTA 
pH 8.5 
1 x Buffer A 1:10 dilution of 10 x Buffer A in H2O 
Inclusion body denaturant 8 M Urea in 1 x Buffer A 
Table 2.7 Buffers used in Aβ40 purification. 
 
BL21 (DE3) pLysS cells were transformed with plasmid encoding Aβ40 as described 
(Section 2.2.3).  A single colony was picked to inoculate 100 mL overnight starter cultures 
(37 °C, 200 rpm).  10 mL of overnight culture was used to inoculate 10 x 500 mL sterile LB 
cultures, prepared in 2 L baffled, conical flasks.  Ampicillin (100 µg/mL) was added to each 
flask before incubation at 37 °C, with 200 rpm agitation, until an optical density (OD600) of 
0.5 was reached.  Protein expression was induced with the addition of filter-sterilised 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM.  Cultures 
were then further incubated until OD600 reached a plateau and cells reached steady state 
(approx. 3.5 h, typical OD600 ~ 1.2).  Cells were harvested by centrifugation at 6000 x g (4 °C 
for 15 min) and pellets were pooled and resolubilised in 25 mL H2O, before storage at -20 °C.  
Optimisation of this protein expression protocol is described in Section 3.3. 
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2.3.1.2 Isolation and lysis of inclusion bodies containing Aβ40 
 
2.5 mL of 10 x Buffer A (4 °C) was added to the 25 mL cell suspension from Section 2.3.1.1 
to establish a 1 x Buffer A solution.  DNase (~0.5 mg), phenylmethanesulfonyl fluoride 
(PMSF, 1 mM) and benzamidine (2 mM) were added to the suspension and stirred at 4 °C 
for 1 h.  The solubilised pellets were passed through a blunt-end syringe needle (Terumo 
Global Pharmaceutical Solutions, NJ, USA) to further homogenise, before sonication for 30 s 
(9.5 mm probe, 10 µm amplitude).  The homogenate was centrifuged at 30,000 x g, 15 min 
at 4 °C, and supernatant removed.  The pelleted inclusion bodies were resolubilised in 1 x 
Buffer A and the sonication – centrifugation process repeated once more.  The pellet was 
resolubilised in inclusion body denaturant (Table 2.7) and agitated using a magnetic 
stirrer, for up to 1 h.  The suspension was then sonicated and centrifuged a third time (as 
before) and the supernatant, now containing solubilised Aβ40, was collected and diluted 1 
in 4 in 1 x Buffer A for anion exchange purification. 
 
2.3.1.3 Anion exchange purification 
 
Anion exchange purification of Aβ40 was performed in batch format to avoid problems 
associated with Aβ aggregation during column chromatography499.  All buffers used in this 
stage of the purification were pre-cooled to 4 °C.  35 mL of Q-Sepharose Fast Flow resin (GE 
Healthcare) was equilibrated with 1 x Buffer A, before addition of the crude urea lysate 
(urea concentration ~2 M after dilution) and incubation at 4 °C, with gentle rocking, for 
30 min.  Batch purification was set up in a 250 mL Büchner funnel, with Whatman 1 filter 
paper, fitted to a vacuum glass bottle and vacuum pump.  The resin was washed twice with 
50 mL pre-chilled 1 x Buffer A, containing 0 then 25 mM NaCl, before peptide elution with 5 
x 50 mL washes of 1 x Buffer A containing 125 mM NaCl.  Finally, high-salt (1 x Buffer A plus 
250 mM NaCl) and high-salt plus urea (1 x Buffer A plus 250 mM NaCl, 8 M urea) fractions 
were applied to the resin to remove any remaining protein species.  Each eluate was stored 
at 4 °C to avoid aggregation before dialysis. 3,500 MWCO dialysis tubing was prepared 
according to manufacturer’s instructions.  Aβ40-containing fractions were dialysed against 
50 mM ammonium bicarbonate, with a total 4 x 5 L changes over 24 h.  Fractions were then 
lyophilised to concentrate the semi-purified peptide.  
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2.3.1.4 Size exclusion chromatography (SEC) 
 
Lyophilised Aβ40, purified partially by anion exchange chromatography, was resolubilised 
in 10 mL of 50 mM Tris-HCL, pH 8.5, containing 7 M guanidinium-HCl.  The solution was 
loaded onto a HiLoad™ 26/60 Superdex 75 prep grade gel filtration column (GE Healthcare), 
connected to an ÄKTA prime LC system, in 5 mL batches.  The column was pre-equilibrated 
in 50 mM ammonium bicarbonate, which was also the mobile phase in which the protein 
was eluted.  The ÄKTA programme used is outlined in Table 2.8.  Aβ40 was eluted in a single 
peak at approximately 180 mL.  All SEC was performed at 4 °C.  Typical yields from this 
Aβ40 preparation was 4 mg/L culture. 
 
Breakpoint (mL) 
Flow rate 
(mL/min) 
Fraction size (mL) 
Injection valve 
position 
0 2 0 Load 
4 2 0 Inject 
20 2 0 Load 
50 2 4 Load 
360 2 0 Load 
362 End 
Table 2.8 ÄKTA programme for size exclusion chromatography of Aβ40. 
 
2.3.1.5 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
A Tris-Tricine buffered SDS-PAGE system was used to monitor protein expression and 
purification as it was deemed most suitable for resolving smaller peptides such as Aβ (Aβ40 
= 4458 Da).  The two-layered gel system was constructed from two glass plates, separated 
by a 1.5 mm spacer, according to manufacturer’s instructions.  Components for the resolving 
and stacking portions of the gel are outlined in Table 2.9. 
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APS and TEMED were added to the other components immediately before pouring.  The 
resolving gel was quickly poured to fill the first 4/5th of the gel plates.  200 µL of H2O was 
carefully dispensed on to the top of the gel to create a straight edge.  This resolving gel 
fraction was allowed to set completely (minimum 1 h) before the water was poured off.  APS 
and TEMED were then added to the stacking gel solution, which was then poured and a 
comb inserted to create sample loading wells.  The assembled gels were allowed to set for a 
further 1 h before electrophoresis. 
Samples were diluted with 2 x SDS reducing loading buffer (Table 2.6) and boiled for 5 min, 
before centrifugation for 10 min at 16,000 x g.   
 
Component 
Volume for resolving gel 
(mL) 
Volume for stacking gel 
(mL) 
30% (w/v) acrylamide:0.8% 
(w/v) bis acrylamide 
7.50 0.83 
3M Tris-HCl, 0.3% (w/v) 
SDS, pH 8.45 
5.00 1.55 
H2O 0.44 3.72 
Glycerol 2.00 - 
10% (w/v) ammonium 
persulphate (APS) 
0.10 0.20 
Tetramethylethylenediamine 
(TEMED) 
0.01 0.01 
Table 2.9 Components of a Tris-tricine buffered SDS-PAGE gel.  Volumes stated to cast two 
8 x 10 cm mini-gels, with a 1.5 mm spacer. 
 
For analysis of whole cell lysates, 1 mL samples were centrifuged at 16,000 x g for 15 min 
and the supernatants removed.  100 µL of loading buffer was added directly to the pellet, 
boiled and centrifuged as described above.  15 µL was loaded onto the gel. 
SDS PAGE was carried out with cathode buffer (Table 2.6) in the inner reservoir of the gel 
tank and anode buffer (Table 2.6) in the outer reservoir.  Gels were run with an initial 
constant current of 30 mA, until the samples had entered the resolving gel, at which point 
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the current was raised to 60 mA.  Gels were run for approximately 1.5 h, until the dye front 
reached the end of the gel.   
Gels were stained (Table 2.3) for 15 min, before de-staining in H2O for a minimum of 1 h 
and imaging with an InGenius Gel documentation system (Syngene, Cambridge, UK). 
 
2.3.2 Expression and purification of α-synuclein 
 
Wild-type α-synuclein (α-syn) was expressed in BL21 DE3 E. coli cells from a pET23a vector 
(Appendix 7.1.2).  10 x 1 L sterile LB fractions were inoculated with 10 mL from an 
overnight 100 mL starter culture (Section 2.3.1.1), in the presence of 100 µg/mL 
carbenicillin.  Cells were incubated at 37 °C for 4 h, prior to induction with 0.5 mM IPTG at 
an approximate OD600 = 0.6.  Protein was expressed for 5 h post-induction, before harvesting 
by centrifugation (6000 x g, 15 min, 4 °C).   
Pellets were resuspended in 25 mM Tris-HCl, pH 8.0 lysis buffer, containing 100 µg/mL 
lysozyme, 50 µg/mL PMSF and 20 µg/mL DNase.  The pellet was then homogenised and 
disrupted by french press (30,000 psi), before heating to 80 °C in a water bath for 10 min.  
The homogenate was then centrifugated (30,000 x g, 4 °C, 30 min) and the protein, isolated 
in the soluble fraction, was precipitated with 50% (w/v) ammonium sulphate at 4 °C, 
30 min.  The suspension was centrifuged at 30,000 x g and the pellet resuspended and 
precipitated again in 50% (w/v) ammonium sulphate, 4 °C, 30 min.  After a further 
centrifugation (30,000 x g, 4 °C, 30 min) the pellet was resuspended in 20 mM Tris-HCl, 
pH 8.0 for anion exchange. 
The partially purified α-syn was loaded onto a 500 mL Q-Sepharose anion exchange column 
with a 20 mM Tris- HCl, pH 8.0 mobile phase.  Protein was eluted with a linear gradient of 
500 mM NaCl and monitored by absorbance at 280 nm.  Fractions containing α-syn were 
analysed by SDS-PAGE, dialysed against 50 mM ammonium bicarbonate and lyophilised. 
Semi-purified protein from anion exchange purification was resuspended in 20 mM sodium 
phosphate, pH 7.5, and loaded onto a HiLoad™ 26/60 Superdex 75 prep grade gel filtration 
column.  The protein was eluted from the column with 20 mM sodium phosphate, pH 7.5 at 
a flow rate of 2 mL/min and the major peak collected and dialysed against 50 mM 
ammonium bicarbonate and lyophilised.  Purified protein was stored at – 20  °C.  A typical 
yield from this preparation was 45 mg/L culture. 
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2.3.3 Quantification and validation of purified protein 
 
Purified peptides were quantified by absorbance at 280 nm (A280).  Concentration (c) was 
calculated with the Beer-Lambert equation (Equation 2.1).  Extinction coefficients at 
280 nm (ε280) were calculated from the peptide sequence in ProtParam500 and are given in 
Table 2.10.  Path length (l) is 1 cm.  
 
𝐴280 =  𝜀280𝑐𝑙 
 
Equation 2.1 
The identity of recombinantly expressed protein was assessed by electrospray ionisation 
mass spectrometry (ESI-MS) analysis.  Any ESI-MS analyses in this thesis were performed 
by Dr. James Ault, MS Facility, School of Molecular and Cellular Biology, University of Leeds. 
 
2.3.4 Acquisition of other peptides  
 
Aβ16-22 was prepared by automated solid-phase peptide synthesis and kindly provided by 
Dr. George Preston and Prof. Andrew Wilson (School of Chemistry, University of Leeds).  
Ccβ-p was synthesised and provided by Dr. Kevin Tipping (School of Molecular and Cellular 
Biology, University of Leeds). 
K16A Aβ40 was expressed and purified according to the WT Aβ40 protocol (Section 2.3.1) 
S129C α-synuclein labelled with a TMR-maleimide fluorescent label (Invitrogen) was made 
by Dr. Matthew Jackson (School of Molecular and Cellular Biology, University of Leeds), 
expressed and purified according to the WT α-synuclein protocol (Section 2.3.2) and 
labelled according to manufacturer’s instructions (Invitrogen). 
Recombinantly expressed L3F Im7 was made and purified by Dr. Alice Bartlett (School of 
Molecular and Cellular Biology, University of Leeds).  Recombinantly expressed β2m was 
made and purified by Dr. Claire Sarell (School of Molecular and Cellular Biology, University 
of Leeds). 
Sequences of all major proteins used in this thesis, and their properties, are given in Table 
2.10. 
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Peptide Sequence 
Production 
method 
Molecular 
Weight 
(Da) 
Extinction 
coefficient 
(ε280/M-1 
cm-1) 
Aβ40 
MDAEFRHDSGYEVHHQKLVF
FAEDVGSNKGAIIGLMVGGVV 
Recombinantly 
expressed 
4458 1490 
Aβ16-22 Ac-KLVFFAE-NH2 Synthetic 853 - 
Ccβ-p Ac-SIRELEARIRELEARIG-NH2 Synthetic 2011 - 
α-
synuclein 
MDVFMKGLSKAKEGVVAAAE
KTKQGVAEAAGKTKEGVLYVG
SKTKEGVVHGVATVAEKTKEQ
VTNVGGAVVTGVTAVAQKTVE
GAGSIAAATGFVKKDQLGKNE
EGAPQEGILEDMPVDPDNEAY
EMPSEEGYQDYEPEA 
Recombinantly 
expressed 
14460 5960 
L3F Im7 
MEHHHHHHEFKNSISDYTEAE
FVQLLKEIEKENVAATDDVLD
VLLEHFVKITEHPDGTDLIYYP
SDNRDDSPEGIVKEIKEWRAA
NGKPGFKQG 
Recombinantly 
expressed 
10881 9970 
β2m 
MIQRTPKIQVYSRHPAENGKS
NFLNCYVSGFHPSDIEVDLLKN
GERIEKVEHSDLSFSKDWSFYL
LYYTEFTPTEKDEYACRVNHV
TLSQPKIVKWDRDM 
Recombinantly 
expressed 
11862 20065 
Table 2.10 Amino acid sequences and properties for the proteins used in this thesis.  
Recombinant peptides contain an additional N-terminal Methionine.  Chemically 
synthesised peptides are both N-terminally acetylated and C-terminally amidated. 
 
2.4 Fibril formation and characterisation 
 
2.4.1 Seeded Aβ40 fibril formation 
 
Original Aβ40 seed stocks of both 2A and 3Q fibril morphologies were kindly provided by 
Dr. Robert Tycko (NIH, Bethesda, USA).   
Aβ40 seeds were diluted to 5% (v/v) in sterile-filtered fibril formation buffer (Table 2.6) 
and sonicated (5 s ON/ 45 s OFF, x 3), with a Soniprep 150 microprobe sonicator (amplitude 
10 µm) on ice.  Lyophilised Aβ40 peptide was dissolved at 0.9 mg/mL in the seed-containing 
buffer and briefly vortexed, before quiescent growth at room temperature for a minimum 
of 18 h.  To produce daughter seeds for further reactions, fibrils prepared as above were 
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grown for 18 h and sonicated for 5 s (microprobe, 10 µm amplitude).  After 7 days of 
elongation, an additional sonication cycle (5 s ON/ 45 s OFF, x 3), was undertaken to 
fragment fibrils into new seeds. 
 
2.4.2 De novo Aβ40 fibril formation 
 
To create fibrils from primary nucleation of monomers, without distinct seeded 
morphologies, Aβ40 peptide was dissolved at 0.9 mg/mL in fibril forming buffer (Table 2.6) 
and aliquotted into 100 µL fractions, in separate wells of a Corning NBS 96 well microplate 
(Corning Life Sci, The Netherlands) and sealed with transparent, gas permeable plastic film 
(Breathe Easy, Sigma Aldrich).  The fibrils were formed at 37 °C with 600 rpm orbital 
agitation, using a NEPHELOstar Galaxy laser-based Microplate nephelometer (BMG 
LABTECH, Germany) as an incubator, for 18 h. Fibril formation was monitored by 
nephelometry. 
 
2.4.3 Seeded α-synuclein fibril formation 
 
Fibrils formed as seed stocks were made by incubation of 300 µM α-synuclein, in 20 mM 
Tris-HCl, 100 mM NaCl, 0.01% (w/v) NaN3 , pH 7.5 buffer, in 500 µL final volumes in 1.5 mL 
Eppendorf tubes.  Samples were agitated constantly at 600 rpm on a Thriller thermoshaker 
incubator (Peqlab).  After 1 week of elongation, fibrils were transferred to 2 mL glass vials 
(Chromacol) and fragmented mechanically via a custom built precision stirrer, at 1000 rpm, 
for 48 h.  This fragmentation yielded seeds which were used to elongate further fibril 
reactions. 
Seeded reactions were set up with the addition of 10% (v/v) pre-formed seed at a final 
protein concentration of 200 µM, in 20 mM Tris-HCl, 100 mM NaCl, 0.01% (w/v) NaN3, 
pH 7.5 buffer.  Mixtures were made up in 1.5 mL Eppendorf tubes and fibril elongation 
carried out at ambient temperature with intermittent shaking (5 s 600 rpm, 10 min 
stationary) on the thriller shaker, to reduce fibril settling.  Fibrils were allowed to form for 
a minimum of 4 days, after which total fibril yield was >95%.  Fibrils containing 10% 
monomer equivalent TMR-labelled S129C α-syn for live-cell imaging studies were made in 
the same manner as wild-type seeded fibrils, at a final protein concentration of 300 µM.  
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Fibrils were fragmented at 1000 rpm with the precision stirrer, for 24 h, before 
experiments. 
 
2.4.4 Aβ16-22 fibril formation 
 
Aβ16-22 fibril reactions were set up by dilution of a 20 mM peptide stock in 100% (v/v) 
DMSO to 400 µM final concentration in 25 mM sodium phosphate, pH 7.0.  The mixture was 
vortexed briefly to ensure homogeneity and incubated at room temperature for a minimum 
of 15 days, without agitation. 
 
2.4.5 Ccβ-p fibril formation 
 
A 10 mM peptide stock in 100% (v/v) DMSO was diluted to 200 µM final concentration in 
phosphate buffered saline (PBS) and incubated at 37 °C, without agitation, for a minimum 
of 18 h. 
 
2.4.6 Transmission electron microscopy 
 
Fibril formation was verified and morphology observed by negative stain transmission 
electron microscopy.  3 µL of sample was loaded onto a carbon coated copper specimen grid 
(Agar Scientific Ltd, UK) and left for 30 s, before blotting against filter paper.  2 x 10 µL drops 
of H2O were loaded to briefly wash the grid, before blotting again and staining with 10 µL 
2% (w/v) uranyl acetate, for 30 s.  The grid was then finally blotted and allowed to dry 
completely.  Images were captured with a Jeol JEM 1400 Transmission Electron Microscope, 
120 kV. 
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2.4.7 Fibril yield determination by SDS-PAGE 
 
40 µL fibril samples were centrifuged at 16,000 x g for 20 min, to separate the insoluble 
fibril pellet from any remaining soluble peptide.  Supernatants were removed and added to 
an equal volume of 2 x SDS reducing loading buffer (Table 2.6).  Pellets were resolubilised 
in 40 µL of 25 mM sodium phosphate, pH 7.5, and also diluted in loading buffer.  20 µL of 
each sample were analysed by SDS PAGE (Section 2.3.1.5) along with 20 µL of whole fibril 
sample (pre-centrifugation) as a reference. 
 
2.4.8 Fibril yield determination by calibrated high performance 
liquid chromatography (HPLC) 
 
Fibril yield for smaller peptide fragments (ccβ-p/Aβ16-22) was estimated with HPLC 
analysis of the remaining soluble fraction after centrifugation of fibril samples.  A calibration 
curve was constructed from 5 µL injections of reference solutions (200, 100 and 50 µM of 
monomeric peptide stock in 100% DMSO) onto a C18 reverse phase column (Phenomenex 
– HPLC performed by Mr Martin Huscroft, School of Chemistry, University of Leeds).  
Separation was monitored with UV absorbance at 210 nm and peak area of each calibrant 
was plotted as a function of concentration.  200 µL fibril samples were separated into 
soluble and insoluble fractions via centrifugation at 16,000 x g for 20 min.  The top 100 µL 
of supernatant was removed and frozen over solid CO2 and lyophilised.  Peptide material 
was then resuspended in 100 µL 100% HFIP, sonicated for 10 s (Soniprep 150, micro probe, 
10 µm amplitude) and incubated at room temperature for 1 h.  The sample was then 
centrifuged briefly at 16,000 x g to remove insoluble buffer salts.  The top 25 µL was 
removed and diluted into 75 µL DMSO for injection.  Peak area from 5 µL injections was 
measured at 210 nm and concentration determined from the calibration.  The value 
calculated was then corrected for 8-fold dilution during sample preparation.  Fibril yield 
was estimated from the concentration of soluble material using Equation 2.2.   
 
 
𝑌𝑖𝑒𝑙𝑑 (%) =  
𝑚𝑜𝑙𝑡𝑜𝑡𝑎𝑙 −  𝑚𝑜𝑙𝑠𝑜𝑙𝑢𝑏𝑙𝑒
𝑚𝑜𝑙𝑡𝑜𝑡𝑎𝑙
 × 100 
Equation 2.2 
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2.5 Target preparation for in vitro selection 
 
2.5.1 Biotin labelling of Aβ40 assemblies 
 
EZ Link™ NHS-LC-LC Biotinylation Reagent (Pierce, Thermo Scientific) was dissolved in 
25 mM sodium phosphate buffer, pH 7.5, to a concentration of 1 mg/mL, immediately before 
use.  The peptide species to be labelled (Aβ40 monomer or fibrils) was dissolved into 25 mM 
sodium phosphate buffer, pH 7.5, and made up to the appropriate protein concentration 
depending on the molar ratio to biotinylation reagent required.  Reactions were allowed to 
proceed for various timescales to obtain the desired level of labelling (discussed in Section 
3.4.2).  Reactions were then quenched with 1/10th volume 1 M Tris -HCl, pH 8.0, before 
buffer exchange to remove free biotin.  For ESI-MS analysis to determine labelling levels, 
dialysis with 2,000 MWCO devices (Slide-A-Lyzer™ MINI, Thermo) was conducted against 
H2O or 100 mM ammonium acetate.  Biotinylated fibrils were pelleted at 4,000 x g, for 20 
min at room temperature, and the buffer removed.  This was repeated three times to achieve 
sufficient buffer salt removal for MS.  The fibrils were then redissolved in the same volume 
of 1,1,1,3,3,3 hexafluoro-2-isopropanol (HFIP) and incubated at 37 °C overnight, with 
200 rpm agitation, to allow complete depolymerisation.  HFIP was dried off with a gentle 
stream of N2 gas, leaving dried sample to be redissolved in 100 mM ammonium acetate, pH 
7.5, suitable for analysis by ESI-MS.  Biotinylated samples for aptamer selection were buffer 
exchanged post labelling into MOPS selection buffer (Table 2.6) via dialysis (monomer) or 
centrifugation (fibrils). 
 
2.5.2 Immobilisation of peptide species to streptavidin-coated 
microspheres 
 
300 µL streptavidin-coated microspheres (10 mg/mL Dynabeads™, Dynal Biotech) were 
washed three times by magnetic partitioning for 2 min, removal of all buffer and exchange 
into the same volume of MOPS selection buffer (Table 2.6), before incubation with biotin-
modified targets.  The concentration required to saturate beads was based on the peptide 
binding capacity (400 pmol/mg) given in the product manual.  Total protein concentration 
added was at a 20 x excess to this value, to allow complete saturation.  Beads were incubated 
MATERIALS AND METHODS 
 
81 
 
at room temperature with gentle agitation for 18 h.  Beads were then washed a further three 
times.  The efficiency of bead binding was assessed by absorbance measurement at 280 nm, 
of the peptide solution, before and after magnetic partitioning. 
 
2.6 RNA methods 
 
2.6.1 Polymerase chain reaction (PCR) 
 
PCR reactions were set up to amplify the initial DNA libraries/individual aptamer clone 
templates to be transcribed.  The technique uses a thermostable DNA polymerase to amplify 
a DNA sequence, with the addition of dNTPs and oligonucleotide primer ends.  Reactions 
were set up in 50 μL total reaction volumes and component quantities are outlined in Table 
2.11. 
 
Component Volume (µL) Final concentration 
5 x KAPA Buffer 10 1 x 
5 x KAPA Enhancer 1 10 1 x 
KAPA dNTP mix (10 mM) 1 0.2 mM each 
Template DNA (1 µM)  1 20 nM 
Primer 1 (100 µM) 0.25 0.5 µM 
Primer 2 (100 µM) 0.25 0.5 µM 
KAPA Robust G2 Polymerase  
(5 U/µL - KAPA Bioscience) 
0.25 1.25 U 
H2O 27.75 - 
Table 2.11 Components of a typical 50 µL PCR reaction using a KAPA2G Robust PCR kit 
(Kapa Biosystems). 
 
The PCR programme used is outlined in Table 2.12. 
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Step Temperature (°C) Time (min) 
Initial denaturation 95 2 
Denaturation 95 0.5 
Annealing 60 0.5 
Elongation 72 0.5 
Repeat denaturation, annealing and elongation (x 10) 
Final elongation 72 2 
Table 2.12 Temperature cycle for a typical PCR reaction. 
 
PCR products were purified by Qiagen PCR purification kit (according to manufacturer’s 
instructions) and DNA eluted in nuclease-free H2O.  In cases where more concentrated PCR 
products were required for high-yield transcriptions, several PCR reactions were pooled 
and concentrated via this PCR purification method.  PCR products were analysed by native 
PAGE (Section 2.6.2) and stored at -20 °C. 
 
2.6.2 Native polyacrylamide gel electrophoresis (Native PAGE) 
 
Native PAGE (rather than typical agarose gel electrophoresis) was used to analyse DNA, to 
allow resolution of shorter sequences.  Samples were diluted in a 5 x GelPilot DNA loading 
dye (Table 2.3).  Gels were cast in 20 x 20 cm glass plates with a 1 mm spacer.  Gel 
components are given in Table 2.13.  Gels were run at 300 V, for 1.5 h in a 1 x TBE running 
buffer.  Gels were stained in 0.1 µg/mL ethidium bromide (EtBr) in TBE and imaged with an 
InGenius Gel documentation system (Syngene, Cambridge, UK). 
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Component Volume (mL) 
30% (w/v) 29:1 acrylamide:bisacrylamide 11.5 
5 x TBE 7 
H2O 16 
10% (w/v) APS 0.35 
TEMED 0.035 
Table 2.13 Components of a 10% acrylamide native PAGE gel.  Volumes allow casting of a 
single 20 x 20 cm gel with 1 mm spacers. 
 
2.6.3 In vitro transcription of 2′F RNA aptamers 
 
In vitro transcription reactions were set up in 50 µL final volumes.  Components are given 
in Table 2.14.  The reaction mixture was incubated at 37 °C for 6 h in a PCR thermocycler.  
Y639F/ H784A T7 RNA polymerase was recombinantly expressed and purified by Dr. David 
Bunka (School of Molecular and Cellular Biology, University of Leeds).  Mutant polymerase 
was required in transcription of non-canonical 2′F RNA.  The Y639F mutation eliminates 
inflexibility of the hydrogen bonding potential of the 2′F substituent of the substrate NTP, 
thereby tolerating 2ʹF modifications.  H784A enhances modified NTP incorporation further, 
by providing more space in the active site, reducing occlusion of the minor groove side of 
the 3′-rNMP:template base pair, therefore relaxing the barrier to efficient extension of 
transcripts during addition of non-canonical NMPs at the 3′-end406.  
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Component Volume (μL) Final concentration 
10 x transcription buffer (Table 
2.6) 
5 1 x 
1 M DTT 2 40 mM 
100 mM NTP mix 
(1:1:1:1 ATP:2′F CTP:GTP:2′F 
UTP) 
2.5 5 mM each 
dsDNA template (from 50 µL 
PCR (Section 2.6.1) – typical 
conc. 500 ng/µL)   
5 50 ng/µL 
Yeast Inorganic 
Pyrophosphatase (YIP) 
(1 U/µL) 
0.5 0.5 U 
Y639F/H784A T7 RNA 
polymerase  
(3.7 µM stock) 
5 370 nM 
DEPC-treated H2O 30 - 
Table 2.14 Components of a typical in vitro transcription reaction. 
 
2.6.4 In vitro transcription of 2′OH RNA aptamers 
 
Transcription of 2′OH RNA does not require mutant T7 RNA polymerase and, therefore, 
HiScribe™ T7 High Yield RNA Synthesis kit (NEB) was used, according to the manufacturer’s 
protocol. Volumes were scaled up for 50 µL reactions. 
 
2.6.5 Transcription with modified nucleotides 
 
2.6.5.1 Alexa488 labelling of RNA by incorporation of modified 
UTP 
 
Incorporation of modified nucleotides requires alteration to the transcription mixes 
outlined in Table 2.14.  To prepare 2′F Alexa UTP labelled RNA, the nucleotide mix was 
supplemented with 1/80th concentration of ChromaTide® Alexa Fluor® 488-5-UTP 
(Molecular Probes – altered nucleotide mix given in Table 2.15) to give final RNA products 
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with 1 fluorescent UTP per molecule, on average.  To calculate average UTP incorporation, 
absorbance at 260 nm was corrected for the dyes contribution using Equation 2.3 and the 
correction factor for Alexa488 UTP at 260 nm = 0.3 (obtained from the manufacturer’s 
protocol).  The absorbance maximum of Alexa488 is 493 nm.  Base: dye ratio was calculated 
using Equation 2.4 where εdye = 62,000 M-1 cm-1 and εbase = 8,250 M-1 cm-1.  This value was 
divided by the number of nucleotides in the sequence to give the average number of dye 
molecules/RNA molecule. 
 
𝑇𝑟𝑢𝑒𝐴𝑏𝑠260 =  (𝐴𝑏𝑠260 − (𝐴𝑏𝑠493  ×  0.3)) 
 
Equation 2.3 
𝑏𝑎𝑠𝑒: 𝑑𝑦𝑒 = (𝑇𝑟𝑢𝑒𝐴𝑏𝑠260  ×  𝜀𝑑𝑦𝑒)/(𝐴𝑏𝑠493  ×  𝜀𝑏𝑎𝑠𝑒) Equation 2.4 
Components for transcription reactions are given in Table 2.16.  
 
Component Volume (mL) 
Final molar concentration 
(mM) 
ATP 5 10 
2′F CTP 5 10 
GTP 5 10 
2′F UTP 6.25 9.875 
ChromaTide® Alexa 
Fluor® 488-5-UTP 
4.94 0.125 
DEPC-treated H2O 23.81 - 
Table 2.15 Components of NTP mix for the enzymatic incorporation of Alexa488 dUTP. 
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Component Volume (μL) Final concentrations 
10 x transcription buffer (Table 
2.6) 
5 1 x 
1 M DTT 2 40 mM 
NTP mix (Table 2.15) 12.5 
4 x dilution mix from 
Table 2.15 
dsDNA template (from 5 x 
50 µL PCR pooled and 
concentrated (Section 2.6.1) – 
typical conc. 2.5 µg/µL) 
10 500 ng/µL 
Yeast Inorganic 
Pyrophosphatase (YIP) 
(1 U/µL) 
0.5 0.5 U 
Y639F/H784A T7 RNA 
polymerase 
(3.7 µM stock) 
10 740 nM 
DEPC-treated H2O 10 - 
Table 2.16 Components of a typical 50 µL transcription reaction used in incorporation of 
Alexa488 dUTP. 
 
2.6.5.2 5′ Biotin labelling of RNA 
 
To prepare 5′ biotin labelled transcripts, the NTP mix was altered according to Table 2.17, 
with 5′ biotin GMP.  Transcription reactions were set up according to the standard protocol 
(Section 2.6.3). 
 
Component Volume (mL) 
Final molar concentration 
(mM) 
ATP 12.5 25 
2′F CTP 12.5 25 
GTP 3.13 6.25 
2′F UTP 12.5 25 
5′ Biotin GMP 9.38 18.75 
Table 2.17 Components of NTP mix for the enzymatic incorporation of 5′ biotin GMP. 
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2.6.6 Alexa488 labelling of RNA via 5′ amino modification 
 
5’ amino modified RNA was fluorescently labelled via an amine-reactive 
sulfodichlorophenol ester.  3 μL of Alexa Fluor® 488 5-SDP Ester (10 mM, Invitrogen) was 
added to 6 μL of 200 μM 5ʹ amino modified RNA in DEPC-treated H2O, with 1 μL 1 M sodium 
borate, pH 8.3.  The reaction mixture was incubated at room temperature for 4 h, with gentle 
agitation on a roller.  10 μL of Gel Loading Buffer II (Ambion) was added to the mixture and 
the labelled RNA was gel purified, as described (Section 2.6.8.2). 
 
2.6.7 Denaturing polyacrylamide gel electrophoresis (Denaturing 
PAGE) 
 
RNA products were analysed (and in some cases purified (Table 2.18, Section 2.6.8.2) by 
denaturing PAGE. 
Gels were constructed from 20 x 20 mm plates with a 1 mm spacer.  The gels were made up 
of 10% (w/v) 19:1 acrylamide:bisacrylamide, in 1 x TBE buffer and 8 M urea (Ultrapure 
Sequagel® urea gel, National Diagnostics – manufacturer’s protocol for a 10% gel) and pre-
run at 15 W for 2 h before sample loading.  Samples were prepared with the addition of Gel 
Buffer II (Ambion) containing 95% deionised formamide, 0.025% (w/v) SDS, 18 mM EDTA, 
bromophenol blue and xylene cyanol, and boiled for 5 min.  Gels were then run at 15 W for 
1.5 h and stained with 0.1 μg/mL EtBr in TBE buffer.   
 
2.6.8 RNA purification methods 
 
Transcripts were subject to DNase treatment by the addition of 1 µL of TURBO™ DNase (Life 
Technologies) and incubation at 37 °C for 15 min.   
RNA was purified via different protocols depending on the level of purity required for the 
subsequent application.  The purification methods used are outlined in Table 2.18. 
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Purification method Application Method 
RNA Clean resin  
(Agencourt RNAClean XP, Beckman Coulter) 
Robotic selections 
According to 
manufacturer’s 
instructions  
Phenol chloroform 
extraction/ethanol 
precipitation 
(Section 2.6.8.1) 
followed by… 
Illustra microspin G-
25 column  
(GE Healthcare) 
Basic desalting 
According to 
manufacturer’s 
instructions 
RNA Clean and 
Concentrate™-5 
column (Zymo) 
2′OH, > 17 nt 
According to 
manufacturer’s 
instructions 
Gel extraction 
2′F, Alexa488 
labelled, high yield 
(Section 2.6.8.2) 
Table 2.18 Summary of purification methods utilised in producing aptamers for various 
applications during this study. 
 
2.6.8.1 Phenol chloroform extraction and ethanol precipitation of 
RNA 
 
Acidified phenol (pH 4.5) was used to partition RNA from protein and DNA contaminants.  
DNase treated RNA was added to 2 x volume of acid phenol:CHCl3 (5:1, pH 4.5, Ambion), 
vortexed for 30 s and centrifuged at 16,000 x g for 30 s, to partition the organic and aqueous 
phases.  The top aqueous layer, containing RNA, was carefully aspirated and added to 2 x 
volume of chloroform:isoamyl alcohol (24:1), before the mixing and centrifuging process 
was repeated.   
RNA was then precipitated by the addition of 1/5th volume of 10 M ammonium acetate, 
1/100th volume 20 mg/mL glycogen (Thermo Scientific, UK) and 2 x volume of ice cold 
ethanol.  Samples were frozen at -20 °C for a minimum of 18 h.  Precipitates were 
centrifuged for 2 h at 16,000 x g, 4 °C, and washed twice with the addition of 500 µL 70 % 
ethanol and 20 min centrifugation at 16,000 x g, 4 °C.  Pellets were dried for 10 min at 40 °C 
in a rotary evaporator and resolubilised in DEPC-treated H2O for storage at -20 °C, before 
further purification. 
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2.6.8.2 Extraction and purification of RNA from denaturing PAGE 
 
To purify RNA products from denaturing gel extracts, gels were constructed according to 
the protocol outlined in Section 2.6.7, with 1.5 mm spacers and larger sample combs for 
loading larger sample volumes.  Gel components were scaled up to 50 mL.   
Samples (post ethanol precipitation) were solubilised in 10-20 µL of Gel Buffer II (Ambion) 
and boiled for 10 min.  Samples were loaded onto gels and run as normal.  Once separation 
was complete, gels were stained in freshly prepared EtBr (0.1 µg/mL) made up in nuclease 
free TBE/H2O, for 10 min and de-stained briefly in water.  Bands were excised and gel 
fragments suspended in 50 µL 10 mM Tris-HCl, pH 8.5 (Buffer EB, Qiagen).  Samples were 
frozen overnight at -80 °C.  Gel fragments were then subject to repeat cycles of 2 h agitation 
on a roller at room temperature, removal of buffer containing RNA and a fresh 50 µL of EB 
applied.  This was repeated three times until a final volume of 150 µL was pooled, 
precipitated as described (Section 2.6.8.1), resolubilised in DEPC-treated H2O, and stored at 
-20 °C. 
 
2.6.9 Reverse transcription PCR (RT-PCR) 
 
Conversion of RNA products to their dsDNA precursors was conducted via reverse 
transcription, followed by PCR.  The typical reaction mixture is given in Table 2.19.  
Samples were incubated at 52 °C for 1.5 h, followed by the addition of PCR mix (Table 2.11, 
scaled up to 80 µL final volumes).  PCR was performed according to the same thermocycling 
programme described in Section 2.6.1, Table 2.12. 
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Component Volume (µL) Final concentrations 
RNA sample 35 - 
5 x Buffer (Transcriptor) 10 1 x 
dNTP mix (10 mM) 2 400 nM 
Primer 2 (100  μM) 1 2 µM 
DEPC-treated H2O 1 - 
Transcriptor Reverse 
Transcriptase (20 U/µL, 
Roche) 
1 20 U 
Table 2.19 Components of a typical 50 µL RT-PCR reaction using a Transcriptor Reverse 
Transcription kit (Roche). 
 
2.7 SELEX methods 
2.7.1 RNA library preparation 
 
RNA libraries were transcribed from naïve DNA library templates designed by Dr. David 
Bunka and synthesised commercially (Thermo Hybaid).  Sequences and associated primers 
are shown in Figure 2.1. 
 
 
Figure 2.1 Schematic representation of the N50 and N30 naïve DNA templates used in this 
study.  Sequences in blue correspond to the T7 promoter sequence in Primer 1 (forward) in 
both libraries. 
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2.7.2 SELEX protocol 
 
The basic SELEX protocol is described here.  Modifications to this standard protocol were 
made to include solution capture rounds and competition elution rounds, which are 
described (Sections 2.7.4 and 2.7.5).  
The naïve 2′F pyrimidine modified RNA library was transcribed as previously described 
(Section 2.6.3) and DNase treated with the addition of 4 µL DNase and 6 µL 10 x DNase 
Buffer (Promega).  RNA was purified by RNAClean XP resin (Agencourt) according to the 
manufacturer’s protocol.  All steps were performed in MOPS selection buffer (Table 2.6) 
unless otherwise stated.  50 µL of purified RNA was added to 50 µL 2 x MOPS selection buffer 
and incubated with 20 µL pre-washed biotin-saturated streptavidin-coated microspheres 
for 15 min at room temperature, with gentle agitation on a roller.  The beads were 
partitioned via a magnetic separation rack (2 min) and the unbound fraction was removed 
and incubated with 20 µL target beads.  Beads were partitioned again (2 min) and the 
unbound fraction was removed.  Beads were washed by sequential additions of 125 µL of 
MOPS selection buffer to partitioned beads (10 x 1 min).  Beads were then resuspended in 
35 µL DEPC-treated H2O and transferred to 200 µL PCR tubes where 40 µL of mineral oil 
was dispensed on top of the mixture to avoid evaporation.  The sample was then heated to 
95 °C for 5 min in a PCR thermocycler.  RNA was reverse transcribed by addition of RT 
mixture (Section 2.6.9) and PCR amplified for the next round.  DNA products were analysed 
by native PAGE (Section 2.6.2) to monitor selection. 
 
2.7.3 Automated selection rounds 
 
Automated selection rounds were undertaken using a Biomek 2000 laboratory automated 
work station (Beckman Coulter).  Selections were carried out in 96-well PCR plates (Thermo 
Fisher Scientific).  Automated programmes were written by Dr. David Bunka and Dr. Simon 
White. 
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2.7.4 Target capture selection rounds 
 
Capture selection rounds were utilised to promote binding specificity for the non-
immobilised, and therefore native target conformation.  50 µL of the RNA pool was 
incubated with 50 µL of the 20 µM biotin-labelled target peptide species (which had not 
been pre-immobilised), for 15 min at 25 °C.  Calculation of the concentration of target 
species required was based on peptide binding capacity (400 pmol/mg).  The mixture was 
then added to 0.5 mg of pre-washed, un-conjugated streptavidin microspheres and 
incubated for 30 min, rolling at room temperature, to capture complexes from solution.  
Beads were then magnetically separated, washed three times with 1 mL of selection buffer, 
before elution as described in the basic SELEX protocol (Section 2.7.2). 
 
2.7.5 Competition elution selection rounds 
 
Following standard immobilised target incubation and washing steps, described in the basic 
protocol (Section 2.7.2), aptamers with greater affinity for native, non-immobilised species 
were competed from their bead bound state with solution target challenges.  35 µL of the 
un-modified target peptide species was incubated with the beads for 10 min (25 °C, rolling).  
Beads were partitioned (2 min) and the buffer (containing competitor peptide species and 
associated RNA) was removed.  This step was repeated with a higher concentration of 
competitor, to challenge further aptamer species from the immobilised target 
(concentrations of competition solutions are given in Sections 3.5.1 and 3.5.2).  After 
removal of this second competition, 35 µL of DEPC-treated H2O was added to the beads and 
heat elution of the remaining aptamers was conducted according to the standard procedure. 
 
2.7.6 Stringency parameters throughout selection 
 
Various experimental conditions were altered in later rounds of the SELEX protocol to 
increase stringency of selection.  These include alterations to incubation times, 
temperatures, target concentrations and numbers of washes.  Alterations are summarised 
for each type of selection round in Table 2.20. 
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Selection 
round 
Incubation 
step 
Incubation 
conditions 
Target bead volume 
(µL) 
Wash conditions 
 
Robotic rounds 1-5 
 
15 min 
25 °C 
20 
125 µL 
1 min            x 10 
25 °C 
Robotic rounds 6-10 
5 min 
37 °C 
10 
125 µL 
1 min            x 13 
25 °C 
Competition 
Target 
binding 
15 min 
25 °C 
20 
125 µL 
1 min            x 10 
25 °C 
Solution 
target 
binding 
10 min 
25 °C 
Target 
capture 
RNA:fibril 
incubation 
15 min 
25 °C 
50 
1 mL 
1 min            x 3 
25 °C 
Bead 
incubation 
30 min 
25 °C 
Table 2.20 Conditions used during different selection rounds to alter selection stringency. 
 
2.7.7 Bioinformatic analysis of next generation sequencing (NGS) 
data 
 
Scripts for aptamer sorting and base-composition evaluation were written by Dr. Eric 
Dykeman (Department of Mathematics, University of York, UK) in Perl programming 
language.  The data obtained from NGS contains both the forward and reverse sequence 
reads.  These two files were amalgamated into a single data file containing all raw 
sequences.  The aptamer sorting script initially searches for user-defined primer sequences, 
in both the forward and reverse direction, with a tolerance threshold where 12 correct 
nucleotides constitutes a “hit”.  The script then generates the complementary sequence of 
any hits in the reverse direction and combines identical pairs as a single read in the forward 
direction.  The script then searches for sequences with the correct random region length 
(user-defined stringency set at ± 15 nucleotides for N50 aptamers, ± 10 for N30).  These 
filtered sequences were then sorted into exact matches, which were quantified and ranked 
in order of frequency of occurrence.   
The output of the above analysis was then used in the base-composition evaluation.  The 
script searches for, and quantifies, the number of times each nucleotide is represented 
within the randomised-region and calculates this as a percentage of total nucleotides. 
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2.8 In vitro techniques 
 
2.8.1 Size exclusion chromatography multi-angle laser light 
scattering (SEC-MALLS) 
 
Size exclusion chromatography was performed on an ÄKTA micro system coupled to a 
Wyatt Dawn TREOS multiangle laser light scattering detector.  MALLS data were analysed 
using Wyatt Astra software (version 6.0).  SEC separation was carried out with a Superdex™ 
Peptide 10/300 GL column (GE Healthcare) with filtered and degassed MOPS selection 
buffer (Table 2.6) and run at a flow rate of 0.3 mL/min, at room temperature.  Lyophilised 
Aβ40 was dissolved in the same buffer, to a concentration of 1 mg/mL.  50 μL was injected 
at time points 0 and 3 h.  The 3 h sample was incubated at 4 °C prior to injection. 
 
2.8.2 Surface plasmon resonance 
 
An SA sensor chip (GE Healthcare) containing a dextran matrix and pre-derivatised with 
streptavidin, was docked into the Biacore 3000 instrument (GE Healthcare), which was 
primed with MOPS selection buffer (Table 2.6) containing 0.005% (v/v) Tween20.  
Biotinylated peptide was injected at a flow rate of 10 µL/min until an appropriate response 
was achieved (typically 25 RU for Aβ40 – appropriate RU of immobilisation for peptides of 
specific MW were calculated with Biacore application support (Available online: 
https://www.biacore.com/lifesciences/Application_Support)).  Flow cell 1 was left blank to 
serve as a baseline.  Further flow cells were either derivatised with control peptides or 
larger doses of target ligand.  Purified RNA to be tested was dialysed against the running 
buffer prior to analysis.  The dialysate was filtered and used directly as the running buffer 
during the experiments, to reduce refractive index changes upon injection.  All assays were 
conducted at a flow rate of 10 µL/min.  Samples were injected for 300 s at 10 µL/min.  
Surfaces were regenerated with buffer containing 50 mM NaCl or 0.05% (w/v) SDS for 
subsequent sample injections.  Data were processed with BIAevaluation software (GE 
Healthcare). 
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2.8.3 Pull-down assays 
 
Aβ40-saturated streptavidin beads were diluted serially into MOPS selection buffer (Table 
2.6) to create a gradient of peptide concentrations.  Aptamer was added at each dilution 
point to the same final concentration (500 nM in gel-based pull-down assays, 30 nM in 
fluorescent pull-down assays).  The complex was incubated at room temperature for 15 min 
to allow association.  Beads were separated from solution on a magnetic rack for 2 min and 
unbound RNA was aspirated off.  In pull-down assays where unbound fluorescent RNA was 
measured, the unbound fraction was loaded into glass capillaries (Nanotemper, standard-
treated) and the fluorescence intensity measured with excitation at 470 nm and emission 
at 520nm, using the Monolith™ NT .115 Microscale thermophoresis (MST) instrument, set 
up to read fluorescence intensity only.  In gel-based pull-down assays, unbound RNA was 
removed and beads were washed three times with buffer (1 min separation on magnet, 
125 µL washes, consistent with standard SELEX conditions - Section 2.7.2).  Elution of 
bound RNA was conducted by the addition of 35 µL DEPC-treated H2O, to each sample, and 
heating to 95 °C for 5 min.  RT-PCR mixtures (Section 2.6.9) were then added directly to the 
samples to amplify all bound RNA.  Bound RNA fractions at each protein concentration were 
analysed by native PAGE (Section 2.6.2) and stained with 0.1 µg/mL EtBr in TBE (Table 2.6) 
for 5 min, before 5 min de-staining in H2O.  Images were taken using an InGenius gel 
documentation system (Syngene) and densitometry of the resultant bands was measured 
with Genetools software.   
Data were fitted, using OriginPro 8.6, to a modified Hill function (Equation 2.5) which takes 
into account signal change upon binding.  START is where the curve begins, END is where 
the curve ends (either higher or lower than START), 𝑥 is concentration of titrant, Kd is the 
dissociation constant and n is the Hill coefficient. 
 
𝑦 = 𝑆𝑇𝐴𝑅𝑇 + (𝐸𝑁𝐷 − 𝑆𝑇𝐴𝑅𝑇)
𝑥𝑛
𝐾𝑑
𝑛 + 𝑥𝑛
 Equation 2.5 
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2.8.4 Microscale thermophoresis (MST) 
 
A stock solution of Alexa488 labelled aptamer was heated in a PCR thermocycler to 98 °C 
for 5 min before cooling by 0.1 °C/s until a final temperature of 25 °C was reached, to 
thermally anneal the RNA.  This stock RNA was then added, at 250 nM final concentration, 
to aliquots of unlabelled Aβ40 peptide at concentrations ranging from 12 nM to 100 µM.  
Mixtures were incubated at room temperature for 15 min.  The RNA: protein mixtures were 
loaded into individual standard treated capillaries (Nanotemper) and analysed with the 
Monolith™ NT.115 MST instrument.  Excitation was 470 nm, emission 520 nm.  MST power 
was 40%, LED power 95%.  Data were processed with NanoTemper Analysis software. 
 
2.8.5 Fluorescence polarisation 
 
A Biomek 2000 laboratory automation work station (Beckman Coulter) was utilised to set 
up fluorescence polarisation (FP) assays in a 384-well plate format.  Pre-formed fibrils were 
diluted serially (a 2/3 regime) into MOPS selection buffer (Table 2.6), in triplicate, before 
addition of Alexa488 labelled aptamer, at a final concentration of 10 nM.  The total volume 
in each well was 40 μL.  Polarisation was measured using a Perkin Elmer EnVision 2103 
MultiLabel plate reader (excitation 480 nm, emission 535 nm).  Polarisation was calculated 
from parallel (III) and perpendicular (I⫠) intensity at 535 nm using Equation 2.6.  The G 
factor is an instrument factor set to 1.  For competition polarisation experiments, titrations 
of competitor ligands were used to dissociate fluorescent aptamers from their complex with 
fibrils.  Aliquots of the fibril: aptamer complex, at concentrations sufficient to produce 65% 
of the FP response in the direct binding experiments, were set up in individual tubes.  
Competitor ligand at varied concentrations (produced through serial dilution into buffer) 
was added to each aliquot of the complex and incubated at room temperature for 30 min.  
Aliquots were transferred to 384-well plates for detection as described above.  Assays were 
set up in triplicate.  Data were plotted as average ± SEM (n = 3) and were fitted to the Hill 
function outlined in Section 2.8.3, Equation 2.5. 
 
𝑃𝑜𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛 =  
𝐼𝐼𝐼 − (𝐺 × 𝐼⫠)
𝐼𝐼𝐼 + (𝐺 ×  𝐼⫠)
 Equation 2.6 
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2.8.6 Niad 4 fluorometry 
 
50 µL samples containing 10 µM Aβ40 and 10 µM Niad 4 in 25 mM sodium phosphate buffer, 
pH 7.5 plus a final concentration of 1% (v/v) DMSO, were prepared in low volume, NBS low 
binding 96-well microplates (Corning) and sealed with hydrophobic, transparent plastic 
film (Breathe-easy®, Sigma).  Plates were incubated at 25 °C in a CLARIOstar plate reader 
for 60 h with intermittent agitation (5 s shaking at 600 rpm, 5 min intervals).  Fluorescence 
intensity was monitored over time with excitation at 490 nm and emission measured at 615 
nm.  When fibril formation was monitored in the presence of aptamer, RNA was added at a 
final concentration of 10 µM with RNase inhibitor (murine, New England Biolabs) at a 1 in 
40 dilution, in line with manufacturer’s recommendations. 
 
2.8.7 Ionic strength calculation 
 
Ionic strength for the glycosaminoglycans used in this study was estimated by taking the 
number of charges on a single disaccharide unit and multiplying by the average number of 
disaccharides in the full-length polymer.  For example, LMW heparin has an average MW of 
4,600 Da, which equates to ~8 repeat units of the disaccharide (Figure 5.27 a).  Therefore, 
the net charge of LMW heparin is taken as -32 and ionic strength (I) calculated according to 
Equation 2.7, where Ci is the molar concentration of ions and Zi is the total charge. 
 
𝐼 =  
1
2
∑(𝐶𝑖) (𝑍𝑖)
2 
 
Equation 2.7 
 
2.9 In vivo techniques 
 
All cell culture and imaging work was carried out with full supervision by Dr. Matthew 
Jackson (School of Molecular and Cellular Biology, University of Leeds).  MTT and ATP 
assays were carried out by Dr. Jackson. 
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2.9.1 Cell culture 
 
SH-SY5Y cells were cultured in Dulbeccos Modified Eagles Medium (DMEM) (Sigma) 
containing phenol red (Sigma), 10% (v/v) foetal calf serum (Biosera), 1% (v/v) Glutamax 
(Invitrogen), 100 IU/mL penicillin and 100 μg/ml streptomycin, in 75 cm3 flasks (Corning).  
Cells were incubated at 37 °C, 5% CO2 and passaged when they reached 60 - 80% confluence, 
using a 1% (v/v) trypsin EDTA solution (Sigma).  
 
2.9.2 MTT/ATP cell viability assays 
 
Cells were plated out at 15,000 cells / well in 96-well microplates in 200 µL DMEM medium.  
Following 24 h incubation, samples were dosed (with fibrils/aptamer/control samples) and 
incubated for a further 24 h at 37 °C, 5% CO2. 1% (w/v) NaN3 was used as a positive control 
for cell death.  In the case of MTT assays, 10 µL of a 10 mg/mL solution of MTT (Sigma), in 
PBS, was added per well and samples were incubated for a further 1.5 h.  The medium was 
then removed and resulting formazan crystals resuspended in DMSO (Sigma).  The amount 
of MTT reduction was quantified by absorbance at 570 nm with subtraction at 650 nm to 
correct for cellular debris.  Cellular ATP levels were measured using a luminescent ATPlite 
assay kit (Perkin Elmer) in accordance with manufacturer’s instructions.  Luminescence 
was measured using a BMG Labtech Plate Reader. 
 
2.9.3 Confocal imaging 
 
Cells were plated out at 300,000 cells per mL in imaging dishes (WPI-Europe FD35-100).  
Following 24 h incubation, samples were dosed with Alexa488 labelled aptamers (Section 
2.6.5.1) and 10% (monomer equivalent) TMR-labelled fibrils and incubated for a further 24 
h at 37 °C, 5% CO2.  Lysotracker deep red or Cell Mask deep red (both Life Technologies) 
were used at 100 nM and 0.5 µg/mL, respectively. Cells were washed three times with 1 mL 
phenol red-free media, prior to imaging on a Zeiss LSM 700 Confocal Microscope with a 63 x 
objective.  
SELECTION OF RNA APTAMERS AGAINST ASSEMBLIES OF Aβ40 
 
99 
 
3 Selection of RNA aptamers against assemblies of Aβ40 
 
3.1 Objectives 
 
The primary aim of the work described in this thesis was to exploit the exquisite molecular 
recognition power of RNA aptamers in amyloid-forming systems; specifically in the 
selection of aptamers able to recognise different species during the aggregation of the 
amyloid-β peptide, Aβ40.  This chapter outlines the rationale behind choosing specific Aβ40 
assemblies as selection targets, the purification of recombinantly expressed Aβ40 peptide 
and the preparation of the target assemblies.  Furthermore, the in vitro selection of RNA 
aptamers against Aβ40 fibrils and their precursor monomeric peptide is described. 
 
3.2 Aβ40 monomer and fibrils as targets for aptamer 
selection 
 
As discussed in Section 1.2.6, the development of agents able to detect and/or treat amyloid 
disorders presents a significant problem in both academic and pharmaceutical research1, 3.  
Structural information into the process of amyloid aggregation is limited and therefore 
development of new ligands, by structure-based design, is especially challenging in these 
systems.  For this reason, an in vitro selection approach was proposed, to develop nucleic 
acid based ligands as potential new tools in the context of Aβ40 aggregation.  The aims were 
to a) aid fundamental studies into the molecular mechanisms underlying the aggregation 
process, b) provide potential new diagnostic reagents and c) develop new intervention 
strategies into Aβ40 assembly into amyloid.  The first major question, therefore, was which 
of the many species involved in this highly complex system are the most appropriate 
selection targets to enable us to meet these objectives. 
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3.2.1 Aβ40 monomer 
 
The natively unstructured monomeric peptide is the starting point of Aβ40 aggregation.  Via 
currently poorly defined mechanisms, this unfolded monomer assembles spontaneously 
into oligomeric species, which may be cytotoxic and are believed to cause the cell death 
associated with neurodegeneration and AD126 (covered in detail in Section 1.3.4).  While the 
identity of the toxic species is hotly debated, species ranging from dimers268, through to 
larger oligomers270, 271, 501 and finally fibrils97, 103, 215, 502 themselves have been implicated.  It 
is logical, therefore, that the monomeric peptide should be one target in our selections, as 
this could lead to several possible avenues of intervention.  It may be possible to trap the 
peptide in this seemingly inert monomeric state, preventing its aggregation to higher order 
and potentially more toxic species, or even to target the peptide for degradation, before 
aberrant accumulation ensues.  
Monomeric Aβ40 is also an attractive selection target from a diagnostic point of view, 
especially as it is the most abundant form of Aβ in the brain, cerebrospinal fluid (CSF) and 
the serum243.  Aβ42 levels in the CSF is an already well-established biomarker in AD, along 
with the detection of tau and phosphorylated tau347.  However, it is the general consensus 
that all three of these biomarkers are required for accurate diagnosis (with confidence 
>90%345) and a single definitive marker has yet to be developed359.  Analysis of the Aβ42:40 
ratio is one common suggestion for improved AD diagnosis358, 503.  The superior recognition 
power achievable by aptamer technologies could help in providing these much needed new 
tools. 
 
3.2.2 Aβ40 fibrils of distinct morphology 
 
Although fibrils are often overlooked as the major toxic entity in amyloid disorders1, 124, 126, 
there remains substantial evidence that these end-point structures are interesting in the 
context of disease.  Toxicity has been attributed to fibrils and plaques in several recent 
studies147, 502, 504 and they are also implicated in producing further toxic species through 
secondary processes.  These include secondary nucleation mechanisms, leading to the 
accumulation of new toxic oligomers via surface mediated catalysis77, 78 or fragmentation, 
and “molecular shedding” of toxic species from pre-formed fibrillar aggregates505.  
Aptamers raised against fibrillar assembles, therefore, could be useful in several of these 
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instances, by specific blockage of secondary nucleation sites or by capping the ends of fibrils 
to prevent production of further toxic structures.   
Structural polymorphism is another important attribute of Aβ fibril formation.  As discussed 
in Section 1.3.4.2, many distinct structures have been proposed for both Aβ40 and Aβ42 
fibrils104, 105, 299.  It has also been suggested that differences in fibril structure could correlate 
with differences in pathology106.  Therefore, development of recognition molecules, able to 
distinguish between fibril structures derived from a single precursor peptide, would be 
invaluable in advancing AD diagnostics.   
The 2A and 3Q structures of Aβ40 fibrils103, 105 (reviewed in Section 1.3.4.3) are ideal targets 
for RNA aptamer selection for a number of reasons.  Firstly, there is structural information 
available for each of these morphologies, which will greatly aid the study of fibril 
recognition by aptamers.  Further, evidence suggests that by producing new fibrils via 
seeded elongation, the individual morphologies are maintained, providing homogenous 
fibril samples for selection103-105.  Raising aptamers against these two fibril morphologies, 
both composed from Aβ40, will demonstrate the power of RNA aptamers as a recognition 
molecule and, if successful, will provide the first instance of ligands able to distinguish 
between different cross-β containing structures of the same protein sequence. 
 
3.3 Expression and purification of recombinant Aβ40 
 
The following expression and purification of Aβ40 was adapted and optimised based on the 
published methodology outlined by Linse and colleagues499.  All optimisation was aided by 
helpful discussions with Dr. Tiernan O’Malley (Brigham and Women’s Hospital, Harvard 
Medical School, MA, USA). 
 
3.3.1 Protein expression trials 
 
The plasmid containing the gene encoding Aβ40 (PetSac-Aβ40, Appendix 7.1.1) was 
transformed into competent BL21 (DE3) pLysS E. coli cells and grown on selective agar 
plates overnight (Section 2.2.3).  Aβ40 produced for this work contains an additional N-
terminal methionine to facilitate recombinant expression and it is this 41-residue product 
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that will be referred to as Aβ40, unless otherwise stated.  Single colonies were used to 
inoculate overnight starter cultures (100 mL, LB media), which in turn were used to 
inoculate 12 x 1 L cultures of LB with antibiotic selection (Section 2.3.1.1) for large-scale 
protein expression.  Cells were cultured at 37 °C, 200 rpm until an optical density at 600 nm 
(OD600) = 0.5 was reached and protein expression was then induced with the addition of 0.5 
mM IPTG.  Cells were then grown overnight (16 h) at 25 °C, 200 rpm, before collection by 
centrifugation.  SDS-PAGE analysis was used to monitor protein expression from induced 
and un-induced samples (Figure 3.1 a). 
Protein expression levels were initially low and varied substantially between flasks.  
Therefore, trials were conducted to optimise expression.  Several parameters were tested 
including most importantly, flask type, culture volume, and the duration and temperature 
of growth post-induction of protein expression with IPTG.  The trials revealed that optimum 
expression was achieved when 500 mL cultures in 2 L baffled, conical flasks were utilised, 
most probably because of the increased aeration volume506 (Figure 3.1 b).  Another 
important factor in increasing expression was culturing the cells at 37 °C post-induction for 
3-4 hours.  By monitoring optical density throughout this phase, cell growth was shown to 
plateau and extending growth beyond 4 hours led to a decrease in expression.  These 
conditions were used, therefore, for the expression of Aβ40 throughout this thesis. 
 
3.3.2 Purification of Aβ40 
 
The purification method also initially followed that described by Linse et al.499.  After 
successful, high level expression, cells were disrupted in Tris-HCl and subjected to several 
rounds of sonication and centrifugation, to isolate and wash the inclusion bodies containing 
Aβ40.  Inclusion bodies were then solubilised with buffer containing 8 M urea (Section 
2.3.1.2) before 1 in 4 dilution to reduce urea concentration and facilitate binding to Q 
Sepharose resin for the next stage of purification.  This inclusion body isolation was also 
optimised from that described499.  By reducing the number of sonication/centrifugation 
rounds, significant product losses were avoided, without compromising on the purity 
achieved at this stage. Figure 3.2 a shows the three supernatants S1, S2 and S3, isolated 
from three successive rounds of sonication followed by centrifugation.  The majority of 
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contaminants are removed in S1 and, by reducing the number of subsequent centrifugation 
steps, less Aβ40 was lost while sufficient purity was maintained.   
 
 
 
Figure 3.1 Optimisation of Aβ40 expression and purification.  (a) Reduced and varied 
expression observed when 1 L E. coli cultures were grown in standard conical flasks at 25 °C, 
overnight.  (b) Typical over-expression levels yielded under optimised conditions, (500 mL 
cultures, 2 L baffled flasks, cultured for 3.5 h post induction with IPTG).  1 mL whole cell 
samples (taken from individual replicate flasks), before (Uninduced) and after (Induced) 
induction were pelleted and boiled in 2 x loading buffer prior to analysis. (Section 2.3.1.5)   
The sizes of molecular weight markers are given in kDa. 
 
Aβ40 was then further purified by ion exchange chromatography in a batch format.  Column 
chromatography was previously shown to be unsuitable at this stage499, as much lower 
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yields of monomeric peptide were obtained.  The batch method presumably avoids aberrant 
aggregation on the ion exchange column, as a result of high local concentration of the semi-
purified product.  Protein was eluted from the resin by firstly washing with Tris-HCl buffer, 
pH 8.5, containing 0 M and then 25 mM NaCl before step-wise elution with 5 x 50 mL 
125 mM NaCl fractions.  All fractions were analysed by SDS-PAGE (Figure 3.2 b).  Those 
confirmed to contain Aβ40 were pooled prior to further purification. 
 
 
 
Figure 3.2 Anion exchange purification of Aβ40.  (a) SDS PAGE analysis of the inclusion 
body isolation stages of the purification protocol.  S1, S2 and S3 denote supernatants from 
three sequential centrifugation steps.  IB indicates the final inclusion-body-containing 
fraction.  Three pure Aβ40 calibrants (containing 1, 2 and 5 μg Aβ40) were loaded to allow 
estimation of peptide yield at each stage.  (b) SDS PAGE of fractions collected during batch 
anion exchange purification.  IB indicates the inclusion body fraction isolated before binding 
to Q-Sepharose resin.  FT denotes the flow-through.  Concentrations of NaCl in the salt-
containing fractions are indicated.  Fractions pooled and taken forward for further 
purification are indicated with the blue bracket.  Size in kDa of the protein markers are 
indicated.  
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The purification protocol described by Linse et al.499 recommends that, following ion 
exchange chromatography, Aβ40 should be further purified by molecular mass 
fractionation, using centrifugal filtration devices, claiming that pure product is obtained 
from this simple two-step method.  However, the results in Figure 3.3 a.i. shown that the 
protein is not sufficiently pure following filtration.  Further purification via Reverse Phase 
High Performance Liquid Chromatography (RP-HPLC) was attempted, whereby the 
concentrated filtrate (final volume 10 mL) was passed through a semi-preparative C18 
column and eluted with an increasing gradient of acetonitrile (Figure 3.3 a.ii.).  A major 
peak was observed at 40% acetonitrile, corresponding to the Aβ40.   
Mass spectrometric analysis of the purified fraction indicated the presence of a 2179 Da 
contaminant, corresponding in mass to a C-terminal degradation product (Figure 3.3 a.iii.).  
Although this fragment existed in low levels (typically ~10% of total peptide yield), this 
degradation was consistently observed between preparations.  Further optimisation was 
conducted in an attempt to remove this contaminant.  It was also observed that the typical 
yields of Aβ40, as a consequence of the additional HPLC purification step, were reduced 
substantially from those reported by Linse et al.499.  The yield was typically <0.5 mg of pure 
Aβ40 per L of culture, compared with the reported 10-20 mg/L499.  The RP-HPLC method 
was switched, therefore, in favour of size exclusion chromatography (SEC).  After the anion 
exchange purification, the peptide-containing fractions were dialysed against 50 mM 
ammonium bicarbonate and lyophilised.  The dried peptide was redissolved in Tris-HCl 
buffer, pH 8.5, containing 7 M guanidinium HCl, to a final volume of 10 mL, and loaded onto 
a Superdex™ 75 GL 10/300 gel filtration column.  The peptide was eluted in 50 mM 
ammonium bicarbonate and monitored by absorbance at 280 nm (Figure 3.3 b.i.).  SEC was 
performed at 4 °C to further reduce the likelihood of degradation of purified product.  
Fractions containing Aβ40 were identified by SDS PAGE analysis, pooled and lyophilised, 
and protein identity was confirmed by mass spectrometry (Figure 3.3 b.ii.). 
This optimised purification method (outlined in detail in Section 2.3.1) was utilised 
hereafter, in producing all Aβ40 peptide species for experiments in this thesis.  Typical 
peptide yields via this methodology are >4 mg pure Aβ40 per L culture.  
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Figure 3.3 Optimisation of Aβ40 purification.  (a) The initial protocol used for the 
purification of Aβ40.  (i) SDS PAGE analysis of the fractions isolated from centrifugal 
filtration.  30,000 FT indicates the flow through isolated after 30,000 MWCO filtration.  
3,000 conc indicates the fraction concentrated by 3,000 MWCO filtration.  (ii) RP-HPLC 
purification of the concentrated fraction (peak containing predominantly Aβ40 highlighted 
in yellow) using a 25-65% gradient of acetonitrile.  Elution was monitored by absorbance 
at 230 nm.  (iii) ESI-MS analysis of the peptide products isolated from the major peak in a. 
ii. indicates a persistent degradation product of 2179 Da, determined as a C-terminal 
fragment of Aβ40.  Sequences and masses of the two possible fragments, compared to full 
length Aβ40 with additional N-terminal Met – table inset.  (b) A typical SEC elution profile 
of Aβ40 monitored at 280 nm.  The peak corresponding to Aβ40 is highlighted yellow.  (b. 
ii)  ESI-MS analysis of purified Aβ40, post-SEC chromatography. 
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3.4 Preparation of Aβ40 targets for aptamer selection 
 
3.4.1 Preparation of Aβ40 fibril morphologies “2A” and “3Q’ via 
seeding 
 
Fibrils were formed via elongation from pre-formed seeds of Aβ40 in either 2A or 3Q 
morphology, kindly provided by Dr. Rob Tycko (National Institutes of Health, MD, USA).  
Seeded fibril formation reactions were set up with 5% (w/v) seed and 0.9 mg/mL 
monomeric Aβ40, in 25 mM sodium phosphate buffer, pH 7.5.  Fibrils were grown for 18 h 
under quiescent conditions and, consistent with the Tycko et al. seeding protocol (103 and 
personal communication), samples were sonicated at this stage to promote an additional 
“self-seeding” event (Section 2.4.1).  This step reportedly leads to increased incorporation 
of any residual monomer by formation of new elongation-competent ends.  Fibrils were 
then grown for a further 5 days, quiescently, and the resulting fibril morphologies assessed 
by negative stain transmission electron microscopy (TEM – Section 2.4.6).  The micrographs 
confirmed the formation of long, un-branched amyloid fibrils, however a large proportion 
of the fibrils formed accumulated into large “clumps” or “plaques” (Figure 3.4 a) which is a 
common observation for amyloid fibrils75.  It was decided that it would be advantageous to 
find suitable conditions where this lateral association was reduced, in order to expose as 
many potential aptamer binding sites as possible along the length of the fibril.  Seeding 
reactions, therefore, were monitored by TEM, at various time points during growth (Figure 
3.4 a), to determine the appropriate incubation time when fibrils were fully elongated, yet 
still diffuse and hence suitable for immobilisation for aptamer selection.  The results 
suggested that after 18 h of elongation and without the additional sonication step, fibrils 
were sufficiently elongated but more sparsely distributed, suggesting less inter-fibril 
association at this time point.  By centrifugation of the fibrils and separation of the pellet 
and soluble fraction, it was possible to assess fibril yield via SDS PAGE analysis (Figure 3.4 
b).  The results show that after 18 h growth, all of the Aβ40 peptide was incorporated into 
fibrils.  Therefore, 18 h was determined as optimal for the preparation of fibrils as selection 
targets. 
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Figure 3.4 Seeded formation of 3Q and 2A fibrils of Aβ40.  (a) TEMs of 3Q and 2A fibrils, 
after 18 h and 5 day incubation.  Scale bar = 200 nm.  (b) Yields of 2A and 3Q fibrils formed 
after incubation for 18 h were determined by SDS PAGE of soluble (S) and pelleted (P) 
fractions and compared with the whole protein content of the sample pre-separation by 
centrifugation (W).  Molecular weight markers are indicated in kDa. 
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3.4.2 Biotin labelling of selection targets for immobilisation 
 
In order to allow partitioning of bound and unbound RNA species during the SELEX protocol 
(outlined in Section 1.4.1), it was decided that immobilisation by biotin modification and 
conjugation of the Aβ40 protein species to streptavidin-coated magnetic microspheres 
would be employed.  Biotin labelling was carried out with EZ Link™ NHS LC LC biotin 
(Section 2.5.1), which is an NHS-ester activated biotinylation reagent for labelling primary 
amines (typically lysine residues or the amino-termini of proteins and peptides).  The extent 
of modification can be fine-tuned by alteration of reaction times, pH, temperature and 
concentrations of reagents.  Therefore, trials were conducted to optimise labelling 
conditions for each target assembly. 
 
3.4.2.1 Biotin labelling trials: Labelling fibrils 
 
Fibril targets were biotin-labelled post fibril formation as it was uncertain whether the 
unique, single morphologies (2A and 3Q) would be maintained if biotin-modified monomers 
were incorporated during the seeded elongation reaction.  It was important, therefore, to 
optimise the biotin labelling of pre-formed fibrils, such that only a small proportion of the 
monomers within the fibril are labelled (less than 10%).  The goal was to ensure that the 
majority of the fibril was un-modified and therefore free of the microsphere surface. 
Biotin labelling trials were set up whereby the stoichiometry of biotin reagent to fibril 
concentration (based on monomer-equivalent) and reaction times were tested.  The degree 
of biotinylation achieved under each condition was assessed by recovering the fibril as a 
pellet by centrifugation, followed by depolymerisation in 100% (v/v) HFIP overnight 
(Section 2.5.1) and mass spectrometric analysis.   
Table 3.1 outlines the conditions explored.  The results revealed that 2A and 3Q fibrils, 
although composed of the same monomeric subunits, react with the biotinylation reagent 
to different extents, presumably due to differences in the availability and/or reactivity of 
primary amines in the two fibril types.  This is unsurprising owing to their differing 
morphologies (Figure 3.5 a and b).  K28 is salt bridged in 2A fibrils, yet only partially salt 
bridged in the 3Q fibril morphology103.  It was found that 2A fibrils required a 2.6 molar 
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excess of biotin reagent (Figure 3.5 c.i.) over a 5 min reaction, to achieve a similar level of 
labelling to 3Q fibrils produced by 4-fold less reagent (1:0.65, Figure 3.5 c.iii.), over 30 s. 
 
Fibril 
Stoichiometry (Molar 
monomer equivalent fibril 
concentration : biotin) 
Reaction duration 
(min) 
% mono-
biotinylated 
2A 
1 : 2.6 30 20 
1 : 2.6 10 20 
1 : 2.6 5 < 10 (Figure 3.5 c.i.) 
3Q 
1 : 2.6 30 50 
1 : 2.6 10 50 
1 : 2.6 5 50 (Figure 3.5 c.ii.) 
1: 0.65 1 10 
1 : 0.65 0.5 < 10 (Figure 3.5 c.iii.) 
Table 3.1 Conditions trialled in biotin labelling of 2A and 3Q fibrils.  See Section 2.5.1 for 
details of the protocol used. 
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Figure 3.5 Labelling of 2A and 3Q fibrils with NHS-ester activated biotin.  Structural models 
of 2A (a) and 3Q (b) fibrils with positions of the reactive lysine residues K16 and K28 (blue 
sticks) and N-terminus indicated.  Models comprise six layers of hydrogen-bonded peptides, 
stacked with the fibril axis running perpendicular to the plane of the page and were 
produced from coordinate pdb files 2LMN and 2LMP, respectively.  The first eight residues 
have been modelled, without NMR restraints, to illustrate the presence of an unstructured 
N-terminal region.  (c) Maximum entropy ESI mass spectra depicting the resultant extent of 
labelling under different biotinylation reaction conditions for 2A (c.i, teal) and 3Q (c.ii and 
c.iii, green) fibrils.  Levels of biotin labelling at a single position are shown at 1:2.6 molar 
ratio of fibril (monomer equivalent) to biotin reagent, with a 30 min reaction time (c.i and 
c.ii) and 1:0.65 molar ratio for 30 s (c.iii).  Expected masses are 4458 Da and 4911 Da for 
un-modified and singly biotinylated Aβ40, respectively. 
SELECTION OF RNA APTAMERS AGAINST ASSEMBLIES OF Aβ40 
 
112 
 
To determine whether there was a difference in the relative positions of the biotin labels 
between the two fibril types, tandem mass spectrometry (MS/MS) with electron transfer 
dissociation (ETD) was performed by Dr. James Ault (Mass Spectrometry Facility, School of 
Molecular and Cellular Biology, University of Leeds).  ETD fragments peptide ions by 
electron transfer from a radical anion, producing c and z peptide fragments507.  This allows 
assignment of fragments containing modifications, in this case biotin, by fragmentation of 
the full-length Aβ40 and can therefore be used to determine the position of the modification.   
Accordingly, samples of both the 2A and 3Q fibrils, biotinylated to approximately 10% 
under the optimised conditions for each, were buffer exchanged and depolymerised as 
described (Section 3.4.2.1) for normal mass spectrometric analysis.  The samples were then 
resolubilised in 50% acetonitrile, 0.1% formic acid and analysed by MS/MS ETD.  The 
fragmentation spectra for each fibril morphology (Appendix 7.2) indicate that 
biotinylation occurs predominantly at the N-terminus and at residue K16 (K17 in this 
recombinantly-expressed Aβ40 with the additional N-terminal methionine) in both fibril 
types.  Far fewer fragments corresponding to K28 labelling are seen, suggesting less 
labelling at this position.  This is consistent with the K28 residue being more buried in the 
loop region of the fibril structure (Figure 3.5).  As there is no significant difference in the 
fragmentation spectra from the two fibril samples, it suggests that the enhanced biotin 
reactivity seen by 3Q fibrils is more likely due to the extra K16 residue per unit length of 
this assembly; a consequence of the 3-fold molecular symmetry. 
To prepare biotinylated fibrils for immobilisation, free biotin was removed from the 
mixture via buffer exchange, by gentle centrifugation and washing of the fibrils (Section 
2.5.1).  Fibrils were exchanged into MOPS selection buffer (80 mM MOPS, 96 mM NaCl, pH 
7.5) and immobilised for selection as described in Section 2.5.2.  Bead loading was verified 
with absorbance measurements at 280 nm of the peptide solution before and after magnetic 
partitioning (data not shown). 
 
3.4.2.2 Biotin labelling trials: Labelling monomeric Aβ40  
 
By contrast with biotinylation of Aβ40 in 2A and 3Q fibrils, where the percent modification 
was carefully controlled to be <10% of the monomers present, the level of Aβ40 monomer 
biotinylation was optimised to give a maximum of one biotin per peptide, whilst minimising 
labelling of two or more primary amines.  This was to ensure that Aβ40 monomers were 
immobilised to the streptavidin beads at a single site, while leaving a number of positively 
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charged residues free, which could be critical in providing binding epitopes for the RNA 
aptamers. 
Table 3.2 provides details of the conditions tested to achieve the most appropriate 
biotinylation levels in labelling Aβ40 monomer.  Samples were dialysed against 100 mM 
ammonium acetate, pH 7.5 and the extent of labelling was assessed by ESI-MS.  The results 
showed that a three-fold molar excess of biotin reagent and a 15 min reaction time was 
necessary to yield 40% biotinylation at a single position (Figure 3.6).  Increasing the 
proportion of biotinylation reagent increased the amount of di, tri and tetra-modifications 
(data not shown).   
 
Stoichiometry (Molar 
concentration : biotin) 
Reaction duration 
(min) 
Biotinylation level 
1 : 1 15 20% mono-biotinylated 
1 : 10 
15 
30 Very high levels of 
doubly or triply labelled 
1 : 20 
15 
30 
1 : 2.5 15 30% mono-biotinylated 
1 : 3 15 
40% mono-biotinylated 
(Figure 3.6) 
 
1 : 4 15 
50% mono-biotinylated 
(levels of additional 
labelling starting to 
increase) 
Table 3.2 Conditions trialled in biotin labelling of Aβ40 monomer.  See Section 2.5.1 for the 
protocol used. 
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Figure 3.6 Biotin labelling of Aβ40 monomer.  ESI-MS analysis indicating biotin (+1 Bio) 
modification at a single site.  Both unmodified Aβ40 and the single biotin labelled form are 
shown in the 4+ charge state only.  Expected masses are 4458 Da and 4911 Da for un-
modified and singly biotinylated Aβ40, respectively. 
 
Once Aβ40 monomer was labelled under these optimised conditions, the reaction mixture 
was quenched with the addition of 1M Tris-HCl, pH 8.0 and the sample dialysed against 
80 mM MOPS, 96 mM NaCl, pH 7.5 (MOPS selection buffer) at 4 °C for 2 h, using 2000 MWCO 
Slide-A-Lyzer™ MINI dialysis devices (Section 2.5.1), to remove free biotin and exchange the 
sample into buffer for selection of RNA aptamers.  
 
3.4.3 Aβ40 remains monomeric over immobilisation timescale 
 
Given the known, rapid aggregation propensity of Aβ4081, 491, 499, it was imperative to analyse 
whether aggregation of the peptide could commence within the biotinylation and 
subsequent purification time course (<3 h) and, therefore, whether the species immobilised, 
and subsequently selected against, was indeed monomeric Aβ40.  SEC traces at time points 
0 and 3 h, post-dissolution of lyophilised peptide into selection buffer, indicated the 
presence of a dominant species, eluting at a volume consistent with monomeric Aβ40 
(Figure 3.7 a).  However, SEC alone could not provide accurate sizing of the Aβ40 species, 
owing to the fact that the elution profile of the unstructured Aβ peptide cannot be compared 
with the behaviour of standard, globular calibrants.  Therefore, SEC combined with multi-
angle laser light scattering (SEC MALLS) was utilised to assess the nature of the Aβ40 
species eluting from the column, as this technique allows absolute measurement of 
molecular weight (MW) by coupling mass separation with light scattering (LS) (Figure 
3.7 b) (Section 2.8.1).  
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Figure 3.7 Aβ40 remains predominantly monomeric over the immobilisation timescale.  (a) 
SEC analysis (Section 2.8.1) of Aβ40 at time points 0 and 3 h post re-solubilisation in MOPS 
selection buffer.  The 3 h sample was incubated at 4 °C before injection.  (b) Absolute 
molecular weights calculated from LS data (using Wyatt Astra software, version 6.0), 
corresponding to the two major peaks in the SEC separation.  Peak 1 and Peak 2 are 
highlighted in yellow and indicated on the chromatograms.   
 
At t = 0 h, the major peak eluting from the SEC column had an absolute molecular weight of 
6.735 x 103 (± 1.9%) Da, indicating a possible monomer-dimer equilibrium at this time point 
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(mass of monomeric Aβ40 = 4.458 x 103 Da).  After 3 h of incubation at 4 °C (mirroring the 
conditions during the buffer exchange of biotinylated monomer for immobilisation) the 
major peak, eluting at approximately the same volume, had a suggested molecular weight 
of 4.514 x 103 (± 2.3 %) Da, corresponding almost exactly to the expected mass of Aβ40 
monomer.  The decrease in mass over the 3 h incubation is probably due to equilibration of 
the sample after re-solubilisation, rather than disaggregation of dimers.  A second peak, 
with a smaller elution volume, indicating the presence of some larger aggregates, was 
observed in low levels at both time points.  LS data could not be used to assign an absolute 
MW for this peak at t = 0, however, as this species became more highly populated at t = 3 h, 
a mass of 9.672 x 104 (± 3.0%) Da was calculated.  This is evidence for the formation of some 
larger aggregates (possibly ~ 20mers) over the 3 h time course.  However, the vast majority 
of Aβ40 remains monomeric under these conditions.  Therefore, the biotinylation and buffer 
exchange protocol devised was deemed suitable in obtaining predominantly monomeric 
peptide for immobilisation.  It was then assumed that after immobilisation on the surface of 
the beads, self-association of the monomeric Aβ40 would no longer be able to occur. 
 
3.5 Selection of RNA aptamers  
 
Selection of RNA aptamers firstly required synthesis of a combinatorial oligonucleotide 
library, made up of a central, randomised region, flanked by two regions with fixed 
sequences (Figure 3.8 a).  These fixed primer regions are necessary for amplification of the 
library, during the selection process, via RT-PCR.  The ssDNA library (N50 –sequence given 
in Section 2.7.1) was designed by Dr. David Bunka (University of Leeds) and synthesised 
commercially.  Although initially thought to be comprised of a completely random library, 
where all 4 nucleotide bases are represented equally within the randomised region, some 
bias in the base-composition exists for this pool and is discussed later (Section 3.7).  A 
random region of 50 nucleotides was chosen as it creates the potential for a highly diverse 
starting library (450 individual sequences).  As detailed in Section 1.4.1, the actual sequence 
space available is more limited in practice, owing to the total number of molecules in a 
typical RNA pool (1015), and consequently only a fraction of the library’s potential sequence 
coverage will be encompassed within the pool.  Nevertheless, an N50 library was deemed 
appropriate, as this longer central region allows for the potential formation of more diverse 
secondary structural elements.  To obtain an RNA library from this DNA template, a T7 
bacteriophage RNA polymerase promoter sequence was incorporated into the 5′ primer 
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extension.  The ssDNA was then amplified by PCR (Section 2.6.1) to produce the dsDNA 
template required for in vitro transcription. 
Modified oligonucleotide libraries are often used in SELEX as they provide aptamers with 
inherent resistance to nuclease-mediated degradation384 (Section 1.4.2).  Accordingly, a 2′F 
modified pyrimidine library (Figure 3.8 b) was used in these selections and to allow 
efficient incorporation of these chemically substituted nucleotides, a Y639F/H784A mutant 
of T7 RNA polymerase was utilised.  This mutant polymerase works by a) eliminating the 
inflexibility of the hydrogen bonding potential and therefore substrate recognition 
compared to the wild-type polymerase and b) providing more space in the active site and 
therefore relaxing the barrier to extension of transcripts with non-canonical nucleotides406, 
508, 509 (Section 2.6.3). 
 
 
 
Figure 3.8 Design of a 2′F pyrimidine modified oligonucleotide library for RNA aptamer 
selection.  (a) Schematic of the ssDNA template used in creating the randomised N50 RNA 
library.  Full sequences for both the DNA template and primer oligonucleotides are given in 
Section 2.7.1.  (b) Comparative chemical structures of 2ʹOH (b.i) and 2′F modified (b.ii) 
nucleotides used in the 2′F pyrimidine library.  Uridine is shown as an example. 
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3.5.1 Selection of RNA aptamers against Aβ40 monomers 
 
Selections against Aβ40 monomer were carried out by Dr. David Bunka as part of my initial 
training into the use of the liquid handling robot and general RNA techniques. 
A 50 μL in vitro transcription reaction, containing a 2′F pyrimidine, 2′OH purine dNTP mix 
(Section 2.6.3) was set up to create the starting naïve RNA pool (~1015 sequences), which 
was DNase treated and purified (Section 2.6.8).  50 μL of RNA was then mixed with 50 µL 
2 x MOPS selection buffer before incubation with 20 μL of biotin linker-saturated 
streptavidin beads.  This step was included during every SELEX round, as a negative 
selection, to ensure that RNA aptamers with affinity towards the biotin linker and/or the 
streptavidin beads themselves were removed at each stage.  The beads were then 
partitioned by magnetic separation and the unbound fraction removed and added to 20 µL 
of Aβ40 saturated beads (35 ng Aβ40 immobilised) for positive selection.  The magnetic 
beads were partitioned, the unbound fraction removed and the beads, with associated 
aptamers, were washed ten times with 125 μL of selection buffer.  35 μL of nuclease-free 
H2O was added to the washed beads and the bound RNA was eluted by heating the mixture 
to 95 °C.  The mixture was then cooled, before the addition of reverse transcription mix 
(Section 2.6.9) to produce cDNA products, which were PCR amplified for the next round.   
After this initial manual selection round, the process was automated by use of a liquid 
handling robot (Section 2.7.3), whereby four iterations of the above protocol were 
performed.  RT-PCR products from each round were then analysed by native PAGE (Section 
2.6.2) to confirm the isolation of aptamers of the correct size (121 bp) (Figure 3.9 a.i.).  A 
second manual selection was then performed (R6) before a further four rounds of 
automated selection (R7-10), which followed the same basic selection process as described 
above.  Some modifications, to increase stringency, were made to these later SELEX rounds.  
Target incubation was altered from 15 min at 25 °C to 5 min at 37 °C.  This was to drive the 
selection of aptamers with faster on rates (Kon), as opposed to during the early selection 
rounds, where stringency was deliberately low to avoid the loss of lowly populated binders.  
The volume of target beads (and therefore the concentration of target peptide) was halved 
to increase the competition between aptamer sequences for the available epitopes.  The 
number of wash steps was also increased, thereby selecting against aptamers with higher 
off rates (Koff) and again promoting selection of aptamers with enhanced affinity.  The 
increased stringency in these latter selection rounds results in the bands corresponding to 
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isolated aptamers becoming progressively less intense, as the stringency drives the 
selection towards fewer, more specific aptamers (Figure 3.9 a.ii.). 
Six solution-competition rounds (R11-16) were included at the later stages of this anti-Aβ40 
monomer selection protocol, to promote recognition of native conformations that had not 
been immobilised or modified.  In these selection rounds, after standard binding and wash 
steps, beads were challenged with various concentrations of un-modified target peptide, in 
solution, to compete bound aptamers from the immobilised targets.  35 µL of 25 µM Aβ40, 
in MOPS selection buffer, was incubated with the target bound RNA for 10 min at 25 °C.  This 
fraction was removed and the process repeated with a 50 µM Aβ40 challenge.  The 
remaining RNA associated with the immobilised Aβ40 was then heat eluted, as described 
for the standard protocol (Section 2.7.2).  All three eluate fractions were then reverse 
transcribed and PCR amplified before analysis by native PAGE.  In rounds 11-15, the DNA 
isolated from the 50 µM Aβ40 competition eluate was taken forward in each case, as this 
was expected to contain aptamers with the highest affinity for solution targets.  In the final 
competition round (R16 - Figure 3.9 b), the 50 μM Aβ40 eluate (after 20 PCR cycles) was 
PCR purified and taken forward for next generation sequencing.   
Figure 3.9 c outlines the overall SELEX procedure for the selection of anti-monomer 
aptamers.  Detailed experimental procedures for each type of selection round, including all 
stringency conditions adopted at each stage, are given in Section 2.7. 
 
3.5.2 Selection of anti-fibril aptamers 
 
The following RNA aptamer selections against the two morphologically distinct Aβ40 fibrils, 
were carried out personally, with supervision from both Dr. David Bunka and Dr. Simon 
White (School of Molecular and Cellular Biology, University of Leeds). 
RNA aptamer selection against the 2A fibril morphology was undertaken with the same N50 
library used in the anti-Aβ40 monomer selections.  Anti-3Q fibril aptamers were selected 
from a different N30 degenerate pool (Section 2.7.1), to avoid problems with cross-
contamination between the N50 and N30 libraries.  Both DNA template libraries were 
designed by Dr. Bunka and synthesised commercially in the same manner as described 
previously (Section 3.5.1), before amplification and transcription to give the initial starting 
RNA library for SELEX.  
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Figure 3.9 Anti-Aβ40 monomer aptamer selection.  (a) Native PAGE analysis of DNA 
products at the end of each selection round (R1-5 (i), R6-R10(ii)) after RT-PCR (10 cycles).  
(b) The final competition round (R16) for anti-monomer SELEX.  The pool amplified from 
the previous round (R15) and the first wash fraction (W) are shown.  Solution challenges, 
with 25 μM Aβ40 (25), 50 μM Aβ40 (50) and the heat elution (H) sampled after both 10 and 
20 PCR cycles are indicated.  Here, and throughout unless otherwise stated, the sizes of 
molecular weight markers (10 bp DNA ladder, Invitrogen) are given in base-pairs.  Data 
courtesy of Dr. David Bunka.  (c) Flow chart outlining the full SELEX protocol for anti-
monomer selection.  * denotes rounds where stringency parameters were increased (See 
Section 2.7 for detailed protocols). 
 
The general procedure for anti-fibril aptamer selection (Figure 3.10 a) was similar to the 
strategy used for selection of Aβ40 monomer aptamers.  The key difference was in the 
inclusion of an initial pull-down capture round, where the RNA pool was first incubated with 
biotin modified fibrils, free in solution.  After incubation, streptavidin beads were added to 
capture the biotin-fibrils and any bound RNA.  Accordingly, 50 µL of the RNA aptamer pool 
was added to 50 µL of a 20 µM biotin-labelled fibril solution and incubated for 15 minutes 
with gentle agitation.  The mixture was then added to 0.5 mg of washed, un-conjugated 
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streptavidin beads and incubated for a further 30 min.  This strategy allowed for the entire 
complex to be pulled out of solution, to aid in the isolation of aptamers against native fibril 
epitopes.  The beads were then separated by magnetic partitioning, washed three times 
with 1 mL MOPS selection buffer and the bound RNA eluted and RT-PCR amplified as 
described (Section 2.7.4).  The resultant RNA pool was then taken forward for subsequent 
automated and competition selection rounds (Figure 3.10 a).  Detailed selection 
procedures for all variations on the standard protocol are given in Section 2.7.   
As in the case of the anti-monomer selection, the final round for each of the fibril selections 
included competition elution with free, unmodified fibril targets in solution (Figure 3.10 b).  
In these instances, challenges were 10 and 20 µM fibril (monomer equivalent 
concentration).  In both cases, the 20 μM eluate was PCR purified and sequenced. 
 
 
 
Figure 3.10 Anti-fibril aptamer selection.  (a) Flow chart outlining the SELEX protocol for 
the anti-fibril aptamer selection.  * denotes rounds where stringency parameters were 
increased.  (b) The final competition elution rounds for each anti-fibril selection analysed 
by native PAGE.  DNA products isolated from the solution challenges with 10 μM (10) and 
20 μM (20) fibrils (monomer equivalent concentration), as well as the heat eluted fraction 
(H), are indicated.   
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3.6 Next generation sequencing of enriched pools 
 
The conventional approach of cloning, colony-picking and Sanger sequencing of a small 
number of colonies (typically 10-100(ref 377)) has shown success in RNA aptamer selections 
by finding the most frequently occurring sequences, enriched through SELEX.  However, by 
use of next generation sequencing (NGS) it is possible to sequence up to 107 different 
sequences from a SELEX pool and therefore analyse sequence frequencies at much higher 
resolution.  This technique was employed here, in the analysis of the enriched pools isolated 
from the three anti-Aβ40 selections.  The DNA pools acquired from the final RT-PCR step of 
the selections were PCR purified (Section 2.6.1) and sent for NGS analysis.  Preparation of 
the DNA libraries and sequencing via an Ilumina MiSeq platform was carried out by Dr. Sally 
Fairweather (Leeds Institute of Molecular Medicine, St. James Hospital, Leeds).   
The general concept of NGS is similar to the Sanger approach, where a DNA polymerase 
catalyses the incorporation of fluorescently-labelled dNTPs into a DNA strand, during 
sequential cycles of DNA synthesis510.  The nucleotides are identified by fluorophore 
excitation, at the point of incorporation, during each successive cycle.  Using a reversible-
terminator based method, addition of a single base, as it is incorporated, can be detected.  
An overview of the NGS library preparation and sequencing chemistry is given in Figure 
3.11.  Briefly, the library is prepared by ligation of adapter oligonucleotides at both the 5ʹ 
and 3ʹ end of the input DNA sequences, which are then PCR amplified and purified.  DNA 
sequences are then captured on a flow-cell via complementary base-pairing to a lawn of 
surface-bound oligonucleotides, corresponding to the adapters.  This allows bridge 
amplification to produce dense clusters of clones.  After cluster generation is complete, 
sequencing can be initiated by the addition of the four reversible, terminator bound, 
fluorescently labelled dNTPs, sequencing primers and DNA polymerase.  Fluorescence upon 
incorporation of a base is recorded for each individual clone cluster, followed by a chemical 
de-blocking step to remove the fluorophore and the 3ʹ-terminal blocking group, for the next 
sequencing cycle.  This way, hundreds of thousands of sequence clusters can be read 
simultaneously, in a parallel process, leading to vast sequence coverage of the enriched 
aptamer pools.   
NGS analysis of the three anti-Aβ40 aptamer selections yielded 660,000 sequence reads for 
the anti-monomer pool, and 41 million and 7.5 million for anti-2A and anti-3Q fibril 
selection pools, respectively. The next challenge, therefore, was to devise a strategy to 
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handle such volumes of sequencing data and to select only a few lead aptamers for further 
work and characterisation. 
 
Figure 3.11 Overview of the next generation sequencing (NGS) process.  (1) The NGS 
library is prepared by ligating specialised oligonucleotide adaptors to both the 3ʹ and 5ʹ 
ends of the DNA.  (2) The library is loaded into a flow cell where the DNA strands hybridise 
to the surface via specific base-pairing to surface-bound oligonucleotides, complimentary 
to the adaptors.  The bound strand is then amplified into a clonal cluster through bridge 
amplification.  (3)  Sequencing reagents (including fluorescently-labelled, reversibly-
terminated dNTPs) are added and the first base is incorporated.  The emission of the newly-
incorporated fluorescent base is recorded for each cluster before removal of the 
fluorophore and 3ʹ blocking group for the next cycle.  Imaging of each fluorescent base, as it 
is incorporated into the complementary strand, allows the sequence of the clone in each 
cluster to be built.  Figure redrawn and adapted from 511. 
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3.7 Analysis of next generation sequencing data 
 
In collaboration with Dr. Eric Dykeman (Department of Mathematics, University of York, 
UK), a bioinformatics-based approach was utilised to identify aptamers for further 
characterisation.  The basis of the strategy was to identify the unique aptamers from within 
the total sequence reads and rank them in order of occurrence.  Then, a closer analysis of 
the most populous unique aptamers, through sequence alignment, would allow clustering 
of related sequences into motif “families” and identification of the extent of minor variation 
between sequences.  Representative aptamers could then be chosen from each cluster for 
downstream characterisation. 
An aptamer sorting script (written by Dr. Dykeman) was applied to identify and rank the 
aptamers in order of the most frequently occurring single sequence.  The script firstly 
identifies the correct 5ʹ and 3ʹ primer regions (specified for each pool) and filters out 
sequences that are not of the correct random region length (details of script stringency 
parameters given in Section 2.7.7).  Once filtered, 395,874 such matches were determined 
from the anti-Aβ40 monomer pool, with 994,679 (2A) and 1,593,643 (3Q) sequences from 
the two anti-fibril pools.  The script then counts and ranks the identical sequences in order 
of their occurrence.  The frequency distributions of the top 500 most populous unique 
sequences, for each of the three selection pools, are given in Figure 3.12 - Figure 3.14.  Part 
b of each of these figures shows a zoomed region of the frequency plots to visualise and 
compare the selected data with the number of occurrences of identical sequences derived 
from NGS analysis of the respective naïve pools.  The data suggest that SELEX has been 
successful in all cases, as individual sequences are clearly enriched above the baseline 
number of individual sequences populated in the un-selected pool.  In addition, there is a 
highly populated lead sequence in each case (aptamer 1) and a rapid decrease in population 
of further sequences.  This is consistent with the principle that the higher affinity binders 
should be preferentially amplified during iterative SELEX rounds.  Ranking unique aptamers 
in order of decreasing occurrence in the sequenced pools also provides a convenient naming 
system, whereby aptamer names correspond to their position in the ranking, e.g. 3Q1: the 
most abundant sequence from the 3Q selection, 3Q2: the second most abundant, etc.. 
From an initial look at the sequences represented within each of the enriched pools, it was 
immediately apparent that there were differences in the relative representation of the four 
nucleotide bases.  Sequences of the randomised regions of the enriched anti-Aβ40 monomer 
and anti-2A fibril selection pools were purine-rich, whereas the anti-3Q fibril aptamers 
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generally contained poly-U repeats.  These differences in base-composition could be an 
indication that aptamers have been selected that are specific for different epitopes between 
these related targets.  Therefore, to probe this further, analysis of the base-composition of 
the filtered sequences was carried out and compared to the base-composition of the naïve 
starting libraries, as a shift in the relative representation of each nucleotide base may, firstly, 
further indicate the successful selection of sequences and, secondly, imply specificity for 
distinct target epitopes.  This was done with a second aptamer analysis script (written by 
Dr. Dykeman- Section 2.7.7), which scans the randomised region of the filtered sequences 
identified from the selected pool and quantifies the number of times each nucleotide base 
is represented.  The same analysis was conducted on the naïve pools, for comparison.  The 
data is given in part c of Figure 3.12, Figure 3.13 and Figure 3.14 for the anti-Aβ40 
monomer, anti-2A and anti-3Q fibril selections, respectively.  There is clearly evidence for 
biases in the relative base-composition between each pool, with anti-Aβ40 monomer and 
anti-2A fibril aptamers containing a GA bias (71.5% and 69.6% GA content, respectively) 
and the anti-3Q fibril aptamers showing a much higher representation of uracil (45.4%).  
However, these base biases are seemingly carried through from the starting libraries, which 
also show the same base preferences (Figure 3.12 - Figure 3.14, purple bars).  Some 
changes in the distribution of represented bases could possibly have resulted as a 
consequence of selection.  For example, the U-bias in the anti-3Q aptamer pool becomes 
more prominent (from 35.5% in the starting pool to 45.4% post-SELEX), but this is difficult 
to interpret.  Nevertheless, the selections were clearly undertaken with naïve pools that 
contained considerable bias, therefore the desired full diversity of a random pool was not 
sampled during SELEX.  Despite this finding, certain sequences were clearly enriched during 
the selection and it is from these highly populated sequences that representative aptamers 
were chosen for further characterisation. 
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Figure 3.12 Bioinformatic analysis of the top 500 most frequently occuring, unique 
aptamer sequences from the anti-Aβ40 monomer selection.  (a) Frequency plot illustrating 
the occurance of each of the top 500 sequences isolated from the filtered NGS data from the 
anti-Aβ40 monomer selection pool.  (b) A closer look at the number of occurances of the 
top 50 sequences from the anti-Aβ40 monomer pool, compared to the number of 
occurances of unique single sequences within the starting library (purple histogram 
overlaid).  (c) The relative distribution of the four nucleotide bases in the enriched, filtered 
pool (blue bars) compared to the starting library (purple bars).  
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Figure 3.13 Bioinformatic analysis of the top 500 most frequently occuring, unique 
aptamer sequences from the anti-2A fibril selection.  (a) Frequency plot illustrating the 
occurance of each of the top 500 sequences isolated from the filtered NGS data from the 
anti-2A fibril selection pool.  (b) A closer look at the number of occurances of the top 50 
sequences from the anti-2A fibril pool, compared to the number of occurances of unique 
single sequences within the starting library (purple histogram overlaid).  (c) The relative 
distribution of the four nucleotide bases in the enriched, filtered pool (teal bars) compared 
to the starting library (purple bars). 
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Figure 3.14 Bioinformatic analysis of the top 500 most frequently occuring, unique 
aptamer sequences from the anti-3Q fibril selection.  (a) Frequency plot illustrating the 
occurance of each of the top 500 sequences isolated from the filtered NGS data from the 
anti-3Q fibril selection pool.  (b) A closer look at the number of occurances of the top 50 
sequences from the anti-3Q fibril pool, compared to the number of occurances of unique 
single sequences within the starting library (purple histogram overlaid).  (c) The relative 
distribution of the four nucleotide bases in the enriched, filtered pool (green bars) 
compared to the starting library (purple bars). 
SELECTION OF RNA APTAMERS AGAINST ASSEMBLIES OF Aβ40 
 
129 
 
The most abundant sequences for each selection pool were analysed for sequence similarity 
using the multiple alignment software Genebee512.  Since Genebee is not designed to process 
more than 500 clones, it was the 500 topmost enriched sequences that were selected for 
analysis.  In each case, the total number of aptamers that are represented within the top 500 
sequences is only a fraction of the total sequences filtered from the sorting script (3.5% for 
anti-Aβ40 monomer, 24% anti-2A fibrils and 0.9% anti-3Q fibrils).  There is clearly a 
significant number of sequences that cannot be analysed via this methodology, however as 
these sequences are significantly less populated, they are therefore likely to be of less 
interest.  The sequences excluded from the Genebee analysis corresponds to those that are 
represented less than 16 times each in the case of both the 3Q and monomer selections, 
compared to the topmost aptamer’s representation of 658 and 613 times, respectively.  In 
the case of 2A fibril aptamers, whose sequencing yielded significantly larger amounts of 
data, the topmost occurring aptamer occurred 51,626 times and the top 500 unique 
sequences represent all aptamers that occurred more than 57 times each.  Table 3.3 
summarises the analysis of selected aptamers for each pool. 
 
Selection 
Raw sequence 
reads 
Filtered 
aptamers 
Total 
sequences in 
top 500 
Total 
sequences in 
top 500: % of 
filtered 
Aβ40 monomer 0.7 million 395,874 13,914 3.5 
2A fibril 41 million 994,679 240,945 24 
3Q fibril 7.5 million 1,593,643 13,810 0.9 
Table 3.3 Summary of the bioinformatics analysis of the three Aβ40 selections.  Raw 
sequence reads corresponds to the unfiltered, raw data from NGS.  Filtered aptamers are 
the sequences with correct SELEX primers and random region length, identified from the 
raw sequence reads. 
 
Genebee analysis of the top 500 most commonly occurring sequences resulted in the 
identification of conserved motifs for each selection pool.  Motifs identified through 
Genebee are ranked in order of their degree of similarity, with a score designated to a given 
motif known as the power of alignment.  The power score is an estimation of the degree of 
similarity and takes into account the length of identical regions within the motifs, as well as 
“thickness” or number of sequences within the motif513.  The ten motif families with the 
highest power score are given as the output of the Genebee analysis.  An example of the 
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strongest local alignment, taken from the anti-2A fibril selection, is given in Figure 3.15 and 
entire datasets, which include the ten strongest families within the top 500 sequences for 
each selection pool, can be found in Appendix 7.3.  
 
 
Figure 3.15 Genebee sequence alignment of the top 500 most commonly occuring 
sequences yields sequence motifs or “families”.  An example of the strongest motif family 
identified from Genebee multiple alignment analysis of the top 500 sequences from the anti-
2A fibril selection pool.  Aptamer number indicates the position of the sequence in the 
occurrence ranking. + indicates strong identity at that position.  Bases are colour coded 
according to the following: G (pink), A (teal), C (green), T (blue).  DNA sequences 
corresponding to the RNA aptamers are shown. 
 
The most abundant aptamer sequences for each pool (the top 5) are generally represented 
within the ten alignment motifs with the highest power scores.  The further sequences 
within the motifs often differ by only a single nucleotide (see Figure 3.15 for one such 
example, Appendix 7.3 for full datasets).  This indicates that the most populous aptamers 
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are likely to be “ancestors” of related sequences and therefore the sequences lower in 
abundance and excluded from the genebee analysis (below top 500) may well be derivatives 
of the highly populated sequences that have been analysed.  Although Illumina MiSeq has 
one of the lowest reported error rates of all the NGS platforms (<0.4% 514), this substitution 
and read error will contribute to the number of imperfect sequences and suggests it is 
indeed valid to take the most populous aptamers forward.    
The ten sequence families isolated for each of the three selection pools were then used to 
find representative sequences to take forward for characterisation.  Mfold secondary 
structure prediction was used to examine structural motifs from within the aligned families.  
Within each motif, a random selection of the sequences were chosen and analysed for their 
predicted secondary structure.  As expected, for the most part, sequences within a given 
family shared common secondary structure and therefore only one representative 
sequence was taken forward.  However, in some cases, where the alignment power was 
generally weaker, more structural diversity was predicted within a family, and therefore 
more than one representative sequence, each with a distinct structural element, were 
considered.  Figure 3.16 shows an example of two motifs from the anti-3Q fibril aptamer 
pool where the secondary structure predication indicate diverse or common structures 
within a given motif.   
Although mentioned above that the most populous sequences are usually represented 
within the ten families derived through Genebee sequence alignment, there are a few cases 
where these abundant sequences are not represented.  This is particularly true for the anti-
Aβ40 monomer selections, where the motifs are not as well populated with related 
sequences as the two anti-fibril pools (Appendix 7.3).  To ensure these highly populated 
sequences were not neglected from our sampling strategy, the five most populous aptamers 
were also analysed for secondary structure.  If the putative fold was distinct from those 
chosen from the alignment motifs, these too were considered for further analysis. 
Between 5 and 8 aptamer sequences (Figure 3.17 a) were chosen from each selection pool, 
based on this bioinformatic sampling (summarised in Figure 3.17 b).  The Mfold secondary 
structure predictions represent the major conserved motifs within each pool and are given 
in Figure 3.18 - Figure 3.20.  Chosen structures generally contain discrete secondary 
structure in the random region which consists of a mixture of extended and interrupted 
stem-loop structures.  In most cases, these are supported by separate structural elements 
formed by the primer regions, however, sometimes the primer region is directly involved 
in forming the base-paired elements of the central region.  Aptamers with these discrete 
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structural elements were chosen, as these regions may represent the functional structure 
or binding epitope of the aptamers.  As shorter aptamers are more easily synthesised and 
more versatile in most downstream applications, it was desirable to isolate aptamers that 
could be easily truncated to their minimal functional binding sequences, once the binding 
properties of the full-length aptamer have been properly characterised.   
Owing to the high proportion of repetitive guanosine residues in the anti-Aβ40 monomer 
and anti-2A fibril aptamers (presumably a result of their selection from the GA biased 
selection libraries), it was hypothesised that these sequences would likely form G-
quadruplex structures.  A G-quadruplex (also known as G-quartet or G-tetraplex) is a 
common structural motif that can be formed from both DNA and RNA.  A G-quadruplex 
consists of G-rich sequences forming various four-stranded structures, where the guanine 
bases associate in a square-planar arrangement through Hoogsteen hydrogen bonding515.  
The structure is further stabilised by monovalent cations that occupy the central cavity 
between the strands.  Using a quadruplex forming G-rich sequences prediction algorithm 
(QGRS)516, the ability to form G-quadruplex structures was predicted for all five anti-2A 
fibril aptamers chosen from the next generation sampling, and all but one of the anti-Aβ40 
monomer aptamer sequences (M1 was the only sequence predicted not to form a G-
quadruplex).  The anti-3Q aptamers generally do not contain repetitive G residues, except 
in the case of 3Q1 which, interestingly, does not display the same U-rich bias as shown for 
the majority of aptamers selected in the anti-3Q fibril selection.  This sequence instead 
displays a bias towards GA nucleotides (76.6%) and is the only anti-3Q fibril aptamer from 
the cohort that is predicted to form a G-quadruplex structure.   
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Figure 3.16 Mfold secondary structure prediction analysis of aptamer motifs.  Examples of 
motifs, derived from the Genebee sequence alignments, where more than one distinct 
structure was populated (a) and, conversely, where structures represented were near 
identical (b).  Only the two sequences from the motifs for which secondary structure 
analysis was performed are shown for clarity.  Full alignment data are given in Appendix 
7.3.  Bases corresponding to the random region of the aptamer are represented with 
coloured circles and the 5′ and 3′ primer regions in black circles.  Bases are colour coded 
according to the same scheme in Figure 3.15. 
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Figure 3.17 Isolation of hit aptamers from bioinformatic sampling.  (a) Sequences of the 
lead aptamers chosen from each selection pool.  (b) Flow chart outlining the bioinformatics 
based strategy employed to process ~107 sequences per selection and isolate lead 
sequences. 
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Figure 3.18 Structures of the lead aptamers from the anti-Aβ40 monomer selection.  Mfold 
predicted secondary structures for the eight lead aptamers chosen from the anti-Aβ40 
monomer selection pool.  The predicted lowest free energy fold is given for each sequence.  
Bases are colour coded according to the same scheme in Figure 3.15.  
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Figure 3.19 Structures of the lead aptamers from the anti-2A fibril selection.  Mfold 
predicted secondary structures for the five lead aptamers chosen from the anti-2A fibril 
selection pool.  The predicted lowest free energy fold is given for each sequence.  Bases are 
colour coded according to the same scheme in Figure 3.15. 
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Figure 3.20 Structures of the lead aptamers from the anti-3Q fibril selection.  Mfold 
predicted secondary structures for the five lead aptamers chosen from the anti-3Q fibril 
selection pool.  The predicted lowest free energy fold is given for each sequence.  Bases are 
colour coded according to the same scheme in Figure 3.15. 
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3.8 Discussion 
 
One of the major requirements in tackling amyloid disorders is the development of new 
diagnostic and therapeutic intervention strategies.  A central challenge in this endeavour is 
the development of ligands that recognise and interact specifically with species involved in 
amyloidosis; a problem that is exacerbated by the lack of structural knowledge of the 
assemblies involved.  In the case of Aβ40, the monomeric precursor is intrinsically 
disordered and, therefore, not amenable to conventional structure based ligand design.  
Only a few examples of rationally designed ligands for Aβ monomer exist.  These are 
generally peptides designed around fragments of the Aβ peptide itself (often the 
aggregation prone residues 16-21) which bind and block further aggregation517, 518, in some 
cases by incorporating β-sheet blocking residues such a prolines188 or through the 
incorporation of bulky chemical groups, such as cholesterol187 .  The vast majority of existing 
anti-Aβ40 monomer ligands have instead been derived via directed evolution type 
approaches.  Peptide-based affimers have been selected via phage display from randomised 
protein libraries and revealed nM affinity to monomeric Aβ40519.  A plethora of small 
molecule binders to Aβ monomers have also been isolated through various screening 
protocols202, 520-526, however specificity is often a major caveat. Many anti-Aβ antibodies 
have been isolated and demonstrate binding to specific portions of the peptide sequence, in 
many cases, leading to the prevention of oligomer and fibril formation527-529.  Although 
antibodies are indispensable research tools and have shown significant promise as 
therapeutic agents in AD animal studies, they have not yet shown success in human clinical 
trials, in targeting AD530 (discussed in detail in Chapter 1, Section 1.3.5).  RNA aptamer 
selection, therefore, was considered an exciting alternative technology to develop Aβ40-
monomer-specific reagents.   
In the case of amyloid fibrils, structural information is more accessible and therefore there 
is more scope for the design of recognition molecules.  Again, there are many examples of 
antibodies developed to recognise fibrillar assemblies of Aβ125, 531, as well as numerous 
small molecule ligands524, 525, 532, 533.  These molecules, although useful as research tools, 
often are not specific to a single amyloid morphology and serve as generic amyloid 
detectors.  To date, no ligand has been developed able to distinguish between different 
cross-β fibril structures of the same sequence.  The aim here, therefore, was to generate 
ligands with superior recognition powers, through nucleic acid aptamer based technologies. 
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Aptamers, although well established in other research areas360, 364, 446, 448, 452, 534, have been 
slow to emerge in the amyloid field.  Of the few examples of Aβ targeted aptamers that 
exist491, 493, 494, most have encountered issues with poor selectivity for their intended targets 
(monomeric or LMW oligomers) and, despite being selected against Aβ40 monomers, have 
shown enhanced affinity for the aggregated form.  It was hoped that with our improved 
selection methodology, combined with NGS, aptamers with affinity for the monomeric Aβ40 
peptide might be selected, for the first time.  Firstly, the immobilisation method used 
involved biotin conjugation with a 30.5 Å alkyl chain spacer arm, to eliminate possible steric 
hindrance by the label.  Such modification has been shown not to interfere with amyloid 
assembly483, 535, suggesting preservation of the native structure.  Target preparation 
conditions were also carefully controlled to maintain the peptide in a monomeric state, as 
much as possible, before selection.  During the selection protocol itself, six of the selection 
rounds comprised of competition elutions, driving the affinity towards un-modified, 
monomeric Aβ40. 
There has so far been little interest in Aβ fibrils as targets for RNA aptamers, most probably 
owing to the fact that oligomeric structures are often considered the main species of interest 
in amyloid toxicity123, 126, 142, 266, 267.  However, anti-Aβ fibril aptamers do exist in the 
literature, in most cases as a by-product of unsuccessful selections against monomeric or 
oligomeric assemblies491, 494.  These aptamers show considerable cross-reactivity with 
fibrils derived from other amyloidogenic peptides, including fibrils of Aβ42, lysozyme, IAPP, 
Prion106-126, calcitonin and insulin494, reinforcing the view that amyloid fibrils share 
common structural features.  To avoid this problem in the selections described here, and 
hence to find aptamers with enhanced recognition properties, the inclusion of counter 
selections against alternative fibril morphologies were considered to drive specificity.  This 
would entail incubation of the RNA pool with an alternative fibril type and only the low 
affinity, unbound fraction would be taken forward for selection against the target 
morphology.  However, previous experience with amyloid selections in our laboratory 
showed that the inclusion of these counter selection rounds could lead to the removal of the 
vast majority of RNA from the pool490.  This observation firstly affirms that there is 
considerable overlap in the epitopes between different amyloid assemblies, but also 
suggests that it is indeed difficult to raise aptamers against such similar polymorphs.  
Therefore, counter selections with fibrils of the alternative morphology were omitted from 
the protocol and it was decided that the two anti-fibril selections would be conducted 
independently and the product RNA sequences would be screened for cross-reactivity post-
selection.  These experiments are described in Chapter 5.  
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One of the major advantages of the protocol developed here was the availability of next 
generation sequencing (NGS) to aid in the development of effective aptamers.  Until recent 
years, and in all anti-Aβ aptamers reported to date491, 493, 494, aptamer sequences were 
isolated from enriched selection pools using traditional cloning and sequencing methods.  
This method, although generally successful in accessing the most frequently occurring 
clones, only allows for the analysis of relatively few sequences (10-100 (ref 377)) compared 
with NGS technologies (107 sequences).  It is possible, therefore, that in previous selection 
attempts, the highest affinity aptamers were not sampled from the selection mixtures, 
owing to the fact that only a small proportion of the selected sequences could be scrutinised 
using conventional methods.   
The anti-Aβ40 monomer and anti-2A and 3Q fibril selections described in this chapter were 
successful in isolating aptamer pools, where specific sequences were enriched and highly 
populated.  Conserved sequence and structural motifs were identified from the 500 most 
abundant sequences, allowing for isolation of lead aptamers for further characterisation.  By 
comparison of the sequences chosen from each selection pool, differences in the overall 
base compositions are apparent (Figure 3.17).  Anti-2A fibril aptamers are purine rich, 
whereas anti-3Q aptamers generally contain poly-U repeats.  Although this was found to be 
a consequence of selection from naïve libraries containing considerable bias, enrichment of 
specific sequences within this pool was still apparent and aptamers were therefore chosen 
from these highly populated sequences.  Interestingly, 3Q1, the most highly populated 
aptamer from the anti-3Q fibril selection, does not contain the same U-rich motif as the 
other aptamers from the corresponding pool.  3Q1 displays instead a more diverse base 
composition, with a bias towards purines (76.6% GA content).  The fact that this aptamer 
sequence (and others possibly derived from it, within its corresponding aligned motif 
(Appendix 7.3)) has been selected despite the prominent uracil bias, is further 
encouragement that this selection has been successful.  With the use of NGS analysis, it has 
recently become clear that base distribution bias is a common feature of synthetic SELEX 
libraries.  Companies are now focusing on the synthesis of superior combinatorial libraries, 
where the bias is eliminated, leading to better quality starting libraries for selection536.  
Although neither this knowledge nor technology was available at the beginning of this 
project, it is worth noting that the diversity of the starting pool, used here, will have been 
compromised to some extent.  Similarly, we must also be aware that there may be certain 
biases in other stages of the selection process (PCR, transcription) and the NGS itself, which 
might contribute to the optimal binding sequences being underrepresented.  For example, 
PCR amplification is known to be biased towards GC-neutral sequences537.  Despite these 
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limitations, which are a problem for all nucleic acid aptamer selection strategies, aptamer 
sequences have been selected and preferentially amplified and only the biophysical 
characterisation of their specificity and affinity towards their cognate targets will confirm 
the success of the SELEX experiments, and their potential in various downstream 
applications.  Characterisation of the anti-Aβ40 monomer and anti-fibril aptamers are 
described in the following two chapters.   
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4 Characterisation of RNA aptamers against Aβ40 
monomer 
 
4.1 Objectives 
 
In Chapter 3, the selection of RNA aptamers against three distinct Aβ40 assemblies was 
described; two fibrils with unique structural morphologies (2A and 3Q) and the intrinsically 
disordered monomeric peptide.  This chapter describes the characterisation of the aptamer 
sequences chosen from the anti-monomer selection.  
Aptamers were selected against monomeric Aβ40 peptide immobilised via biotin linkage to 
streptavidin microspheres.  As the SELEX protocol included several rounds of competition 
elution, it was expected that individual aptamers would display enhanced affinity for the 
peptide monomer in solution, over its immobilised counterpart.  In this chapter, 
development of assays to assess aptamer binding to Aβ40 monomer is discussed.  
 
4.2 Development of assays to monitor aptamer binding to 
monomeric Aβ40 in solution 
 
By use of the bioinformatic sampling, described in Chapter 3 (Section 3.7), the 0.7 million 
potential binding aptamers, isolated from NGS, were reduced to eight lead sequences 
(Figure 3.18).  The next objective was to characterise the binding properties of these eight 
aptamers, in order to rank the sequences for binding affinity.  By isolating aptamers with 
the highest affinity for the native monomeric Aβ40 target, and demonstrating specificity in 
binding this peptide, it would then be possible to focus the study on one, or a few, “hit” 
aptamers.  This would enable detailed structural characterisation and, hopefully, lead on to 
development of RNA molecules as inhibitory or discriminatory compounds.   
The first challenge was the design of appropriate in vitro assays to determine binding by the 
individual aptamers to Aβ40.  Owing to the aggregation propensity of Aβ40, one 
requirement of the binding assays was that they were able to be conducted over short 
timescales and at relatively low concentrations.  Also, for the purpose of screening several 
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aptamers, the RNA itself could only be synthesised on a relatively small scale (3 μg from a 
typical 50 µL in vitro transcription reaction- Section 2.6.3).  Therefore, the binding assays 
tested also required the use of as little material as possible.  Techniques often used to study 
protein: nucleic acid interactions in solution, such as isothermal titration calorimetry 
(ITC)538 and nuclear magnetic resonance (NMR)539 were ruled out at this initial screening 
stage, as large quantities and relatively high concentrations of RNA would be required.  
Because the main aim of the anti-monomer selections was to isolate aptamers able to 
recognise monomeric peptide, assays involving modification to the peptide structure, such 
as addition of fluorescent tags, were also not desirable.  
 
4.2.1 Microscale thermophoresis 
 
Microscale thermophoresis (MST) is a powerful method for analysis and quantification of 
biomolecular interactions, which works by measuring the behaviour of biomolecules in 
microscopic temperature gradients.  During an MST experiment (Figure 4.1) a localised 
temperature gradient is induced by an infrared laser, focused onto the sample in low volume 
glass capillaries.  Fluorescently labelled molecules, which are initially evenly distributed 
and diffusing freely in solution, experience a thermophoretic force in the temperature 
gradient.  The movement of the fluorescent molecule can be monitored by the change in 
fluorescence intensity at a fixed point within the capillary.  When the laser is switched off, 
the molecules diffuse back to establish a homogenous mixture once more.  The motion of 
the molecule within the temperature gradient is sensitive to changes in hydration shell, size 
or charge, any of which can be affected upon ligand binding.  By monitoring thermophoresis 
of the fluorescent molecule at a range of non-fluorescent ligand concentrations, changes in 
thermophoretic properties upon binding can be observed.  Binding constants can therefore 
be elucidated via this method540-543.  
MST was considered an appropriate assay to quantitate the binding by the aptamer 
sequences to Aβ40 monomer, as experiments can be conducted on extremely small sample 
volumes (< 4 μL) and at low concentrations (pM-nM)540.  The method has previously been 
applied to a range of studies, from monitoring small molecule interactions544, 545 to protein: 
protein546-548 and protein: nucleic acid549-551 interactions, and even in monitoring large 
protein complex formation552, 553.  The technique can accurately deduce dissociation 
constants in less than 10 min per sample and access a vast range of affinities (from pM to 
mM)540.  MST was especially desirable as solution measurements could be made, without 
CHARACTERISATION OF RNA APTAMERS AGAINST Aβ40 MONOMER 
 
 
145 
 
need for immobilisation of one of the binding partners.  However, fluorescent labelling was 
required and it was decided that optimisation of an aptamer labelling protocol would first 
be undertaken. 
 
 
 
Figure 4.1 Principles of microscale thermophoresis (MST) analysis of molecular 
interactions.  MST measures the movement of fluorescent molecules in a temperature 
gradient.  (a) Molecules which are diffusing free in solution (I) are irradiated with an 
infrared laser (represented by red spot) producing a microscopic temperature gradient.  
The fluorescent molecule will move within this gradient (II) and can be monitored over time 
as the fluorescence intensity changes from a fixed point (III).  When the laser is switched 
off, molecules return to re-establish an equilibrium (IV).  (b) Differences in thermophoresis 
of the molecule at different ligand concentrations is monitored and changes in the 
fluorescence before the laser is switched on (I) and after thermophoresis (II) are plotted as 
a function of ligand concentration to quantify binding.  Adapted from 540. 
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4.2.1.1 Optimisation of fluorescent labelling of RNA 
 
In order to produce individual aptamer sequences for binding assays, DNA templates for 
each of the eight aptamers were commercially synthesised (Eurofins Genomics, Ebersberg, 
Germany).  Each sequence was flanked by the same primer sequences from the N50 library 
(Section 2.7.1) to allow PCR amplification.  These were then amplified with the same primer 
oligonucleotides used for the initial libraries, which introduce the T7 promoter sequence 
into the dsDNA product, for in vitro transcription.  Y639F/H784A T7 RNA polymerase was 
again used to allow the incorporation of the 2′F modified pyrimidines.   
The synthesis of fluorescently labelled RNA can be achieved through the addition of 
fluorescently labelled nucleotides, directly into the transcription mixture, leading to 
incorporation of the fluorophore at random sites within the sequence.  Using this method, 
the fluorescent nucleotides can be added at variable concentrations to limit labelling levels.  
A protocol already established in the Stockley laboratory by Dr. David Bunka, was used to 
produce fluorescently labelled aptamers via the incorporation of ChromaTide® AlexaFluor® 
488-5-dUTP (Figure 4.2).  The NTP mix was altered to include a 1/80th dilution of this 
modified UTP and added to the transcription reaction (components given in Section 2.6.5.1).  
This protocol produces aptamers with approximately one fluorescent dye per RNA 
molecule, on average, which can be calculated from UV-Vis absorbance measurements at 
260 nm and the absorbance maxima of the dye, 493 nm.  However, optimisation of both the 
standard transcription reaction (Section 2.6.3) and purification of the resultant aptamers 
was required to improve both yield and purity of the RNA produced.   
 
 
 
Figure 4.2 Chemical structure of ChromaTide® Alexa Fluor® 488-5-dUTP used to 
fluorescently label aptamers for binding studies. 
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To improve the amount of total RNA produced during in vitro transcription, trials were 
conducted into the optimum polymerase and DNA template concentrations required.  
Increasing the final Y639F/H784A T7 RNA polymerase concentration to 740 nM (2 x that 
required in standard transcription, Section 2.6.3) and increasing the DNA template 
concentration, by pooling and concentrating five PCR reactions (Section 2.6.1 - final DNA 
template concentration of ~ 500 ng/µL), improved the amount of 2ʹF modified, Alexa488 
labelled RNA produced (Figure 4.3 a), as assessed by denaturing PAGE. 
The next stage to be optimised was the purification of the fluorescent transcripts.  The 
general protocol for RNA purification involves DNase treatment and acidified phenol 
chloroform extraction of the RNA (Section 2.6.8.1), followed by ethanol precipitation.  This 
was then usually followed by a rapid, column purification step (Illustra microspin G-25, GE 
Healthcare) to remove free nucleotide and other small contaminants.  However, it became 
clear that in the case of the fluorescently-labelled aptamers, this standard desalting method 
was not sufficient to remove all free-nucleotides (Figure 4.4).  The final yield of aptamer 
was also dependent on several stages of this purification, including the ethanol precipitation 
and free-nucleotide removal steps, and these too required some optimisation.    
Addition of the carrier, or co-precipitate, glycogen, was firstly shown to make a significant 
difference in the yield of RNA during the precipitation stage, again estimated from 
denaturing PAGE (Figure 4.3 b).  On the other hand, trials into the use of different salts or 
alcohols (conditions trialled outlined Figure 4.3 b, table inset) during the precipitation, 
demonstrated no major effect on the yield of recovered RNA (Figure 4.3 b).  The addition 
of 1/5th volume 10 M ammonium acetate, 1/100th volume 20 mg/mL glycogen and 2 x 
volume ethanol was shown to achieve marginally higher recovery than the other conditions 
trialled (Figure 4.3 b) and, therefore, was implemented in all subsequent aptamer 
purifications. 
In the case of the removal of free-nucleotide, several commercially available columns were 
tested, including various size exclusion columns and silica-gel based RNA clean-up systems, 
as well as gel extraction from denaturing PAGE gels (Section 2.6.8.2) (results summarised 
in Table 4.1).  All nucleotide removal methods had a significant impact on total RNA 
recovery (estimated to be less than 10% recovered, based on PAGE analysis Figure 4.4).  
However, extraction of RNA by gel extraction was found to be a more effective method as, 
although the technique has a similar impact on total RNA recovery, free-nucleotide removal 
was 100% (Figure 4.4).  Total yield of RNA via this methodology remained variable, with 
yields of ~1 μM in 50 μL being typical.  This was sufficient for most applications, but when 
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higher yields of fluorescent aptamer were required, the production was scaled up, by 
pooling several transcription reactions before the phenol chloroform extraction stage.   
 
 
 
Figure 4.3 Optimisation of the transcription conditions and ethanol precipitation of 2′F 
Alexa488 labelled aptamers.  (a) Denaturing PAGE analysis comparing levels of RNA 
transcription under “normal” transcription conditions (N - used for transcription of non-
fluorescent 2ʹF aptamers (Section 2.6.3)), with increased polymerase concentration (+T7) 
and with increased polymerase and DNA template concentration (+T7/+DNA).  (b) 
Denaturing PAGE analysis showing levels of RNA yielded under different ethanol 
precipitation conditions, compared with a sample before precipitation (+) (conditions 1, 2 
and 3 are outlined in the accompanying table).  – glycogen indicates an RNA sample treated 
as condition 3, without glycogen.   
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Technique 
Separation 
technology 
Score Conclusion 
Illustra G-25 microspin 
column 
SEC * 
Poor removal of nucleotides and very 
poor yield of total RNA in both cases.  
Slightly better yield of RNA when 
larger volume, gravity flow NAP5 
columns used over G-25. 
Illustra NAP5 column SEC ** 
RNeasy mini column Silica-based * Nucleotide removal good but yield of 
total RNA extremely poor.  Both 
methods work well for unlabelled 
RNA.  RNeasy columns only work for 
aptamers > 100 nucleotides. 
Clean & Concentrator™-5 
column 
Silica-based ** 
Gel extraction PAGE *** 
Generally poor yield of total RNA but 
nucleotide removal is 100%.  Method 
can be easily scaled up to increase 
yield. 
Table 4.1 Methods tested to optimise free-nucleotide removal in the purification of 
Alexa488 labelled aptamers.  Conditions are scored from the most (three stars) to the least 
(one star) favourable. 
 
A typical absorbance spectrum of purified 2ʹF Alexa488 labelled aptamer (aptamer M1 – 99 
nucleotides) is shown in Figure 4.5, where average dye incorporation is calculated (Section 
2.6.5.1, Equations 2.3 and 2.4) by the absorbance measurements at 260 nm and the 
absorbance maximum of the fluorophore at 493 nm.  In this example, average Alexa 
incorporation is 1.48 Alexa molecules/RNA.  Dye incorporation was found to vary between 
preparations (1.0 - 1.5 dye/RNA on average).  A260/280 ratios greater than 2.0 (indicating 
pure RNA554) were typically achieved via this optimised methodology (in this example 
A260/280 = 2.1).  The overall yield of RNA in this example is 4.3 µM in 50 µL.   
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Figure 4.4 Comparison of techniques to remove contamination with free-nucleotides.  
Denaturing PAGE analysis comparing yield and removal of free-nucleotides by different 
purification methods.  The amount of nucleotide remaining can be seen at the bottom of the 
right hand gel image (denoted Alexa-UTP).  Purification by NAP-5 column, G-25 column and 
gel extraction are indicated.  Different volumes of sample were loaded to aid comparison 
(indicated 5 x and 1 x) and only 1 x lanes (further marked *) can be directly compared for 
yield.  Products from each purification method are compared with a sample before 
purification (+).  The same gel is shown analysed by both ethidium bromide staining and 
fluorescence scanning with a Fujifilm 5100 fluorescence image analyser (indicated). 
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Figure 4.5 Verification of Alexa488 UTP incorporation in a typical labelled aptamer sample.  
A typical UV-Vis absorbance scan of a 2ʹF Alexa488 labelled aptamer is shown (teal).  
260/280 ratio is 2.1, indicating pure RNA.  Average dye incorporation is calculated by 
Equations 2.3 and 2.4 (Section 2.6.5.1), which in this case equates to 1.48 Alexa dye 
molecules/RNA molecule.  Comparison to an unlabelled RNA sample of similar 
concentration (2.8 µM) is shown in the blue spectrum. 
 
4.2.1.2 Analysis of aptamer binding to Aβ40 monomer by MST 
 
MST experiments to assess the binding by the aptamer sequences to Aβ40 monomer were 
conducted in the same MOPS buffer used during selection.  A final concentration of 250 nM 
2ʹF Alexa488 aptamer was incubated with aliquots of freshly resolubilised Aβ40 peptide, at 
peptide concentrations ranging from 12 nM to 100 µM.  Solutions were incubated for 15 min 
at room temperature, before 4 μL of each titration point was loaded, via capillary diffusion, 
into individual glass capillaries and analysed (Section 2.8.4).  Four aptamers, M1, M50, M53 
and M214 (a selection of the eight planned to be screened) were tested via this method 
(Figure 4.6), in order to set up suitable assay parameters.  The data obtained suggested that 
for all four aptamers, there was no impact on their thermophoretic properties upon addition 
of increasing concentration of monomeric Aβ40 peptide, suggesting there was no 
interaction.  Thermal denaturation and re-annealing of the aptamer stocks, to promote 
correct folding of the aptamers, before incubation with the peptide ligand, was shown to 
have no effect (shown for aptamers M50, M53 and M214, Figure 4.6) and hence no 
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interactions between the selected aptamers and monomeric Aβ40 were observed by this 
method.   
 
 
 
Figure 4.6 MST shows no interaction between anti-Aβ40 monomer aptamers and Aβ40 in 
solution.  2ʹF Alexa488 labelled aptamers were assayed against a titration of Aβ40 monomer 
by MST.  Data for aptamers M1 (blue), M50 (pink), M53 (green) and M214 (yellow) are 
indicated. 
 
4.2.2 Development of further solution binding studies 
 
Since the MST data suggested that the selected aptamers do not bind monomeric Aβ40 in 
solution, further assays were conducted to detect binding.  One approach considered was 
monitoring the change in intrinsic fluorescence of Aβ40 upon aptamer interaction.  Intrinsic 
fluorescence of proteins is derived from the aromatic amino acids tryptophan, tyrosine and, 
to a lesser extent, phenylalanine, and can be sensitive to structural changes that may occur 
upon binding555.  Aβ40 has no tryptophan residues and only one tyrosine at position 10, 
meaning the peptide is weakly fluorescent and therefore may be insensitive to binding.  
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Nevertheless, tyrosine quenching experiments have been used previously to quantitate 
Aβ40 interactions556, 557.  When incubated with the unlabelled aptamer M1, no fluorescence 
change was observed upon aptamer titration (results not shown).  It was unclear whether 
the lack of signal change was due to a lack of aptamer binding to Aβ40 monomer or whether 
an interaction could be taking place which did not alter the fluorescence of Aβ40’s single 
tyrosine residue.  Similarly, incubation of Aβ40 with Alexa488 labelled aptamer did not 
result in any detectable fluorescence intensity change (Figure 4.7 a and b).  These assays 
support the conclusion that aptamers do not bind Aβ40 monomers significantly. 
Next, fluorescence polarisation (which is discussed in more detail in Section 5.2.1) was used 
to monitor binding of Aβ40 and aptamer M1.  In this assay, the degree of polarisation of light 
emitted by a fluorophore is sensitive to the change in mass as a consequence of a binding 
event558.  Again, it was uncertain whether the small mass change induced upon Aβ40 (MW 
= 4458 Da) binding to the RNA aptamers (MW ~30 kDa) would induce a significant change 
in polarisation, however the technique has been employed previously in studying this 
peptide binding to fluorescently labelled RNA493.  The titration of Aβ40 monomer against a 
fixed concentration (10 nM) of the Alexa488 fluorescently-labelled aptamer M1 (Figure 4.7 
c) resulted in no change in fluorescence polarisation of the RNA.  This data also supports 
the conclusion that there is no detectable interaction between the aptamer and the 
monomeric Aβ40 peptide in solution.  
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Figure 4.7 Solution assays demonstrating no detectable interaction between Aβ40 
monomer and aptamer M1.  (a) Fluorescence emission spectra of Alexa488 labelled 
aptamer M1 upon titration with Aβ40 monomer.  (b)  Intensity at 520 nm from the series of 
emission scans in (a, dotted line) was plotted as a function of Aβ40 concentration.  No 
quenching of the Alexa488 dye is observed.  (c)  Fluorescence polarisation of Alexa488 
labelled aptamer M1 upon titration with Aβ40 monomer. 
 
4.3 Investigation of aptamer binding to immobilised 
Aβ40 
 
Despite the inclusion of six rounds of solution competition elution during the SELEX 
procedure (Section 3.5.1), introduced to promote binding to native peptide, the aptamers 
were not able to recognise Aβ40 monomer by any of the techniques discussed above.  It was 
therefore decided that the aptamers affinity for the immobilised peptide would be 
investigated, to confirm whether surface immobilisation was required to present the Aβ40 
conformation that was recognised and selected against. 
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4.3.1 Surface plasmon resonance (SPR) 
 
Surface plasmon resonance is a technique that monitors real-time biomolecular 
interactions.  The technique (Figure 4.8) monitors the formation of complexes on a surface 
and displays a signal proportional to the extent of this interaction559, 560.  The test ligand is 
directly conjugated to a gold-coated surface and the potential binding partner, or analyte, is 
injected as a continuous flow over the surface.  Light is focused onto the gold surface where 
it is reflected.  At a specific angle of incidence the phenomenon of SPR occurs, where some 
of the reflected light is absorbed, with energy transferring to electrons in the gold layer, 
producing surface plasmons.  This results in decreased intensity of light detected at this 
resonance angle.  The angle at which SPR occurs is dependent, and highly sensitive to, the 
changes in refractive index at the surface.  These changes in refractive index are induced 
through mass changes on the surface and, therefore, can be used to monitor association and 
dissociation of biomolecules.  Once a test analyte is injected and the interaction monitored, 
the surface is regenerated, removing the analyte and resulting in a new ligand-saturated 
surface for the next sample to be tested.   
 
Figure 4.8 Principles of surface plasmon resonance (SPR).  SPR monitors the change in 
refractive index (RI) when biomolecules interact on a gold-coated surface.  The angle of 
incidence at which plasmons are produced is dependent on the RI and detected as a 
decrease in intensity, which is monitored over the time course of an interaction.  Adapted 
from 559. 
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SPR was thought to be a useful alternative method to screen the aptamers against the 
immobilised monomeric Aβ40 target.  By use of an SA sensor chip (GE Healthcare), pre-
derivatised with streptavidin, the same biotin immobilisation strategy optimised for 
aptamer selection (Section 3.4.2) could be used to immobilise the peptide for analysis by 
SPR.  By immobilisation through sequential injection of a dilute solution of biotin-modified 
Aβ40, aggregation could also be avoided.  Aβ40, therefore, was biotin labelled, as previously 
described, and immobilised onto the SPR sensor chip (Section 2.8.2).  The theoretical, 
optimal level of peptide to be deposited on the flow cell for effective SPR can be calculated 
(Section 2.8.2) and is often maintained at the lowest level possible to give an acceptable 
response, in order to reduce limitations of ligand binding rates through mass transport of 
the analyte561.  Therefore, in accordance with these recommendations, only 25 response 
units (RU) of Aβ40 monomer were deposited on the sample flow cell.  Another flow cell with 
500 RU Aβ40 was prepared to ensure a sufficient response would be seen.  To account for 
any background response, a reference flow cell was left blank as a control.  Similarly, a 
control protein, β2-microglobulin (β2m) (kindly provided by Dr. Claire Sarell, University of 
Leeds) was immobilised on the final available flow cell, as an additional reference, and to 
allow assessment of binding specificity.   
The 2ʹF aptamers M1 and M50 were transcribed in vitro and purified, before dialysis into 
the SPR running buffer, which was again the same MOPS buffer used in the aptamer 
selections, with the addition of 0.005% (v/v) Tween 20.  The dialysate directly taken from 
the aptamer dialysis was used as the running buffer in the experiment to minimise any 
refractive index changes on the surface, as a result of buffer injection only.  10 µL of 1 µM 
aptamer RNA was injected over the flow cells and the association and dissociation 
monitored, before regeneration of the surface (with 0.5 M NaCl) for the next aptamer 
injection (Section 2.8.2).  The results of these experiments did not provide any evidence of 
specific association of the aptamers with the immobilised Aβ40 monomers.  A typical 
response from injection of aptamer M1 is shown in Figure 4.9, where the response seen in 
all four flow cells, including the controls, was similar.  The response is also very low (<30 
RU) and therefore presumably reflects a small RI change on the surface as a result of the 
analyte injection.  After background correction, therefore, no binding response was 
observed for either of the aptamers with monomeric Aβ40 on the sensor surface.   
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Figure 4.9 SPR analysis of the aptamer M1 association with immobilised monomeric Aβ40.  
Aptamer M1 demonstrates no specific interaction with Aβ40 monomers immobilised onto 
a streptavidin chip surface.  The relative response from all four flow cells are colour coded 
as indicated. 
 
Various changes were made to the experimental conditions, in an attempt to optimise the 
assay.  Running buffers containing higher concentrations of surfactant (up to 0.05% (v/v) 
Tween 20) were trialled to reduce any non-specific interactions with the control flow cells, 
which may have been masking any association seen with Aβ40.  Injections of higher 
concentrations of aptamer (aptamer M1 assayed up to 5 µM, results not shown) were also 
explored, to enhance any signals upon binding.  Despite these attempts, no aptamer 
association was observed with Aβ40 monomers, under any of these conditions, using SPR.   
Although the Aβ40 monomer was immobilised to the SPR chip using the same biotin 
modification used during selection, the surface of the SA chip differs to the bead surface, as 
the streptavidin tetramers are conjugated to carboxymethlyated dextran.  It is possible, 
therefore, that this difference in immobilisation surface could be altering the conformation 
of the target peptide and, therefore, the aptamer binding epitopes available.  In order to test 
the affinity towards the actual selection target, binding assays, where Aβ40 was 
immobilised to the streptavidin-coated microspheres used in selection, were developed, as 
described in the following section. 
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4.3.2 Aptamer pulldown assays 
 
In order to quantify binding of the selected RNA aptamers to the bead-immobilised form of 
Aβ40, a pulldown assay was developed.  Streptavidin-coated microspheres, identical to 
those used in the aptamer selection, were saturated with Aβ40, as described (Section 2.5.2).  
Sequential dilutions of these Aβ40 beads were then set up to create a gradient of protein 
concentrations ranging from 80 nM to 1.6 µM.  Each aptamer was added to each dilution of 
beads at a final RNA concentration of 500 nM.  After incubation for 15 min and removal of 
the unbound RNA by magnetic separation, the beads were washed 10 times with selection 
buffer, consistent with the SELEX conditions (Section 2.7.2).  Any remaining bound RNA at 
each peptide concentration was then heat eluted and reverse-transcribed by the addition of 
a master solution of RT mix (Section 2.6.9) directly to the boiled-bead aliquots.  Resultant 
DNA was then amplified for analysis by native PAGE.  Levels of associated RNA at each Aβ40 
peptide concentration were determined through the measurement of band densitometry, 
from gels stained with ethidium bromide (EtBr).  Raw densitometry values were then 
plotted as a function of peptide concentration, to determine binding constants for each 
aptamer.   
Preliminary experiments with aptamer M1 showed promising results in that there was a 
clear association of this aptamer with the immobilised peptide (Figure 4.10 a).  The 
dissociation constant for this single experiment could be calculated as 125 nM, using a Hill 
fit of the data (Section 2.8.3, Equation 2.5).  However, upon extension of this gel 
densitometry approach to a 96-well format, where all aptamer sequences were tested in 
triplicate, it became clear that this method was not reproducible.  An example showing three 
further replicates of aptamer M1 binding to Aβ40-loaded beads (Figure 4.10 b) 
demonstrates an apparent dissociation constant of 3.9 ± 58 nM.  The error in this case is 
considerable and indicates the difficulty in accurate determination of affinity via this 
method.  Error in this assay is most probably derived from inaccuracy in densitometry.  
Because analysis by native PAGE requires detection with EtBr staining after the gel has run 
(as opposed to addition of EtBr in the gel mixture, pre-casting) staining can be non-uniform 
across the gel, leading to error in the densitometry readings.   
The pulldown experiment indicates that there is an association of the aptamers and Aβ40 
when immobilised to a bead.  Quantitative comparison of the binding of the eight aptamers 
via this method was, however, not feasible owing to the lack of reproducibility.   
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Figure 4.10  Preliminary pulldown experiments indicate aptamer M1 association with 
immobilised Aβ40 peptide.  (a) Native PAGE analysis of RT-PCR products from RNA 
associated with Aβ40 saturated beads at a range of peptide concentrations.  Densitometry 
values are plotted as a function of immobilised Aβ40 concentration (teal) and a dissociation 
constant of 125 nM (inset) can be determined.  (b) Three replicate gels of aptamer pulldown 
over a larger concentration range demonstrate the irreproducibility in this assay, reflected 
as the large errors in the densitometry plot (blue).  The data is fitted to a Hill equation 
(Equation 2.5), weighted by the error, to guide the eye, and the putative dissociation 
constant determined (inset). 
 
To circumvent the problem of irreproducibility associated with indirect detection using RT-
PCR followed by gel staining and densitometry, other methods for direct detection of the 
RNA were investigated.  Alexa488 labelling of the RNA was deemed an appropriate reporter, 
as the preparation of fluorescent RNA transcripts was previously optimised for experiments 
using MST (Section 4.2.1.1) and sensitive detection could be achieved.  Therefore, an assay 
was designed in which the concentration of RNA was measured by fluorescence intensity of 
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the unbound fraction, after bead partitioning.  Aβ40 saturated beads were again 
sequentially diluted to create the peptide concentration gradient.  In this case, beads were 
first concentrated to 10 mg/mL (through partitioning and resolubilising the beads in 1/10th 
volume of buffer) to enable higher peptide concentrations to be assayed (up to 20 μM).  
Fluorescently labelled aptamer was added at a final concentration of 30 nM to each dilution 
of beads and incubated for 15 min.  Beads were partitioned on a magnetic rack and the 
unbound fractions were transferred to fresh tubes before the fluorescence intensity of each 
was measured (Section 2.8.3).  Analysis of the eight anti-Aβ40 monomer aptamers against 
the Aβ40 saturated beads demonstrated a clear association, with an average binding 
constant of ~ 1.8 ± 0.2 µM (Figure 4.11).   
 
 
 
Figure 4.11 Aptamers associate with streptavidin-bead immobilised Aβ40 with 
micromolar affinity.  Fluorescence intensity of the unbound RNA fraction at a range of 
immobilised peptide concentrations are indicated for each of the eight aptamer sequences.  
Dissociation constants derived from a Hill function (Equation 2.5) are given (inset).  
Fluorescence was normalised to the intensity of free RNA when incubated with no target. 
 
Each of the eight aptamers tested were shown to bind to bead immobilised Aβ40 monomers 
with similar affinity (Figure 4.11, inset table).  This was perhaps surprising as the 
sequences do not originate from the same consensus motif generated during the sequence 
alignments and are predicted to display different structures (Figure 3.18).  They were also 
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represented with very different relative frequencies in the selected pools (613 times for M1, 
compared with only 22 times for M233), which should suggest they have different affinities 
to the target and hence were amplified to different extents throughout the selection.  
However, the aptamers are all GA rich and this similar base composition within their key 
structural elements could be the major requirement in their target recognition.   
Further pulldown assays were performed, with each of the eight aptamers, to different 
batches of Aβ40 saturated beads, to determine the reproducibility of the assay.  A 
representative example is given in Figure 4.12 a, where aptamer M50 is assayed against 
three separate preparations of Aβ40-loaded beads.  The results revealed that the 
experiment is not highly reproducible, in that M50 shows binding constants ranging from 
270 ± 11.9 nM to 12.4 ± 3.4 μM to the different bead batches.  This variability implies that 
the aptamer-binding epitope on Aβ40 may be displayed differently when immobilised in 
different bead batches.  However, despite these apparently large inconsistencies, the 
association is specific to Aβ40.  This was demonstrated by assaying the aptamers in this 
same pulldown format against biotin-saturated control beads and beads conjugated to a 
control protein, Im7 (Figure 4.12 b).  Im7 is an 87-residue immunity protein562, with a 
similar pI to Aβ40 (4.98 compared with 5.30 for Aβ40) but has a predominantly alpha-
helical structure and, therefore, was used as a control for non-specific interactions.  Over an 
equivalent concentration range, the majority of RNA is recovered in the unbound fraction.  
This indicates that there is no association to the biotin linker and that the aptamers are 
specific to bead immobilised Aβ40 epitopes. 
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Figure 4.12 Analysis of the reproducibility and specificity of aptamer binding to 
immobilised Aβ40.  (a) Fluorescence pulldown assay demonstrating the variability in 
apparent binding affinities between three separate batches of Aβ40-saturated streptavidin 
beads and Alexa488 labelled aptamer M50.  The association of aptamer M50 to the three 
different batches are represented in teal, blue and green.  (b) Fluorescence pulldown assay 
demonstrating the specificity of binding of aptamer M50 to immobilised Aβ40.  Aptamers 
display association to Aβ40 (teal) that is not observed over an equivalent titration of beads 
saturated with biotin (orange) or Im7 (pink).  Fluorescence is normalised to the intensity of 
RNA when incubated with no target. 
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4.4 Discussion 
 
Selection of RNA aptamers against the monomeric Aβ40 target was carried out with the 
main aim of finding recognition molecules for this intrinsically disordered peptide.  This 
could in turn pave the way for the development of new inhibitors or diagnostic reagents.  
Chapter 3 describes the selection of RNA aptamers against Aβ40 monomer, isolating an RNA 
pool enriched with sequences which fell into discrete structural motifs.  This enrichment in 
frequency of single sequences, over that seen in the naïve pool, demonstrates that aptamers 
have been selected preferentially and, therefore, should display affinity and selectivity for 
the target peptide. 
Although the first ten rounds of selection were against a monomeric model of Aβ40 (Aβ40 
immobilised by biotin modification and conjugated to streptavidin via a 30 Å spacer arm), 
the final six rounds of selection involved competitive elution of aptamers with Aβ40 
monomer, free in solution.  It was expected, therefore, that the aptamers chosen from the 
enriched pool would display affinity for the free monomer and the aim of the work 
described in this chapter was to confirm this. 
 
4.4.1 Quantitation of RNA aptamer binding to Aβ40 monomer 
 
A major challenge of the work described in this chapter was finding appropriate binding 
assays to study interactions of the RNA molecules with monomeric Aβ40, without need for 
immobilisation of the peptide.  Assay development was hindered by two major factors: 
firstly the limitations in synthesis of large quantities of 2ʹF modified RNA and secondly, the 
properties of Aβ40.   
Many of the conventional biophysical methods used to study protein: nucleic acid 
interactions in solution (without significant modification or immobilisation), such as ITC538 
and NMR539 were not possible for analysis of the selected RNA aptamers, at this initial 
screening stage.  This is due to the requirement of large quantities of concentrated sample 
for these techniques.  ITC, a gold-standard assay for determination of binding constants in 
solution563, requires no modification to either binding partner or immobilisation and, 
therefore, is a true label-free method.  Biomolecular interactions are measured directly 
through the heat evolved upon association and parameters such as the dissociation constant 
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(Kd) and stoichiometry of a given interaction can be determined directly538.  However, the 
major drawback of ITC, that which made it unsuitable in the investigation described herein, 
is the large sample consumption required to generate a sufficiently strong heat signal, 
typically 0.5 - 1.5 mL of 10-5 M solutions564.  Another technique used to study solution 
interactions is NMR which, through titration experiments, can provide information about 
binding constants565, 566, specificity of binding567, as well as detailed information into the 
structure and epitopes of the interacting molecules568. Again, these experiments require 
concentrated (typically ~ 100 μM in ~300 μL569), isotopically labelled and homogenous 
samples565 which would be difficult to provide in the case of an aptamer-Aβ40 interaction 
(at least for the 121 nucleotide length aptamers used in this chapter).  If lead aptamer 
sequences were discovered through other binding assays, and minimal, functional RNA 
structures determined, shorter RNA molecules could be chemically synthesised on larger 
scales, making either of these methods feasible. 
Mass spectrometry was also considered as an option to study the association of the 
aptamers and Aβ40 monomer, as measurements of dissociation constants have been 
demonstrated using this technique570-573.  Soft ionisation methods such as electrospray 
ionisation (ESI) allow non-covalent interactions to be maintained in the gas-phase574 and 
binding parameters elucidated this way have previously shown good agreement to solution-
derived Kds575, 576.  However, the technique requires optimisation of instrumental conditions 
and extensive sample clean-up to be viable.  Samples would need to be exchanged into MS 
compatible buffers, and all traces of non-volatile salts removed, to produce spectra of 
sufficient quality to extract binding coefficients.  Owing to the relatively low yields of 2ʹF 
RNA produced by in vitro transcription and the poor recovery via most desalting methods 
(Figure 4.3, Table 4.1) this route of analysis was not pursued.  
In order to study the association with monomeric Aβ40 peptide, it was important to avoid 
modifications to the protein that may interfere with the binding epitope.  Therefore addition 
of external fluorophores to the peptide, necessary for experiments such as fluorescence 
polarisation (FP) was ruled out.  Use of a peptide’s intrinsic fluorescent properties can be 
exploited to monitor binding events, if the association induces structural changes that 
impinge upon the environment of the aromatic residues555.  As mentioned in Section 4.2.2, 
intrinsic fluorescence quenching experiments were attempted and indicated no detectable 
association of Aβ40 monomer with aptamer M1.  However, it was unclear whether the 
fluorescence of Aβ40 was too low to detect binding or whether an interaction was occurring 
at a position distal to the single tyrosine residue. 
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As options for suitable assays were clearly limited, it was decided that fluorescent labelling 
of the aptamers would provide the best alternative.  There was still the problem of external 
fluorophores interfering with binding, but this would be less so when labelling the RNA over 
the peptide, for two reasons.  Firstly, the labelling strategy utilised involved random 
incorporation of the fluorescent UTP at several sites within the structure.  This means that 
the resultant RNA will contain a random distribution of molecules, with labels at various 
positions.  Therefore, if the label is obscuring the epitope in one area of the molecule, then 
the heterogeneous RNA mix will contain aptamers where the label is elsewhere and should 
not interfere with binding.  Secondly, the aptamers are larger than Aβ40, with more possible 
labelling sites, again allowing production of a more heterogeneous mixture when labelled.  
Unfortunately, when fluorescence polarisation (FP) studies were carried out, no change in 
polarisation was observed upon titration with Aβ40, again indicating a lack of association 
with the labelled aptamer.  The only drawback to labelling the RNA in a FP experiment, is 
that the assay is dependent on mass change upon binding, which means the more sensitive 
titrant should be the larger of the two species558.  In this case, as Aβ40 was the unlabelled 
ligand, the changes in polarisation of light emitted from the larger labelled aptamer may be 
minimal, rendering the assay insensitive. 
Microscale thermophoresis is a relatively new technology to measure biomolecular 
interactions and was also considered as a method to quantitate binding of aptamers to Aβ40 
monomers in solution.  The major advantages of MST is the small sample volumes (< 4 µL) 
and low concentrations of labelled aptamer required (nM), as well as the dynamic range of 
dissociation constants accessible (pM to mM)541.  Unlike the previously mentioned 
fluorescence-based assays, this technique should provide more conclusive insights into the 
binding event, as it is not dependent on a single property of the binding molecule, such as 
mass or intrinsic fluorescence.  Although the exact theory is debated577, 578, the behaviour of 
molecules in a thermal gradient is thought to be sensitive to size, charge and hydration shell.  
Because at least one of these properties should be perturbed in a given interaction, MST is 
considered a flexible and sensitive technique540, 543.  Indeed, MST has previously been used 
to monitor interactions between peptides of similar size to Aβ40547, 548, 579, as well as small 
molecules544, 545.  In fact, it is stated that there is virtually no limitation on size or molecular 
weight for this technique541.  Despite the advantages of the method, no binding was 
observed between the aptamers and Aβ40 in solution.  
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4.4.2 Insights from surface binding studies 
 
When it became clear that aptamer binding to Aβ40 in solution could not be detected, the 
hypothesis that surface presentation of the monomer might be required for binding was 
explored.  Indeed, binding of all eight aptamers was observed for Aβ40-saturated 
streptavidin beads in the fluorescent aptamer pulldown assay (Figure 4.11).  Moreover, the 
binding was specific to Aβ40 (Figure 4.12).  However, the assay was not reproducible 
between bead preparations; in fact the different batches exhibited a profound effect on 
apparent binding ability of the RNA (Kds differ by 2 orders of magnitude in the case of 
aptamer M50 Figure 4.12 b).  Discrepancies in total immobilised peptide concentration 
should not be a contributing factor, as the beads are prepared via incubation with a large 
excess of modified Aβ40 (20-fold, Section 2.5.2).  This means that complete saturation of 
available streptavidin binding sites should be achieved each time.  Another explanation 
could be that different conformations or assemblies of Aβ40 exist and become trapped on 
the surface of the beads, and that this heterogeneous mixture of conformations cannot be 
faithfully reproduced between each preparation.  If aptamers are only able to recognise a 
single conformation, and this is represented to different extents between bead batches, then 
the effective concentration of this conformer would differ each time.  Therefore, the 
apparent binding affinity would also change, depending on the proportion of the epitope 
presented in that batch. 
If the conformation recognised by the aptamers was not the monomer but instead a small 
proportion of aggregate, this same effect would be expected.  These data therefore call into 
question the species against which aptamers were originally selected.  It was assumed that 
aggregation would not occur after immobilisation and great care was taken to avoid 
aggregation before biotin modification and conjugation to beads (Section 3.4.3).  If however 
a small proportion of aggregate did persist before immobilisation, it is possible that this was 
selected against.  The local concentration of peptide created near the surface, upon 
immobilisation, could have accelerated the aggregation, leading to the deposition of some 
higher order species.  It is not inconceivable that aptamers may preferentially bind to an 
ordered, structured aggregate over the disordered monomer, even if the aggregated species 
existed in relatively low abundance.   
The data also suggest that the solution elution rounds of selection, included to promote 
binding to soluble monomer, may have failed to produce such aptamers.  The hypothesis 
that aptamers may have been selected against small amounts of higher order assemblies on 
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the bead surface, could explain the lack of solution binding observed.  If the selected RNA 
sequences have a preference for the structured aggregate, the elution with monomeric 
peptide could be isolating the aptamers with the poorest affinity for the aggregate, which 
are readily dissociated when challenged with a competitor.  Albeit, these RNA sequences 
will have had enough affinity to avoid dissociation during wash steps, however non-specific 
associations with the monomer could have liberated some lower-affinity bound RNA from 
the bead targets.  Alternatively, a small amount of aggregate may have existed in the Aβ40 
monomer solutions used as competitive targets during these competition selection rounds 
and, again, been preferentially bound by the aptamers, resulting in dissociation from the 
bead-bound state.   
 
4.4.3 A precedent for higher order aggregate binding by anti-
Aβ40 aptamers 
 
Among the few other anti-Aβ40 monomer aptamers described in the literature, recognition 
of higher-order amyloid assemblies, despite selection against purified low-molecular 
weight (LMW) targets, is a common theme.  Ylera et al.491 demonstrated the selection of RNA 
aptamers against an N-terminally cysteine modified variant of Aβ40.  The thiol moiety was 
used to covalently couple the peptide to a thiopropyl-activated Sepharose column for 
selection.  These authors endeavoured to maintain the monomeric state of the peptide by 
performing the coupling reaction in 60% (v/v) HFIP, a commonly used agent to monomerise 
amyloid structures580, 581.  After eight rounds of SELEX, aptamers were isolated with 
conserved sequence motifs, indicative of successful selection.  However, upon investigation 
of a single sequence (β55), it became apparent that the aptamer had no affinity for 
monomeric Aβ40.  Analytical affinity chromatography demonstrated an apparent Kd of 29 
nM against the immobilised target, yet the authors were unable to demonstrate monomer 
affinity by counter elution with free peptide, nor via a mobility shift assay.  Instead, the 
aptamer’s affinity for amyloid fibrils was demonstrated via electron microscopy.  The 
authors concluded that the lack of specific interaction with monomer was most probably 
due to aggregation of the Aβ40 on the Sepharose column, and hence aptamers were selected 
against an aggregated form.  This is in spite of monomerising treatment with HFIP.  It should 
be noted, however, that most protocols require 100% (v/v) solutions of HFIP to promote 
complete fibril depolymerisation581; in fact stable oligomers of Aβ40 have been shown to 
form in solutions containing lower concentrations of this fluorinated alcohol582.  
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Aggregation of target peptide in the environment of the same affinity column employed in 
their SELEX, has also been demonstrated previously in the selection of aptamers against 
another disordered peptide, substance P583.   
The problem of isolating a single purified Aβ40 conformation for selection is further 
demonstrated in a study by Rahimi et al.494.  Here, the authors attempted to select aptamers 
against a covalently-stabilised trimer of Aβ40, generated using photo-induced cross-linking 
of unmodified proteins (PICUP)584 and purification via PAGE585.  When characterising 
sequences isolated from the enriched pools, it was found that none of the aptamers bound 
to the trimeric target in solution, or LMW (predominantly monomeric) Aβ40.  Again, 
aptamers were instead found to bind to fibrillar assemblies.  These limited examples, along 
with the work described in this chapter, suggest that the immobilisation strategies required 
in selection protocols are a source of aberrant aggregation and, therefore, it is difficult to be 
sure which species is being selected for.  
Aptamers generated by Takahashi and colleagues493 are the only example of aptamers 
reported to display measurable affinity to monomeric Aβ40.  Aptamers were selected 
against Aβ40 conjugated to colloidal gold nanoparticles and two sequences were obtained 
and characterised.  These aptamers demonstrated affinity for immobilised Aβ40 via a 
pulldown assay (no Kds reported) as well as recognition of Aβ40 in solution, with binding 
constants in the order of 10-5 M.  However, the fluorescence anisotropy method used to 
elucidate these dissociation constants show a change in anisotropy of 0.008 units 
(equivalent to ~ 8 mP units in the FP analysis of the aptamers shown in Figure 4.7).  
Although the authors comment on this small change as a result of the small mass of Aβ40, 
this level of signal would lie within the noise of this experiment and therefore binding 
parameters extracted from this data are doubtful. 
The gold nanoparticle conjugation method of immobilisation utilised in the work described 
by Takahashi et al.493 was originally developed as a molecular mimic of spherical oligomers 
in the generation of the oligomer-specific antibody A11586.  By coupling Aβ40 to the colloidal 
gold in this manner, the resultant gold-peptide conjugates displayed remarkably similar 
properties to naturally occurring Aβ40 oligomers587.  Using this molecular mimic as the 
antigen, the antibody produced was found to be specific for oligomeric structures and 
showed no reactivity with soluble Aβ or fibrillar assemblies. It is possible, therefore, that 
the arrangement of Aβ40 monomers on the surface of nanoparticles, such as in the case of 
the streptavidin beads used in this study, could be mimicking higher order assemblies and, 
therefore, aptamers may reflect a preference for these structures.   
CHARACTERISATION OF RNA APTAMERS AGAINST Aβ40 MONOMER 
 
 
169 
 
Data presented in this chapter suggest that although there was a clear enrichment of specific 
sequences from SELEX, individual aptamers were not able to recognise the monomeric 
target in solution.   The aim of isolating specific recognition molecules towards this 
intrinsically disordered peptide, therefore, has not been achieved, most probably owing to 
problems with the immobilisation strategy required for selection.  Affinity for the 
immobilised target was confirmed, however reproducibility in the binding ability of the 
aptamers highlights the issues in selecting against heterogeneous samples of Aβ40.  It was 
decided that the project would now be focused on aptamer recognition of fibrillar and 
higher-order assemblies of Aβ.  Chapter 5 focuses on aptamers derived from the two anti-
fibril selections and their reactivity and specificity.  Recognition of fibrillar assemblies by 
the anti-monomer aptamers, discussed in this chapter, is also investigated, to test the 
hypothesis that these aptamers might have affinity for aggregated forms of Aβ40.   
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5 Characterisation of RNA aptamers against amyloid 
fibrils of distinct morphology 
 
5.1 Objectives 
 
As discussed in Chapter 3, selections were carried out against two distinct structural 
morphologies of Aβ40 fibrils, 2A and 3Q.  Analysis of the resultant sequences demonstrated 
an enrichment of sequences, from which five lead aptamers were chosen for each target 
fibril, based on consensus sequence motifs and predicted secondary structure. 
The aim of this chapter was to assess the specificity of these aptamers for their target fibril 
morphology and their ability to recognise amyloid fibrils derived from other amyloidogenic 
peptides.  This is important as no other ligand has yet been developed able to recognise a 
single amyloid morphology and would be invaluable as a research tool and diagnostic 
reagent, especially in light of the recent implication of fibril polymorphism in the etiology of 
different disease pathologies106. 
 
5.2 Assessment of aptamer binding to cognate fibril 
targets 
 
The first objective was to confirm that single aptamer sequences had affinity for the fibril 
targets against which they were selected.  Five aptamers were chosen from each pool 
(Figure 3.17) based on their different structural elements (Figure 3.19 and Figure 3.20).  
Anti-2A aptamers were selected from an N50 library and demonstrated a purine-rich base 
composition, whereas the N30 derived anti-3Q aptamers generally contained poly-U 
repeats within the stems and loops of their randomised regions.  The only exception was 
3Q1, the most populous aptamer sequence from the 3Q selection (represented 658 times) 
which demonstrates a GA rich sequence, more consistent with the anti-2A aptamers.  
Although it is difficult to predict RNA binding specificity based on sequence alone 
(especially since the aptamers were seemingly selected from biased starting libraries, 
discussed in Section 3.7), these observations might suggest that aptamers from the two 
pools should demonstrate selectivity for unique epitopes between the fibril structures.  On 
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the other hand, 3Q1 might be expected to demonstrate recognition for a conserved 
structure between these two Aβ40-derived fibrils. 
 
5.2.1 Fluorescence polarisation (FP) 
 
Fluorescence polarisation (FP), mentioned briefly in Section 4.2.2, was the main technique 
employed in the assessment and quantitation of binding by the anti-fibril RNA aptamers.  
FP (Figure 5.1) is based on the measurement of the degree of polarisation of light emitted 
from a fluorescent molecule, which is inversely proportional to the rate of molecular 
rotation.  When a fluorescently labelled molecule is excited by polarised light, the resultant 
emission will be largely depolarised owing to the rapid reorientation of the fluorophore 
during the lifetime of the excited state.  However, if this labelled ligand is bound by a larger 
molecule, the rotational speed of the complex will be reduced and thus the emitted light will 
remain significantly polarised.  This property of FP means it can be used to measure binding 
events (as long as there is a significant decrease in the rotation correlation time), as the 
observed polarisation will be proportional to the fraction of bound ligand555, 558.   
FP was used in Section 4.2.2, to monitor monomer binding by fluorescently labelled anti-
Aβ40 monomer aptamers.  It was unclear whether the small molecular weight change upon 
Aβ40 binding (4458 Da) would produce a change in FP sufficient for detection or whether 
the peptide would not associate with the aptamers tested.  In the case of fibril binding, the 
high molecular weight of the polymeric fibrillar complex (estimated > 30 MDa based on the 
mass-per-length of 3Q fibrils103 and an estimated average fibril length of 1 µm) should be 
sufficient to induce a substantial change in polarisation and was therefore considered an 
ideal assay to determine whether the aptamers selected against fibrils bind to their targets.  
FP is also amenable to semi-high throughput analysis, requiring low nM amounts of 
fluorescent aptamer and < 30 µL sample volumes, when performed in a multi-well plate 
format.  Assays were set up in 384-well plates and fibril titrations were delivered by robotic 
dispensing (Section 2.8.5). 
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Figure 5.1 Principles of fluorescence polarisation (FP).  (a) Schematic representation of a 
fluorescence polarisation experiment.  Fluorophores in the sample are excited by polarised 
light, emitting light that is depolarised to a degree dependent on the rate of molecular 
tumbling, (b).  The intensity of polarised light in both the z (III) and the y (I﬩) axis is 
measured as a function of ligand concentration (c) to quantitate the interaction.  Adapted 
from588. 
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5.2.2 Aptamers bind to their cognate fibril targets in solution 
 
The five aptamer sequences isolated from each selection (Figure 3.17) were produced by 
in vitro transcription from individual DNA templates and were fluorescently labelled via the 
enzymatic incorporation of Alexa488 dUTP, according to the protocol optimised in Section 
4.2.1.1.  200 μM stocks of 2A or 3Q fibrils were made via seeding reactions for 18 h (Section 
2.4.1) as described for the production of fibrils as selection targets.  As before, the presence 
of long straight amyloid fibrils was confirmed by EM (Figure 5.2 a and Figure 5.3 a) and 
100% incorporation of monomer into the fibrillar aggregate was confirmed by SDS PAGE 
analysis of soluble and insoluble peptide fractions after centrifugation (example data shown 
for both fibril types in Figure 3.4).  These stocks were then titrated serially against a fixed 
concentration (10 nM) of fluorescent aptamer, in 384-well plates, by use of a liquid handling 
robot (Section 2.8.5).  Concentrations of fibril were calculated as monomer equivalent, 
based on the concentration of starting peptide material in the fibril formation reactions.  
Titrations for each aptamer sequence were set up in triplicate to demonstrate the 
reproducibility of the results.  
In the case of every aptamer sequence assayed, titration against its own fibril target resulted 
in an increase in polarisation, consistent with binding (Figure 5.2 b and Figure 5.3 b).  The 
degree of reproducibility between replicates was variable, owing to the inherent 
heterogeneity of the fibril samples.  Although a single structural morphology can be 
reproduced faithfully through seeded elongation105, the average length distribution of fibrils 
will vary between samples.  This would lead to a variable number of available epitopes and 
could contribute to the variability observed.  Nevertheless, upon averaging three replicates 
for each aptamer sequence and plotting on the same axis for comparison (Figure 5.4 a and 
b), apparent dissociation constants in the high nM to low μM range were elucidated by 
fitting to a modified Hill function (Equation 2.5).  The sigmoidal response observed 
suggests that binding is specific and the Hill coefficients (n) of 1 ± 0.25, found for each 
aptamer, indicate non-cooperative binding to a single site (inset tables in Figure 5.4 a and 
b).   
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Figure 5.2 Analysis of 2A fibril binding by anti-2A aptamers.  (a) Negative stain EM of 2A 
fibrils.  A cartoon representation of the 2A fibril is inset (pdb file 2LMN) with unstructured 
residues 1-8 omitted for clarity.  (b) Normalised FP responses for each aptamer sequence 
as a function of monomer equivalent fibril concentration.  Experiments were carried out in 
MOPS selection buffer, pH 7.5 at 25 °C.  Three replicates for each aptamer are shown.  The 
identity of each aptamer is labelled in each plot. 
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Figure 5.3 Analysis of 3Q fibril binding by anti-3Q aptamers.  (a) Negative stain EM of 3Q 
fibrils.  A cartoon representation of the 3Q fibril is inset (pdb file 2LMP) with unstructured 
residues 1-8 omitted for clarity.  (b) Normalised FP responses for each aptamer sequence 
as a function of monomer equivalent fibril concentration.  Experiments were carried out in 
MOPS selection buffer, pH 7.5 at 25 °C.  Three replicates for each aptamer are shown.  The 
identity of each aptamer is labelled in each plot. 
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Figure 5.4 Individual aptamers are able to bind to their cognate fibril target.  FP analysis 
from Figure 5.2 b (a) and Figure 5.3 b (b) showing individual aptamers binding to their 
cognate fibril targets, 2A and 3Q, respectively.  Cartoon representations of each fibril 
structure are also given (inset - pdb files 2LMN and 2LMP, respectively).  An average of three 
replicates for each anti-fibril aptamer are shown.  The dissociation constants (Kd) and n 
values (n) for each interaction are given in the corresponding tables.   
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Dissociation constants for 2A aptamers against 2A fibrils demonstrated weaker binding, in 
general, than 3Q aptamers for 3Q fibrils (1.8 – 8.1 μM and 0.6 - 2.3 μM, respectively).  The 
FP analysis also enabled the five aptamers from each selection to be ranked in order of 
binding affinity.  Although aptamers demonstrate similar affinity for their cognate fibril 
targets, the dissociation constants generally correlate with the order of the aptamer’s 
frequency from the selected pool, further evidence that the highest affinity sequence from 
the pool was preferentially amplified in the SELEX procedure.  This correlation is 
particularly clear for the anti-3Q aptamers.  In the case of the anti-2A aptamers, 2A1 
demonstrated the highest affinity value of 1.8 ± 0.26 μM, whereas the aptamers 2A39, 
2A359, 2A416 and 2A417 displayed similar binding curves, with Kd values in the 5 - 8 μM 
range.  A titration against aptamer 2A29, a sequence not chosen for the initial screen, was 
added to determine whether it would display a dissociation constant intermediate of that 
seen between the tightest binder 2A1 and the remaining four sequences, which was indeed 
the case (Figure 5.4 a).  Plotting the dissociation constants determined from the FP analysis, 
as a function of aptamer frequency from the NGS of each of the selected pools, further 
illustrates the correlation (Figure 5.5).  
 
 
 
 
Figure 5.5 Dissociation constants for aptamers binding to their cognate fibril targets 
correlates with the aptamers’ frequency from the selected pools.  Graphical representation 
of the correlation between aptamer frequency from the selected pools and the Kd for their 
cognate target association, determined from the FP experiments (Figure 5.4).   
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To ensure that the binding observed by these aptamers was not an artefact of fluorescent 
labelling, a competition experiment was designed in which displacement of the 
fluorescently-labelled aptamer upon titration with its unlabelled counterpart was 
measured.  If the fluorescently labelled aptamer is displaced fully by the unlabelled 
competitor, the FP response should fall from the more polarised bound state to the 
depolarised state, as seen for the labelled ligand free in solution.  To examine this 
hypothesis, 2ʹF modified aptamer 2A1, without the fluorescent label, was titrated against 
the fluorescent 2A1 aptamer:2A fibril complex, which was fixed at a concentration 
equivalent to 65% bound (26 µM fibril: 10 nM aptamer), calculated from the direct binding 
experiment in Figure 5.4.  The identical aptamer, but lacking Alexa488, was able to displace 
the labelled RNA indicating that the binding is not driven by the presence of the fluorophore 
(Figure 5.6).  The dissociation constant of the unlabelled RNA, was estimated from this 
experiment as 310 nM, substantially tighter binding than that seen in the direct binding 
assay.  This suggests that the presence of the fluorescent label (one Alexa488 per aptamer 
sequence – Section 4.2.1.1) reduces the binding affinity and therefore leads to an 
underestimation of the dissociation constant.  The competition FP experiment may thus give 
a more accurate representation of affinity.  Unfortunately, the concentration of unlabelled 
competitor RNA required for this single experiment (> 10 µM aptamer) is much greater than 
the concentration of labelled aptamer needed in the direct binding set up (< 10 nM) and 
therefore was not feasible in the assessment of several aptamers, with the number of 
replicates required to ensure reproducibility. 
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Figure 5.6  Aptamer binding is not facilitated through the fluorescent modification in FP.  A 
titration of unlabelled 2ʹF aptamer 2A1 was added (up to 8 µM) to a mixture of 2A fibrils 
(26 µM) and Alexa488-labelled aptamer (10 nM), leading to a displacement of the labelled-
aptamer, as monitored by FP.  The experiment was conducted in MOPS selection buffer, pH 
7.5, at room temperature. 
 
A similar experiment was set up to determine whether the 2ʹF modification, present in all 
aptamers throughout the selection, altered the binding affinity of the aptamers tested.  2ʹOH 
aptamers 2A1, 2A417, 3Q1 and 3Q319 (lacking Alexa488 dUTP labelling) were made from 
an unmodified-dNTP containing transcription mix (Section 2.6.4) and titrated against their 
equivalent Alexa488-labelled 2ʹF counterparts in complex with their cognate fibrils 
(aptamers 2A1 and 2A417 in complex with 2A fibrils, aptamers 3Q1 and 3Q319 in complex 
with 3Q fibrils).  Again, 2ʹOH aptamers were able to dissociate the bound 2ʹF RNA and 
dissociation constants were determined for three out of the four aptamers assayed (3Q319 
did not reach a plateau over the concentration range studied and data could not be fitted).  
Kds differed from those found for the 2ʹF Alexa488 labelled aptamers, with both 2A1 and 
2A417 showing tighter binding when not 2ʹF modified and 3Q1 showing weaker binding in 
the 2ʹOH form.  The results suggest that the modification with 2ʹF pyrimidines influences 
the aptamer recognition motifs but, nonetheless, binding is observed for all aptamers in 
both their 2ʹOH and 2ʹF forms. 
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Figure 5.7 2ʹOH aptamers are able to bind to the fibril targets.  Competitive FP experiments 
for aptamers 2A1 (teal), 2A417 (blue), 3Q1 (green) and 3Q319 (pink) against their 2ʹF 
Alexa488 aptamer counterparts in complex with their cognate fibrils.  Data are shown for a 
single experiment for each aptamer.  Dissociation constants determined from a Hill fit 
(methods) are indicated in the accompanying tables for aptamers 2A1, 2A417 and 3Q1, and 
compared to the Kd and n values determined for 2ʹF modified aptamers in the direct FP 
experiments shown in Figure 5.4. 
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5.3 Cross-reactivity with alternative Aβ40 fibril 
morphologies 
 
To determine whether the aptamers selected are able to recognise fibrils of the alternative 
morphology, the direct FP binding experiment was repeated, but the non-cognate fibril type 
was titrated against the fluorescently-labelled aptamers from the other selection pool (3Q 
fibrils were titrated against anti-2A selected aptamers and vice versa).  In each case, two 
aptamers were assayed (2A1 and 2A417 against 3Q fibrils and 3Q1 and 3Q319 against 2A 
fibrils - Figure 5.8).  The results showed that all aptamers cross-react with the alternative 
fibril morphology.    
Dissociation constants observed for all eight aptamer-fibril combinations tested lie within 
the same range as those seen for their cognate targets (high nM to low μM).  However, due 
to the different batches of fibrils used in the analyses, the precise Kd values for individual 
aptamers differ from those previously seen.  From this it became clear that Kd values of 
different fibril batches could not be used to accurately compare the ability of the aptamers 
to bind the different fibril targets.  Only a direct comparison of the aptamers, on the same 
single batch of fibrils, can give insight into the relative affinity to an individual fibril type.  
Therefore, comparison of the binding of four aptamers 2A1, 2A417, 3Q1 and 3Q319 against 
a single batch of 2A fibrils was carried out (Figure 5.8 a).  The results of this experiment 
demonstrated that the anti-2A aptamers indeed possess higher affinity to 2A fibrils than the 
non-cognate anti-3Q1 aptamers (inset table in Figure 5.8 a).  Contrastingly, when the same 
four aptamers were tested against a single batch of 3Q fibrils, no significant discrimination 
was seen.  All four aptamers bound with approximately the same affinity (~ 1 µM Figure 
5.8 b), with non-cognate aptamer 2A1 demonstrating marginally tighter binding over the 
four sequences tested.  These data demonstrate that although the aptamer sequences have 
different sequence and structure, anti-2A and anti-3Q aptamers bind both fibril 
morphologies with similar affinity, displaying some discrimination in the case of the 2A 
fibrils and not for 3Q.  This suggests that the aptamers recognise epitopes conserved 
between the two fibril types.  
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Figure 5.8 Aptamers are able to recognise fibrils of different structural morphology.  FP 
analysis of aptamers 2A1 (teal), 2A417 (green), 3Q1 (blue) and 3Q319 (pink) against 2A (a) 
or 3Q (b) fibrils.  Three replicates were averaged for each aptamer-fibril association.  
Negative stain electron micrographs of the fibril sample used in each experiment are inset 
along with the cartoon representation of the fibril morphology in each case (pdb files 2LMN 
and 2LMP for 2A and 3Q fibrils, respectively).  Dissociation constants for each interaction 
are given in the respective tables, obtained by fitting the data to the Hill equation (Equation 
2.5).  All FP experiments were conducted in MOPS selection buffer, pH 7.5, at room 
temperature. 
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To analyse whether the aptamers cross-react with other Aβ40 fibril morphologies, fibrils 
were formed via de novo growth (without the addition of pre-formed seeds) and assayed 
against the same four aptamer sequences as above.  De novo derived fibrils contain an array 
of different morphologies103, 589 and, therefore, serve as a stringent assessment of whether 
the aptamers display recognition to epitopes found within all Aβ40 fibrils or features unique 
to the seeded fibrils studied so far.   
Fibrils were formed by incubation of 200 μM monomeric Aβ40, overnight, with agitation at 
600 rpm in a NEPHALOstar plus plate reader, in the same buffer used in the seeded fibril 
reactions (Section 2.4.2).  Fibril formation was monitored by nephalometry (Figure 5.9 a) 
and fibrils were shown to be fully elongated within 6 hours.  After 18 h elongation, the yield 
of fibrils was calculated to allow accurate estimation of monomer equivalent fibril 
concentration for the FP titrations.  This was assessed in the same manner as for the seeded 
fibrils (by SDS PAGE analysis of the soluble and pelletable fractions after separation by 
centrifugation – Section 2.4.7).  This analysis confirmed that 100% of the monomeric 
peptide had been incorporated into the fibrils in 18 h (Figure 5.9 b).  Assessment of fibril 
morphology by electron microscopy confirmed the presence of long, unbranched and 
sometimes twisted fibrils (Figure 5.9 c).   
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Figure 5.9  Formation and characterisation of de novo Aβ40 fibrils.  (a)  Nephelometry of 
fibrils formed from 200 µM monomeric Aβ40 in 25 mM sodium phosphate buffer, pH 7.5, 
with 600 rpm agitation, shown over the first 12 h.  Data from three representative wells are 
shown.  (b)  SDS PAGE analysis of fibril yield after 18 h elongation, comparing soluble (S) 
and pelleted (P) fractions to a whole protein sample from the fibril mix, pre-separation (W).  
Molecular weight markers are indicated in kDa.  (c)  Negative stain electron micrographs of 
de novo Aβ40 fibrils after 18 h elongation. 
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Analysis by FP demonstrated that all four of the aptamers assayed associate with the de 
novo fibrils of Aβ40 of mixed morphology (Figure 5.10 a).  The dissociation constants (1.3 
– 1.8 μM) indicate similar binding affinity to that demonstrated against their target fibril 
assemblies.  As seen with 3Q fibrils, the different aptamer sequences demonstrate no 
significant differences in their ability to bind these Aβ40 fibrils.  
One discernible difference in the binding demonstrated against this fibril morphology was 
the difference in Hill coefficient (n), which is indicative of the cooperativity of binding590.  
The slope of the binding curves observed against de novo Aβ40 fibrils is clearly steeper 
(shown more clearly in Figure 5.10 b for aptamer 2A1).  The average n value for the four 
aptamers tested against the de novo fibrils is 1.6 ± 0.12.  An n value > 1 suggests that there 
are two or more binding sites and that there is positive cooperativity, where the binding of 
one substrate facilitates the binding of another.  Cooperativity is difficult to interpret in the 
case of fibrillar targets, as the binding response is monitored as a function of monomer 
equivalent concentration and not fibril molarity.  Nevertheless, the differences between the 
curves presented for each of the four aptamers tested against de novo fibrils, compared with 
the seeded structures, suggests there may be differences in the binding modes, even though 
the apparent affinity is similar. 
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Figure 5.10  Aptamers are able to cross-react with unseeded (de novo) Aβ40 fibrils.  (a)  FP 
analysis demonstrating similar binding responses by aptamers 2A1 (teal), 2A417 (green), 
3Q1 (blue) and 3Q319 (pink) to de novo derived Aβ40 fibrils.  Three replicates were 
averaged for each association.  Dissociation constants (Kd) and n values are indicated for 
each interaction in the corresponding table.  (b)  A single replicate of aptamer 2A1 binding 
to 2A fibrils (teal circle), 3Q fibrils (blue triangle) and de novo fibrils (pink circle) are 
overlaid to compare differences in apparent binding cooperativity. 
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5.4 Analysis of aptamer cross-reactivity with fibrils from 
other amyloidogenic proteins 
 
To determine whether the aptamers 2A1, 2A417, 3Q1 and 3Q319 are able to cross-react 
with fibrils derived from other precursor peptides, binding studies were conducted against 
a selection of unrelated fibrils with varying structural features, including Parkinson’s 
disease associated α-synuclein (α-syn), an amyloidogenic fragment of full-length Aβ (Aβ16-
22) and the synthetic amyloid ccβ-p. 
 
5.4.1 α-synuclein 
 
α-synuclein (α-syn) is a 140 amino acid protein (Figure 5.11 a) from a family of peptides 
found to be abundant in the brain.  Synucleins (including α, β and γ-synuclein) share 55-
62% sequence identity and are all comprised of a similar three-domain organisation 
(Figure 5.11 b).  The amino terminal domains are made up of a series of 11-residue repeats, 
with the consensus sequence KTKEGV separated by inter-repeat regions of 5-8 amino 
acids591.  In α-syn, this region is able to form α-helical structure upon interaction with 
membranes592-594.  The central domain of α-syn is predominantly hydrophobic and is known 
as the non-amyloid-β component (NAC) domain, named so as it was originally discovered 
through its co-purification with Aβ from amyloid plaques from AD patients595.  This region 
is thought to be essential in the formation of amyloid fibrils from α-syn596.  The acidic C-
terminal domain of α, β and γ-synuclein is comprised of mostly negatively charged residues 
and remains largely unfolded, even in the lipid-bound form591.  Synucleins are found 
concentrated in the nerve terminals and close to synaptic vesicles597-599 and, although their 
cellular function is poorly understood, it has been suggested that they are involved in the 
trafficking of synaptic vesicles600-602 and regulation of neurotransmitter release603-605.   
Despite the conserved sequence identity and domain organisation between the three 
synucleins, α-syn is the only fibril-forming peptide of the family606 and the only synuclein 
associated with the filamentous inclusions known as Lewy bodies607, 608, the main 
neuropathic feature of Parkinson’s disease.  Lewy bodies are round, cytoplasmic inclusions 
made predominantly of fibrillar aggregates of α-syn, but also containing other proteins such 
as ubiquitin609 and the molecular chaperone αB-crystallin610.   
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Figure 5.11  Sequence and structure of α-syn fibrils.  (a)  The amino acid sequence of α-
synuclein.  The amphipathic N-terminal region (which consists of a series of imperfect 11-
residue repeats containing the consensus sequence KTKEGV), the NAC region, and the C-
terminal acidic tail are highlighted in different colours to correspond to the domain 
organisation outlined in (b).  (c)  The proposed secondary structural elements in the core 
region (residues 31 - 109) of α-syn fibrils based on ssNMR measurements by Comellas et 
al.611.  Black arrows indicate β-strands, curved yellow lines correspond to turn or loop 
regions, and dashed lines indicate areas where no experimental data was available.  The 
unstructured N- and C- terminal regions are represented as pink solid lines. 
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Monomeric α-syn is natively unstructured612, 613 and assembles from a random-coil 
conformation, via a range of intermediate species, into typical β-sheet rich, amyloid 
fibrils606.  As with Aβ amyloidosis, the oligomeric structures are most often linked to 
neurotoxicity614 and a range of spherical615, 616, annular617, 618 and chain-like619 structures 
have been implicated.  Fibrils are often considered to be the inert end-point of aggregation, 
although there is evidence to suggest a toxic mechanism for these higher order species107, 
147. 
There is currently no definitive structure known for α-syn fibrils, but several studies have 
shown them to be composed of several protofilaments, in which the β-sheets are organised 
perpendicular to the fibril axis606, parallel and in-register620, 621.  Limited proteolysis, EPR 
and ssNMR studies have shown that residues 31 - 109 of the protein are folded in a repeated 
β-sheet motif that forms the core of the protofibril620-626 and the N- and C-terminal regions 
remain flexible and disordered (Figure 5.11 c).  Hydrogen/deuterium exchange NMR 
experiments by Vilar et al. reported five distinct protected regions in this core leading to 
their model of a protofilament composed of five layered β-sandwich623.  However, a more 
recent study611, with more comprehensive assignment of secondary structure within this 
core region, was proposed indicating that this region is formed by six distinct strands; two 
repeats of a long β-strand followed by two shorter β-strands.  The consensus, however, is 
that the β-sheet rich core region stacks to form the protofilament structure and the C- and 
N-terminal regions remain disordered on the surface.  These protofilaments are then 
thought to assemble into mature fibrils of at least two distinct structural isoforms623, 624, the 
most well characterised of these being the ribbon and fibrillar morphologies where 
protofilaments lie parallel to each other (ribbon) or twist around each other (fibrillar)107. 
Given the wealth of structural information606, 620, 621, 623, 624 and the prevelence of PD127, α-syn 
fibrils were selected as a second model amyloid in order to determine the extent of aptamer 
cross-reactivity with fibrils formed from unrelated, larger protein sequences. 
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5.4.2 Aptamers display cross-reactivity with α-synuclein fibrils 
 
Wild-type α-syn was expressed from a pET23a plasmid containing a synthetic gene 
encoding its sequence (Appendix 7.1.2) and purified by anion exchange chromatography, 
followed by size exclusion separation (Figure 5.12 a).  Full details of the expression and 
purification protocols are given in (Section 2.3.2).  The purity of the resultant protein was 
verified by mass spectrometric analysis (Figure 5.12 b) and the preparation protocol was 
found to yield 45 mg pure protein/L culture.  This protein was then used to form fibrils for 
the aptamer binding analysis.   
 
 
 
Figure 5.12  Purification of recombinantly expressed α-syn.  (a)  A typical α-syn elution 
profile from the final SEC stage of the purification (detailed in Section 2.3.2).  Pure α-syn 
elutes as the dominant species (highlighted yellow).  (b)  ESI-MS analysis of purified α-syn.  
The observed mass of 14459.88 Da is indicated in the spectrum, (expected mass 
14460.1 kDa).   
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In order to create fibril samples, a seeding protocol was employed rather than formation via 
de novo assembly, as work previously conducted in the group by Dr. Matthew Jackson and 
Dr. Theo Karamanos found that seeded samples demonstrate much higher efficiency of 
monomer incorporation (unpublished results).  The seed stocks were first made by 
incubation of α-syn at 300 μM final protein concentration, in 20 mM Tris-HCl, 100 mM NaCl, 
0.01% (w/v) NaN3, pH 7.5, with constant 600 rpm shaking on a thriller thermoshaker 
(Section 2.4.3).  After 7 days of elongation, the resultant fibrils were fragmented with 1000 
rpm stirring on a home-built precision stirrer (Section 2.4.3), for 48 h.  The seeds were then 
used to elongate further fibril samples.  10% (v/v) seed stock was added to 200 μM 
monomeric peptide, in the same buffer, and incubated for a minimum of 4 days, this time 
with only intermittent shaking (5 s at 600 rpm, at 5 min intervals), introduced to reduce 
fibril settling during formation (Section 2.4.3).  The incorporation of monomer after 4 days 
of elongation was assessed by SDS-PAGE analysis (Figure 5.13 a).  The results showed that 
> 95% of the peptide is incorporated into the insoluble fibrillar pellet.  α-syn has self-
proteolytic properties627 which is evident here from the existence of some fragment bands 
seen in the SDS-PAGE gel.  The presence of some proteolytic fragments was unavoidable in 
all fibril formation reactions, but as the vast majority of the peptide in the fibrils remains 
full-length, the fibril samples made by this protocol were considered of sufficient quality to 
conduct the aptamer binding investigations.  Negative stain TEM of the fibril samples 
confirmed the presence of long, unbranched amyloid fibrils (Figure 5.13 b), mostly 
presenting a straight morphology consistent with the model of protofibrils laterally 
associating107.  α-syn fibrils are inherently polymorphic and the presence of a twisted 
protofibril morphology was also evident in some micrographs (Figure 5.13 b, inset). 
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Figure 5.13  Formation and characterisation of α-syn fibrils.  (a)  SDS PAGE analysis of fibril 
yield, comparing soluble (S) and pelleted (P) fractions to a whole protein sample from the 
fibril mix, pre-separation (W).  Molecular weight markers are indicated in kDa.  (b)  Negative 
stain electron micrographs of α-syn fibrils presenting a dominant “straight” morphology 
with some instances of twisted morphologies present (inset). 
 
Fluorescence polarisation was again utilised to assess whether the α-syn fibrils are 
recognised by the four aptamers 2A1, 2A417, 3Q1 and 3Q319 (Figure 5.14).  An increase in 
polarisation as a function of fibril concentration was again observed, indicative of the 
aptamers binding to this unrelated fibril type.  Dissociation constants for the interactions 
range from 2.7 – 21 μM a lower affinity than for the cognate Aβ40 fibrils, for which Kds 
ranged from 0.58 – 8.1 µM, in the direct-binding polarisation experiments (Section 5.2.2).  
Aptamer recognition of fibrils, therefore, is not simply dependent on the precursor protein 
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sequence, but the affinity of the interaction may be effected to some extent by it.  Of the four 
aptamers tested, differences were observed in their relative ability to bind α-syn fibrils, with 
the same order of affinity shown against the Aβ40 fibril morphology 2A being observed 
(2A1 is the tightest binder, followed by 2A417, 3Q1 then 3Q319).  The cooperativity of 
binding is also similar to that seen in the aptamer-2A fibril interactions (n = ~1), except for 
3Q1, however this fit could be skewed due to larger errors in the pre-transition (unbound) 
data points of this binding curve.  It is clear from these data that aptamers are able to bind 
generic features of amyloid that are conserved between assemblies, even when derived 
from entirely different precursor peptides. 
 
 
 
Figure 5.14  Aptamers are able to recognise fibrils from the unrelated amyloid protein α-
syn.  FP analysis demonstrating α-syn fibril binding by aptamers 2A1 (teal), 2A417 (green), 
3Q1 (blue) and 3Q319 (pink).  Three replicates were averaged for each association.  
Dissociation constants (Kd) and n values are indicated for each interaction in the 
corresponding table.   
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5.4.3 Aβ16-22 
 
To examine the nature of the conserved aptamer binding epitope, the simple cross-β 
architecture synonymous with amyloid fibrils was considered a likely candidate.  Typical 
cross-β structure is formed when individual β-sheets are organised perpendicular to the 
axis of the fibril and are spaced 4.7 Å apart82 (Figure 1.6).  This gives rise to a characteristic 
X-ray diffraction pattern, with meridional and equatorial bands at 4.7 Å and ~ 10 Å, 
respectively, which are observed for all amyloid fibrils15, 82.  To determine whether this 
simple feature of amyloid is the main epitope for aptamer binding, a fibril which contains a 
simple cross-β architecture was chosen.  Aβ16-22 (KLVFFAE - Figure 5.15) is a self-
assembling fragment of full-length Aβ which spans the central hydrophobic region of the 
peptide and, along with many other Aβ fragments100, 628-632, has been shown to form amyloid 
fibrils in vitro633-636.  This peptide has been identified as forming the cross-β spine of full-
length fibrils95, 104, 628 and, therefore, was chosen as the model amyloid structure to examine 
aptamer selectivity for the cross-β motif.  
Fibrils of Aβ16-22 were first described and modelled in atomic detail by Balbach et al.633.  
Using X-ray diffraction, Fourier transform infrared spectroscopy (FTIR) and ssNMR, the 
authors determined that the fibril structure of Aβ16-22 is comprised of anti-parallel, in-
register β-sheets (Figure 5.15).  The proposed in-register alignment leads to a β-sheet 
arrangement in which the side chains present in such a way as to produce two distinct faces 
of the β-strand; Leu17, Phe19 and Ala21 forming the hydrophobic face and Lys16, Val18, 
Phe20 and Glu22 displaying on the opposing, hydrophilic side (Figure 5.15).  The precise 
structure in terms of β-sheet stacking is unknown for these fibrils, although several 
molecular dynamic (MD) simulations suggest that 2, 3, 4637 or even 5634 anti-parallel 
β-sheets can associate to form the mature fibril.  Unlike the amyloid fibrils studied in this 
thesis so far, Aβ16-22 fibrils have no dynamic unstructured regions decorating the surface 
of the fibril and, therefore, should provide insight into whether the cross-β spine itself is 
involved in the aptamer recognition motif. 
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Figure 5.15  Sequence and structure of Aβ16-22.  (a)  The amino acid sequence of the 
Aβ16-22 peptide represented as a β-strand conformation as seen along the β-sheet plane, 
where amino acid side chains are represented as spheres.  (b)  Schematic representation 
depicting the anti-parallel, in-register β-sheet structure formed by Aβ16-22 peptides.  
Residues are coloured according to their properties: positively charged (blue), negatively 
charged (red), hydrophobic (green). 
 
Fibrils of Aβ16-22 were formed from synthetic peptide, synthesised and purified by Dr. 
George Preston (School of Chemistry, University of Leeds).  Fibril reactions were set up at 
final peptide concentrations of 400 μM, in 25 mM sodium phosphate buffer, pH 7.5, and 
incubated, without shaking, at room temperature for 15 days (Section 2.4.4).  After 15 days 
of elongation, the presence of fibrillar structures was confirmed by negative stain EM.  The 
results showed fibrils with a high degree of polymorphism (Figure 5.16 a).  It was 
necessary to assess fibril yield and, therefore, to estimate monomer equivalent fibril 
concentration in the binding experiments, however, SDS-PAGE analysis of the pelletable 
material was not feasible because of the size of the peptide.  Aβ16-22 also lacks aromatic 
residues and hence it is not visible by UV spectroscopy at 280 nm.  Therefore, the monomer 
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remaining in the soluble fraction after separation by centrifugation was measured by a 
calibrated HPLC approach, in which peptide content was monitored by absorbance at 210 
nm (Section 2.4.8).  Figure 5.16 b shows the HPLC calibration by injection of 50, 100 and 
200 μM samples of monomeric Aβ16-22.  Injection of an equal volume of the soluble fraction 
taken from a pelleted fibril sample (after 15 days incubation) showed that 72% of the 
peptide was incorporated into fibrils.  This fibril yield is consistent with the efficiency of 
fibril formation documented previously for this peptide638.   
 
 
 
Figure 5.16  Formation and characterisation of Aβ16-22 fibrils.  (a)  Negative stain EM of 
Aβ16-22 fibrils displaying several distinct morphologies.  (b. i.)  HPLC calibration used to 
estimate fibril yield.  (b. ii.) Peak area was calculated from an injection of the equivalent 
volume of the soluble fraction after fibril sample separation, calculated from the standard 
curve and expressed as a percentage of total peptide before fibril formation (400 µM). 
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To assess binding of Aβ16-22 fibrils to aptamers 2A1, 2A417, 3Q1 and 3Q319 and to allow 
comparison of binding over the same fibril concentrations assayed for the previous fibril 
types, the monomer equivalent concentration of fibril titrated was corrected for this 72% 
yield.  FP analysis over this concentration range showed that the four aptamers tested were 
unable to recognise these fibrils (Figure 5.17).  This was compared with a single control 
assay of 3Q1 binding to 3Q fibrils conducted on the same day as a positive control.  These 
data suggest that the cross-β backbone structure present in the Aβ16-22 fibrils is not 
sufficient for aptamer binding.  The amyloid binding ability of aptamers 2A1, 2A417, 3Q1 
and 3Q319, therefore, presumably does not result from their common cross-β fold. 
 
 
 
 
Figure 5.17  Aptamers are unable to bind Aβ16-22 fibrils.  FP analysis demonstrating the 
inability of aptamers 2A1 (teal), 2A417 (green), 3Q1 (blue) and 3Q319 (pink) to bind 
Aβ16-22 fibrils.  Three replicates were averaged for each association.  The data are 
compared with a single replicate of positive control aptamer 3Q1 binding to 3Q fibrils, 
conducted on the same day (pale blue), fitted to the Hill equation (Kd = 1.34 ± 0.24 µM, n = 
0.71 ± 0.10). 
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5.4.4 ccβ-p 
 
ccβ-p (Figure 5.18 a), is a 17-residue, synthetic, amyloid-forming peptide.  It was originally 
designed by Kammerer and colleagues639 as a model peptide for studying the molecular 
interactions required for amyloid formation.  ccβ-p forms a native coiled-coil structure at 
ambient temperatures that rapidly converts to amyloid fibrils at elevated temperatures.  
These fibrils possess the typical cross-β architecture, as confirmed by CD, TEM, 
characteristic Congo-red green birefringence and X-ray diffraction data639.  FTIR also 
indicates that the β-strands forming the core of the fibrils are anti-parallel and ssNMR 
distance measurements indicates an out-of-register alignment where Ala7 is hydrogen 
bonded to Leu14 on the adjacent strand.  The structural model proposed for ccβ-p (Figure 
5.18 b and c) and the related ccβ-Met640 is a laminated cross-β structure made up of a 
minimum of three β-sheets, where each strand is fully extended.  The inter- and intra-sheet 
packing is composed of the maximum number of hydrophobic contacts and this results in 
the out-of-register, anti-parallel arrangement, consistent with experimental data639.   
This model fibril was chosen as a further control for aptamer cross-reactivity as it is again 
predicted to form a simple cross-β structure without the flexible termini present in the 
predicted Aβ40 and α-syn fibril structures.  Ccβ-p fibrils also present a number of positively 
charged residues on the surface (Figure 5.18), as opposed to the fibrils formed from 
Aβ16-22 which possess only a single lysine residue (K16) at the edge of the β-strand 
(Figure 5.15).  The ccβ-p model peptide fibril, therefore, would provide insight into 
whether the presence of positively charged residues on the surface of the cross-β structure 
is necessary and sufficient for amyloid binding by the anti-Aβ40 aptamers. 
CHARACTERISATION OF RNA APTAMERS AGAINST AMYLOID FIBRILS 
 
 
200 
 
 
 
Figure 5.18  Sequence and structure of ccβ-p.  (a)  The amino acid sequence of the ccβ-p 
peptide represented as a β-strand conformation, as seen along the β-sheet plane, where 
amino acid side chains are represented as spheres.  (b)  A schematic representation of four 
β-strands viewed perpendicular to the fibril axis, depicting the anti-parallel and out-of-
register conformation proposed.  The grey and yellow arrows discriminate between the two 
faces of the β-strand.  (c) View of the proposed model for the fibril cross-section.   Residues 
are coloured according to their properties: positively charged (blue), negatively charged 
(red), hydrophobic (green), polar or glycine (black).  Adapted from639. 
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Ccβ-p was synthesised and kindly provided by Dr. Kevin Tipping (School of Molecular and 
Cellular Biology, University of Leeds).  Fibrils were formed from monomeric ccβ-p by 
incubation at 37 °C, without agitation, for 18 h, yielding fibrils with 100% monomer 
incorporation, as assessed by calibrated HPLC analysis (Figure 5.19 a).  Negative stain EM 
was again used to confirm that the aggregates formed were indeed fibrillar (Figure 5.19 b). 
 
 
 
Figure 5.19  Formation and characterisation of ccβ-p fibrils.  (a)  HPLC calibration used to 
estimate fibril yield.  Peak area was calculated from an injection of the equivalent volume of 
the soluble fraction, after fibril sample separation, calculated from the standard curve and 
expressed as a percentage of total peptide before fibril formation (200 µM).  (b) Negative 
stain electron micrograph of ccβ-p fibrils. 
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Figure 5.20 shows the FP analysis of aptamers 2A1 and 3Q1 against synthetic ccβ-p 
amyloid fibrils and, as seen for the peptide fragment fibril Aβ16-22, demonstrates that the 
two aptamer sequences are unable to recognise this fibril morphology.  The results were 
again compared with a single replicate of the positive control aptamer 3Q1 binding to 3Q 
fibrils, performed on the same day.  These data further support the hypothesis that 
aptamers have some discrimination between amyloid assemblies and that recognition 
cannot be simply due to the presence of positively charged residues on the fibril structures, 
or a cross-β fold.   
 
 
 
Figure 5.20  Aptamers are unable to bind to ccβ-p fibrils.  FP analysis demonstrating an 
inability for aptamers 2A1 (green) and 3Q1 (blue) to bind ccβ-p fibrils.  Three replicates 
were averaged for each association.  Data are compared to a single replicate of positive 
control aptamer 3Q1 binding to 3Q fibrils, conducted on the same day (pale blue), fitted to 
a Hill equation (Kd = 4.15 ± 1.30, n = 0.69 ± 0.14). 
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5.5 Examining the influence of aptamer sequence and 
structure on amyloid binding specificity 
 
5.5.1 Primary RNA sequence 
 
The cross-reactivity studies presented so far have shown that the aptamer sequences 
selected against defined structures of Aβ40 fibrils are able to bind fibrils of different 
morphology, from the same Aβ40 peptide precursor and the unrelated protein sequence of 
α-syn, but not amyloid fibrils formed from shorter peptide sequences (Aβ16-22 and ccβ-p).  
To understand the nature of the selectivity for generic amyloid epitopes, investigation into 
common features of the RNA aptamers themselves was next undertaken. 
The differences in base composition and lack of conserved motifs between aptamer 
sequences isolated from the two pools (Figure 3.17) initially suggested that the aptamers 
would possess specificity for their selection targets.  This was based on the assumption that 
RNA sequences would dictate the secondary structural elements that confer binding 
specificity.  The data presented thus far suggests that binding specificity is not strongly 
dependent on RNA sequence, as aptamers with little sequence similarity bind the various 
fibrils with similar affinity.  The small differences in affinity seen between some aptamer 
sequences may indicate that primary sequence has a role in modulating the binding, but 
presumably is not the dominant process driving the recognition. 
To test this further, a series of aptamers with unrelated primary sequences were tested for 
their ability to recognise the various amyloid fibrils.  β55 (Figure 5.21 a) is an aptamer 
sequence characterised by Ylera et al.491 that was originally selected against monomeric 
Aβ40 yet, according to their publication, shows enhanced affinity for Aβ40 fibrillar 
assemblies.  β55 shares no sequence similarity with the aptamers selected against monomer 
or fibrillar Aβ40 in this study and, therefore, was used as a further test of how the primary 
sequence of RNA may determine or modulate binding specificity.   
β55, fluorescently-labelled with Alexa488 dUTP as described in Section 4.2.1.1, was 
transcribed (Section 2.6.5.1) and FP analysis against 2A and 3Q fibrils was conducted 
(Figure 5.21 b).  The data indicate similar binding affinity of β55 for both fibril types (2.47 
± 0.33 µM for 2A and 1.69 ± 0.12 µM for 3Q) which is also similar to that determined for the 
anti-2A and anti-3Q aptamers (0.6 - 8.1 µM).   
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Figure 5.21  The control anti-Aβ40 monomer aptamer β55 binds to 2A and 3Q fibrils with 
similar affinity.  (a)  The sequence and predicted secondary structure of aptamer β55.  (b)  
FP analysis demonstrating binding of β55 to 2A (teal) and 3Q (pink) fibrils.  Data were 
compared with a single replicate of control aptamer 3Q1 binding 3Q fibrils, conducted on 
the same day (positive – blue triangles).  The dissociation constant (Kd) and n values are 
given in the corresponding table, obtained by fitting a Hill plot (Equation 2.5 – solid line). 
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Similarly, the aptamer sequence M1, selected against monomeric Aβ40 in this study, was 
also tested for its ability to bind Aβ40 fibrils.  As discussed in Chapter 4, aptamers from the 
anti-monomer selection were characterised and found unable to recognise monomeric 
Aβ40 peptide, unless immobilised on a bead surface.  It was predicted that the aptamers 
may have been selected against an aggregated Aβ40 species, trapped during the 
immobilisation process, and this was tested here.  Indeed, using FP analysis, M1 was shown 
to bind 2A, 3Q and de novo Aβ40 fibrils (Figure 5.22), confirming the notion that the anti-
monomer aptamers are able to recognise higher-order species, but also providing further 
evidence that the aptamer recognition is not entirely dependent on RNA sequence.  M1 
shares no substantial extended sequence motifs in common with the 3Q aptamers and is 
only similar to the 2A aptamers in the GA bias (alignment data in Appendix 7.4), which was 
a consequence of their selections from the same naïve library.  Nevertheless, binding 
affinities of M1 to each Aβ40 fibril morphology (1.56 – 3.5 µM given in table in Figure 5.22) 
was comparable to that of aptamers selected against these fibrillar targets (0.6 - 8.1 µM).   
 
 
 
Figure 5.22  Anti-monomer aptamer M1 binds to Aβ40 fibrils.  FP analysis demonstrating 
binding of M1 to 2A (blue), 3Q (teal) and de novo (pink) Aβ40 fibrils.  Three replicates were 
averaged for each association.  The Kd and n values are given in the corresponding table, 
calculated from a Hill plot of the data (Equation 2.5). 
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Next, RNA aptamer sequences selected by others against a series of unrelated, non-amyloid 
targets were tested for their ability to recognise amyloid fibrils.  Sequences isolated from 
selections (conducted by Dr. David Bunka, Dr. Simon White and Dr. Nicola Derbyshire, 
respectively - all University of Leeds) against viral proteins (dengue virus E protein, 
aptamer DV1, and rabies virus glycoprotein, aptamer RVGP1), as well as an aminoglycoside 
aptamer418 (NGGA1) were chosen for this analysis (Figure 5.23).  Aptamer DV1 was 
selected from a 2ʹOH N50 library, whereas aptamers NGGA1 and RVGP1 were selected from 
2ʹF N30 and N50 libraries, respectively, and, therefore, these control sequences are of 
similar size to the anti-Aβ40 aptamers.  Sequence alignment with Genebee513 confirmed that 
there are no obvious conserved extended sequence motifs between these sequences and 
any of the aptamers selected against the three Aβ40 targets (Appendix 7.4). 
The three control aptamers were transcribed in the presence of Alexa488 dUTP from a 2ʹF 
pyrimidine NTP mix, as described (Section 2.6.5.1), for FP analysis.  Aptamer DV1 was 
shown to bind with similar affinity (Kd = 0.67 – 1.99 µM) as the anti-2A and anti-3Q aptamers 
when assayed against both 2A and 3Q fibrils (Figure 5.24 a).  The aptamers NGGA1 and 
RVGP1, were also able to bind to 2A/3Q fibrils.  They each display similar affinity for 3Q 
fibrils as demonstrated by the anti-fibril aptamers (Kds = 2.5 and 2.1 µM for NGGA1 and 
RVGP1, respectively) and lower apparent affinity for 2A fibrils (data could not be fitted over 
the concentration range assayed - Figure 5.24 b).  NGGA1 and RVGP1 were also assayed 
against Aβ16-22 fibrils and show no association with this fibril type.  Taken together, these 
data confirm that the primary sequence of the RNA aptamers is not the dominant process 
driving recognition.  Moreover, the results suggest that RNA sequences may possess a 
generic ability to bind to fibril structures (at least of longer protein sequences).   
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Figure 5.23  Control aptamer sequences.  (a) RNA sequences of the three aptamers DV1, 
NGGA1418 and RVGP1.  (b)  Mfold predicted secondary structure of the control aptamers.  
Randomised regions are highlighted in teal. 
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Figure 5.24  Aptamer recognition of amyloid assemblies is not dependent on primary RNA 
sequence.  (a)  Aptamer DV1 binds to 2A (teal) and 3Q (pink) fibrils with similar affinity to 
positive control aptamer 3Q1 against 3Q fibrils (blue triangle).  (b)  FP analysis of aptamers 
NGGA1 (i) and RVGP1 (ii) against 2A fibrils (teal), 3Q fibrils (pink) and Aβ16-22 fibrils 
(green).  Three replicates were averaged for each association and compared with a single 
replicate of positive control 3Q1 binding to 3Q fibrils (blue triangle).  Data were fitted to a 
Hill equation (Equation  2.5), except in the case of NGGA1 and RVGP1 binding to 2A (b. i. 
and b.ii) where data did not reach a plateau over the tested concentration range and could 
not be fitted, and in binding to Aβ16-22 where there is no association.  Kd and n values for 
each association are given in the accompanying table. 
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5.5.2 The effect of secondary structure of the RNA aptamer on 
fibril recognition 
 
The aptamer sequences, studied in this thesis so far, display different secondary structural 
motifs.  Extent of base pairing and the positions and sizes of loop and bulge regions 
(discussed in Chapter 3 for all the lead anti-Aβ40 aptamers – Section 3.7) within the 
predicted structures vary, and there is no clear conserved structural element that could 
explain the similar binding properties of the different aptamers against the amyloid targets.  
To investigate the role of the secondary structure of RNA in amyloid binding, a 118 
nucleotide, unstructured RNA R118 (designed by Dr. Alexander Borodavka, University of 
Leeds) was analysed for amyloid fibril binding by FP.  This sequence is comprised of 92% C 
and U repeats and predicted by Mfold analysis to form little stable secondary structure 
(Figure 5.25).  The RNA molecule was synthesised commercially, from wild-type 2ʹOH 
NTPs and modified with a 5ʹ-amino group.  This was used for Alexa488 labelling with an 
Alexa Fluor® 488 5-sulfodichlorophenol ester (Section 2.6.6), which was also carried out 
by Dr. Borodavka. 
Interestingly, the results of the FP analysis showed that the RNA sequence R118 was able to 
bind to all three of the Aβ40 fibril types (2A, 3Q and de novo) with comparable affinity to 
each other (1.4 – 4.6 µM) and to that of the cognate RNA aptamers 2A1, 2A417, 3Q1 and 
3Q319.  R118 also displays the same difference in cooperativity previously observed for 
aptamers binding 3Q/2A fibrils versus de novo Aβ40 fibrils (Table inset in Figure 5.26).  
Again, R118 did not bind Aβ16-22 fibrils, mirroring the behaviour of all other aptamers 
analysed.  These results clearly indicate that RNA possesses generic amyloid binding ability 
that is not dependent on its primary sequence or secondary structure.  The amyloid epitope 
recognised by the RNA is currently unclear, but is not the simple cross-β spine of the fibrils 
as demonstrated by the lack of association, of all aptamers studied, to Aβ16-22 assemblies. 
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Figure 5.25  Sequence and structure of R118 aptamer.  (a) RNA sequence of unstructured 
RNA molecule R118.  (b)  The Mfold predicted secondary structure for the RNA sequence, 
R118. 
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Figure 5.26  Unstructured RNA molecule, R118, can associate with amyloid fibrils.  FP 
analysis demonstrates binding of R118 to 2A (teal), 3Q (pink) and de novo Aβ40 fibrils 
(blue), as well as a lack of recognition of Aβ16-22 fibrils (green).  Data are compared with a 
positive control aptamer 3Q1 association with 3Q fibrils (pale blue diamonds).  Dissociation 
constants and n values are given for each interaction, derived from a Hill fit of the data 
(Equation 2.5). 
 
5.5.3 Analysing the effects of polyanions on fibril recognition 
 
Glycosaminoglycans are highly negatively charged linear polysaccharides made up of repeat 
disaccharide units of an amino sugar (N-acetylated or N-sulphated hexosamine) and either 
a uronic acid or galactose (Figure 5.27 a)641.  There are two types of GAGs: non-sulphated, 
such as hyaluronic acid, and sulphated GAGs that include heparin, heparan sulphate and 
chondroitin sulphate, amongst others642.   
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GAGs have been found to be associated with amyloid assemblies isolated from AD brains643-
645 and many, if not all, extracellular amyloid plaques646.  Indeed, many in vitro studies have 
shown GAGs to play important roles in accelerating fibril formation329, 647-650, stabilising 
fibril structures651, 652 and altering the resultant fibril morphology653.  Heparin is the most 
highly sulphated GAG and has been the focus of most studies into GAG associations with 
amyloid646.  Heparin has been shown to accelerate the rate of fibril formation by several 
amyloid proteins, including tau654, 655, α-syn656, human islet amyloid polypeptide (hIAPP)657, 
β2m658, 659 as well as Aβ648-650.  It is thought that heparin is particularly influential in amyloid 
formation because of its high sulphate content.  This sulphate moiety has been shown to be 
critical in the Aβ-GAG interaction649, 660, 661, supporting the idea that electrostatics are 
important in the association of GAGs with amyloid fibrils.  Precisely how Aβ fibrils and GAGs 
interact is currently unknown, although residues 13-16 (HHQK) are predicted to be 
involved, consistent with the nature of non-amyloid GAG binding proteins, where clusters 
of basic residues are important642, 662.  Interestingly, work by Madine et al.663 demonstrated 
differential heparin binding ability by the two Aβ40 morphologies used as selection targets 
in this work, 2A and 3Q.  LMW heparin (average MW = 4.6 kDa) was shown to associate 
much more weakly with 2A fibrils than 3Q.  ssNMR of the 3Q-LMW heparin interaction 
indicated that the chemical shift of residues in the unstructured N-terminus and apices of 
the triangular morphology were most perturbed by heparin, indicating these areas as 
potential binding sites (discussed in detail later, Section 5.8, Figure 5.35).  Very few 
chemical shifts were seen for the 2A-heparin interaction leading to the conclusion that the 
heparin interaction is weak in this case.   
A competition FP experiment was set up to determine whether the fluorescently-labelled 
aptamers could be dissociated from their fibril-bound state, by titration with an increasing 
concentration of LMW heparin (Figure 5.27 a), to deduce whether the two polyanions 
share similar binding properties and epitopes.  The results showed that the four aptamers 
2A1, 2A417, 3Q1 and 3Q319 were each competed from their fibril-bound state (with both 
2A and 3Q fibrils) by LMW heparin (Figure 5.27 b and c).  Heparin was shown to readily 
dissociate the aptamers from 3Q fibrils, producing a sigmoidal response with a steep 
transition, indicative of a specific competition for the aptamer binding site.  Surprisingly, 
given that heparin has been previously shown to associate only very weakly with 2A 
fibrils663, the same dissociation profile, induced by titration with LMW heparin, was 
demonstrated for aptamers from this fibril type, indicating that heparin must be competing 
for the aptamer epitope in the same way as seen against 3Q fibrils.  The dissociation 
constants for heparin binding to the fibrils was determined as ~2-4 µM by these 
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Figure 5.27  LMW heparin competes for the aptamer binding site.  (a) Structure of a single 
disaccharide unit of heparin.  (b)  Competition fluorescence polarisation showing 
dissociation of aptamer 2A1 (green), 2A417 (teal), 3Q1 (blue) and 3Q319 (pink) from 3Q 
fibrils, as a function of LMW heparin concentration.  (c) As (b) but for 2A fibrils.  Three 
replicates were averaged for each competition and the data fitted to a Hill equation 
(Equation 2.5).  Kd and n values are given for all competitions in the accompanying tables.   
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competition assays, tighter than that previously estimated for LMW heparin and 3Q fibrils 
(34 µM)663, and the average n value of 2.3 indicates some cooperativity.  The possibility that 
the heparin was competing for aptamer binding by an association with the RNA itself was 
unlikely as the FP signal returns to the value of free labelled RNA (raw data shown in Figure 
5.28 a).  This possibility was further ruled out using a gel-shift assay, where RNA pre-
incubated with LMW heparin ran in line with free RNA samples, suggesting no interaction 
(Figure 5.28 b).   
 
 
 
Figure 5.28  RNA dissociation by heparin is due to competition for fibril epitopes.  (a) Raw 
data from Figure 5.27 demonstrating the FP signal plateau after dissociation which is 
consistent with free fluorescent RNA in solution.  Aptamer dissociation from 2A fibrils (solid 
lines) and 3Q fibrils (dotted lines) are shown for each aptamer.  Aptamer colour codes are 
the same as Figure 5.27 and fitted to a Hill equation in the same way.  (b)  Gel-shift assay 
at three RNA concentrations (500, 250 and 125 nM – as indicated).  Samples plus or minus 
50 µM LMW heparin are shown for each RNA concentration. 
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As interactions of heparin with amyloid fibrils are thought to be electrostatically driven649, 
660, electrostatics may also be important in the interactions of RNA.  It was postulated that if 
aptamer binding was simply due to electrostatic contacts with fibrils, titration of 
monovalent salt of the equivalent ionic strength as LMW heparin would also perturb the 
binding in the same manner.  The ionic strength of LMW heparin was estimated (Section 
2.8.7) based on the average of eight disaccharide units in LMW heparin and four negative 
charges per disaccharide unit.  This calculation indicated that 5 mM NaCl has an equivalent 
ionic strength as 10 µM LMW heparin.  However, titration of 50 mM NaCl was unable to 
dissociate the aptamer 2A1 from its complex with 2A fibrils (Figure 5.29 a).  Indeed, the 
aptamer was only shown to dissociate at salt concentrations exceeding 600 mM, with a 
much shallower dissociation profile, consistent with non-specific competition.  These data 
suggest, therefore, that the interaction of LMW heparin and RNA with amyloid fibrils cannot 
be entirely due to simple electrostatic interactions.  Rather, the spacing and multivalancy of 
the negative charges of these polyanionic chains must play a role in recognition.  To test this 
further, titration of the equivalent concentration of the non-sulphated GAG, hyaluronic acid, 
(HA- Figure 5.29 b) against both the 2A1 aptamer-2A fibril and the 3Q1 aptamer-3Q fibril 
complexes (Figure 5.29 c. i.) was carried out, as this is the only GAG that completely lacks 
sulphate groups641.  It was employed as a control GAG in these titration experiments to 
determine whether the periodic arrangement of the negative charges in heparin were 
responsible for the displacement of the aptamers.  Interestingly, HA was not able to 
dissociate the aptamers, providing further evidence that it is the spacing of the negatively 
charged sulphates that gives rise to the affinity of LMW heparin to amyloid.  A further 
control experiment with an increasing concentration of Na2SO4 was conducted to ensure the 
competition was not a consequence of the sulphate moiety and thus owing to the structural 
arrangement on the polymer.  Accordingly, 2.5 M Na2SO4 was unable to displace the 
aptamers (Figure 5.29 c. ii.).  This result also suggests that ionic strength alone cannot 
account for the aptamer displacement seen by high concentrations of NaCl (the Na2SO4 
solution with much higher overall ionic strength was unable to cause dissociation) and the 
interaction, therefore, may be anion specific, but further work is required to confirm this.   
Taken together the data presented indicate that a generic amyloid binding model exists for 
both RNA aptamers and LMW heparin that, in the case of the RNA, could be driven by the 
negatively charged phosphodiester backbone, analogous to the periodic, negatively charged 
sulphate-driven interaction demonstrated for LMW heparin.  If this were the case, it would 
explain why primary sequence and secondary structure of the RNA apparently have little 
effect on the fibril binding ability of RNA. 
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Figure 5.29  Spacing of the sulphate moieties in GAGs are required for aptamer dissociation 
from amyloid fibrils.  (a)  Competition FP showing aptamer 2A1 is not displaced from the 
complex with 2A fibrils by 50 mM NaCl (i) and only begins to dissociate at concentrations 
exceeding 0.6 M (ii).  (b) Structure of a single disaccharide unit of hyaluronic acid (HA).  (c. 
i.)  Competition FP of aptamer 2A1 and 2A fibrils (green) and 3Q1 and 3Q fibrils (blue) upon 
titration of with HA.  (c. ii) Competition FP of the aptamer 2A1:2A fibril complex (pink) with 
Na2SO4. 
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5.6 Assessing aptamer sensitivity for amyloid with in 
vitro cell imaging 
 
Given the amyloid binding propensity so far demonstrated by the anti-Aβ40 aptamers 
selected in this thesis, it was next investigated whether the anti-Aβ40 fibril aptamers are 
able to detect amyloid in cell culture models, with the potential for further development as 
optical imaging tools.   
Previous work in the Radford laboratory664-668 has shown that fibrils formed from β2m, α-
syn and other disease-associated amyloid fibrils, interact with, and disrupt, lipid 
membranes.  The fibril-membrane association can be visualised via confocal microscopy, by 
co-localisation of fluorescently-labelled amyloid fibrils and membrane-specific fluorescent 
dyes.  This approach has previously been used to monitor both the plasma membrane 
association by amyloid fibrils and the internalisation of fibril fragments via the endocytic 
pathway, both of which occur in a fibril length dependent manner664.  It is thought that this 
internalisation of amyloid fibrils by cells leads to perturbation of the endolysosomal 
pathway, altering the trafficking of lysosomal membrane proteins and disrupting protein 
degradation processes666.  This is supported by the observation that the incubation of 
fragmented fibrils with human cells has been shown to lead to a decrease in the cellular 
reduction of the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)666, a substrate commonly used to measure cell viability669, that is indicative 
of lysosomal function.  However, the MTT reduction induced by amyloid fibrils has recently 
been shown not to correlate with cell viability, as determined through cellular ATP 
assays669.  It is therefore suggested that amyloid fibrils impart an effect on intracellular 
trafficking pathways, which does not result in cell death, yet may play a role in amyloid 
diseases. 
Here, the SH-SY5Y cells (a human neuroblastoma cell-line, commonly used to study 
neuronal function670) were incubated with a mixture of fluorescently-labelled α-syn fibrils 
and Alexa488 aptamers, in order to assess a) whether the aptamer-fibril complex could be 
visualised using live-cell confocal microscopy and b) whether the incubation of aptamers 
alters the ability of the amyloid fibrils to associate with membranes and cause cellular 
defects.  TMR-labelled S129C α-syn monomers (kindly provided by Dr. Matthew Jackson, 
University of Leeds) were mixed 1 in 10 with wild-type α-syn monomers and used to form 
fibrils at a final protein concentration of 300 µM, in 20 mM Tris-HCl, 100 mM NaCl buffer, 
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pH 7.5 (Section 2.4.3).  The fibrils were fragmented using a home-built precision stirrer 
(Section 2.4.3) for 24 h, to give a final average length of 300 - 400 nm, measured using AFM 
(kindly performed by Dr. Matthew Jackson) using methods as described664.  Labelled fibril 
samples were then incubated for 2 h, at a final monomer-equivalent protein concentration 
of 80 µM, with 500 nM Alexa488 labelled aptamer 3Q319.  The mixture was then added to 
SH-SY5Y cells at a final protein concentration of 1 µM (6.25 nM aptamer concentration) and 
incubated overnight (18 h – Section 2.9.3).  The localisation of the amyloid-fibrils and 
aptamers was then visualised using live-cell confocal microscopy (all cell culture and 
imaging work was conducted with Dr. Jackson, Section 2.9).   
Cells incubated with labelled α-syn fibrils alone demonstrate both an association with the 
plasma membrane and internalisation to lysosomes, which can be seen by the co-
localisation of the TMR-labelled fibrils with membrane specific dyes CellMask and 
Lysotracker, respectively (Figure 5.30 and Figure 5.31, α-syn fibrils alone panel).  Samples 
where fibrils were pre-incubated with Alexa488 aptamers demonstrate complete co-
localisation on the plasma membrane surface and, in some instances, within the lysosomes 
(Figure 5.30 and Figure 5.31, aptamer + α-syn fibrils).  Importantly, fluorescent aptamer 
could not be detected in the background (Figure 5.30 and Figure 5.31, aptamer alone) and 
was detected only when associated with the fibrils. 
In order to assess whether pre-incubation with aptamer alters the fibril internalisation 
process, and the resultant perturbation of lysosomal function, MTT and ATP assays were 
conducted (by Dr. Jackson, Section 2.9.2).  The results indicate that aptamer incubation had 
no effect on the MTT reduction induced by the α-syn fibrils (Figure 5.32 a).  The aptamer 
also imparted no further effect on cell viability, as assessed by cellular ATP levels (Figure 
5.32 b).  Together, these data and the confocal imaging indicate that fluorescently-labelled 
anti-fibril aptamer 3Q319, and presumably other aptamer sequences that have been shown 
to bind to fibrils to similar extents in vitro (although not tested here), could indeed be 
developed as sensitive amyloid detection reagents in cell assays.  The amyloid-aptamer 
complex was visualised at a low final RNA concentration (6.25 nM used in this instance) and 
demonstrated no background interactions with other cell components. 
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Figure 5.30 Alexa488 labelled aptamer 3Q319 demonstrates co-localisation with TMR-
labelled α-syn fibrils and association with the plasma membrane.  SH-SY5Y cells were 
incubated overnight with 1 µM (monomer equivalent) fragmented, TMR-labelled α-syn 
fibrils, which had been previously incubated (2 h) with Alexa488 aptamer 3Q319.  Cells 
were also stained with the plasma membrane specific dye CellMask and cell associated 
fluorescence was visualised by live-cell confocal microscopy.  TMR, Alexa488, CellMask and 
phase-contrast (bright-field) images are shown individually and merged.  In the merged 
image, yellow indicates co-localisation of aptamer (Alexa488) and α-syn fibrils (TMR), 
white indicates co-localisation of aptamer, fibril and the CellMask dye.  Scale bar = 10 µM.  
Experiments performed with Dr. Matthew Jackson. 
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Figure 5.31 Alexa488 labelled aptamer 3Q319 demonstrates co-localisation with TMR-
labelled α-syn fibrils and association with the lysosomes.  SH-SY5Y cells were incubated 
overnight with 1 µM (monomer equivalent) fragmented, TMR-labelled α-syn fibrils, which 
had been previously incubated (2 h) with Alexa488 aptamer 3Q319.  Cells were also stained 
with the lysosome-specific dye Lysotracker and cell associated fluorescence was visualised 
by live-cell confocal microscopy.  TMR, Alexa488, Lysotracker and phase-contrast (bright-
field) images are shown individually and merged.  In the merged image, yellow indicates co-
localisation of aptamer (Alexa488) and α-syn fibrils (TMR).  Areas where co-localisation of 
aptamer, fibril and the Lysotracker dye can be seen are further indicated with white arrows. 
Scale bar = 10 µM.  Experiments performed with Dr. Matthew Jackson. 
 
CHARACTERISATION OF RNA APTAMERS AGAINST AMYLOID FIBRILS 
 
 
221 
 
 
 
Figure 5.32  Aptamer 3Q319 has no effect on fibril induced cell defects.  SH-SY5Y cells were 
incubated for 24 h in the presence of 6.25 nM Alexa488 3Q319 aptamer (Aptamer - green), 
1 µM TMR-labelled, fragmented α-syn fibrils (Fibril - red) or pre-incubated samples of 
aptamer and fibrils, mixed at the same final concentration (Fibril + Aptamer – purple).  The 
reduction of MTT (a) or reduction of cellular ATP levels (b) were assayed.  The percentage 
of MTT reduction and the ATP concentration relative to control cells treated with fibril 
formation buffer (Buffer – blue) are given.  Data courtesy of Dr. Matthew Jackson. 
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5.7 Evaluation of the effect of aptamer binding on fibril 
formation 
 
It is commonly known that polyanionic molecules, such as GAGs649, 650, 654, 656, 657, 659, can 
influence the aggregation pathways of amyloidogenic proteins and, in some cases, are 
necessary to initiate such reactions654, 671, 672.  Therefore, the effect of the RNA aptamer 
sequences selected in this thesis, on the formation of amyloid by Aβ40, was assessed.   
Aptamers 2A1, 3Q1 and M1 (the most frequently occuring aptamer sequences isolated from 
the anti-2A fibril, anti-3Q fibril and anti-Aβ40 monomer selections, respectively) were 
transcribed in vitro from 2ʹOH dNTPs and purified (Section 2.6.4).  Aptamers were then 
mixed at a 1:1 molar ratio with monomeric Aβ40 (final concentrations 10 µM) in 25 mM 
sodium phosphate buffer, pH 7.5, in the presence of 10 µM Niad 4; an amyloid specific dye 
that exhibits increased fluorescence upon amyloid binding and, therefore, can be used to 
monitor amyloid fibrillation kinetics673.  Assays also included the presence of an RNase 
inhibitor, owing to the use of nuclease-susceptible 2ʹOH aptamers (Section 2.8.6).  Assays 
were set up in triplicate.  The morphology of resultant aggregates was also assessed using 
TEM analysis. 
The results of these experiments (Figure 5.33) showed that, under these experimental 
conditions and in the absence of aptamer, Aβ40 forms amyloid fibrils with an average lag 
time of 23.7 ± 1.4 h.  The fibrils display a typical long, straight morphology by negative stain 
TEM (Figure 5.33 – positive).  Incubation with anti-fibril aptamers 2A1 and 3Q1 results in 
a similar overall increase in Niad 4 fluorescence, consistent with fibril formation, with no 
significant effect on the average lag times (22.2 ± 2.2 h and 18.5 ± 0.5 h, respectively - Figure 
5.33 d).  Amyloid fibrils of typical long straight morphology were observed by TEM analysis, 
however, a large population of amorphous aggregate (that was not observed in Aβ40 alone 
control samples) was seen in all samples where 2A1 or 3Q1 aptamers were present.  
Interestingly, in the case of the anti-Aβ40 monomer aptamer M1, two of the three replicates 
showed no increase in Niad 4 fluorescence over 60 h and only amorphous aggregate by TEM, 
indicating possible inhibition of fibril formation by this aptamer.  The TEM analysis of the 
single replicate that did display increased Niad 4 fluorescence, with a comparable lag-time 
to the positive control samples (25.2 h compared with 23.7 h - Figure 5.33 d), again 
contained a large proportion of amorphous aggregate.  Based on these data, it is possible 
that incubation of the anti-Aβ40 aptamers may have an effect on fibril formation by Aβ40, 
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especially in the resultant morphology of aggregates.  However, further work at excess 
aptamer concentrations may be necessary to confirm the inhibitory effect seen by aptamer 
M1.   
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Figure 5.33  Assessment of the effects of aptamer incubation on Aβ40 fibril formation and 
morphology.  Aβ40 fibril formation kinetics were monitored by Niad 4 fluorescence over 
60 h, in 25 mM sodium phosphate, pH 7.5, at a final peptide concentration of 10 µM.  2ʹOH 
aptamer samples M1 (a), 3Q1 (b) and 2A1 (c) were added at a final concentration of 10 µM 
and resultant Niad 4 fluorescence profiles are shown in blue, purple and orange, 
respectively.  10 µM Aβ40 alone (positive control) samples are shown in red and samples 
with 10 µM Niad 4 in fibril formation buffer are shown in green, in each case.  
Representative TEM images are given for each experimental condition assayed.  In (a) a 
representative TEM is given for both the single replicate that showed enhanced Niad 4 
fluorescence (a. i) and from a sample replicate that showed full inhibition of fibril formation 
(a. ii).  In (b) and (c), representative TEM images from samples incubated in the presence 
of 3Q1 and 2A1, respectively, are given.  Scale bars = 500 nm.  (d)  The average lag times for 
each condition were calculated by extrapolation of the slope of the elongation phase, of each 
replicate, to the time on the x-axis.   
 
5.8 Discussion 
 
Development of specific amyloid recognition molecules remains a major unmet need in 
diagnosis and therapeutic intervention for the many disorders related through this aberrant 
protein self-assembly reaction.  Detailed knowledge of the structures and mechanisms 
underlying amyloid disorders also remains scarce, despite extensive research efforts, which 
hinders the rational design of such molecules.  In this chapter, the specificity of RNA 
aptamers selected against two structurally distinct amyloid fibrils of Aβ40 was discussed, 
in an attempt to characterise ligands specific to single amyloid morphologies.  It was found 
that, despite different RNA sequences being represented in the two selections, the resulting 
aptamers were able to recognise both assemblies with almost equal affinity.  This cross-
reactivity was extended to further amyloid fibril morphologies, assembled from both Aβ40 
and the unrelated protein sequence α-synuclein.  The reactivity was shown to be largely 
RNA sequence independent, but did depend on protein sequence to some extent, as shown 
by a lack of aptamer affinity for two simple, cross-β containing, fibrils formed from Aβ16-22 
and ccβ-p. 
A tendency towards generic amyloid fibril binding by RNA aptamers has been demonstrated 
by several other groups and in previous work in our laboratory.  Bunka et al.483 
demonstrated that aptamer WL-2, raised against a worm-like β2m fibril morphology, was 
able to react with three further forms of β2m fibrils, as well as fibrils formed from unrelated 
protein sequence hen egg lysozyme.  This aptamer was, however, not able to recognise 
fibrils from Aβ40, apomyoglobin or transthyretin, although the dot-blot assay used 
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provided only a qualitative assessment of binding.  The results further the notion that 
amyloid assemblies share common epitopes, but protein sequence is influential in RNA 
binding.  An RNA aptamer selected against scrapie-associated fibrils of the prion protein 
(PrP), isolated from hamster brain, was shown to bind both the target fibrils and a β-sheet 
rich oligomeric variant PrP-β, which also assembles into cross-β fibres476.  In the case of 
anti-Aβ40 aptamers, Chapter 4 discussed the common theme of preferential fibril binding 
by aptamers raised against immobilised monomeric Aβ40 or its oligomeric assemblies, 
which was replicated in the data presented here (Figure 5.22).  The anti-Aβ40 aptamer 
sequences generated by Rahimi and colleagues494 which did not associate with their cognate 
oligomeric target, were shown to bind to fibrils from Aβ40, IAPP, lysozyme, prion 106-126 
and, more weakly, calcitonin and insulin.  Again this work further supports the data 
presented here, that aptamer recognition of fibrillar assemblies involves generic features of 
fibrils and/or RNA aptamers, and raising RNA aptamers against a specific fold is thus 
difficult to achieve.   
In this work, the affinity of RNA aptamers for amyloid was assessed from a structural 
perspective.  One obvious conserved feature of amyloid is the arrangement of β-strands in 
the cross-β architecture and this was perhaps the most likely candidate for providing a 
universal epitope for an RNA interaction.  However, by use of model amyloid fibrils (from 
Aβ16-22 and ccβ-p) it was clear that the cross-β motif was not sufficient for binding.  
Comparison of these model amyloid structures, with the fibrils shown to have reactivity 
with the RNA (Aβ40 polymorphs and α-syn), is hindered in that there remains a lack of 
structural data for some of these assemblies, namely de novo Aβ40 and α-syn.   
One commonality between the Aβ40 fibrils and those formed from α-syn, is the presence of 
disordered termini (residues 1-8 in 2A and 3Q fibrils and 1-30/109-140 in α-syn611, 623).  In 
the seeded Aβ40 fibrils, the disordered N-terminus decorates the surface of the fibril 
(Figure 5.34) and, based on the proposed stacking of the core, rigid region of α-syn611 
(Figure 5.11), is likely to present in a similar manner on these fibrils.  It is possible that a 
generic binding site could lie in these regions and evidence from binding of LMW heparin 
supports this hypothesis.  A model for the LMW heparin-3Q fibril interaction determined 
using ssNMR by Madine et al. indicates that the flexible N-terminus is likely to be involved 
in the GAG binding epitope, although other binding sites were possible, based on their 
data663.  Residues E3, R5 and H6 underwent significant chemical shift changes when 
incubated with excess LMW heparin, as well as residues E22, S26, N27 and K28, all of which 
are located in the turn of the β-strands, which lie in close proximity to the N-terminal region, 
due to the triangular geometry of this structure (Figure 5.35 a and b).  As LMW heparin is 
CHARACTERISATION OF RNA APTAMERS AGAINST AMYLOID FIBRILS 
 
 
226 
 
able to completely dissociate the RNA aptamers 2A1, 2A417, 3Q1 and 3Q319 from their 
bound state on this fibril, it suggests that RNA shares this heparin binding epitope.  The fact 
that several of the amino acids involved in the flexible N-terminus of Aβ40 fibrils are 
positively charged, could be important, as the nature of the interaction is most likely 
electrostatic, based on the inability of the uncharged GAG, hyaluronic acid, to dissociate the 
same aptamers (Figure 5.29).  As α-syn also possesses several positively charged residues 
in its flexible N-terminal region (5 lysines within the first 30 amino acids –Figure 5.11), it 
is feasible that the shared aptamer binding site accommodates these residues.  On the other 
hand, the disordered C-terminal regions of α-syn fibrils are largely acidic and, therefore, are 
unlikely to be involved in the binding interface.    
 
 
 
Figure 5.34 Structural models for (a) 2A104 and (b) 3Q105 Aβ40 fibrils.  All structures are 
colour coded: polar (magenta), hydrophobic (green), positive (blue) and negatively charged 
(red) residues, except the N-terminal flexible regions (residues 1-8) which are not coloured, 
for clarity.  Flexible N-terminal regions are modelled onto the fibrils without NMR 
restraints.  Each model represents six layers of peptides arranged according to their 2- or 
3-fold symmetries and viewed down the fibril axis, or turned 90° where indicated.  90° 
orientations display the cross-β architecture of the “flat-edge” of the fibril, with arrows 
representing the direction of the fibril axes.  Images were made using pdb files 2LMN (a) 
and 2LMP (b) using PyMOL Molecular Graphics System (Schrödinger, LLC).   
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Figure 5.35 LMW heparin-3Q fibril binding models.  (a) Two proposed binding models for 
LMW heparin to the “corner” epitope of 3Q fibrils.  Models were generated using Autodock 
Vina and are taken, with permission, from Madine 2012663.  Heparin can orientate along (i) 
or perpendicular (ii) to the fibril axis.  (b) A single layer of three monomers in the 3Q fibril 
structure highlighting the residues subject to the largest chemical shift perturbations in 
ssNMR experiments (blue sticks).  The proposed binding site is circled.  (c) A second 
potential binding site at the position of residues HHQK is highlighted (blue sticks, circled).  
Images made from pdb file 2LMP using PyMOL Molecular Graphics System (Schrödinger, 
LLC).   
 
An alternative potential binding site explored was the cluster of basic residues (HHQK) in 
the structured β-sheet regions of the fibrils.  This was a second possible binding site for 
LMW heparin proposed by Madine et al.663 (Figure 5.35), based on docking simulations and 
comparisons of simulated NMR data for theoretical binding sites to the experimentally 
derived spectra.  This was ultimately not the preferred model due to fewer similarities in 
the data and fewer chemical shift perturbations in this area, although, of all the residues on 
CHARACTERISATION OF RNA APTAMERS AGAINST AMYLOID FIBRILS 
 
 
228 
 
the external face of the β-sheet, only E22 and H14 are assigned663.  Exploration of this line 
of enquiry was further motivated by the fact that the binding was likely to be mediated 
through the regular spacing of sulphate moieties in heparin (and possibly phosphates in 
RNA).  It was thought that a periodic arrangement of positive charges on a fibril structure 
might complement the polyanionic pattern, in a scenario whereby the fibril acts as a 
polycation.  This could be rationalised in entropic and enthalpic terms, as polyelectrolytes 
such as GAGs and polynucleotides possess charged groups linked by covalent bonds and, 
therefore, will bind tightly to counter ions, to decrease intramolecular electrostatic 
repulsions.  They would therefore bind especially tightly to a polyelectrolyte carrying the 
opposite charge.  This would also explain why much higher concentrations of salts were 
required to dissociate RNA structures from fibrils (Figure 5.29).  In the cross-β architecture 
of amyloid, β-strands are spaced 4.7 Å apart.  When β-strands are arranged parallel and in-
register, as proposed for 2A and 3Q Aβ40 fibrils and α-syn, residues on the surface of the 
β-strands will align, forming a “stripe” of a single residue along the axis of the fibril (Figure 
5.34).  To test this hypothesis the model amyloid fibril ccβ-p (which is basic overall Figure 
5.18) was used to probe the requirement for positive charges on a fibrillar surface but was 
shown not to associate with RNA.  However, owing to the out-of-register arrangement of 
β-sheets, the positive charges are arranged in a staggered formation along the length of this 
fibril (Figure 5.18) and may not produce an optimal electrostatic surface for polyanions to 
bind.   
In the case of 2A and 3Q fibrils, K16 presents on the surface, creating a well aligned 
positively charged “stripe”.  This residue, therefore, could be a potential polycationic site for 
RNA or GAGs to associate.  Indeed, some preliminary data (Figure 5.36) with fibrils of 
variant K16A Aβ40 support this hypothesis.  The ability of aptamers 2A1 and 3Q1 to bind 
to 2A and 3Q fibrils, elongated with K16A Aβ40 monomer, was reduced substantially 
compared with the WT Aβ40 fibrils.  These mutant fibrils lack the stripes of positive charge 
on the fibril surface and the reduction in RNA association clearly indicates a role for this 
feature in the recognition.  The in-register arrangement proposed for α-syn fibrils also 
produces a similar charge pattern and may explain the cross-reactivity for this fibril.  
Further work to examine the cross-reactivity between RNA and fibrils from other 
amyloidogenic peptides is required to evaluate the extent of this generic binding model.  
More structural information is also needed to allow a more detailed comparison of elements 
conserved between the fibrils that associate with RNA and those that do not.  A more 
comprehensive mutagenesis study could also be employed to elucidate the likely binding 
CHARACTERISATION OF RNA APTAMERS AGAINST AMYLOID FIBRILS 
 
 
229 
 
epitopes in Aβ40 fibrils, along with ssNMR characterisation, similar to that performed for 
LMW heparin663. 
 
 
Figure 5.36 Aptamers display reduced affinity for K16A Aβ40 fibrils.  FP analysis of 
aptamers 2A1 (green) and 3Q1 (pink) with increasing concentrations of 2A (solid lines) or 
3Q (dotted lines) K16A fibrils.  Data are compared to a single replicate of 3Q1 binding WT 
3Q fibrils (pale blue squares) which is fitted to the Hill equation (Equation 2.5); Kd = 1.62 
± 0.25, n = 0.92 ± 0.14.   
 
One issue with the comparison of the GAG and RNA binding mechanism presented here, is 
that LMW heparin was shown to dissociate the aptamer from both 3Q and 2A fibrils in a 
remarkably similar manner.  This was surprising as the ssNMR data suggest that LMW 
heparin binds only weakly to 2A fibrils663.  Binding of LMW heparin certainly does not 
induce the same chemical shift perturbations of the residues involved in binding, as 
observed in the 3Q interaction.  This would suggest that if LMW heparin does bind 2A fibrils, 
even weakly, it would occur at a different site that is not detected by ssNMR.  The 
competition data presented in this study, however, suggests a conserved binding 
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mechanism between LMW heparin and both fibrils, as the aptamer dissociation profiles are 
so similar (Figure 5.27).  The preferred binding site proposed for the 3Q interaction 
encompasses the apices of the triangular 3Q fibril geometry, a feature that is not conserved 
in 2A fibrils.  The possible secondary binding model, involving residues H13 and H14 
(Figure 5.35 c), is close to K16 and consistent with the HHQK GAG binding epitope 
proposed by McLaurin et al.652, 656  This site is located on the flat surface of the β-sheet and, 
therefore, is similarly arranged in both fibril types.  Therefore, it may be possible that a 
second GAG binding site exists at this HHQK region, which is not detected through chemical 
shift perturbation, and could be the shared binding site for the RNA aptamers.   
The idea of generic polyanion binding to amyloid fibrils has been studied by others, previous 
to this work.  Indeed, GAGs are not the only polyanion found to be associated with fibrils in 
vivo674, 675.  Nucleic acids have been found associated with both tau inclusions and Aβ40 
plaques in ex vivo brain samples674.  The effect of RNA and DNA on the promotion of tau654, 
676 and α-syn677 aggregation, as well as the conversion of PrPc to β-sheet rich PrPSc, has been 
documented and indicates an association by these molecules.  DNA has also been shown to 
associate with the functional amyloid curli675.  A study by Calamai and colleagues660 went 
further in characterising the ubiquitous nature of polyanionic binding to amyloid, by 
comparing the associations of both ssDNA and dsDNA, ATP and two GAGs (heparin and 
heparan sulphate) to pre-formed aggregates of lysozyme and human muscle 
acylphosphatase (AcP), both of which form amyloid fibrils in vitro.  They found all 
polyanions tested were able to bind to amyloid fibrils.  These negatively charged species 
also increased the rate of aggregation of AcP.  The data led to the conclusion that the 
interaction by polyanions is largely non-specific, as there was no obvious dependence on 
type of charged groups or structure of the polymers, or on the structure of the amyloid 
protein, in terms of either precursor monomer or aggregate morphology.  The binding was 
also considered largely electrostatic, as high concentrations (> 100 mM) of magnesium salts 
were shown necessary to suppress the binding.  From this it was concluded that polyanions 
are likely to contribute to the promotion of amyloid formation and the stabilisation of such 
species.   
The initiation of tau amyloidosis is also known to be facilitated by negatively charged 
cofactors including heparin654, 672, fatty acids678, 679 and, crucially, RNA676, 680.  In the absence 
of these accessory molecules, tau does not aggregate, except under extreme temperatures, 
pH or high salt concentrations681.  Recently, Dinkel et al.671 demonstrated that incubation of 
tau with RNA was able to produce the same fibril morphology as seen as a result of heparin-
assisted nucleation.  In addition, RNA was able to sustain tau propagation during successive 
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seeding rounds, indicating that the role of RNA is not limited to the initial nucleation step, 
but also drives the fibril elongation.  The effect of RNA was confirmed to be due to a tight 
association of the polynuclotide and the fibril (rather than a transient interaction), by the 
addition of 500 mM NaCl, which reportedly caused only minor dissociation of the RNA 
molecules.  Heparin was also used in their study to demonstrate the likelihood of a shared 
polycationic epitope and RNA displacement with a 2-fold excess concentration of heparin 
was seen. 
The data presented here and that published by others, therefore, indicate that RNA 
associates with amyloid fibrils in a manner resembling several other negatively charged 
polymers.  The interaction is likely to be electrostatically driven, but largely non-specific in 
terms of both the RNA sequence and that of the aggregated target structure. 
The primary aim of this thesis was to determine whether specific aptamer sequences could 
be selected with a preference for individual amyloid morphologies, in the hope that novel 
research tools or diagnostic reagents could be developed to aid in the study and treatment 
of Alzheimer’s disease.  Owing to the generic, and probably backbone mediated, recognition 
of amyloid structures by RNA molecules, this was not achieved.  The work, however, did 
reveal new insights into the nature of RNA-amyloid interactions, by changing both the 
amyloid and RNA structures and sequences.  The study suggests a possible role of both 
nucleotide and amino acid sequences in modulating the associations, as seen by the 
differences (10-fold change in Kd) in dissociation constants observed for different aptamer 
sequences and/or amyloid precursors.  This explains why certain sequences were amplified 
over others during selection.  In addition, data indicates that RNA molecules could be 
influential on fibrillation pathways and the resultant morphology of aggregates.  
Furthermore, aptamers could be developed to serve as generic amyloid recognition 
reagents in amyloid imaging.  Chapter 6 discusses possible future directions for this work 
and the wider implications of a universal amyloid binding model for RNA. 
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6 Concluding remarks and future directions 
 
6.1 Implications 
 
The isolation of specific detection reagents for amyloid assemblies is of paramount 
importance in advancing our knowledge of the structures involved in many of the most 
prevalent diseases in the developed world, including AD.  The ability to discriminate 
between various distinct structures would enable identification of toxic assemblies, as well 
as aid in the development of more specific diagnostics and novel treatments. This thesis 
details work towards reaching this goal, through the development of nucleic acid aptamer 
based recognition molecules.  RNA aptamers were selected against a few of the many 
assemblies of Aβ40 associated with AD, including the monomeric peptide and fibrils of 
distinct morphology.  Chapter 3 outlines the selection process and the isolation of RNA pools 
enriched for sequences with clear conserved motifs and secondary structural elements, 
indicative of successful enrichment of specific aptamers.  However, work in Chapter 4 
determined that the aptamers selected against the monomeric Aβ amyloid precursor were 
unable to recognise this target assembly and instead displayed recognition of the 
aggregated form.  During the characterisation of the anti-fibril RNA aptamer selections in 
Chapter 5, it became clear that RNA is able to recognise amyloid assemblies in a largely non-
specific manner, analogous to other highly negatively charged polymers, such as GAGs.  The 
binding mechanism is likely to be derived from phosphate backbone contacts with 
positively charged regions of the amyloid structures and, therefore, is not critically 
dependent on RNA sequence or secondary structure. 
Collectively, the work indicates that RNA-based reagents may not be the most suitable 
technologies to employ in the development of specific recognition molecules towards 
different amyloid assemblies.  Despite RNA aptamers previously demonstrating powerful 
discrimination between targets with only subtle structural differences682, 683, this has yet to 
be replicated in the amyloid field.  The data presented here suggest that selection of 
aptamers able to make specific contacts through unique secondary structural elements 
derived from their primary sequences, able to recognise different amyloid species, was not 
achieved, owing to the more energetically favourable interactions between the RNA 
backbone and the fibrillar targets dominating the selection process.  Similarly, selections for 
aptamers with enhanced affinity for the monomeric peptide may not be possible due to the 
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inherent affinity of RNA for β-sheet rich aggregates, small amounts of which are inevitably 
present in the preparation of aggregation-prone peptides for selection.  Even if the 
immobilisation strategy for the monomeric target could be improved to contain purely non-
aggregated peptide, the propensity for backbone-mediated recognition of aggregates may 
outweigh any RNA sequence specific association with the monomer, which would render an 
aptamer insensitive in recognising monomers from a complex mix of amyloid assemblies.   
Based on work conducted here and evidence described elsewhere494, 671, the interaction of 
RNA and amyloid aggregates seems to be a general phenomenon.  The nature of the 
interaction also extends to other biological polyanions such as GAGs, DNA and ATP660.  This 
general polyanionic association could have significant biological implications.  One likely 
outcome is that these negatively charged molecules contribute to the promotion of fibril 
formation, or stabilisation of resultant aggregates, in vivo.  The fibrillation inducing effect of 
RNA, DNA and GAGs on several amyloidogenic proteins in vitro649, 650, 654, 656, 657, 659, 660, 671 lends 
further credence to this conclusion.  RNA674, 684, predominantly neuronal mRNA685, has been 
shown to be sequestered in amyloid plaques, which could result in compromised cellular 
proteostasis and represent a model for amyloid-induced toxicity, that has not been explored 
previously.  Similarly, cellular functions mediated through other common cellular 
polyanions, such as GTP, ATP or even the protein-based polyanions tubulin and actin, could 
also be compromised upon abnormal association with aggregates.  Native complexes 
formed by polyanionic molecules with ions or other biological electrolytes (ATP and Mg2+, 
for example) could be disrupted by a more favourable association with polycationic amyloid 
structures, leading to cellular dysfunction.   
Evidence for seemingly ubiquitous RNA-amyloid interactions also allows further 
speculation into the idea that amyloid structures could have had a role in the origin of life.  
It is generally agreed that RNA molecules, capable of both storing genetic information and 
catalysing the chemical reactions necessary to sustain life, preceded the current situation of 
DNA-based genetic material coding for proteins as the major biological catalysts686.  
However, the prebiotic formation of stable ribonucleotide polymers remains unclear, 
although catalysis on the surface of clay minerals is one possible route that is generally 
acknowledged687-689.  Amyloid has also been proposed as an ancient protein conformation690 
and even postulated as a potential pre-RNA genetic molecule, through its ability to transfer 
information via templating and self-replication691.  It has also been shown to function as a 
primordial enzyme692.  It is possible that through a non-specific yet high affinity interaction, 
amyloid structures could have provided a surface template for early RNA polymerisation 
and stabilisation, more flexible and possibly more effective than clay.  At the same time, RNA 
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interactions with amyloid could have stimulated further fibril growth.  This suggests a 
possible mechanism where protein and nucleic acids co-evolved through the formation of 
amyloid structures693.  The discovery of polyphosphate (polyP) as an ancient, universally-
conserved and entirely inorganic molecular chaperone, with no clear substrate 
specificity694, further indicates a role for polyanions in the very earliest stages of life. 
 
6.2 Future directions 
 
To enable a more thorough understanding of the amyloid-RNA interaction from a structural 
perspective, a more comprehensive cohort of fibrils would need to be tested and direct 
comparison of the structural elements involved in nucleic-acid binding probed.  
Mutagenesis studies or ssNMR mapping of the generic binding epitope could also shed some 
light on the residues involved in the interface, revealing any similarities between each fibril 
type.  Further competition experiments could also be used to elucidate whether the generic 
binding is indeed shared by the many other biological polyanions mentioned above.  To 
confirm whether the affinity for amyloid is mediated through the phosphate backbone as 
proposed, a comparison with an RNA molecule modified to contain a methylphosphonate 
backbone could be conducted.  The methylphosphonate modification, where one of the non-
bridging oxygen atoms of the inter-nucleotide linkage is replaced by a methyl group, 
renders the RNA backbone neutral and would therefore confirm the polyanionic binding 
mechanism proposed.  
It would also be interesting to probe further the effect of RNA on amyloid formation and 
toxicity in vitro and in vivo.  Investigation into the length-dependence of RNA binding and 
its effect on fibril formation in vitro, along with comparison to other polyanions known to 
affect fibril formation, would add further evidence to a general role for negatively charged 
polymers in amyloid formation.  Sequencing the specific RNAs found associated with AD 
plaques might also help identify any possible toxic mechanisms involving alterations to 
proteostasis as a direct consequence of RNA sequestration.  This would open up many 
interesting questions as to how the extracellular plaques collect the RNA molecules 
transcribed intracellularly; whether they associate with fibrillar assemblies in the cytosol 
and are subsequently trafficked out of the cell or whether the plaques simply sequester the 
RNA released from damaged neurons.  
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One practical outcome of these aptamer selections could be the development of generic 
amyloid detection reagents, based on the preliminary live-cell imaging demonstrated with 
fluorescently-labelled aptamer 3Q319 (Figure 5.30 and Figure 5.31).  Analysis of the 
ability of these RNA sequences to detect fibrillar structures seeded from ex vivo brain 
samples or to recognise plaques in post-mortem tissue, would further indicate a potential 
for these aptamers as imaging reagents in an in vivo setting.  Whether aptamers are able to 
recognise pre-fibrillar, oligomeric structures is also yet to be assessed.  If this proved to be 
the case, aptamers could provide invaluable insights into generic epitopes shared between 
oligomeric assemblies or provide novel, anti-oligomer detection reagents in vivo. 
In order to use aptamer technologies to develop specific recognition molecules, able to 
distinguish between fibril morphologies or aggregation prone monomeric peptides, the 
inherent amyloid binding tendency would have to be addressed.  If the generic aptamer 
binding epitope could be identified, selections against amyloid structures devoid of this 
structural element may prove effective.  For example, selection against K16A Aβ40 fibrils, 
based on the suggestion that this single basic residue is important in the non-specific 
interaction (Figure 5.36), could promote recognition of other epitopes of the fibril 
structure, unique to that fibril morphology, and essentially overcome the bias posed by a 
more favourable backbone-mediated interaction.   
Although the original aim of providing highly specific nucleic acid based recognition 
molecules for Aβ40 assemblies was not realised, work described herein demonstrates that 
RNA-amyloid interactions are dominated by backbone interactions, with bases adding only 
marginal specificity to different amyloid structures.  The idea of using RNA aptamer 
selections to achieve this goal was motivated by the powerful discrimination demonstrated 
in other, non-amyloid selections, as well as the large number of possible conformations 
accessible to RNA-based ligands.  The use of RNA aptamers also allowed access to great 
electrostatic potential in binding, and the known amyloid binding properties of GAGs serves 
as proof of polyanions as amyloid-binding reagents.  This, coupled with the additional 
complexity in RNA structures, was hoped to lead to the generation of sequences with affinity 
and selectivity for the distinct assemblies.  The finding that the RNA-amyloid interaction is 
generic and backbone-mediated has major implications, from novel toxicity mechanisms in 
amyloid disorders to the very fundamentals of biology. 
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7 Appendices 
7.1 Appendix 1: Plasmid maps 
7.1.1 PetSac MAβ40  
 
 
 
 
Appendix 7.1.1 Plasmid map of PetSac Aβ40 (a modified Pet3a plasmid with NdeI and SacI 
cloning sites), kindly provided by Professor Dominic Walsh (Harvard Institute of Medicine, 
USA) and Dr. Sara Linse (Lund University, Sweden). 
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7.1.2 pET23a α-syn 
 
 
 
Appendix 7.3.2 Plasmid map of pET23a α-syn, kindly provided by Professor Jean Baum 
(Department of Chemistry and Chemical Biology, Rutgers University, NJ, USA). 
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7.2 Appendix 2: MS/MS ETD fragmentation spectra 
 
Appendix 7.2.1 Tandem MS (MS/MS) ETD data indicating the position of biotin 
modifications within the 2A fibril morphology.  The spectrum has been split to focus on 
different m/z areas due to the high abundance of peaks.  Peaks indicative of biotin location 
are labelled as follows: N-terminal modification (blue), K16 modification (green), K28 
modification (red), either N-terminal or K16 modification (purple).   
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Appendix 7.2.2 MS/MS ETD data indicating the position of biotin modifications within the 
3Q fibril morphology (as Appendix 7.2.2). 
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7.3 Appendix 3: Genebee multiple alignment analyses of 
NGS data 
 
Consensus motifs are identified from the top 500 aptamer sequences from the filtered NGS 
data, for each of the selections: Aβ40 monomer (Appendix 7.3.1), 2A fibrils (Appendix 
7.3.2) and 3Q fibrils (Appendix 7.3.3).  In each case, the ten “supermotifs” with the highest 
power score (defined in reference 513) are given.  The corresponding power score is 
indicated in bold above each motif.  Power scores higher than 7.00 are considered to 
significant.  Aptamers within each motif are identified by their number (which corresponds 
to their frequency of occurrence) followed by the number of occurrences, e.g. 1-613 would 
indicate the most commonly occurring sequence (1) which occurs 613 times in the filtered 
data.   The consensus of each motif is represented as a sequence logo (Weblogo695), with the 
height of each residue corresponding to the conservation at that position.  Nucleotide bases 
at each position are colour coded as follows: A (green), T (red), G (yellow), C (blue).  DNA 
sequences corresponding to RNA aptamers are given. 
 
7.3.1 Anti-Aβ40 monomer aptamer selection 
 
 
 
LOCAL SUPERMOTIF number 1, power 20.37 
                     
.+.++++++++++++++++++++++.+++++++++++++++.++++++++ 
1-613  TAAGGGAAGTGTGCTGAGAGAGGGAAGTTGCGTAGCGAAGCACGATAACG 
327-19 TATGGGAAGTGTGCTGAGAGAGGGAAGTTGCGTAGCGAAGCACGATAACG 
372-18 TAAGGGAAGTGTGCTGAGAGAGGGAAGTTGCGTAGCGAAGCGCGATAACG 
497-16 TAAGGGAAGTGTGCTGAGAGAGGGAGGTTGCGTAGCGAAGCACGATAACG 
532-15     CAAGGGAAGTGTGCTGAGAGAGGGAAGTTGCGTAGCGAAGCACGATAACG 
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LOCAL SUPERMOTIF number 2, power 12.12 
 
                      
+++++++++++++++++++++++++++++++++++++++++++++++++ 
230-22 ACAAGAGGGGAAGGCAGGGGATAGGGAGAGAAGGGCGCGGAGAAAGAGGA 
238-22     gCAAGAGGGGAAGGCAGGGGATAGGGAGAGAAGGGCGCGGAGAAAGAGGA 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 3, power 12.12 
 
                     
+++++++++++++++++++++++++++++++++++++++++++++++++ 
50-41  AAGGGAAGGCAGATAAGTGAGAGTAAGAGTGGAAGGGAAGAAAGTACACA 
454-16     gAGGGAAGGCAGATAAGTGAGAGTAAGAGTGGAAGGGAAGAAAGTACACA 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 4, power 12.03 
 
 
           +++++++++++++++++++++++++++++++++++++++++++++++++++ 
214-23 AAGGGGAACAGAAAGAGGGAAAGGAGGGGAAAAAGGACAAAGCGAGAAAGG 
540-15     AAGGGGAACAGAAAGAGGGAAAGGAGGGGAAAAAGGATAAAGCGAGAAAGG 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
243 
 
LOCAL SUPERMOTIF number 5, power 12.00 
 
 
           ++++++++++++++++++++++++++++++++++++++++++++++++++ 
233-22 GAGGATGGGAAGAGCCG-CGGAGGTAATGTTACAAAATGAGGTAGGAGGA 
324-19     GAGGATGGGAAGAGCCGCCGGAGGTAATGTTACAAAATGAGGTAGGAGGA 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 6, power 11.92 
 
 
            ++++++++++++++++++++++++++++++++++++++++++++++++++ 
61-38       GAATGAGCGCGAAGGAGTATAAGAGGAGGAGGTAAAAGAGGGAACGAGGA 
549-15      GAATGAGCGCGAAGGAGTATAAGAGAAGGAGGTAAAAGAGGGAACGAGGA 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 7, power 11.92 
 
 
         ++++++++++++++++++++++++++++++++++++++++++++++++++ 
4-114  GTAGAAAAGGACATGTAGGCATGATAGAAATTGAAGGGGGAAAGAACGCG 
414-17     GTAGAAAAGGACATGTGGGCATGATAGAAATTGAAGGGGGAAAGAACGCG 
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LOCAL SUPERMOTIF number 8, power 11.92 
 
 
           ++++++++++++++++++++++++++++++++++++++++++++++++++ 
88-33  TAGGGAAAGGTAAAGAGAGTACCATGGATATGCTGGCGTAGCTAGACAAG 
174-25     TAGGGAAAGGTAAAGAGAGTACCATGGACATGCTGGCGTAGCTAGACAAG 
 
 
 
 
 
LOCAL SUPERMOTIF number 9, power 11.92 
 
 
           ++++++++++++++++++++++++++++++++++++++++++++++++++ 
53-41  ACACGAAGCGCGCGAATGGGTACGAAGGGAAGAGGAGGAGCGAGAAGGGA 
80-34      ACACGAAGCGCGCGAAGGGGTACGAAGGGAAGAGGAGGAGCGAGAAGGGA 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 10, power 11.61 
 
                      
+++++++++++++++++++++++++++++++++++++++++++++ 
79-35  gAACAGGTAGGAGGTAAAAAGGGGATCGCGAGGAGAGGTGGAGAGG 
588-14     TAACAGGTAGGAGGTAAAAAGGGGATCGCGAGGAGAGGTGGAGAGG 
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7.3.2 Anti-2A fibril aptamer selection 
 
LOCAL SUPERMOTIF number 1, power  44.35 
 
 
             ++++++++++++++++++++++++++++++++++++++++++++++++++ 
2-16019  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
28-1303  gCAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
117-239  tCAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
148-192  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGTGGAGGGA 
153-187  ACAAGAGGGAGGAGAGGGAGGAGCGTTAGGGTAGCCGAGGAGCGGAGGGA 
161-177  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTGGCCGAGGAGCGGAGGGA 
175-165  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGCAGCCGAGGAGCGGAGGGA 
234-124  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCTGAGGAGCGGAGGGA 
252-116  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGGGGAGCGGAGGGA 
253-115  ACAAGAGGGGGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
265-113  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGTCGAGGAGCGGAGGGA 
275-109  cCAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
318-94  ACAAGAGGGAGGAGAGGGAGGAATGTTAGGGTAGCCGAGGAGCGGAGGGA 
331-89  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGaa 
337-87  ACGAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
353-83  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGc 
364-81  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCAAGGAGCGGAGGGA 
403-74  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGGGGGA 
415-71  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGg 
422-70  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGGGCGGAGGGA 
432-67  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCAGAGGGA 
434-67  ACTAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
436-67  ACAAGAGGGAGGAGAGGGGGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
440-66  ACAGGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
447-65  ACAAGGGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGGAGCGGAGGGA 
482-58  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGATAGCCGAGGAGCGGAGGGA 
495-57  ACAAGAGGGAGGAGAGGGAGGAACGTTGGGGTAGCCGAGGAGCGGAGGGA 
500-57  ACAAGAGGGAGGAGAGGGAGGAACGTTAGGGTAGCCGAGAAGCGGAGGGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
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LOCAL SUPERMOTIF number 2, power  31.50 
                +++++++++++++++++++++++++++++++++++++++++++++++++ 
3-13560  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
134-210  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCCGACAGCG 
139-204  -tCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
192-150  -GCGAAAGGGACGGATGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
207-138  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCc 
216-134  -GCGAAAGGGGCGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
282-107  -GCGAAAGGGACGGACGGAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
290-104  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGGCAGCG 
292-103  -GCGGAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
297-101  -GCGAAAGGGACGGACGAAAGGGTAGGGAAGGGCAGGGGATCTGACAGCG 
301-100  -GCGAGAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
354-83  -GCGAAGGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
355-82  -GCGAAAGGGACGGACGAGAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
387-75  -GCGAAAGGGTCGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
396-75  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGGTCTGACAGCG 
397-74  gcgaAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
399-74  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACGGCG 
427-68  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGTTCTGACAGCG 
429-67  -aCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
438-66  -GCGAAAGGGACAGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
444-65  -GCGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACTGCG 
468-61  -gtGAAAGGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
480-58  -GCGAAAGGGACGGACGAAGGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
481-58  –GCGAAATGGACGGACGAAAGGGAAGGGAAGGGCAGGGGATCTGACAGCG 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 3, power  27.20 
                     
...+++++++++++++++++++++++++++++++++++++++++++++++ 
1-51626 GGCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
16-2149 tGCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
75-397 gaCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
92-320 GGCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCac 
164-174 gtCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
199-144 cGCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
264-114 aGCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
381-78 GGAAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
452-64 GGGAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC 
 
 
APPENDICES 
 
 
247 
 
LOCAL SUPERMOTIF number 4, power  25.12 
                      
+++++++++++++++++++++++++++++++++++++++++++++. 
4-12818 AAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAG 
11-2655 AAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAC 
23-1625 GAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAG 
39-766 TAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAG 
101-278 GAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAC 
173-167 cAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAG 
266-113 TAGCGAAGGGAGGGCAGGGAGAAGGGCGCTATGGATGGTACGATAAC 
 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 5, power  24.39 
 
             ++ ++++++++++++++++++++++++++++++++++++++++++++++++  
1-51626 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
16-2149 TG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
27-1347 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAGGCCGC- 
37-932  GG-CAAACGGTAAGGCCGAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
38-788  GG-CAGACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
48-647  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGGAAGCCGC- 
49-627  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGGTAGAAAGCCGC- 
60-496  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATGGAAAGCCGC- 
75-397  -gaCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
76-391  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAGAGCCGC- 
82-358  GG-CAAACGGTAAGGCCAGAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
89-333  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAagccgc 
90-330  GG-CGAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
92-320  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCac- 
94-316  GGCAAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
95-315  GG-CAAACGGTAAGGCCAAAGGGATGAGGGTAGAGATTGATAGAAAGCCGC- 
97-310  GG-CTAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
125-227 GG-CAAACGGTAAGGCCAAAGGGACGAGGGCAGAGATTGATAGAAAGCCGC- 
128-221 GG-CAAACGGTAAGGCCAAAGGGACAAGGGTAGAGATTGATAGAAAGCCGC- 
131-217 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGACTGATAGAAAGCCGC- 
133-213 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGGTTGATAGAAAGCCGC- 
143-198 GG-CATACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
145-195 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGACAGAAAGCCGC- 
146-194 GG-CAAACGGTAAGGCCAAAGGGGCGAGGGTAGAGATTGATAGAAAGCCGC- 
164-174 -gtCAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
165-173 GG-CAAACGGTAAGGCCAAGGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
181-161 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATTGAAAGCCGC- 
182-160 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTTGAGATTGATAGAAAGCCGC- 
186-156 GG-CAAGCGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
199-144 cG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
203-138 GG-CAAACGGTGAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
206-138 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGATAGCCGC- 
APPENDICES 
 
 
248 
 
214-136 GG-CAAACGGTAAGACCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
219-133 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATCGATAGAAAGCCGC- 
224-132 GG-CAAACGGTAAGGCCAAAGGGACGGGGGTAGAGATTGATAGAAAGCCGC- 
240-122 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGGGATTGATAGAAAGCCGC- 
245-119 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTGGAGATTGATAGAAAGCCGC- 
248-117 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGTGATTGATAGAAAGCCGC- 
250-116 GGCTAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
259-115 GG-CAAACGGTAAGGCCATAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
264-114 aG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
267-113 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAAAGATTGATAGAAAGCCGC- 
269-112 GG-CAAACGGTAAGGCTAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
272-111 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAATGCCGC- 
283-106 GG-CAAACGGTAAGGCCGAAGGGACGAGGGTAGAGATTGATAGAAGGCCGC- 
296-101 GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCTGC- 
306-98  GG-TAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
307-98  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGACAGCCGC- 
309-98  GG-CAAACGGTAAGGTCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
314-96  GG-CAAACGGTAAGGCCAAAGGGACGAGGGAAGAGATTGATAGAAAGCCGC- 
329-90  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGTAAGCCGC- 
333-89  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGTTAGAAAGCCGC- 
335-88  GG-CAAACGGTAAGGCCTAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
343-87  GG-CAAACGGTAGGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
350-83  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAACGCCGC- 
366-81  GG-CAAACGGTAAGGCCAATGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
369-80  GG-CAAACAGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
372-79  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAAATTGATAGAAAGCCGC- 
375-79  TG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAGGCCGC- 
376-78  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATAGATAGAAAGCCGC- 
381-78  GG-AAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
391-75  GG-CAAACGGTAAGGCCAAAGAGACGAGGGTAGAGATTGATAGAAAGCCGC- 
413-72  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAAAAAGCCGC- 
414-71  GG-CAAACGATAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
416-71  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGGTAGAAGGCCGC- 
420-71  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTAATAGAAAGCCGC- 
423-69  GG-CAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATATAAAGCCGC- 
442-66  GG-CAAATGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
452-64  GG-GAAACGGTAAGGCCAAAGGGACGAGGGTAGAGATTGATAGAAAGCCGC- 
473-59  GG-CAAACGGTAAGGCCAAAGGGACGTGGGTAGAGATTGATAGAAAGCCGC- 
485-58  GG-CAAACGGTAAGGCCAAAGGGACGAAGGTAGAGATTGATAGAAAGCCGC- 
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LOCAL SUPERMOTIF number 6, power  23.28 
 
                     
+++.+++++++++++++++++++++++++++++++++++++++++++++. 
10-3079 GGGTAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGAGATGAGT 
17-2147 GGGGAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGAGATGAGT 
20-1908 GGGTAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGAGATGAGC 
55-536 GGGGAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGAGATGAGC 
345-85 GGGTAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGGGATGAGC 
405-74 tGGGAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGAGATGAGT 
410-72 GGGGAGGGCAAGGGTAAGGGACCTGCGTACTGTCGTGTAAAGAGATGAGT 
433-67 GGGGAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAATAGATGAGT 
476-59 GGGGAGGGCAAGGGTAAGGGACCAGCGTACTGTCGTGTAAAGAGATGGGT 
 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 7, power  20.64 
 
                      
++++++++++++++++++++++++++++++++++++++++++++++++. 
14-2401 ATCACGAGTTCGGTCGATAGGGAAGGGAAGGGATGGAGGGACGACTGGAG 
344-85 gTCACGAGTTCGGTCGATAGGGAAGGGAAGGGATGGAGGGACGACTGGAG 
374-79 cTCACGAGTTCGGTCGATAGGGAAGGGAAGGGATGGAGGGACGACTGGAG 
417-71 ATCACGAGTTCGGTCGATAGGGAAGGGAAGGGATGGAGGGACGACTGGAc 
424-68 tTCACGAGTTCGGTCGATAGGGAAGGGAAGGGATGGAGGGACGACTGGAG 
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LOCAL SUPERMOTIF number 8, power  20.50 
 
                     
.++++++.+++++++++++++++++++++++++++++++++++++++++. 
26-1409 AAGGGTGAAGGGAAGGGTGAAGGGAAGTTGACTTAGCGAGGTAATCAGTG 
108-259 tAGGGTGAAGGGAAGGGTGAAGGGAAGTTGACTTAGCGAGGTAATCAGTG 
158-181 gAGGGTGAAGGGAAGGGTGAAGGGAAGTTGACTTAGCGAGGTAATCAGTG 
239-123 AAGGGTGAAGGGAAGGGTGAAGGGAAGTTGACTTAGCGAGGTAATCAGTc 
294-102 AAGGGTGTAGGGAAGGGTGAAGGGAAGTTGACTTAGCGAGGTAATCAGTG 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 9, power  18.29 
 
                      
..++++++++++++++++++++++++++++++++++++++++++++++ 
6-5043 -GAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGA 
119-233 gagaAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGA 
142-199 -tAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGA 
183-159 -GAGGAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGA 
305-98 -ggGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGA 
358-82 -GAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGc 
359-82 -GAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAGAGACTACATCGCGGA 
421-70 -GAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAGGACTACATCGCGGA 
470-60 -GAGAAGAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACTACATCGCGGA 
486-58 -GAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGGCTACATCGCGGA 
497-57 -GAGAAAAGTCTGAGGGAGGAGAGAGGGAGGAAAAGACAACATCGCGGA 
 
 
 
 
 
 
 
 
APPENDICES 
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LOCAL SUPERMOTIF number 10, power  17.88 
 
                      
+++++++++++++++++++++++++++++++++++++++++++++++++ 
40-761 aCCGGCAGGGATTAACAAAAGGGACGAGGGATGAGGGAAGAGGGGAATTG 
225-131 tCCGGCAGGGATTAACAAAAGGGACGAGGGATGAGGGAAGAGGGGAATTG 
271-112 gCCGGCAGGGATTAACAAAAGGGACGAGGGATGAGGGAAGAGGGGAATTG 
431-67 cCCGGCAGGGATTAACAAAAGGGACGAGGGATGAGGGAAGAGGGGAATTG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
252 
 
7.3.3 Anti-3Q fibril aptamer selection 
 
LOCAL SUPERMOTIF number 1, power  19.50 
             . .  . ..  ..   . .  . .   .. ....+++++++++++++ .. .  . . ..   
7-88 ----------------------------------TTTGTTTTCTTTCTCTTCTCtaaggacgga-- 
16-68 -------------------acgT-----------TTTCTTTTCTTTCTCTTACATCcagg------ 
36-44 gtgtgGTATTTTCTTTCTCTTCTTCAGcac------ 
135-28 -------------------------------------CTTTTCTTTCTCTTTTTCttctaccttga 
151-27 ------------------------------cgTATTTATTTTCTTTCTCTTGTCACggat------ 
158-26 ----------------------------caatgttaCATTTTCTTTCTCTTGTTACaa-------- 
168-26 ----------------------gttttcacgATGATTGTTTTCTTTCTCTTT-------------- 
174-26 ----------------------------------agaTTTTTCTTTCTCTTAAGTctttagatg-- 
179-25 -----------------------------------cTATTTTCTTTCTCTTCCTGTtctacgtga- 
183-25 -------------------------------gggTTTTCTTTCTTTCTCTTGATTGtcttg----- 
251-22 ----aagtctcCG------------------------ATTTTCTTTCTCTTTGTGcta-------- 
276-21 tttcatgatttCG------------------------ATTTTCTTTCTCTTGga------------ 
279-21 ----------------------------cgaATAATTGTTTTCTTTCTCTCGTTCAct-------- 
286-20 ---------------------------tttgtTGATCATTTTCTTTCTCTTTAGgcc--------- 
288-20 ----------------tcacgaT-----------TGTCTTTTCTTTCTCTTCAGTGc--------- 
301-20 --------------------------------aggTCATTTACTTTCTCTTTTGACtatagt---- 
319-20 ------------------------atatcacgttaGTTTTTTCTTTCTCTTAAC------------ 
322-20 ----------------------------tcatttttcacaTTCTTTCTCTTGTactag-------- 
326-19 ----------------------------gttgcAATTATTTTCTTTCTCTTTGTGTCa-------- 
333-19  ----------------------------------tcTCGTTTCTTTCTCTTTCTTTCtctgtgg-- 
384-18 -------------acTG--------------------GTTTTCTTTCTATTCTTCctgtgtgt--- 
396-18 -----------------------------ttacATTTATTATCTTTCTCTTTCGTCtgt------- 
411-18 ---------------------------caacttcttcgTTTTATTTCTCTTAACgaa--------- 
416-18 ---------------cttttgtT-----------TGTTTTTTCTTTCTCTTCGTGaa--------- 
422-18 -----------attgTG--------------------GTTTTCTTTCTCTTCTTCAGtcg------ 
 
 
 
 
LOCAL SUPERMOTIF number 2, power  13.13 
             ++++++++++.++.+++++++.++++++++ 
1-658  GGAGGGACATAGGAGTAGTGCATGGGTAGG 
14-73  GGAGGGACATAGGAGTAGTGCGTGGGTAGG 
308-20  GGAGGGACATGGGAGTAGTGCATGGGTAGG 
442-17  GGAGGGACATAGGGGTAGTGCATGGGTAGG 
 
 
 
APPENDICES 
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LOCAL SUPERMOTIF number 3, power  13.08 
              ....   ......+.++++++++++++.. .....  .   
28-53  tgaatatgtTTATATCTTTCTTTCTCTTca----------- 
174-26  -----------AGATTTTTCTTTCTCTTAAGTctttagatg 
183-25  --------gggtTTTCTTTCTTTCTCTTgattgtcttg--- 
198-24  ---acacgaTTATTTGTTTCTTTCTCTTACGTt-------- 
229-23  ---acggataattgaCTTTCTTTCTCTTAACat-------- 
237-22  caaatcatgaTACATCTTTCTTTCTCTTtg----------- 
319-20  -atatcacgTTAGTTTTTTCTTTCTCTTAAC---------- 
412-18  ----------ttcTTGTTTCTTTCTCTTAGtctgcggtaa- 
418-18  ---------atcTTTCTTTCTTTCTCTTAGctgtctga--- 
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LOCAL SUPERMOTIF number 4, power  11.63 
                           ...     .  .... +.+.+.++..+++++.....    .  .  
19-65  ---------------------gTTTATTTCTCTTTCTTCtctaggaacgaa 
42-41  cgataatTT-------------TCTCTTTTGCTTTCTTTTGAa-------- 
53-38  ---------------ctaATACTTTCTCTTTCTTTCTCTGTtgtg------ 
67-35  ------acT-------------TCTCTTTTCTTTCCTTCTATcacgcaa-- 
69-35  --------------caatttcATTTCTCATACTTTCTCTTGaa-------- 
73-34  ------tttttcacgattATTCTTTCTCTTGCTTTC--------------- 
79-33  -cgaattTT-------------TCTTTCTTACTTTCTCTTGcgt------- 
97-31  -------aT-------------TCTCTTTTGTTTTCTTCTGAtctgcgaa- 
136-28  ----------------------TTTGTTTTTCTTTCTCATCAaatacttgg 
156-26  --------------------ttcTTGTTTATCTTTCTCTTCaTCGTCgta- 
158-26  ----caATG-------------TTACATTTTCTTTCTCTTGTtacaa---- 
170-26  -actgtttT-------------TCTCTTTTCTTTCTTCCTgtg-------- 
183-25  --------------------gggTTTTCTTTCTTTCTCTTGaTTGTCTtg- 
207-24  --------------cgaatatcaGT-tTTTTCTTTCTCATCtcta------ 
217-23  ----ttcTT-------------TCTCTTATACTTTCTCTTGTccatt---- 
219-23  --------------------ACTTTCTCTTATTTTCTCTGTat-------- 
232-22  --------------ttggtactaaTCTTTTTCTTTCTCTGgata------- 
257-22  ---------------cgggTAATTTCTTTTTCTTTCTCTTGgagt------ 
275-21  ------------------cTTCTTTCTCTTTCTTTCTtcttttacgga--- 
288-20  --tcacgaT-------------TGTC-TTTTCTTTCTCTTCAgtgc----- 
322-20  ----tcATT-------------TTTCACATTCTTTCTCTTGTactag---- 
333-19  -------------tctcgtTTCTTTCTCTTTCTTTCTCTGTgg-------- 
343-19  ttgacattT-------------TCTCTTTTCTCTCCGTCAATt-------- 
414-18  --------------agttaTAATTTATTTTTCTTTCTTCacggt------- 
416-18  --------------cttttgtttGT-TTTTTCTTTCTCTTCgtgaa----- 
418-18  ---------------------aTCTTTCTTTCTTTCTCTTAgCTGTCTga- 
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LOCAL SUPERMOTIF number 5, power  11.56 
                     ....  ...... .....+.+++++++++++...  .   .    
5-112  --------ttttTCATTAA---TGTCTTTTCTTTCTCGGGa--------- 
16-68  ----acgTTT--------------TCTTTTCTTTCTCTTacatccagg-- 
25-55  --------------------TTTGTTTTGTTTTTCTCTTCtcgataacgt 
111-30  ------------------gaTTTGTTTTGTTTTTCTCTTAttcacgga-- 
123-29  -------ctgaaTCATTAA---TATCTTTTCTTTCTCTGG---------- 
256-22  ------atcT--------------TCTTTTCTTTCTCacagtgcgtagaa 
257-22  cgggtaaTTT--------------CTTTTTCTTTCTCTTggagt------ 
269-21  --------atctgcgtatA---TATCTTTTCTTTCTCGGGg--------- 
288-20  ---------------TCACGATTGTCTTTTCTTTCTCTTCagtgc----- 
319-20  ------------ataTCACGTTAGTTTTTTCTTTCTCTTAac-------- 
376-18  --------agtgttatttcatggGTATTTTCTTTCTCT------------ 
416-18|  --------------cttttGTTTGTTTTTTCTTTCTCTTCgtgaa----- 
 
 
 
 
 
 
LOCAL SUPERMOTIF number 6, power  11.55 
                . ..  ..  ...++++.++++++++   .          
76-33  ------tacatgtaAGTTTTTTTCTCTTTTtacgga------ 
116-30  -------gatttctacTTTTCTTCTCTTTGAtaacgt----- 
182-25  -------------CAGTTTTTTTCTCTTTTctctaaatcctc 
199-24  ----aacctttcgaATTTTTCTTCTCTTTACGga-------- 
270-21  ------catttaaCATTTTTCTTCTCTTTTaaatcg------ 
310-20  ------aacattatcTTTTTCTTCTCTTTcgtcatt------ 
321-20  ---------attcttcTTTTCTTCTCTTTACGcgttaat--- 
379-18  gatccatgaacacatTTTTTCTTCTCTTTG------------ 
433-17  ---------actgCAGTATTTTTCTCTTTTgccccagga--- 
447-17  tcacgtttgtacaatTTTTTCTTCTCTTGGA----------- 
 
 
 
 
 
 
          
APPENDICES 
 
 
256 
 
LOCAL SUPERMOTIF number 7, power  11.40 
 
             +++++++++++++++++++. ++++++++++ 
46-39  AATTAGAAAACGTTTTTTTT-GGTCCGAGTA 
122-29  AATTAGAAAACGTTTTTTTTtGGTCCGAGTA 
359-19  AATTAGAAAACGTTTTTTT—GGTCCGAGTA 
 
 
 
 
 
LOCAL SUPERMOTIF number 8, power  11.11 
 
             ...+.+.+++++++++++++++++++++++++ 
51-38  ---GTTGTTTTTTTCACGTCTTGTCTGTGCAA 
238-22  GTTGTTTTTTTTTTCACGTCTTGTCTGTGCAA 
252-22  GTTG-TTTTTTTTTCACGTCTTGTCTGTGCAA 
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LOCAL SUPERMOTIF number 9, power  10.43 
               .  ..   . .. .  .      . .. ..           ... ... .    . 
4-119 ---------------------------------------------------------act 
16-68 -------------------------------------------------acgT------- 
40-43 ------------------------------------------aggttttagT-------- 
62-36 ---------gCA------------------------------------------------ 
73-34 -------------tttttcacG-------------------------------------- 
76-33 --------------------------tacaTG-------------------T-------- 
110-30 -----------------------------------------------aacgT-------- 
113-30 --------------------------------------------------atT------- 
116-30 ----------------------------------------------------------ga 
119-29 ------------------------------------------------------------ 
134-28 ----------------------acttctcgTG-------------------T-------- 
174-26 --------------------AG-------------------------------------- 
183-25 --------------------ggGT---------------------------T-------- 
198-24 ------------------------------------------acacgattAT-------- 
207-24 ------------cgaatatcAG-------------------------------------- 
211-23 -------------------agG-------------------------------------- 
229-23 acggataaTTG------------------------------------------------- 
232-22 ------------------------------ttggtactA-----------AT-------- 
237-22 ---------------------------------------------------caaatcatg 
251-22 --aagtctccG------------------------------------------------- 
257-22 ------------------------------------------cgggtaattT-------- 
285-20 ------------------------------------------------------------ 
286-20 -------------------------------------------tttgttgAT-------- 
319-20 ----------atatcacgttAG-------------------------------------- 
320-20 ----------------------------------------------------atagctgt 
321-20 ------------------------------------------------------------ 
322-20 --tcatttTTC------------------------------------------------- 
326-19 ---------------------------------gttgcA-----------AT-------- 
333-19 ------------------------------------------------------------ 
338-19 -------------------------------------------------CAT-------- 
347-19 ----------------------GT---------------------------T-------- 
348-19 -------------------------------------------------aAT-------- 
382-18 -------------------------caacaTG-------------------T-------- 
383-18 ------------------------------------------------------acggat 
412-18 ------------------------------------------------------------ 
416-18 ------------cttttgtttG-------------------------------------- 
418-18 ------------------------------------------------atcT-------- 
423-18 --------ctCA------------------------------------------------ 
428-17 --------------------------------------gatttcacgaaCAT-------- 
 
 
                   .......+++.++++++++. .. .. . .   
4-119 (4)  tcTCTTTGTTCTTTCTCTTAACgagta----- 
16-68 (5)  --TTTCTTTTCTTTCTCTTACatccagg---- 
40-43 (11)  ----TTCATTCTTTCTCTTTCacg-------- 
62-36 (4)  ----ATTTTCCTTTATCTTTTCtctttgtcg- 
73-34 (10)  ----ATTATTCTTTCTCTTGCTttc------- 
76-33 (8)  ----AAGTTTTTTTCTCTTtttacgga----- 
110-30 (6)  ----TATTTTCTTTCTTCTTcgagttcac--- 
113-30 (4)  --TCTCTTTACTTTCTCTTAACgaactac--- 
116-30 (3)  tTtctacttttcttctcttTgataacgt---- 
119-29 (1)  ---cTTTTTTCTTTCTGTTttctctctcgttc 
134-28 (12) ----TTGTTTTTTTCTCTTGtgc--------- 
174-26 (3) ----ATTTTTCTTTCTCTTAAgtctttagatg 
183-25 (6) ----TTCTTTCTTTCTCTTGattgtcttg--- 
198-24 (11)  ----TTGTTTCTTTCTCTTACgtt-------- 
207-24 (11)  ----TTTTTTCTTTCTCatctcta-------- 
211-23 (4)  ----TTTTTTCTTTCTtcaggattatcgcga- 
229-23 (12)  -----ACTTTCTTTCTCTTAACat-------- 
232-22 (12)  ----CTTTTTCTTTCTCTggata--------- 
237-22 (10)  atacaTCTTTCTTTCTCTTTG----------- 
251-22 (10)  -----ATTTTCTTTCTCTTTGTgcta------ 
257-22 (11)  ----CTTTTTCTTTCTCTTGgagt-------- 
285-20 (1)  agTCTTTGTTTTTTCTCTTGCTcctcatcg-- 
286-20 (10)  ----CATTTTCTTTCTCTTtaggcc------- 
319-20 (13)  ----TTTTTTCTTTCTCTTAAC---------- 
320-20 (9)  tTTCTTTTTTACTTCTCTTAGg---------- 
321-20 (1)  aTtcttcttttcttctcttTacgcgttaat-- 
322-20 (10)  -----ACATTCTTTCTCTTgtactag------ 
326-19 (9)  ----TATTTTCTTTCTCTTTGTgtca------ 
333-19 (1)  --TCTCGTTTCTTTCTCTTTCTttctctgtgg 
338-19 (4)  ----TATTTTCTTTTTCCTTGTtgtaaatgt- 
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347-19 (4)  ----CTCTTTGTTTCTCTTTCTatgcataga- 
348-19 (4)  ----TTGTTTTTTTCACTTcttcattgtgt-- 
382-18 (9)  ----TTTTTCTTTTCTCTTacgggt------- 
383-18 (7)  ccaaTCTTTACTTTCTCTTgtcca-------- 
412-18 (1)  -TTCTTGTTTCTTTCTCTTAGTctgcggtaa- 
416-18 (11)  ----TTTTTTCTTTCTCTTcgtgaa------- 
418-18 (5)  ----TTCTTTCTTTCTCTTAgctgtctga--- 
423-18 (5)  ----ATTATTCTTTCTCTTTTCgcgatttt-- 
428-17 (15)  ----TTTTTCCTTTTTCCTT------------ 
 
 
 
LOCAL SUPERMOTIF number 10, power  10.18 
                        . ...... .+++.++++..++++.. ....... .   
6-90  -----------acgttttgaTTTCTCTTTACTTCTTCAGTc------- 
32-47  ----------atTCT----TTTTCTCTTATCTTCTTCGGTgtcg---- 
56-38  ---------------gTTCTTTTCTATTTTCTTTCtCACTACGaa--- 
63-36  ------------aCT----TTTTTTCTTTCCTTCTtATCGACGaca-- 
67-35  --------------acttctcTTTTCTTTCCTTCTAtcacgcaa---- 
127-29  ------------------CTTTTTTCTTTTCTTCCtGTCTACGcggaa 
170-26  ----------actgT----TTTTCTCTTTTCTTtcttcctgtg----- 
261-22  acgtattctgcgaaT----TTTTCTCTTTCCTTC-------------- 
291-20  -----------actT----TTTTTTCTTTCCTTCTtATCGACGaca-- 
312-20  ---------------gatgTTGTTTATTTTCTTCTtCACTAacaa--- 
315-20  ----------------tttgTTTTTCTTTTCTTCTAgttcacgtta-- 
339-19  ------------acttTTCTTTTCTCTTATCTTCgaatgatg------ 
375-18  ------------TCT----TTTTCTCTTGTCTTCTtATgtccaatt-- 
384-18  ------------actggttTTCTTTCTATTCTTCCtGTgtgt------ 
432-17  ------------------acTTTCTCTTTTCTTCTggaatag------ 
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7.4 Appendix 4: Multiple alignment comparison with 
control aptamer sequences 
 
The top ten consensus sequences comparing the lead aptamers from the three Aβ40 
selections described in this thesis (Figure 3.17) to the control aptamer sequences used in 
Chapter 5, β55, DV1, RVGP1 and NGGA1 (Sections 5.5.1).  Power scores are given as 
described in Appendix 7.3.   
 
LOCAL SUPERMOTIF number 1, power  10.36 
       ++++++++++++++++++++++++++++++++++++++ +++++ +++++ 
2A1 GGCAAACGGUAAGGCCAAAGGGACGAGGGUAGAGAUUGAUAGAAAGCCGC 
2A416 GGCAAACGGUAAGGCCAAAGGGACGAGGGUAGAGAUUGGUAGAAGGCCGC 
 
 
LOCAL SUPERMOTIF number 2, power   8.60 
.......... ......++..+...++++.....++..+..+..+.+....  .... .  
2A1 ggcaaacgguAAGGCCAAAGGGACGAGGGUAGAGAUUGAUAGAAAGCCgc--------- 
2A359 -------------GAGAAAAGUCUGAGGGAGGAGAGAGGGAGGAAGAGAcuacaucgcg 
2A416 ggcaaacgguAAGGCCAAAGGGACGAGGGUAGAGAUUGGUAGAAGGCCgc--------- 
M1 ----------------uAAGGGAAGUGUGCUGAGAGAGGGAAGUUGCGuagcgaagcac 
M3 ---------gAGGUCGAAGGGGAUGAUGAAGUAGAAUUAGAGCA--------------- 
M214 ----------AAGGGGAACAGAAAGAGGGAAAGGAGGGGAAAAAGGACAaagcgagaaa 
 
 
LOCAL SUPERMOTIF number 3, power   7.20 
 ... ..... .....+.+..+ ...++.++.....+.... .  .. . 
2A1 -------ggcaAACGGUAAGGCCAAAGGGACGAGGGUAgagauugaua 
2A359 -------------GAGAAAAGUCUGAGGGAGGAGAGAgggaggaagag 
2A416  -------ggcaAACGGUAAGGCCAAAGGGACGAGGGUAgagauuggua 
2A417  ggucgauaggGAAGGGAAGGGAUGGAGGGACGACUGGAc--------- 
M1     gugugcugagagAGGGAAGUUGCGUAGCGAAGcacgauaacg------ 
M50    gugagaguaaGAGUGGAAGGGAAGAAAGUACaca-------------- 
M53    gaauggguacGAAGGGAAGAGGAGGAGCGAGAAGGGA----------- 
M214   agggaaaggaggggaaaAAGGACAAAGCGAgaaagg------------ 
 
 
LOCAL SUPERMOTIF number 4, power   6.9 
              .+...++..  +  ......+.+.....+ ..+.. ........ ....      
2A359 ------gAGAAAAGUCUGAGGGAG--GAGAGAGGGAGGAAGAGA-----CUACAucgcgga 
M1 -----uAAGGGAAGUGUGCUGAGAGAGGGAAGUUGCGUA-GCGAAGCACGAUAACg----- 
M50 ------AAGGGAAGGCAGAUAAGUGAGAGUAAGAGUGGAAGGGAAGAAAGUACACa----- 
M214 aaggggAACAGAAAGAGGGAAAGGAGGGGAAAAAGGACAAAGCGAGAAAGg---------- 
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LOCAL SUPERMOTIF number 5, power   6.82 
                .        . ++.+++.+.+... +...++..  .  .... 
2A39           -----------uAGCGAAGGGAGGGCAGGGAGAagggcgcuau 
2A417          aguucggucgAUAGGGAAGGGAAGGGAUGGAGGgacgacugga 
M50            -----------aAGGGAAGGCAGAUAAGUGAGAguaagagugg 
M214           gggaacagaaAGAGGGAAAGGAGGGGAAAAAGGacaaagcgag 
 
LOCAL SUPERMOTIF number 6, power   6.70 
             . ... . . ..       .  . ......++.+........ ++.+....... 
2A39 -----------------------------uagCGAAGGGA-----GGGcAGGGAG-AAGG 
2A417 cggucgauagGG----------------------AAGGGAAGGGAUGG-AGGGACGACUG 
M5 ---gauaugcGG----------------------CAGGAAAGGAAACA-AGAGUACugcg 
M50 ------aagggaaggcagauaagugagaguaagaguGGAAGGGAAGAA-AGUACACa--- 
M53 ----------acacgaagcgcgcgaauggguaCGAAGGGAAGAGGAGG-AGCGAG-AAGG 
M174 ---------------------------------uAGGGAAAGGUAAAG-AGAGUACCAUG 
M214 ---------------------------------aAGGGGAACAGAAAG-AGGGAA-AGGA 
 
 
             ..   .  .. .  
2A39 (26)  Gcgcuauggaugg 
2A417 (48)  GAC---------- 
M5 (35)  acag--------- 
M50 (51)  ------------- 
M53 (49)  Ga----------- 
M174 (27)  GACaugcuggcgu 
M214 (26)  Ggggaaaaaggac 
 
 
LOCAL SUPERMOTIF number 7, power   6.70 
               ...  . ......++..... ............... 
2A39           ------uagcGAAGggagggCAGGGAGAAGGGcgcu 
2A359          gagaaaagucugAGggaggaGAGAGGGAGGAAgaga 
2A417          ggucgauagggAAGGGAAGGGAUGGAgggacgacug 
M1             ---------uaAGGgaagugUGCUGAGAGAGGgaag 
M5             -------gauaugcGGCAGGAAAGGAaacaagagua 
M50            -----------AAGggaaggCAGAUAAGUGagagua 
M53            gaagcgcgcgaAUGgguacgAAGGGAAGAGGaggag 
M174           ----------uAGGgaaaggUAAAGAGAGuaccaug 
M214           ggaacagaaaGAGGgaaaggAGGGGAAAAAGGacaa 
M233           -------gaggauGggaagaGCCGCGGAGGUAaugu 
 
LOCAL SUPERMOTIF number 8, power   6.69 
        ... . ........ .. ...... . .+.............+..+ ....+...  
B55  -----------uuuACC---------------GUAAGGCCugucuucguuugacagcggcu 
2A1 ---------gGCAAACG---------------GUAAGGCCAaagggaCGAGGGUAGAGAUU 
2A416 ---------gGCAAACG---------------GUAAGGCCAaagggaCGAGGGUAGAGAUU 
M3 -----------------------gaggucgAAGGGGAUGAUgaaguaGAAUUAGAGCA--- 
M50 ----aagggaaggcagauaagugagaguaagaguggaagggAAGAAAGUACaca------- 
M53 cacgaagcgcGCGAAUG---------------GGUACGAAGggaagaGGAGGAGCGAGAAG 
M174 --------------uaG---------------GGAAAGGUAAAGAGAGUACcauggacaug 
M214 ----------aaggggaacagaaagagggaAAGGAGGGGAAaaaggaCAAAGCGAGAAAGG 
M233 ----------------gaggaugggaagagccgcgGAGGUAauguuaCAAAAUGAGGUAGG 
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LOCAL SUPERMOTIF number 9, power   6.60 
 
           ...... .....+.+...++.+.. .............++. . .. . .        
2A1 ggcaaacgguaAGGCCAAA--GGGACG--AGGGUAGAGAUUGAUAGAAAgccgc------ 
2A417 -aucacgaguuCGGUCGAUAGGGAAGG-GAAGGGAUGGAGGGACGacuggac-------- 
M3 ----------GAGGUCGAAGGGGAUGA-UGAAGUAGAAUUAGAGCa-------------- 
M5 ---------gauaugC-----GGCAGGaAAGGAAACAAGAGUACUGCGAcag-------- 
M53 ---acacgaaGCGCGCGAAUGGGUACG-AAGGGAAGAGGAGGAGCGAGAAggga------ 
M214 -----------------AAGGGGAACA-GAAAGAGGGAAAGGAGGGGAAAaaggacaaag 
 
 
LOCAL SUPERMOTIF number 10, power   6.58 
        .   .  .. .+..++..............++++............  .     
2A417 guucggucgauAGGGAAGGGAAGGGAUGGAGGGACGACUGGAC---------- 
M1 ---------uaAGGGAAGUGUGCUGAGAGAGGGAAGuugcguagcgaagcacg 
M50 gaaggcagauAAGUGAGAGUAAGAGUGGAAGGGAAGAAAGUACaca------- 
M214 ----aaggggAACAGAAAGAGGGAAAGGAGGGGAAAAAGG-ACaaagcgagaa 
 262 
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